cvm_10k.htm

0001654954-21-013417.txt : 20211221 0001654954-21-013417.hdr.sgml : 20211221 20211221163358 ACCESSION NUMBER: 0001654954-21-013417 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211221 DATE AS OF CHANGE: 20211221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 211509870 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-K 1 cvm_10k.htm ANNUAL REPORT cvm_10k.htm

FORM 10-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended September 30, 2021.

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________.

Commission file number 1-11889

CEL-SCI CORPORATION

(Exact name of registrant as specified in its charter)

Colorado		84-0916344
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

8229 Boone Blvd., Suite 802 Vienna, Virginia		22182
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange

on which registered

Common Stock

CVM

NYSE American

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an “emerging growth company”. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging Growth Company	☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐ No ☒

The aggregate market value of the voting stock held by non-affiliates of the Registrant, based upon the closing sale price of the registrant’s common stock on March 31, 2021, as quoted on the NYSE American, was $595,537,907.

As of December 10, 2021, the Registrant had 43,244,498 issued and outstanding shares of common stock.

Documents Incorporated by Reference: None

FORWARD-LOOKING STATEMENTS

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as “anticipates,” “believes,” “expects,” “intends,” “future,” “could,” “estimates,” “plans,” “would,” “should,” “potential,” “continues” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:

	·	the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;

	·	our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceeding;

	·	the success of our clinical studies for our product candidates;

	·	our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;

	·	our expectations regarding federal, state and foreign regulatory requirements;

	·	the therapeutic benefits and effectiveness of our product candidates;

	·	the safety profile and related adverse events of our product candidates;

	·	our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;

	·	our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;

	·	business disruption and related risks resulting from the recent pandemic of the novel coronavirus 2019 (COVID-19);

	·	our expectations as to future financial performance, expense levels and liquidity sources;

	·	our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;

	·	anticipated trends and challenges in our potential markets;

	·	our ability to attract, retain and motivate key personnel;

	·	our ability to continue as a going concern; and

	·	our liquidity.

All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained in this report, speak only as of their respective dates. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this report may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.

PART I

ITEM 1. BUSINESS

CEL-SCI Corporation (CEL-SCI) is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. For its lead investigational therapy Multikine® (Leukocyte Interleukin, Injection) CEL-SCI has announced top line data from its pivotal Phase 3 clinical trial for patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck for which CEL-SCI has received Orphan Drug Status from the U.S. Food and Drug Administration, or FDA. The study was fully enrolled with 928 patients in September 2016.

On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6% survival, Multikine arm 62.7% survival.

The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival.

However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to the Company becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this the Company will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.

CEL-SCI’s investigational immunotherapy Multikine is being used in a different way than cancer immunotherapy is usually used. It is given before any other therapy has been administered because that is when the immune system is thought to be strongest (i.e., as a neoadjuvant). It is also administered locally around the tumors and near the draining lymph node. In the Phase 3 clinical trial, Multikine was given locally for three weeks, five days per week as a first line treatment before surgery, radiation or radiochemotherapy. The goal is to help the intact immune system “see” the cancer and kill the micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that local administration and administration of Multikine before weakening of the immune system by surgery, radiation and chemotherapy will result in improved outcomes and better overall survival rates for patients suffering from head and neck cancer.

CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform.

CEL-SCI was formed as a Colorado corporation in 1983. CEL-SCI’s principal office is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182. CEL-SCI’s telephone number is 703-506-9460 and its website is www.cel-sci.com. CEL-SCI does not incorporate the information on its website into this report, and you should not consider it part of this report.

CEL-SCI makes its electronic filings with the Securities and Exchange Commission (SEC), including its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports available on its website free of charge as soon as practicable after they are filed or furnished to the SEC.

CEL-SCI’S PRODUCTS

CEL-SCI is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:

	1)	Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers;

	2)	L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with CEL-4000 as a product candidate under development for the potential treatment of rheumatoid arthritis.

MULTIKINE

CEL-SCI’s lead investigational therapy, Multikine, is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase 1 and Phase 2 clinical trials suggest that Multikine may help the immune system “see” the tumor and then attack it, enabling the body’s own anti-tumor immune response to fight the tumor. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the FDA, in connection with CEL-SCI’s future anticipated regulatory submission for approval in the United States. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency, such as the European Medicine Agency, or EMA, and neither its safety nor its efficacy been established.

Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines. If commercial approval is obtained, CEL-SCI intends to manufacture Multikine in a proprietary manner in CEL-SCI’s manufacturing facility. CEL-SCI spent over 10 years and more than $100 million developing and validating the manufacturing process for Multikine. The pro-inflammatory cytokine mixture includes interleukins, interferons, chemokines and colony-stimulating factors, which contain elements of the body’s natural mix of defenses against cancer.

Multikine is designed to be used in a different way than cancer immunotherapy is generally being used. Generally, cancer immunotherapy is given to patients who have already failed other treatments such as surgery, radiation and/or chemotherapy and most of the time it is administered systemically. Multikine on the other hand is administered locally to treat tumors and their microenvironment before any other therapy has been administered because it is believed that this is the time when the immune system would be strongest and most amenable to activation against the tumor. For example, in the Phase 3 clinical trial, Multikine was injected locally around the tumor and near the adjacent draining lymph nodes for three weeks, five days a week as a first treatment before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system recognize and kill the tumor micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that the local administration of Multikine before weakening of the immune system by surgery, chemotherapy and radiation will result in better anti-tumor response than if Multikine were administered after surgery, radiation and chemotherapy. In clinical studies of Multikine, administration of the investigational therapy to head and neck cancer patients has demonstrated the potential for lesser or no appreciable toxicity.

Source: Adapted from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005

The first indication CEL-SCI is pursuing for its investigational drug product candidate Multikine is an indication for the neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, or SCCHN (hereafter also referred to as advanced primary head and neck cancer).

This trial was under the management of two clinical research organizations, or CROs: ICON plc., or ICON, and Ergomed Clinical Research Limited, or Ergomed.

Since CEL-SCI launched its Phase 3 clinical trial for Multikine, CEL-SCI has incurred expenses of approximately $62.2 million as of September 30, 2021 on direct costs for the Phase 3 clinical trial. CEL-SCI estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., preparations for the potential commercial manufacture of the drug.

Ultimately, the decision as to whether CEL-SCI’s drug product candidate is safe and effective can only be made by the FDA and/or by other regulatory authorities based upon an assessment of all of the data from an entire drug development program submitted as part of an application for marketing approval. As detailed in the Risk Factors section of this report, the current Phase 3 clinical study for CEL-SCI’s investigational drug may or may not be able to be used as the pivotal study supporting a marketing application in the United States, and, if not, at least one entirely new Phase 3 pivotal study would need to be conducted to support a marketing application in the United States. However, CEL-SCI does not believe that this is likely.

Development Agreements for Multikine

In August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical Industries Ltd., or Teva, that gives Teva the exclusive right and license to market, distribute and sell Multikine, if approved, in Israel and Turkey for treatment of head and neck cancer. The agreement terminates on a country-by-country basis 10 years after the product launch in each country or upon a material breach or upon bankruptcy of either party. The agreement will automatically extend for additional two year terms unless either party gives notice of its intent not to extend the agreement. If CEL-SCI develops Multikine for other oncology indications and Teva indicates a desire to participate, the parties have agreed to negotiate in good faith with respect to Teva’s participation and contribution in future clinical trials.

Teva has agreed to use all reasonable efforts to obtain regulatory approval to market and sell Multikine in its territory at its own cost and expense. Pursuant to the agreement, it is CEL-SCI’s responsibility to supply Multikine and Teva’s responsibility to sell Multikine, if approved by regulatory authorities in the relevant countries. Net sales will be divided 50/50 between the two parties. Teva also initially agreed to fund certain activities relating to the conduct of a clinical trial in Israel as part of the global Phase 3 trial for Multikine. In January 2012, pursuant to an assignment and assumption agreement between CEL-SCI, Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of its rights and obligations concerning the Phase 3 trial in Israel to GCP.

In July 2011, Serbia and Croatia were added to Teva’s territory, pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o., or PLIVA, an affiliate of Teva’s, subject to similar terms as described above.

In consideration for the rights granted by CEL-SCI to PLIVA under the joinder agreement, CEL-SCI will be paid by PLIVA (in U.S. dollars):

	·	$100,000 upon EMA grant of Marketing Authorization for Multikine;

	·	$50,000 upon Croatia’s grant of reimbursement status for Multikine in Croatia; and

	·	$50,000 upon Serbia’s grant of reimbursement status for Multikine in Serbia.

In November 2000, CEL-SCI signed an agreement with Orient Europharma Co., Ltd., or Orient Europharma, of Taiwan, which was amended in October 2008 and again in June 2010. Pursuant to this agreement, as amended, Orient Europharma has the exclusive marketing and distribution rights to Multikine, if approved by regulatory authorities, for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer indications in Taiwan, Singapore, Malaysia, Hong Kong, the Philippines, South Korea, Australia and New Zealand. CEL-SCI has granted Orient Europharma the first right of negotiation with respect to Thailand and China.

The agreement requires Orient Europharma to fund 10% of the cost of the clinical trials needed to obtain marketing approvals in these countries for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer.

If Multikine is approved for sale, Orient Europharma will purchase Multikine from CEL-SCI for 35% of the gross selling price in each country. Orient Europharma is obligated to use the same diligent efforts to develop, register, market, sell and distribute Multikine in its territory as with its own products or other licensed products.

The agreement will terminate on a country-by-country basis 15 years after the product approval for Multikine in each country, at which point the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement. The agreement may also be terminated upon the bankruptcy of either party or material misrepresentations that are not cured within 60 days. If the agreement ends before the 15 year term through no fault of either party, CEL-SCI will reimburse Orient Europharma for a prorated part of Orient Europhorma’s costs towards the clinical trials of Multikine. If Orient Europharma fails to make certain minimum purchases of Multikine during the term of the agreement, Orient Europhorma’s rights to the territory will become non-exclusive.

CEL-SCI has a licensing agreement with Byron Biopharma LLC, or Byron, under which CEL-SCI granted Byron an exclusive license to market and distribute Multikine in the Republic of South Africa, if approved. This license will terminate 20 years after marketing approval in South Africa or after the bankruptcy or uncured material breach by either party. After the 20-year period has expired, the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement.

Pursuant to the agreement, Byron will be responsible for registering Multikine in South Africa. If Multikine is approved for sale in South Africa, CEL-SCI will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Sales revenues will be divided equally between CEL-SCI and Byron.

LEAPS

CEL-SCI’s patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses “heteroconjugates” to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.

The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body’s selection of the “inappropriate” immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and drugs in attacking an underlying disease.

LEAPS Candidate: LEAPS COV-19

CEL-SCI began developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. On March 23, 2020, CEL-SCI signed a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COV-19 immunotherapy. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it.

On July 24, 2020, CEL-SCI announced it had concluded animal experiments using its LEAPS COV-19 conjugate that provide the basis for moving forward into animal challenge studies with live virus SARS-CoV-2, the causative agent of COVID-19, at the UGA’s Center for Vaccines and Immunology. The animal experiments showed that LEAPS COV-19 conjugates induced faster and much higher than expected antibody responses against a non-mutating region of the virus that causes COVID-19 after only one injection. It is important to note that IgG antibodies response was generated within 10 days of a single immunization. Generation of IgG requires activation of dendritic, T and B cells in order to promote the class switch from IgM to IgG antibody.

On December 1, 2020, CEL-SCI announced that LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in studies conducted at the University of Georgia Center for Vaccines and Immunology. The animals were therapeutically treated with CEL-SCI’s LEAPS COV-19 peptides one day after infection with a lethal dose of SARS-CoV-2. Of the LEAPS treated mice, forty percent (40%) were alive, recovering and regained lost weight, attaining > 90% of their starting weight, by the study’s end. In contrast, mice in the two control groups lost 20% or more of their body weight by day 8 and all of them died between day 5 and day 8 post challenge. The success of this therapy was statistically significant at a 95% level. An additional study conducted using LEAPS as a vaccine to prevent disease resulted in similar findings to the above described study, but with a slightly lower level of statistical significance. In this study, the Human(h) ACE2 transgenic mice were dosed twice with the LEAPS conjugate 28 and 14 days prior to being challenged with a lethal dose of SARS-CoV-2 virus. CEL-SCI will not continue with this project since its resources need to be focused on the approval of Multikne.

LEAPS Candidates: CEL-2000, CEL-4000 and DerG-PG275(Cit)

On September 19, 2017, CEL-SCI announced that it had been awarded a Phase 2 Small Business Innovation Research (SBIR) grant in the amount of $1.5 million from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or NIAMS, which is part of the U.S. National Institutes of Health (NIH). This grant provided funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application for a Phase 1 safety study, by funding IND enabling studies and additional mechanism of action studies, among other preclinical development activities. Work on CEL-4000 was conducted at CEL-SCI’s research laboratory and Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery & Biochemistry. The SBIR grant was awarded based on published data described below by Dr. Glant's team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental proteoglycan induced arthritis (PGIA or GIA) when it was administered after the disease was induced in animals. This grant has been fully expended.

In May 2019, CEL-SCI announced that a newly discovered LEAPS conjugate acts alone and can complement CEL-4000 therapeutically when administered in combination to an animal model of Rheumatoid Arthritis (RA). This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. The data was presented at the American Association of Immunologists 103rd Annual Meeting (Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI’s Senior Vice President of Research, Cellular Immunology. The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois and was funded by the SBIR Phase 2 Grant.

In July 2019, one of CEL-SCI’s collaborators from Rush, Dr. Adrienn Markovics presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry. Data presented was for a new second RA conjugate discovered which acts alone and can complement the existing CEL-4000 RA vaccine in an animal model of RA. The combination of the two RA conjugates provided not only broader epitope coverage, but also a greater therapeutic effect than either conjugate alone. The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and a newly discovered LEAPS conjugate, DerG-PG275Cit. Both conjugates were evaluated alone and in combination in the model of proteoglycan [PG] induced arthritis (PGIA) called recombinant PG G1 domain-induced arthritis (GIA), an autoimmune mouse model of RA.

In February 2017 and November 2016, CEL-SCI announced preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential to treat rheumatoid arthritis. This study was supported in part by the SBIR Phase I Grant and was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at Rush University Medical Center in Chicago, IL. This work was published in an article entitled “An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis” and can be found online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568759/.

Prior to the SBIR Phase 2 grant in 2014, CEL-SCI was awarded a Phase 1 SBIR grant in the amount of $225,000 from NIAMS. This grant funded the development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis, an autoimmune disease of the joints. The work was conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of Medicine.

With the support of these SBIR grants, CEL-SCI is developing several new drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic treatments. The data from animal studies using the CEL-2000 treatment suggests that it could be used against rheumatoid arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments currently on the market for arthritic conditions associated with the Th17 signature cytokine TNF-a. The preclinical data indicates these peptides could be used against rheumatoid arthritis where a Th1 signature cytokine (IFN-γ) is dominant. CEL-2000 and CEL-4000 each have the potential to become a personalized, disease-specific therapy, that acts at an earlier step in the disease process than current therapies, and which may be useful in patients not responding to existing rheumatoid arthritis therapies. CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.

In March 2015, CEL-SCI and its collaborators published a review article on vaccine therapies for rheumatoid arthritis based in part on work supported by the SBIR Phase 1 grant. The article is entitled “Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic Ligand Epitope Antigen Presentation System vaccines for models of rheumatoid arthritis” and was published in Expert Review of Vaccines 1 - 18 and can be found online at http://www.ncbi.nlm.nih.gov/pubmed/25787143.

Other LEAPS experiments: LEAPS-H1N1-DC

Using the LEAPS technology, CEL-SCI has also tested in preclinical studies a potential peptide treatment for H1N1 (swine flu) hospitalized patients, a disease which does not represent a problem any more. Therefore CEL-SCI is no longer developing a treatment against H1N1. This LEAPS flu treatment was designed to focus on the conserved, non-changing epitopes of the different strains of Type A Influenza viruses (H1N1, H5N1, H3N1, etc.), including “swine”, “avian or bird”, and “Spanish Influenza”, in order to minimize the chance of viral “escape by mutations” from immune recognition.

In May 2011 NIAID scientists presented data at the Keystone Conference on “Pathogenesis of Influenza: Virus-Host Interactions” in Hong Kong, China, showing the positive results of efficacy studies in mice of LEAPS H1N1 activated dendritic cells (DCs) to treat the H1N1 virus. Scientists at the NIAID found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control DCs. The work was performed in collaboration with scientists led by Kanta Subbarao, M.D., Chief of the Emerging Respiratory Diseases Section in NIAID’s Division of Intramural Research, part of the National Institutes of Health, USA.

In July 2013, CEL-SCI announced the publication of the results of influenza studies by researchers from the NIAID in the Journal of Clinical Investigation (www.jci.org/articles/view/67550). The studies described in the publication show that when CEL-SCI’s investigational J-LEAPS Influenza Virus treatments were used “in vitro” to activate DCs, these activated DCs, when injected into influenza infected mice, arrested the progression of lethal influenza virus infection in these mice. The work was performed in the laboratory of Dr. Subbarao.

Accordingly, even though the various LEAPS candidates have not yet been given to humans, they have been tested in vitro with human cells. They have induced similar cytokine responses that were seen in these animal models, which may indicate that the LEAPS technology might translate to humans. The LEAPS candidates have demonstrated protection against lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as a prophylactic or therapeutic agent in animals. They have also shown some level of activity in animals in two autoimmune conditions, curtailing and sometimes preventing disease progression in arthritis and myocarditis animal models.

None of the LEAPS investigational products have been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from the early-phase, preclinical-trials data involving these investigational products. Before obtaining marketing approval from the FDA in the United States, and by comparable agencies in most foreign countries, these product candidates must undergo rigorous preclinical and clinical testing which is costly and time consuming and subject to unanticipated delays. There can be no assurance that these approvals will be granted.

INTELLECTUAL PROPERTY

Patents and other proprietary rights are essential to CEL-SCI’s business. CEL-SCI files patent applications to protect its technologies, inventions and improvements to its inventions that CEL-SCI considers important to the development of its business. CEL-SCI’S intellectual property portfolio covers its proprietary technologies, including Multikine and LEAPS, by multiple issued patents and pending patent applications in the United States and in key foreign markets.

Multikine is protected by a U.S. patent, which is a composition-of-matter patent issued in May 2005 that, in its current format, expires in 2023. Additional composition-of-matter patents for Multikine have been issued in Germany (issued in June 2011 and currently set to expire in 2025), China (issued in May 2011 and currently set to expire in 2024), Japan (issued in November 2012 and currently set to expire in 2025), and three in Europe (issued in September 2015, May 2016 and October 2017, currently set to expire in 2025 and 2026). The most recent patent issued in October 2017, patent # EP 1 879 618 B1, titled “A Method for Modulating HLA Class II Tumor Cell Surface Expression With A Cytokine Mixture,” addresses Multikine’s mechanism of action to make tumors more visible to the immune system. This new patent is important because, along with the other Multikine issued patents, it addresses how Multikine enables the immune system to recognize and attack the tumor. One way tumor cells evade the immune system is by expressing human leukocyte antigens (HLA) on the tumor cell surface, thus appearing as ‘self’ to the immune cells and therefore the tumor cells are not attacked. It is important to note that the tumors of the Multikine-treated best responders in CEL-SCI’s prior Phase 2 studies had no HLA Class II expressed on the cell surface following Multikine treatment as compared to controls. This points to Multikine’s ability to modulate HLA expression on the tumor cell surface, thereby allowing the immune system to recognize and attack the tumor.

In addition to the patents that offer certain protections for Multikine, the method of manufacture for Multikine, a complex biological product, is held by CEL-SCI as a trade secret.

LEAPS is protected by patents in the United States issued in February 2006, April 2007, August 2007, January 2019 and March 2019. The LEAPS patents, which expire in 2021, 2022, 2021 and three in 2032, respectively, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format. One issued U.S. application is a joint application with Northeast Ohio Medical University (“Neoucom”) and CEL-SCI will share the ability to use the patent, unless CEL-SCI licenses the rights to the patent from Neoucom. In October 2017 and October 2020, patents were issued in Europe for LEAPS, which expire in 2029 and 2034, respectively.

CEL-SCI has five patent applications pending in the United States for LEAPS, which, if issued, would extend protection through 2040, subject to any potential patent term extensions.

As of December 9, 2021, there were no contested proceedings and/or third party claims with respect to CEL-SCI’s patents or patent applications.

MANUFACTURING FACILITY

Before starting the Phase 3 clinical trial, for reasons related to regulatory considerations, CEL-SCI built a dedicated manufacturing facility to produce its investigational biological product candidate Multikine. This facility produced multiple clinical lots for the Phase 3 clinical trial and has also passed quality systems review by a European Union Qualified Person on several occasions. CEL-SCI is currently expanding the manufacturing facility so CEL-SCI will be able to meet the expected demand for Multikine, if a license is granted. This expansion was completed in the fall of 2021, allowing CEL-SCI employees to return to work inside the manufacturing facility.

CEL-SCI’s lease on the manufacturing facility expires on October 31, 2028. At that time CEL-SCI can either purchase the facility or extend its lease. See Item 2 of this report for more information concerning the terms of this lease.

GOVERNMENT REGULATION

The FDA and other regulatory authorities at federal, state and local levels and in foreign countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing and post-approval monitoring and reporting of biologics such as those CEL-SCI is developing. CEL-SCI, along with third party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which it wishes to conduct studies or seek approval or licensure of its product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.

U.S. Food and Drug Administration Regulation of Biological Products

In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:

	·	completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;

	·	submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually;

	·	approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is initiated;

	·	performance of adequate and well-controlled human clinical trials in compliance with Good Clinical Practice, or GCP, regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;

	·	preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of clinical trials;

	·	satisfactory completion of an FDA Advisory Committee review, if applicable;

	·	a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;

	·	satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the biological product’s continued safety, purity and potency, and of selected clinical investigations to assess compliance with GCPs; and

	·	FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.

Prior to commencing the first clinical trial with a product candidate in the U.S., CEL-SCI must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to commence a clinical trial.

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial commences at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board (DSMB) or independent data monitoring committee (IDMC), which provides recommendations for whether or not a study should move forward at designated check points based on access to certain data from the study and may suggest halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.

For purposes of approval of a Biologics License Application, or BLA, human clinical trials are typically conducted in three or four sequential phases that may overlap.

● Phase 1 — The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses.

● Phase 2 — The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

● Phase 3 — The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.

● Phase 4 — In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. The FDA may also make these so-called Phase 4 or post-marketing studies a condition to approval of the BLA.

Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

BLA Submission and Review by the FDA

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators.

In most cases, the submission of a BLA is subject to a substantial application user fee. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA’s goal is to review the BLA within ten months after it accepts the application for filing, or, if the product relates to an unmet medical need in a serious or life-threatening indication and has received a priority review designation, six months after the FDA accepts the application for filing.

After filing the marketing application, the FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product’s continued safety, purity and potency. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve a biological product for marketing unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the data provided in the application, or the manufacturing process or manufacturing facilities for the product are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA also may refer applications for novel biologic candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval.

After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the biological product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete but the application is not ready for approval. A Complete Response Letter may request additional information or clarification, including new clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the re-submitted BLA does not satisfy the criteria for approval.

If a product receives regulatory approval, such approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which can materially affect the potential market and profitability of the product. The REMS plan could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may prevent or limit further marketing of a product based on the results of post- marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Expedited Review and Approval

A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA’s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A fast track designated product candidate may also qualify for priority review.

Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic’s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a breakthrough therapy at the time of or any time after the submission of an IND, but ideally before an end-of-phase 2 meeting with the FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment.

Fast Track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.

Post-Approval Requirements

All therapeutic products manufactured or distributed pursuant to FDA approval or licensure are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements under the Prescription Drug User Fee Act (PDUFA) for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications containing clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose significant procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements on manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. CEL-SCI cannot be certain that it, or CEL-SCI’s present or future suppliers, will be able to comply with the cGMP regulations and other FDA regulatory requirements. If CEL-SCI is not able to comply with these requirements, the FDA may, among other things, take enforcement action or seek sanctions against use, impose restrictions on a product or its manufacturer, require CEL-SCI to recall a product from distribution, or withdraw approval of the BLA.

The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

	·	restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

	·	fines, warning letters or holds on post-approval clinical studies;

	·	refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;

	·	product seizure or detention, or refusal to permit the import or export of products;

	·	injunctions or the imposition of civil or criminal penalties; and

	·	consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.

The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved, or “off-label,” uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.

In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market a drug for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. Orphan drug exclusivity also could block the approval of one of CEL-SCI’s products for seven years if a competitor obtains approval of a product before CEL-SCI does, as defined by the FDA, for the same indication CEL-SCI is seeking, or if CEL-SCI’s product candidate is determined to be contained within the scope of the competitor’s product for the same indication or disease. If one of CEL-SCI’s products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.

Orphan drug designation must be requested before submitting a BLA to the FDA for review and approval. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

Multikine has received Orphan Drug Status from the FDA.

Other U.S. Health Care Laws

CEL-SCI’s sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services and state and local governments. CEL-SCI’s promotional and scientific/educational programs must comply with the anti-kickback provisions of the Social Security Act, the Foreign Corrupt Practices Act, the False Claims Act, the Physician Payments Sunshine Act, the Veterans Health Care Act and similar state laws.

Depending on the circumstances, failure to meet these applicable regulatory requirements can result in criminal prosecution, fines or other penalties, exclusion from government health care programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private “qui tam” actions brought by individual whistleblowers under the False Claims Act in the name of the government or refusal to allow CEL-SCI to enter into supply contracts, including government contracts.

Coverage, Pricing and Reimbursement in the U.S.

Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products and new drug classes, including biological products such as CEL-SCI’s product candidates. CEL-SCI may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of its products. The product candidates that CEL-SCI develops may not be considered cost-effective. It is time consuming and expensive for CEL-SCI to seek reimbursement from third- party payors. Reimbursement may not be available or sufficient to allow CEL-SCI to sell its products on a competitive and profitable basis.

The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect CEL-SCI’s ability to sell its products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

Foreign Regulation

In addition to regulations in the United States, CEL-SCI will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent CEL-SCI chooses to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.

ITEM 1B. RISK FACTORS

The risks described below could adversely affect the price of CEL-SCI’s common stock.

Risk Factor Summary

CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.

CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates’ development or commercialization efforts.

The costs of the product candidates development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.

CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.

CEL-SCI depends heavily on the success of Multikine, for which top line Phase 3 data has been announced, while its other candidates are still in preclinical phases. CEL-SCI’s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI’s business will be materially harmed.

Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.

CEL-SCI’s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.

Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI’s operations.

The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.

CEL-SCI’s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.

CEL-SCI’s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.

Much of CEL-SCI’s intellectual property is protected as trade secrets or confidential know-how, not by patents.

You may experience future dilution as a result of future equity offerings or other equity issuances by CEL-SCI.

The price of CEL-SCI’s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI’s shareholders.

CEL-SCI faces business disruption and related risks resulting from the recent pandemic of COVID-19 which could have a material adverse effect on CEL-SCI's business plan.

Risks Related to CEL-SCI

CEL-SCI faces business disruption and related risks resulting from the recent pandemic of COVID-19 which could have a material adverse effect on our business plan.

The development of CEL-SCI’s product candidates could be disrupted and materially adversely affected by the outbreak of COVID-19. As a result of measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines intended to contain this outbreak. The spread of SARS CoV-2 from China to other countries has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020. International stock markets have reflected the uncertainty associated with the slow-down in the world economies and the significant declines in the Dow Industrial Average early in 2020 were largely attributed to the effects of COVID-19. CEL-SCI knows that COVID delayed the time to reach data lock for its Phase 3 clinical trial and that COVID has delayed the expansion of CEL-SCI’s manufacturing facility for Multikine. CEL-SCI is still assessing our business plans and the impact COVID-19 may have on our ability to conduct the preclinical studies and clinical trials other than CEL-SCI’s Phase 3 trial, but there can be no assurance that this analysis will enable CEL-SCI to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact CEL-SCI’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.

CEL-SCI has a history of net losses, expects to incur substantial losses and have negative operating cash flow for the foreseeable future, and may never achieve or maintain profitability. Since the date of its formation and through September 30, 2021, CEL-SCI incurred net losses of approximately $418 million. CEL-SCI has relied principally upon the proceeds from the public and private sales of its securities to finance its activities to date. To date, CEL-SCI has not commercialized any products or generated any revenue from the sale of products, and CEL-SCI does not expect to generate any product revenue for the foreseeable future. CEL-SCI does not know whether or when it will generate product revenue or become profitable.

CEL-SCI is heavily dependent on the success of Multikine for which top line Phase 3 data has been announced. CEL-SCI cannot be certain that Multikine will receive regulatory approval or be successfully commercialized even if CEL-SCI receives regulatory approval. Multikine is the only product candidate in late-stage clinical development and CEL-SCI’s business currently depends heavily on its successful development, regulatory approval and commercialization. CEL-SCI has no drug products for sale currently and may never be able to develop approved and marketable drug products.

Even if CEL-SCI succeeds in developing and commercializing one or more of its product candidates, CEL-SCI expects to continue to incur significant operating and capital expenditures as CEL-SCI:

	·	continues to undertake preclinical development and clinical trials for product candidates;

	·	seeks regulatory approvals for product candidates; and

	·	implements additional internal systems and infrastructure.

To become and remain profitable, CEL-SCI must succeed in developing and commercializing product candidates which must generate significant revenue. This will require CEL-SCI to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of its product candidates, discovering or acquiring additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which CEL-SCI may obtain regulatory approval. CEL-SCI is only in the preliminary stages of most of these activities. CEL-SCI may never succeed in these activities and, even if CEL-SCI does, may never generate revenue that is significant enough to achieve profitability.

Even if CEL-SCI does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The failure to become and remain profitable could depress the value of CEL-SCI’s common stock and could impair its ability to raise capital, expand its business, maintain research and development efforts, diversify product offerings or even continue in operation. A decline in the value of CEL-SCI’s common stock could cause its stockholders to lose all or part of their investment.

CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements, however, this concern has been alleviated by management’s plans.

Primarily as a result of CEL-SCI’s losses incurred to date, CEL-SCI’s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI’s ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company’s budgeted cash requirements, the substantial doubt about the Company’s ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.

As of September 30, 2021, CEL-SCI had cash and cash equivalents of approximately $36.1 million. CEL-SCI believes that it will continue to expend substantial resources for the foreseeable future developing Multikine, LEAPS and any other product candidates or technologies that it may develop or acquire. These expenditures will include costs associated with research and development, potentially obtaining regulatory approvals and having the products manufactured, as well as marketing and selling products approved for sale, if any. In addition, other unanticipated costs may arise. Because the outcome of the current and anticipated clinical trials is highly uncertain, CEL-SCI cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of the product candidates.

CEL-SCI’s future capital requirements depend on many factors, including:

	·	the rate of progress of, results of and cost of completing Phase 3 clinical development of Multikine for the treatment of certain head and neck cancers;

	·	the results of the applications to and meetings with the FDA, the EMA and other regulatory authorities and the consequential effect on operating costs;

	·	the cost, timing and outcome of the efforts to obtain marketing approval for Multikine in the United States, Europe and in other jurisdictions, including the preparation and filing of regulatory submissions for Multikine with the FDA, the EMA and other regulatory authorities;

	·	the scope, progress, results and costs of additional preclinical, clinical, or other studies for additional indications for Multikine, LEAPS and other product candidates and technologies that CEL-SCI may develop or acquire;

	·	the timing of, and the costs involved in, obtaining regulatory approvals for LEAPS if clinical studies are successful;

	·	the cost and timing of future commercialization activities for the products, if any of the product candidates are approved for marketing, including product manufacturing, marketing, sales and distribution costs;

	·	the revenue, if any, received from commercial sales of the product candidates for which CEL-SCI receives marketing approval;

	·	the cost of having the product candidates manufactured for clinical trials and in preparation for commercialization;

	·	the ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

	·	the costs involved in preparing, filing and prosecuting patent applications and maintaining, defending and enforcing its intellectual property rights, including litigation costs, and the outcome of such litigation; and

	·	the extent to which CEL-SCI acquires or in-licenses other products or technologies.

CEL-SCI will need to raise additional funds in order to continue its operations and additional funds may not be available when CEL-SCI needs them on terms that are acceptable to CEL-SCI, or at all. If adequate funds are not available to CEL-SCI on a timely basis, CEL-SCI may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for Multikine, LEAPS, or any other product candidates or technologies that CEL-SCI develops or acquires, or delay, limit, reduce or terminate its sales and marketing activities that may be necessary to commercialize its product candidates.

Clinical and other studies necessary to obtain approval of a new drug or biologic can be time consuming and costly, especially in the United States, but also in foreign countries. The estimates of the costs associated with future clinical trials and research may be substantially lower than what CEL-SCI actually experiences. It is impossible to predict what CEL-SCI will face in the development of a product candidate such as Multikine. The purpose of clinical trials is to provide both CEL-SCI and regulatory authorities with safety and efficacy data in humans. The difficult and often complex steps necessary to obtain regulatory approval, especially that of the FDA and the EMA, involve significant costs and may require several years to complete. CEL-SCI expects that it will need substantial additional financing over an extended period of time in order to fund the costs of future clinical trials, related research, and general and administrative expenses.

CEL-SCI’s LEAPS technology may not result in a viable drug candidate

Using CEL-SCI’s LEAPS technology, CEL-SCI is also developing a LEAPS immunotherapy for the potential treatment of Rheumatoid Arthritis. However, the development of this technology is in a preliminary stage. There can be no assurance that the LEAPS technology will be successful in treating any disease. CEL-SCI’s primary focus right now is seeking the approval of Multikine for the treatment of head and neck cancer.

An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.

CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litigation could result in substantial costs and divert management’s attention and resources. These legal proceedings may result in large judgments or settlements against CEL-SCI, any of which could have a material adverse effect on its business, operating results, financial condition and liquidity.

Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.

Changing laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty regarding compliance matters. New or changed laws, regulations and standards are subject to varying interpretations in many cases. As a result, their application in practice may evolve over time. CEL-SCI is committed to maintaining high standards of corporate governance and public disclosure. Complying with evolving interpretations of new or changing legal requirements may cause CEL-SCI to incur higher costs as CEL-SCI revises current practices, policies and procedures, and may divert management time and attention from potential revenue-generating activities to compliance matters. If the efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, CEL-SCI’s reputation may also be harmed. Further, CEL-SCI’s board members, chief executive officer, and other executive officers could face an increased risk of personal liability in connection with the performance of their duties. As a result, CEL-SCI may have difficulty attracting and retaining qualified board members and executive officers, which could harm its business.

CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.

CEL-SCI has not established a definitive plan for marketing Multikine nor has CEL-SCI established a price structure for any of its product candidates, if approved. However, CEL-SCI intends, if it is in a position to do so, to sell Multikine itself in certain markets where it is approved, and or to enter into written marketing agreements with various third parties with established sales forces in such markets. The sales forces in turn would, CEL-SCI believes, focus on selling Multikine to targeted cancer centers, physicians and clinics involved in the treatment of head and neck cancer. CEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa. CEL-SCI believes that these companies will have the resources to market Multikine appropriately in their respective territories, if approved, but there is no guarantee that they will. There is no assurance that CEL-SCI will be able to find qualified third-party partners to market its products in other areas, on terms that are favorable to CEL-SCI, or at all.

CEL-SCI may encounter problems, delays and additional expenses in developing marketing plans with third parties. In addition, even if Multikine, if approved, is cost-effective and demonstrated to increase overall patient survival, CEL-SCI may experience other limitations involving the proposed sale of Multikine, such as uncertainty of third-party coverage and reimbursement. There is no assurance that CEL-SCI can successfully market Multikine, if approved, or any other product candidates it may develop.

CEL-SCI hopes to expand its clinical development capabilities in the future, and any difficulties hiring or retaining key personnel or managing this growth could disrupt its operations.

CEL-SCI is highly dependent on the principal members of its management and development staff. CEL-SCI expects to expand its clinical development and manufacturing capabilities, which will involve hiring additional employees. Future growth will require CEL-SCI to continue to implement and improve its managerial, operational and financial systems and continue to retain, recruit and train additional qualified personnel, which may impose a strain on its administrative and its operational infrastructure. The competition for qualified personnel in the biopharmaceutical field is intense. CEL-SCI is highly dependent on its ability to attract, retain and motivate highly qualified management and specialized personnel required for clinical development. Due to limited resources, CEL-SCI may not be able to manage effectively the expansion of its operations or recruit and train additional qualified personnel. If CEL-SCI is unable to retain key personnel or manage its future growth effectively, CEL-SCI may not be able to implement its business plan.

If product liability or patient injury lawsuits are brought against CEL-SCI, CEL-SCI may incur substantial liabilities and may be required to limit clinical testing or future commercialization of Multikine or its other product candidates.

CEL-SCI faces an inherent risk of product liability as a result of the clinical testing of Multikine and other product candidates, and will face an even greater risk if CEL-SCI is able to commercialize any of its product candidates. For example, CEL-SCI may be sued if its Multikine or LEAPS product candidates, or any other future product candidates, allegedly cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing or, if approved, marketing, sale or during administration to patients. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.

Furthermore, Multikine is made, in part, from components of human blood. There are inherent risks associated with products that involve human blood such as possible contamination with viruses, including hepatitis or HIV. Any possible contamination could cause injuries to patients who receive contaminated Multikine, or could require CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI to possible financial losses, lawsuits and harm to its business.

If CEL-SCI cannot successfully defend itself against product liability claims, CEL-SCI may incur substantial liabilities or be required to limit or cease the clinical testing or commercialization of its product candidates, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

	·	decreased demand for Multikine or other product candidates, if approved and commercialized, or clinical holds or suspension of the IND while the candidates are still in clinical development;

	·	injury to CEL-SCI’s reputation;

	·	withdrawal of existing, or failure to enroll additional, clinical trial participants;

	·	costs to defend any related litigation;

	·	a diversion of management’s time and resources;

	·	substantial monetary awards to trial participants or patients;

	·	recalls of approved products, withdrawal of BLA approvals or new labeling, marketing or promotional restrictions;

	·	loss of revenue;

	·	inability to commercialize Multikine or other product candidates; and

a decline in the price of CEL-SCI’s common stock.

Although CEL-SCI has product liability insurance for Multikine in the amount of $10 million, the successful prosecution of a product liability case against CEL-SCI could have a materially adverse effect upon its business if the amount of any judgment exceeds the insurance coverage. Any claim that may be brought against CEL-SCI could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by CEL-SCI’s insurance or that is in excess of the limits of the insurance coverage. CEL-SCI’s insurance policies also have various exclusions, and CEL-SCI may be subject to a claim for which CEL-SCI has no coverage. CEL-SCI may have to pay any amounts awarded by a court or negotiated in a settlement that exceed the coverage limitations or that are not covered by its insurance, and CEL-SCI may not have, or be able to obtain, sufficient capital to pay such amounts. CEL-SCI commenced the Phase 3 clinical trial for Multikine in December 2010. Although no claims have been brought to date, participants in the clinical trials could bring civil actions against CEL-SCI for any unanticipated harmful effects allegedly arising from the use of Multikine or any other product candidate that CEL-SCI may attempt to develop.

Even if CEL-SCI obtains regulatory approval for its product candidates, any resulting product may not gain market acceptance among physicians, healthcare payors, patients and the medical community, which are critical to commercial success. Market acceptance of any product candidate for which CEL-SCI receives approval depends on a number of factors, including:

	·	the efficacy and safety of the products as demonstrated in clinical trials;

	·	the timing of market introduction of such product as well as competitive products;

	·	the clinical indications for which the biological product is approved;

	·	the approval, availability, market acceptance and reimbursement for the companion diagnostic, if appropriate or necessary;

	·	acceptance by physicians, major operators of cancer clinics and patients of the biologic as a safe and effective treatment;

	·	the potential and perceived advantages of such product candidate over alternative treatments, especially with respect to patient subsets that are targeted with such product;

	·	the safety of such product seen in a broader patient group, including its use outside the approved indications;

	·	the cost of treatment in relation to alternative treatments;

	·	the availability of adequate reimbursement and pricing by third-party payors and government authorities;

	·	relative convenience and ease of administration;

	·	the prevalence and severity of adverse side effects; and

	·	the effectiveness of sales and marketing efforts.

If CEL-SCI’s product candidates are approved, but fail to achieve an adequate level of acceptance by physicians, healthcare payors and patients, CEL-SCI will not be able to generate significant revenues, and CEL-SCI may not become or remain profitable.

Under CEL-SCI’s amended bylaws, stockholders that initiate certain proceedings may be obligated to reimburse CEL-SCI and its officers and directors for all fees, costs and expenses incurred in connection with such proceedings if the claim proves unsuccessful.

On February 18, 2015, CEL-SCI adopted new bylaws which include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event any stockholder initiates or asserts a claim against CEL-SCI, or any of its officers or directors, including any derivative claim or claim purportedly filed on CEL-SCI’s behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse CEL-SCI and any of its officers or directors named in the action, for all fees, costs and expenses of every kind and description that CEL-SCI or its officers or directors may incur in connection with the claim. In adopting Article X, it is the intent that:

	·	all actions, including federal securities law claims, would be subject to Article X;

	·	the phrase “a judgment on the merits” means the determination by a court of competent jurisdiction on the matters submitted to the court;

	·	the phrase “substantially achieves, in both substance and amount” means the plaintiffs in the action would be awarded at least 90% of the relief sought;

	·	only persons who were stockholders at the time an action was brought would be subject to Article X; and

	·	only the directors or officers named in the action would be allowed to recover.

The fee-shifting provision contained in Article X of the bylaws is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. Fee-shifting bylaws are relatively new and untested. The case law and potential legislative action on fee-shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether the ability to invoke the fee-shifting bylaw in connection with claims under the federal securities laws would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a claiming stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of the fee-shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. CEL-SCI cannot assure its shareholders that CEL-SCI will or will not invoke the fee-shifting bylaw in any particular dispute. In addition, given the unsettled state of the law related to fee-shifting bylaws, such as CEL-SCI’s, CEL-SCI may incur significant additional costs associated with resolving disputes with respect to such bylaw, which could adversely affect CEL-SCI’s business and financial condition.

If a stockholder that brings any such claim, suit, action or proceeding is unable to obtain the required judgment, the attorneys’ fees and other litigation expenses that might be shifted to a claiming stockholder are potentially significant. This fee-shifting bylaw may therefore dissuade or discourage stockholders and their attorneys from initiating lawsuits or claims against CEL-SCI or its directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs’ attorneys to represent the stockholders or otherwise discourage plaintiffs’ attorneys from representing the stockholders at all. As a result, this bylaw may limit the ability of stockholders to alter CEL-SCI’s management and direction, particularly through litigation or the threat of litigation.

The provision of the amended bylaws requiring exclusive venue in the U.S. District Court for Delaware for certain types of lawsuits may have the effect of discouraging lawsuits against CEL-SCI and its directors and officers.

Article X of CEL-SCI’s amended bylaws provides that stockholder claims brought against CEL-SCI, or its officers or directors, including any derivative claim or claim purportedly filed on its behalf, must be brought in the U.S. District Court for the district of Delaware and that with respect to any such claim, the laws of Delaware will apply.

The exclusive forum provision may limit a stockholder’s ability to bring a claim in a judicial forum the stockholder finds favorable for disputes with CEL-SCI or its directors or officers, and may have the effect of discouraging lawsuits with respect to claims that may benefit CEL-SCI or its stockholders.

A provision in our Bylaws regarding shareholder claims may not be enforceable.

Article X of our bylaws provides that stockholder claims brought against us, or our officers or directors, including any derivative claim or claim purportedly filed on our behalf, must be brought in the U.S. District Court for the district of Delaware.

Although it is our intent that this provision applies to actions arising under the Securities Act of 1933 and the Securities Exchange Act of 1934 there is uncertainty as to whether a court would enforce this provision since Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations under the Securities Act.

In addition, since this provision in our bylaws applies to state law claims there is uncertainty as to whether any court would enforce this provision.

Risks Related to Clinical Development, Government Approvals and the Marketing of Biopharmaceutical Products

CEL-SCI depends heavily on the success of Multikine, for which top line Phase 3 data has been announced, while our other candidates are still in preclinical phases. CEL-SCI’s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI’s business will be materially harmed.

CEL-SCI currently has no products approved for sale and CEL-SCI cannot guarantee that it will ever have marketable products. CEL-SCI’s product candidates are subject to premarket approval from the FDA in the United States, the EMA in the European Union, and by comparable agencies in most foreign countries before they can be sold. Before obtaining marketing approval, these product candidates must undergo costly and time consuming preclinical and clinical testing which could subject CEL-SCI to unanticipated delays and may prevent CEL-SCI from marketing the product candidates in the future. There can be no assurance that such approvals will be granted on a timely basis, if at all.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of the product candidates may not be predictive of the results of later-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. CEL-SCI’s current and future clinical trials may not be successful.

CEL-SCI is in the early development stages for the candidates designed using its LEAPS technology and has not yet initiated any clinical studies for any of those product candidates. Clinical trials can be delayed for a variety of reasons, including delays related to:

	·	the availability of financial resources needed to commence and complete the planned trials;

	·	obtaining regulatory approval to commence a trial;

	·	reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

	·	obtaining Institutional Review Board, or IRB, approval at each clinical trial site;

	·	recruiting suitable patients to participate in a trial;

	·	having patients complete a trial or return for post-treatment follow-up;

	·	clinical trial sites deviating from trial protocol or dropping out of a trial;

	·	adding new clinical trial sites; or

	·	manufacturing sufficient quantities of the product candidate for use in clinical trials.

Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the competence of the CRO running the study, size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications CEL-SCI is investigating. Furthermore, CEL-SCI relies on CROs and clinical trial sites to ensure the proper and timely conduct of the clinical trials and while CEL-SCI has agreements governing their committed activities, CEL-SCI has limited influence over their actual performance.

CEL-SCI could also encounter significant delays and/or need to terminate a development program for a product candidate if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of the product candidates while existing treatments have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by CEL-SCI, one or more of the IRBs for the institutions in which such trials are being conducted, by CEL-SCI upon a final recommendation by the Independent Data Monitoring Committee, or IDMC, with which CEL-SCI agrees for such trial, or by FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or the clinical protocols, as a result of inspection of the clinical trial operations or trial site(s) by FDA or other regulatory authorities, the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. The occurrence of any one or more of these events would have significant and severe material consequences for CEL-SCI and could impact CEL-SCI’s ability to continue as a going concern.

If CEL-SCI experiences termination of, or delays in the completion of, any clinical trial of its product candidates, the commercial prospects for the product candidates will be harmed, and the ability to generate product revenues will be delayed. In addition, any delays in completing the clinical trials will increase the costs, slow the product development and approval process and jeopardize the ability to commence product sales and generate revenues. Any of these occurrences may harm CEL-SCI’s business, prospects, financial condition and results of operations significantly. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to a delay or the denial of regulatory approval for the product candidates.

CEL-SCI cannot be certain when or under what conditions it will undertake future clinical trials. Early trials for the other product candidates, or the plans for later trials, may not satisfy the requirements of regulatory authorities, such as the FDA. CEL-SCI may fail to find subjects willing to enroll in the trials. Accordingly, the clinical trials relating to the product candidates may not be completed on schedule, the FDA or foreign regulatory agencies may order CEL-SCI to stop or modify research, or these agencies may not ultimately approve any of the product candidates for commercial sale. Varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of the product candidates. The data collected from the clinical trials may not be sufficient to support regulatory approval of the various product candidates, including Multikine. The failure to adequately demonstrate the safety and efficacy of any of the product candidates would delay or prevent regulatory approval of the product candidates in the United States, which could prevent CEL-SCI from achieving profitability.

The development and testing of product candidates and the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, termination of the Phase 3 study, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, and payment of civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on CEL-SCI.

The requirements governing the conduct of clinical trials, manufacturing and marketing of the product candidates, including Multikine, outside the United States vary from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional testing and different trial designs. Foreign regulatory approval processes include all of the risks associated with the FDA approval process. Some of those agencies also must approve prices for products approved for marketing. Approval of a product by the FDA or the EMA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory requirements for product approval in any country during the clinical trial process and regulatory agency review of each submitted new application may cause delays or rejections.

CEL-SCI has only limited experience in filing and pursuing applications necessary to gain regulatory approvals. The lack of experience may impede its ability to obtain timely approvals from regulatory agencies, if at all. CEL-SCI will not be able to commercialize Multikine and other product candidates until CEL-SCI has obtained regulatory approval. In addition, regulatory authorities may also limit the types of patients to which CEL-SCI or its third-party partners may market Multikine (if approved) or the other product candidates. Any failure to obtain or any delay in obtaining required regulatory approvals may adversely affect CEL-SCI’s or its third-party partners’ ability to successfully market the product candidates after they are approved.

Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.

If CEL-SCI’s investigational products receive regulatory approval, either in the United States or internationally, those products will be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, and may contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance of the safety and efficacy of the investigational products. CEL-SCI will continue to be subject to extensive regulatory requirements. These regulations are wide-ranging and govern, among other things:

	·	product design, development and manufacture;

	·	product application and use

	·	adverse drug experience monitoring reporting;

	·	product advertising and promotion;

	·	product manufacturing, including compliance with good manufacturing practices

	·	record keeping requirements;

	·	registration and listing of products with the FDA, EMA and other state and national agencies;

	·	product storage and shipping;

	·	drug sampling and distribution requirements;

	·	electronic record and signature requirements; and

	·	labeling changes or modifications.

CEL-SCI and any of its third-party manufacturers or suppliers must continually adhere to federal regulations setting forth human drug and biologic manufacturing requirements, known as current Good Manufacturing Practices, or cGMPs, and their foreign equivalents, which are enforced by the FDA, the EMA and other national regulatory bodies through their facilities inspection programs. If the facilities, or the facilities of the contract manufacturers or suppliers, cannot pass a pre-approval inspection by regulators or fail such inspections in the future, the FDA, EMA or other national regulators will not approve the marketing applications for the product candidates, or may withdraw any prior approval. In complying with cGMP and foreign regulatory requirements, CEL-SCI and any of its potential third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that the product candidates meet applicable specifications and other requirements.

If CEL-SCI does not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, CEL-SCI may be subject to, among other things, license suspension or revocation, criminal prosecution, seizure, injunction, fines, be forced to remove a product from the market or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval for such products or for other product candidates for which CEL-SCI seeks approval. This could materially harm CEL-SCI’s financial results, reputation and stock price. Additionally, CEL-SCI may not be able to obtain the labeling claims necessary or desirable for product promotion. If CEL-SCI or other parties identify adverse effects after any of the products are on the market, or if manufacturing problems occur, regulatory approval may be suspended or withdrawn. CEL-SCI may be required to reformulate products, conduct additional clinical trials, make changes in product labeling or indications of use, or submit additional marketing applications to support any changes. If CEL-SCI encounters any of the foregoing problems, its business and results of operations will be harmed and the market price of its common stock may decline.

The FDA and other governmental authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI’s product candidates. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects and ability to achieve or sustain profitability. CEL-SCI cannot predict the extent of adverse government regulations which might arise from future legislative or administrative action. Without government approval, CEL-SCI will be unable to sell any of its product candidates.

Undesirable side effects caused by its product candidates could cause CEL-SCI or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of the clinical trials could reveal a high and unacceptable severity and/or prevalence of these or other side effects. In such an event, the trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order CEL-SCI to cease further development of, or deny approval of, the product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm CEL-SCI’s business, financial condition and prospects significantly.

Additionally, if one or more of the product candidates receives marketing approval, and CEL-SCI or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to the following:

	·	regulatory authorities may withdraw approvals of such product or require product recalls;

	·	regulatory authorities may require additional warnings on the label or impose restrictions on product distribution or use;

	·	regulatory authorities may require CEL-SCI to conduct new post-marketing studies or clinical trials;

	·	CEL-SCI could receive warning or untitled letters from the FDA or comparable notices of violations from foreign regulatory authorities;

	·	CEL-SCI may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

	·	CEL-SCI could be sued and held liable for harm caused to patients; and

	·	CEL-SCI’s reputation may suffer.

Any of these events could prevent CEL-SCI from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm its business, results of operations and prospects.

CEL-SCI relies on third parties to conduct its preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties and meet regulatory requirements, or meet expected deadlines, CEL-SCI may not be able to obtain regulatory approval for or commercialize the product candidates and its business could be substantially harmed.

CEL-SCI does not have the ability to independently conduct large clinical trials. CEL-SCI has relied upon and plans to continue to rely upon third-party CROs to prepare for, conduct, monitor and manage data for its ongoing preclinical and clinical programs, including the global Phase 3 trial for Multikine. CEL-SCI relies on these parties for all aspects of the execution of its clinical trials and although CEL-SCI diligently oversees and carefully manages the CROs, CEL-SCI directly controls only certain aspects of their activities and relies upon them to provide timely, complete, and accurate reports on the conduct of the studies. Although such third parties provide support and represent CEL-SCI for regulatory purposes in the context of the clinical trials, ultimately CEL-SCI is responsible for ensuring that each of the studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and the reliance on the CROs does not relieve CEL-SCI of its regulatory responsibilities. CEL-SCI and the CROs acting on CEL-SCI’s behalf, as well as principal investigators and trial sites, are required to comply with Good Clinical Practice, or GCP, and other applicable requirements, which are implemented through regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of the products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If CEL-SCI or any of the CROs fail to comply with applicable GCPs or other applicable regulations, the clinical data generated in the clinical trials may be determined to be unreliable and CEL-SCI may therefore need to enroll additional subjects in the clinical trials, or the FDA, EMA or comparable foreign regulatory authorities may require CEL-SCI to perform an additional clinical trial or trials before approving the marketing applications. Moreover, if CEL-SCI or any of the CROs, principal investigators, or trial sites, fail to comply with applicable regulatory and GCP requirements, CEL-SCI, the CROs, principal investigators, or trial sites may be subject to enforcement actions, such as fines, warning letters, untitled letters, clinical holds, civil or criminal penalties, and/or injunctions. CEL-SCI cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of the clinical trials comply with cGCP regulations. In addition, the clinical trials must be conducted with product produced under cGMP regulations. The failure to comply with these regulations may require CEL-SCI to delay or repeat clinical trials, which would delay the regulatory approval process.

If any of the relationships with the third-party CROs terminate, CEL-SCI may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, the CROs are not CEL-SCI’s employees, and except for remedies available to CEL-SCI under the agreements with such CROs, CEL-SCI cannot control whether or not they devote sufficient time and resources to the on-going clinical, nonclinical and preclinical programs. If CROs do not successfully fulfill their regulatory obligations, carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to the clinical protocols, regulatory requirements or for other reasons, the clinical trials may be extended, delayed or terminated, and CEL-SCI may not be able to obtain regulatory approval for, or successfully commercialize, the product candidates. As a result, CEL-SCI’s results of operations and the commercial prospects for the product candidates would be harmed, the costs could increase and the ability to generate revenues could be delayed.

Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact CEL-SCI’s ability to meet the desired clinical development timelines. Though CEL-SCI diligently oversees and carefully manages its relationships with the CROs, there can be no assurance that CEL-SCI will not encounter similar challenges or delays in clinical development in the future or that these delays or challenges will not have a material adverse impact on CEL-SCI’s business, financial condition and prospects.

CEL-SCI has obtained orphan drug designation from the FDA for Multikine for neoadjuvant, or primary, therapy in patients with squamous cell carcinoma of the head and neck, but CEL-SCI may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.

Even though CEL-SCI has received orphan drug designation for Multikine for the treatment of squamous cell carcinoma of the head and neck, CEL-SCI may not be the first to obtain marketing approval of a product for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. CEL-SCI believes this to be unlikely since it does not know of any other company with a similar technology in Phase 3 studies. In addition, exclusive marketing rights in the United States may be limited if CEL-SCI seeks approval for an indication broader than the orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially defective or if CEL-SCI is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if CEL-SCI obtains orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI’s operations.

The successful discovery, development, manufacturing and sale of biological products like CEL-SCI’s candidates is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell its biological product candidates would adversely impact CEL-SCI’s business and future results of operations.

CEL-SCI may face substantial competition, which may result in others discovering, developing or commercializing competing products more quickly or more successfully than CEL-SCI.

The development and commercialization of new drug and biological products is highly competitive. CEL-SCI expects to face competition with respect to any product candidates that CEL-SCI may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

Many of the companies which CEL-SCI may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical studies, conducting clinical trials, obtaining marketing approvals and marketing approved products than CEL-SCI. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of CEL-SCI’s potential competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with CEL-SCI in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, CEL-SCI’s programs.

CEL-SCI may be unable to successfully scale-up manufacturing of its lead product candidate Multikine in sufficient quality and quantity, which would delay or prevent CEL-SCI from commercializing this product, if approved for marketing by the FDA or other regulatory agencies.

In order to commercialize its product candidates, CEL-SCI will need to manufacture them in large quantities. At the present time, CEL-SCI is not manufacturing Multikine while the manufacturing plant for Multikine is being validated to produce commercial quantities of Multikine, if approved. CEL-SCI may be unable to successfully increase the manufacturing capacity for its lead product candidate Multikine in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities.

Further, in order to release product and demonstrate stability of product candidates for future commercial use, CEL-SCI’s analytical methods must be validated in accordance with regulatory guidelines. CEL-SCI may not be able to successfully validate, or maintain validation of its analytical methods during scale-up or demonstrate adequate purity, stability or comparability of its biological product candidates in a timely or cost-effective manner, or at all. Even if CEL-SCI believes its manufacturing processes meets all of the regulatory manufacturing requirements, the FDA will review those processes and the manufacturing facility as part of the review of the future BLA for Multikine, if submitted after completion of the Phase 3 trial in advanced head and neck cancer. If CEL-SCI is unable to successfully scale up the manufacture of Multikine in sufficient quality and quantity, or if CEL-SCI encounters validation issues, the development, testing, and clinical trials of future product candidates, may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product, including Multikine, may be delayed or may not be successfully achieved.

Although CEL-SCI does not currently have any products on the market, if CEL-SCI begins commercializing its product candidates, CEL-SCI will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which CEL-SCI conducts its business. Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which CEL-SCI obtains marketing approval. The current and future arrangements with healthcare professionals, principal investigators, consultants, potential customers and third-party payors may expose CEL-SCI to broadly applicable healthcare laws, including, without limitation:

	·	the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

	·	federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

	·	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

	·	HIPAA, which also imposes obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

	·	the U.S. federal physicians payment transparency requirements, sometimes called the “Sunshine Act” and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report to the Centers for Medicare & Medicaid Services, or CMS, information related to physician payments and “other transfers of value” to physicians and teaching hospitals (and, beginning in 2021, for transfers of value to other healthcare providers), as well as the ownership and investment interests held by physicians and their immediate family members;

	·	analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;

	·	the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and

	·	state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Efforts to ensure that the future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that the business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If CEL-SCI’s operations are found to be in violation of any of these laws or any other governmental regulations, CEL-SCI may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of the operations, all of which could significantly harm CEL-SCI’s business. If any of the physicians or other healthcare providers or entities with whom CEL-SCI expects to do business, including current and future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also adversely affect CEL-SCI’s business.

Failure to obtain or maintain adequate coverage and reimbursement for the product candidates, if approved, could limit the ability to market those products and decrease CEL-SCI’s ability to generate revenue.

Sales of CEL-SCI’s product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of the approved products will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. CEL-SCI anticipates that government authorities and other third-party payors will continue efforts to contain healthcare costs by limiting the coverage and reimbursement levels for new drugs and biologics. If coverage and reimbursement are not available, or are available only to limited levels, CEL-SCI may not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow CEL-SCI to establish or maintain pricing sufficient to realize a return on its investment. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for CEL-SCI’s product candidates.

Moreover, in some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. If reimbursement of its products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI’s business could be harmed, possibly materially.

Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.

If CEL-SCI’s product candidates do not achieve an adequate level of acceptance, CEL-SCI may not generate significant product revenues and CEL-SCI may not become profitable. The degree of market acceptance of its product candidates, including Multikine if approved for commercial sale, will depend on a number of factors, including:

	·	the timing of CEL-SCI’s receipt of any marketing approvals;

	·	the terms of any approvals and the countries in which approvals are obtained;

	·	the efficacy and safety and potential advantages and disadvantages compared to alternative treatments, including future alternative treatments;

	·	the prevalence and severity of any side effects associated with CEL-SCI’s product candidates;

	·	the indications for which its products are approved and the scope of risk information required to be included in the product labeling;

	·	adverse publicity about CEL-SCI’s products or favorable publicity about competing products;

	·	the approval of other products for the same indications as CEL-SCI’s products;

	·	CEL-SCI’s ability to offer its products for sale at competitive prices;

	·	the convenience and ease of administration compared to alternative treatments;

	·	the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

	·	the success of CEL-SCI’s physician education programs;

	·	the strength of CEL-SCI’s marketing and distribution support; and

the availability of third-party coverage and adequate reimbursement.

If any product candidate CEL-SCI commercializes fails to achieve market acceptance, it could have a material and adverse effect on CEL-SCI’s business, financial condition, results of operation and prospects.

CEL-SCI currently has no marketing and sales force. If CEL-SCI is unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market its product candidates, CEL-SCI may not be able to effectively sell or market its product candidates, if approved, or generate product revenues.

CEL-SCI currently has a no sales and marketing infrastructure due to the fact that all of its product candidates are still in clinical development. To achieve commercial success for any approved product candidate for which CEL-SCI retains sales and marketing responsibilities, CEL-SCI must build its sales, marketing, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services. For example, CEL-SCI has entered into agreements with certain foreign distributors to commercialize Multikine, if approved, within their respective territories. However, CEL-SCI may determine that there is a need to building its own sales force in the United States for the future marketing of Multikine, if approved, rather than seeking a U.S. co-marketing partner or relying on a contracted sales force. There are risks involved with either establishing its own sales and marketing capabilities or entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which CEL-SCI recruits a sales force and establishes marketing capabilities is delayed or does not occur for any reason, CEL-SCI would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and its investment would be lost if CEL-SCI cannot retain or reposition its sales and marketing personnel.

Factors that may inhibit CEL-SCI’s efforts to commercialize its product candidates on its own include:

	·	CEL-SCI’s inability to recruit, hire, retain and incentivize adequate numbers of effective sales and marketing personnel;

	·	the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use and administer CEL-SCI’s future products;

	·	the lack of complementary products to be offered by sales personnel, which may put CEL-SCI at a competitive disadvantage relative to companies with more extensive product lines; and

	·	unforeseen costs and expenses associated with establishing an independent sales and marketing organization.

If CEL-SCI does not establish sales and marketing capabilities successfully, either on its own or in collaboration with third parties, CEL-SCI will not be successful in commercializing Multikine, if approved, or any of its other product candidates that receive marketing approval or any such commercialization may experience delays or limitations.

CEL-SCI’s business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which CEL-SCI operates or will operate in the future.

CEL-SCI has conducted and has ongoing studies in international locations, and may in the future initiate additional studies in countries other than the United States. Moreover, CEL-SCI has entered into agreements with foreign distributors to commercialize Multikine, if approved, in various territories outside of the United States. As a result, CEL-SCI’s business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which CEL-SCI operates. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.

CEL-SCI’s business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe biopharmaceuticals are employed by their government, and the purchasers of biopharmaceuticals are government entities; therefore, CEL-SCI’s dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of CEL-SCI’s employees, agents or contractors conducting business abroad will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against CEL-SCI, its officers or employees, the closing of CEL-SCI’s facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of CEL-SCI’s business. Any such violations could include prohibitions on CEL-SCI’s ability to offer its product candidates, if approved, in one or more countries and could materially damage its reputation, its brand, its future international marketing efforts, its ability to attract and retain employees and its business, prospects, operating results and financial condition.

Healthcare legislative reform measures may have a material adverse effect on CEL-SCI’s business and results of operations.

Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI’s product candidates. CEL-SCI cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs that may result in more limited coverage or downward pressure on the price CEL-SCI may otherwise receive for its product candidates. For example, in March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under federal healthcare programs. The ACA contains a number of provisions that affect coverage and reimbursement of drug and biological products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminates the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. In a May 2018 report, the Congressional Budget Office estimated that, compared to 2018, the number of uninsured will increase by 3 million in 2019 and 6 million in 2028, in part due to the elimination of the individual mandate. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. Pending appeals, which could take some time, the ACA is still operational in all respects.

CEL-SCI’s industry continues to face potential changes in the legal and regulatory landscape on the federal, state and international levels. Additional legislative actions to control U.S. healthcare or other costs have passed. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2027 unless additional Congressional action is taken. There has also been increasing and considerable public and government interest in the United States with respect to specialty drug pricing practices, including proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, put in place limits and caps on pharmaceutical prices, request rebates for certain pharmaceutical products, and reform government program reimbursement methodologies for drugs. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what biopharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and control the prices of medicinal products for human use.

CEL-SCI expects that current or future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product, including Multikine if it is approved for commercialization. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent CEL-SCI from being able to generate revenue, attain profitability or commercialize its product candidates.

Legislative and regulatory proposals also have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. CEL-SCI cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations for biological products will be changed, or what the impact of such changes on the marketing approvals of its product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval and decision-making processes may significantly delay or prevent marketing approval, as well as subject CEL-SCI to more stringent product labeling and post-marketing testing and other requirements.

Foreign governments often impose strict price controls, which may adversely affect CEL-SCI’s future profitability.

CEL-SCI intends to seek approval to market its lead investigational product, Multikine, in both the United States and foreign jurisdictions. If CEL-SCI obtains approval in one or more foreign jurisdictions, CEL-SCI will be subject to rules and regulations in those jurisdictions relating to Multikine. In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug candidate. Coverage and reimbursement decisions in one foreign jurisdiction may impact decisions in other countries. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct clinical trials that demonstrate the product candidate is more effective than current treatments and that compare the cost-effectiveness of Multikine to other available therapies. If reimbursement of Multikine is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI may be unable to achieve or sustain profitability.

If CEL-SCI fails to comply with environmental, health and safety laws and regulations, CEL-SCI could become subject to fines or penalties or incur costs that could harm its business.

CEL-SCI is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes generated in its biologic manufacturing facility. CEL-SCI cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, including radioactive materials used in its research laboratory, CEL-SCI could be held liable for any resulting damages, and the amount of the liability could exceed its resources. CEL-SCI also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.

Risks Related to Intellectual Property

CEL-SCI may not be able to achieve or maintain a competitive position, and other technological developments may result in its proprietary technologies becoming uneconomical or obsolete.

CEL-SCI is involved in a biomedical field that is undergoing rapid and significant technological change. The pace of change continues to accelerate. The successful development of product candidates from the compounds, compositions and processes, through research financed by CEL-SCI, or as a result of possible third-party licensing arrangements with pharmaceutical or other companies, is not assured. CEL-SCI may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all.

Many companies are working on drugs designed to cure or treat cancer. Many of these companies have financial, research and development, and marketing resources, which are much greater than CEL-SCI’s, and are capable of providing significant long-term competition either by establishing in-house research groups or by forming collaborative ventures with other entities. In addition, smaller companies and non-profit institutions are active in research relating to cancer and infectious diseases. The future market share of Multikine or the other product candidates, if approved, will be reduced or eliminated if the competitors develop and obtain approval for products that are safer or more effective than CEL-SCI’S product candidates. Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are often evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, CEL-SCI does not know whether:

	·	CEL-SCI was the first to make the inventions covered by each of its issued patents and pending patent applications;

	·	CEL-SCI was the first to file patent applications for these inventions;

	·	others will independently develop similar or alternative technologies or duplicate any of CEL-SCI’s technologies;

	·	any of the pending patent applications will result in issued patents;

	·	any of the patents will be valid or enforceable;

	·	any patents issued to CEL-SCI or its collaboration partners will provide CEL-SCI with any competitive advantages, or will be challenged by third parties;

	·	CEL-SCI will be able to develop additional proprietary technologies that are patentable;

	·	the U.S. government will exercise any of its statutory rights to CEL-SCI’s intellectual property that was developed with government funding; or

	·	its business may infringe the patents or other proprietary rights of others.

CEL-SCI’s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.

CEL-SCI’s commercial success will depend in part on its ability to obtain additional patents and protect its existing patent position, as well as its ability to maintain adequate intellectual property protection for the technologies, product candidates, and any future products in the United States and other countries. If CEL-SCI does not adequately protect its technology, product candidates and future products, competitors may be able to use or practice them and erode or negate any competitive advantage CEL-SCI may have, which could harm CEL-SCI’s business and its ability to achieve profitability. The laws of some foreign countries do not protect the proprietary rights to the same extent or in the same manner as U.S. laws, and CEL-SCI may encounter significant problems in protecting and defending its proprietary rights in these countries. CEL-SCI will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that its proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.

Certain aspects of CEL-SCI’s technologies are covered by U.S. and foreign patents. In addition, CEL-SCI has a number of new patent applications pending. There is no assurance that the applications which are pending or which may be filed in the future will result in the issuance of any patents. Furthermore, there is no assurance as to the breadth and degree of protection any issued patents might afford CEL-SCI. Disputes may arise between CEL-SCI and others as to the scope and validity of these or other patents. Any defense of the patents could prove costly and time consuming and there can be no assurance that CEL-SCI will be in a position, or will deem it advisable, to carry on such a defense. A suit for patent infringement could result in increasing costs, delaying or halting development, or even forcing CEL-SCI to abandon a product candidate. Other private and public concerns, including universities, may have filed applications for, may have been issued, or may obtain additional patents and other proprietary rights to technology potentially useful or necessary to CEL-SCI. CEL-SCI is not currently aware of any such patents, but the scope and validity of such patents, if any, and the cost and availability of such rights are impossible to predict.

Much of CEL-SCI’s intellectual property is protected as trade secrets or confidential know-how, not as a patent.

CEL-SCI considers proprietary trade secrets and/or confidential and unpatented know-how to be important to its business. Much of the intellectual property pertains to CEL-SCI’s manufacturing methodologies, certain aspects of which may not be suitable for patent filings and must be protected as trade secrets and/or confidential know-how. This type of information must be protected diligently by CEL-SCI to protect its disclosure to competitors, since legal protections after disclosure may be minimal or non-existent. Accordingly, much of the value of this intellectual property is dependent upon the ability of CEL-SCI to keep its trade secrets and know-how confidential.

To protect this type of information against disclosure or appropriation by competitors, CEL-SCI’s policy is to require its employees, consultants, contractors and advisors to enter into confidentiality agreements with CEL-SCI. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose the confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.

In addition, in some cases a regulator considering the application for product candidate approval may require the disclosure of some or all of the proprietary information. In such a case, CEL-SCI must decide whether to disclose the information or forego approval in a particular country. If CEL-SCI is unable to market its product candidates in key countries, CEL-SCI’s opportunities and value may suffer.

Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect CEL-SCI’S competitive position. Moreover, competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, competitors could limit the use of such trade secrets and/or confidential know-how.

CEL-SCI may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.

CEL-SCI may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in its patents or other intellectual property. CEL-SCI may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing the product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If CEL-SCI fails in defending any such claims, in addition to paying monetary damages, CEL-SCI may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on its business. Even if CEL-SCI is successful in defending against such claims, litigation could result in substantial costs and be a distraction to CEL-SCI’s management and employees.

Risks Related to CEL-SCI’s common stock

Future equity offerings or other equity issuances may result in dilution to existing shareholders.

CEL-SCI expects that significant additional capital will be needed in the future to continue its planned operations. To raise additional capital, CEL-SCI may in the future offer additional shares of its common stock or other securities convertible into or exchangeable for its common stock. To the extent CEL-SCI raises additional capital by issuing equity securities, CEL-SCI’s stockholders may experience substantial dilution and new investors could gain rights superior to existing stockholders.

The exercise of outstanding warrants and options will cause dilution.

As of September 30, 2021, there were outstanding warrants which allow the holders to purchase 1,621,667 shares of common stock, with a weighted average exercise price of $4.88 per share, and outstanding options which allow the holders to purchase up to 11,049,709 shares of common stock, with a weighted average exercise price of $10.08 per share. The exercise of these outstanding warrants and options will cause dilution to holders of our common stock.

Since CEL-SCI does not intend to pay dividends on its common stock, any potential return to investors will result only from any increases in the price of its common stock.

At the present time, CEL-SCI intends to use available funds to finance its operations. Accordingly, while payment of dividends rests within the discretion of its board of directors, no common stock dividends have been declared or paid by CEL-SCI and CEL-SCI has no intention of paying any common stock dividends in the foreseeable future. Additionally, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on CEL-SCI’s common stock. Any return to CEL-SCI’s shareholders will therefore be limited to appreciation in the price of its common stock, which may never occur. If CEL-SCI’s stock price does not increase, CEL-SCI’S shareholders are unlikely to receive any return on their investments in CEL-SCI’s common stock.

The price of CEL-SCI’s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI’s shareholders.

CEL-SCI’s stock price has been, and is likely to continue to be, volatile. As a result of this volatility, CEL-SCI’s shareholders may not be able to sell their shares at or above its current market price. The market price for CEL-SCI’s common stock may be influenced by many factors, including:

	·	actual or anticipated fluctuations in CEL-SCI’s financial condition and operating results;

	·	actual or anticipated changes in CEL-SCI’s growth rate relative to competitors;

	·	competition from existing products or new products or product candidates that may emerge;

	·	development of new technologies that may make CEL-SCI’s technology less attractive;

	·	changes in physician, hospital or healthcare provider practices that may make CEL-SCI’s product candidates less useful;

	·	announcements by CEL-SCI, its partners or competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;

	·	developments or disputes concerning patent applications, issued patents or other proprietary rights;

	·	the recruitment or departure of key personnel;

	·	failure to meet or exceed financial estimates and projections of the investment community;

	·	actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

	·	variations in its financial results or those of companies that are perceived to be similar to CEL-SCI;

	·	changes to coverage and reimbursement levels by commercial third-party payors and government payors, including Medicare, and any announcements relating to reimbursement levels;

	·	general economic, industry and market conditions; and

	·	the other factors described in this “Risk Factors” section.

ITEM 1B. UNRESOLVED SEC COMMENTS

None

ITEM 2. PROPERTIES

CEL-SCI leases office space at 8229 Boone Blvd., Suite 802, Vienna, Virginia at a monthly rental of approximately $8,000. The lease on the office space expires on November 30, 2025. CEL-SCI believes this arrangement is adequate for the conduct of its present business.

CEL-SCI has a 17,900 square foot laboratory located in Baltimore, Maryland. The laboratory is leased by CEL-SCI at a cost of approximately $20,000 per month. During the period ended September 30, 2021, the laboratory lease was extended ten years and expires on February 28, 2032.

In August 2007, CEL-SCI leased a building near Baltimore, Maryland (the San Tomas lease). The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI’s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI’s Phase 3 clinical trial and sales of the drug, if approved by the FDA. The lease expires on October 31, 2028 and required annual base rent payments of approximately $2.2 million during the twelve months ended September 30, 2021. The annual base rent escalates each year at 3% beginning on November 1st. CEL-SCI is also required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities, which were approximately $44,000 per month as of September 30, 2021. The lease allows CEL-SCI, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. In August 2011, CEL-SCI was required to deposit approximately $1.7 million, the equivalent of one year of base rent. The $1.7 million was required to be deposited when the amount of CEL-SCI’s cash balance had dropped below the amount stipulated in the lease and is included in non-current assets at September 30, 2021.

In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred. The Company started repaying these costs on March 1, 2021 through increased lease payments which will continue over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year on the $2.4 million financed. An additional deposit of $240,000 was made at that time and is included in non-current assets at September 30, 2021.

ITEM 3. LEGAL PROCEEDINGS

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. MARKET FOR CEL-SCI'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

As of September 30, 2021, there were approximately 559 record holders of CEL-SCI’s common stock. CEL-SCI’s common stock is traded on the NYSE American under the symbol “CVM”.

Shown below are the range of high and low quotations for CEL-SCI’s common stock for the periods indicated as reported on the NYSE American. The market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions.

Quarter Ending	High		Low
12/31/2019	$	9.74	$	6.00
3/31/2020	$	17.80	$	6.35
6/30/2020	$	18.00	$	9.64
9/30/2020	$	15.10	$	11.29

12/31/2020	$	16.70	$	10.76
3/31/2021	$	40.91	$	11.88
6/30/2021	$	27.86	$	8.20
9/30/2021	$	12.90	$	7.08

Holders of common stock are entitled to receive dividends as may be declared by CEL-SCI’s Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI’s assets after payment of liabilities. CEL-SCI’s Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.

The provisions in CEL-SCI’s Articles of Incorporation relating to CEL-SCI’s preferred stock allow CEL-SCI’s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI’s common stock. The issuance of preferred stock with such rights may make more difficult the removal of management even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.

The market price of CEL-SCI’s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI’s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products which may be developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI’s common stock.

ITEM 6. SELECTED FINANCIAL DATA

CEL-SCI is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Commission and is not required to provide the information required under this item.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the financial statements and the related notes thereto appearing elsewhere in this report.

On June 28, 2021, CEL-SCI announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine^® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.

However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to CEL-SCI becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this CEL-SCI will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

CEL-SCI also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). CEL-SCI is using its LEAPS technology platform to investigate its lead peptide-based immunotherapy (CEL-4000) as a vaccine treatment for rheumatoid arthritis.

All of CEL-SCI’s projects are under development. As a result, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, CEL-SCI has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. CEL-SCI will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as CEL-SCI becomes profitable, any or all of these financing vehicles or others may be utilized to assist CEL-SCI’s capital requirements.

Results of Operations

No grant income was received during the year ended September 30, 2021. Prior year grant income included amounts earned on a Small Business Innovation Research (SBIR) grant, which was not received in the current year. The nature and amount of grants awarded depends on the timing and availability of such funds.

During the year ended September 30, 2021, research and development expenses increased by approximately $5.3 million, or 30%, compared to the year ended September 30, 2020. Major components of this increase include approximately $0.5 million in expenses to prepare for the potential filing of a Biologics License Application (BLA) and commercial manufacture of Multikine, approximately $2.4 million increase in employee stock compensation expense, and an approximate $2.7 million increase in expenses related to the Phase 3 clinical trial. This increase was offset by a net decrease in other miscellaneous research and development expenses of approximately $0.3 million.

During the year ended September 30, 2021, general and administrative expenses increased by approximately $1.4 million, or 12%, compared to the year ended September 30, 2020. A major component of the increase is an approximate $1.1 million increase in employee stock compensation costs, most of which related to the options granted under the 2021 Non-Qualified Stock Option Plan, and an approximately $0.3 million net increase in other general and administrative costs.

During the years ended September 30, 2021 and 2020, CEL-SCI recorded derivative losses of approximately $0.7 million and $0.3 million, respectively. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of CEL-SCI’s common stock.

Other non-operating gain increased by approximately $0.8 million from approximately $0.9 million for the year ended September 30, 2020 to approximately $1.7 million for the year ended September 30, 2021. This gain relates to the Securities Purchase Agreement described in Note 12 to the financial statements included as part of this report. The amount of the gain or loss is a result of the timing of shares issued to Ergomed and the subsequent re-sale of those shares. No shares were issued to Ergomed during the year ended September 30, 2021. During the year ended September 30, 2020, the Company issued 150,000 shares to Ergomed and recorded a non-operating loss equal to the fair value of those shares of approximately $1.8 million. During the years ended September 30, 2021 and 2020, Ergomed received approximately $1.7 million and $2.7 million, respectively, from the resale of these shares.

Net interest expense increased by approximately $0.1 million for the year ended September 30, 2021 compared to the year ended September 30, 2020 primarily due to the amortization of the Company’s lease liabilities.

Research and Development Expenses

CEL-SCI’s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project during the reporting periods.

	Year ended September 30,
	2021		2020
Multikine	$	21,508,026	$	16,146,248
LEAPS		1,600,871		1,694,042
Total research and development	$	23,108,897	$	17,840,290

CEL-SCI’s Phase 3 clinical trial began in December 2010 after the completion and validation of CEL-SCI’s dedicated manufacturing facility. The Phase 3 clinical trial was fully enrolled in September 2016, reached its primary endpoint in April 2020 and achieved database lock in December 2020. The data was unblinded in June 2021, and the primary endpoint results were announced in June 2021. CEL-SCI is currently preparing the BLA to submit to the FDA.

As explained in Item 1 of this report, clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Liquidity and Capital Resources

CEL-SCI has had only limited revenues from operations since its inception in March 1983. CEL-SCI has relied primarily upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, CEL-SCI has utilized short-term loans to meet its capital requirements. Capital raised by CEL-SCI has been used to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system and for clinical trials. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and for CEL-SCI’s laboratory and manufacturing facilities. CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result, CEL-SCI has been dependent primarily upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future. During fiscal year 2021 and 2020, CEL-SCI raised net proceeds of approximately $54.0 million and $25.8 million, respectively, through a combination of the sale of common stock and the exercise of warrants and options.

In August 2007, CEL-SCI leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI’s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI’s Phase III clinical trials and sales of the drug if approved by the FDA. The lease expires on October 31, 2028, and required annual base rent payments of approximately $2.2 million during the twelve months ended September 30, 2021. See Item 2 of this report for more information concerning the terms of this lease.

In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 30-day option to purchase up to an additional 210,000 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in June 2021 resulting in additional net proceeds to the Company of approximately $4.4 million.

In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate net proceeds of approximately $13.6 million.

The following charts list the warrants that were exercised and the proceeds received during the years ended September 30, 2021 and 2020.

Fiscal Year 2021

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series Z		79,200	$	13.75	$	1,089,000
Series ZZ		20,000	$	13.75		275,000
Series AA		100,000	$	13.75		1,375,000
Series CC		132,798	$	5.00		663,990
Series MM		464,201	$	1.86		863,414
Series NN		138,755	$	2.52		349,663
Series RR		165,888	$	1.65		273,715
Series SS		126,064	$	2.09		263,474
Series TT		370,964	$	2.24		830,959
		1,597,870			$	5,984,215

Fiscal Year 2020

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series CC		128,820	$	5.00	$	644,100
Series FF		68,048	$	3.91		265,812
Series HH		6,300	$	3.13		19,687
Series JJ		9,450	$	3.13		29,531
Series LL		26,398	$	3.59		94,867
Series MM		95,858	$	1.86		178,296
Series NN		124,956	$	2.52		314,889
Series OO		50,000	$	2.52		126,000
Series RR		39,467	$	1.65		65,121
Series SS		156,580	$	2.09		327,252
Series TT		188,125	$	2.24		421,400
Series UU		61,207	$	2.80		171,380
Series V		674,164	$	13.75		9,269,755
Series VV		82,500	$	1.75		144,375
		1,711,873			$	12,072,465

CEL-SCI entered into Securities Purchase Agreements (SPAs) with Ergomed plc, one of CEL-SCI’s Clinical Research Organizations responsible for managing the Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, CEL-SCI issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, CEL-SCI expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.

During the year ended September 30, 2021 and 2020, CEL-SCI issued Ergomed 0 and 150,000 shares, respectively.

The following table summarizes the Other Non-operating gains for the years ended September 30 relating to these agreements:

	2021		2020
Amount realized through the resale of shares	$	1,685,379	$	2,652,605
Fair value of shares upon issuance		-		1,769,500
Other non-operating gain (loss)	$	1,685,379	$	883,105

As of September 30, 2021, Ergomed had no shares remaining for resale. As of September 30, 2020, Ergomed held 102,521 shares.

During the year ended September 30, 2021, the Company’s cash increased by approximately $20.6 million after the purchase of $6.1 million of U.S. Treasury bills (T-bills). Net of the purchase of the T-bills, cash increased by approximately $26.7 million. Significant components of the increase include approximately $47.1 million in net proceeds from the sale of common stock through public offerings, approximately $6.7 million in proceeds from the exercise of warrants and options, the receipt of approximately $1.6 million in lease incentives and $0.2 million in sales of stock to employees, offset by net cash used to fund the Company’s operations, including its Phase 3 clinical trial, of approximately $18.8 million, approximately $9.0 million of equipment and leasehold improvement expenditures and approximately $1.1 million in lease payments.

During the year ended September 30, 2021, 1,597,870 warrants were exercised at a weighted average exercise price of $3.75 for total proceeds of approximately $6.0 million.

Prepaid expenses decreased by approximately $0.3 million during the year ended September 30, 2021 as compared to September 30, 2020 primarily due to the timing of payments and recognition of related expenses relating to the Company’s Phase 3 clinical trial status.

Supplies are purchased for use in the Company’s manufacturing and R&D efforts and vary with the study requirements. During the year ended September 30, 2021, the supplies increased by approximately $1.2 million in support of the work on modifications of the manufacturing facility to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA.

Primarily as a result of CEL-SCI’s losses incurred to date, its expected continued future losses, and limited cash balances, CEL-SCI has included a disclosure in its financial statements expressing substantial doubt about its ability to continue as a going concern. CEL-SCI has included this disclosure on numerous occasions in the preceding years.

Future Capital Requirements

CEL-SCI’s material capital commitments include funding operating losses, funding its research and development program and making required lease payments. Additionally, the Company recently completed upgrading the manufacturing facility to prepare for the potential commercial production of Multikine. Total costs of this upgrade are approximately $10.6 million. The landlord of the property agreed to finance the final $2.4 million of costs and allow for the repayment through increased lease payments which began on March 1, 2021. As of September 30, 2021, the landlord had provided approximately $1.6 million of the total funding. Because of the change in lease payments, the new financing arrangement was considered a lease modification. The remaining $0.8 million lease incentive is expected to be realized in quarter ended December 31, 2021.

For information on employment contracts, see Item 11 of this report.

Further, CEL-SCI has contingent obligations with vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be determined at this time. CEL-SCI estimates it will incur additional expenses of approximately $1.1 million for the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug.

CEL-SCI will need to raise additional funds, either through the exercise of outstanding warrants/options, through debt or equity financings or a partnering arrangement, to bring Multikine to market. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. However, it is possible that CEL-SCI will not be able to generate enough cash to continue operations at its current level. CEL-SCI’s management has engaged in fundraising for over 25 years and believes that the manner in which it is proceeding will produce the best possible outcome for the shareholders. There can be no assurances that CEL-SCI will be successful in raising additional funds.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of CEL-SCI’s clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products.

In the absence of revenues, CEL-SCI will be required to raise additional funds through the sale of securities, debt financings or other arrangements in order to continue with its research efforts. However, there can be no assurance that such financing will be available or be available on favorable terms. Ultimately, CEL-SCI must complete the development of its products, obtain appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

Since all of CEL-SCI’s projects are under development, CEL-SCI cannot predict with any certainty the funds required for future research and clinical trials, the timing of future research and development projects, or when it will be able to generate any revenue from the sale of any of its products.

CEL-SCI's cash flow and earnings are subject to fluctuations due to changes in interest rates on its bank accounts, and, to an immaterial extent, foreign currency exchange rates.

Critical Accounting Policies

CEL-SCI's significant accounting policies are more fully described in Note 3 to the financial statements included as part of this report. However, certain accounting policies are particularly important to the portrayal of CEL-SCI’s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate.

Management believes that the following critical accounting policies require the most significant judgments and estimates with respect to the preparation of CEL-SCI’s financial statements.

Lease Accounting -The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incrernental borrowing rate, which involves complex judgment by management. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting policy. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts.

Share-based Compensation– Share-based compensation cost to employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.

In October 2019, the Company adopted ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. Adoption of the new guidance had no impact on the financial statements and related disclosures.

Derivative Instruments—CEL-SCI enters into financing arrangements that consist of freestanding derivative instruments or hybrid instruments that contain embedded derivative features. CEL-SCI accounts for these arrangements in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities, as well as related interpretations of these standards. In accordance with accounting principles generally accepted in the United States (“GAAP”), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the statement of financial position and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. Fair value is generally calculated using a Black-Scholes valuation model. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and recognized at fair value with changes in fair value recognized as either a gain or loss in earnings if they can be reliably measured. When the fair value of embedded derivative features cannot be reliably measured, CEL-SCI measures and reports the entire hybrid instrument at fair value with changes in fair value recognized as either a gain or loss in earnings.

ITEM 7A. Quantitative and Qualitative Disclosure About Market Risks

Not applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See the financial statements included with this report.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of CEL-SCI’s management, including CEL-SCI’s Chief Executive Officer and Chief Financial Officer, CEL-SCI carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of September 30, 2021. CEL-SCI maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to CEL-SCI’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. CEL-SCI’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.

CEL-SCI’s Chief Executive and Principal Financial Officer has concluded that CEL-SCI’s disclosure controls were effective as of September 30, 2021.

Management’s Report on Internal Control over Financial Reporting

CEL-SCI’s management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of CEL-SCI’s principal executive officer and principal financial officer and implemented by CEL-SCI’s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of CEL-SCI’s financial statements in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including CEL-SCI’s Chief Executive and Principal Financial Officer, CEL-SCI evaluated the effectiveness of its internal control over financial reporting as of September 30, 2021 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO Framework. Management’s assessment included an evaluation of the design of CEL-SCI’s internal control over financial reporting and testing of the operational effectiveness of those controls. CEL-SCI's Chief Executive and Financial Officer concluded that as of such date, CEL-SCI's internal controls over financial reporting were effective.

Changes in Internal Control over Financial Reporting

During the fiscal year ended September 30, 2021, CEL-SCI implemented additional controls over financial reporting which include a thorough review of all leases and relevant accounting guidance such that the accounting for any leases complies with U.S. generally accepted accounting principles.

No other changes in CEL-SCI’s internal control over financial reporting occurred during the fiscal year ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, CEL-SCI’s internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Officers and Directors

Name	Age	Position
Geert R. Kersten, Esq.	62	Director, Chief Executive and Financial Officer and Treasurer
Patricia B. Prichep	70	Senior Vice President of Operations and Corporate Secretary
Dr. Eyal Talor	65	Chief Scientific Officer
Dr. Daniel H. Zimmerman	80	Senior Vice President of Research, Cellular Immunology
John Cipriano	79	Senior Vice President of Regulatory Affairs
Dr. Peter R. Young	76	Director
Bruno Baillavoine	69	Director
Robert Watson	64	Director

The directors of CEL-SCI serve in such capacity until the next annual meeting of CEL-SCI's shareholders or until their successors have been duly elected and qualified. The officers of CEL-SCI serve at the discretion of CEL-SCI's directors.

All of CEL-SCI’s directors have served as directors for a significant period of time. Consequently, their long-standing experience with CEL-SCI benefits both CEL-SCI and its shareholders.

The principal occupations of CEL-SCI's officers and directors, during the past several years, are as follows:

Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.

Patricia B. Prichep joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep became CEL-SCI's Corporate Secretary in May 2000. She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI’s independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD’s Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.

Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine’s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (‘Adapt’) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.

Daniel H. Zimmerman, Ph.D. was CEL-SCI's Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.

John Cipriano was CEL-SCI’s Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. Mr. Cipriano brings to CEL-SCI over 30 years of experience with both biotech and pharmaceutical companies. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.

Peter R. Young, Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis. Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex®. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor's degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants.

Bruno Baillavoine joined CEL-SCI’s board of directors in June 2015. Since 2017 Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris based leading French consulting firm, Pericles Consulting Holdings SAS. Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 350 institutional clients. He has also been an advisor to the Board of CSL Inc, Combatives Sports League a US Mixed Martial Arts company since 2017 and was appointed to the Board in 2019. Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects from concept through final operations. From 2012-2016 Mr. Baillavoine was the Executive Chairman of Globomass Holdings. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), an FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division. In this capacity, he developed plans for Grand Met’s trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The £2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company. Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976).

Robert Watson has been a director of CEL-SCI since December 2017. Mr. Watson has been the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) since July 2017. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 35 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold four companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University.

All of CEL-SCI's officers devote substantially all of their time to CEL-SCI's business.

CEL-SCI’s Board of Directors does not have a “leadership structure”, as such, since each director is entitled to introduce resolutions to be considered by the Board and each director is entitled to one vote on any resolution considered by the Board. CEL-SCI’s Chief Executive Officer is not the Chairman of CEL-SCI’s Board of Directors.

CEL-SCI’s Board of Directors has the ultimate responsibility to evaluate and respond to risks facing CEL-SCI. CEL-SCI’s Board of Directors fulfills its obligations in this regard by meeting on a regular basis and communicating, when necessary, with CEL-SCI’s officers.

Dr. Peter R. Young, Bruno Baillavoine and Robert Watson are independent directors as that term is defined in section 803 of the listing standards of the NYSE American.

CEL-SCI has adopted a Code of Ethics which is applicable to CEL-SCI’S principal executive, financial, and accounting officers and persons performing similar functions. The Code of Ethics is available on CEL-SCI’s website, located at www.cel-sci.com.

If a violation of this code of ethics act is discovered or suspected, any person (anonymously, if desired) may send a detailed note, with relevant documents, to CEL-SCI’s Audit Committee, c/o Dr. Peter Young, 208 Hewitt Drive, Suite 103-143, Waco, TX 76712.

For purposes of electing directors at its annual meeting, CEL-SCI has a nominating committee that is made up of CEL-SCI’s independent directors. The nominating committee selects the nominees to the Board of Directors which are subject to election by CEL-SCI’s shareholders.

CEL-SCI does not have any policy regarding the consideration of director candidates recommended by shareholders and under Colorado law, any shareholder can nominate a person for election as a director at the annual shareholders’ meeting. However, CEL-SCI’s Board of Directors will consider candidates recommended by shareholders. To submit a candidate for the Board of Directors the shareholder should send the name, address and telephone number of the candidate, together with any relevant background or biographical information, to CEL-SCI’s Chief Executive Officer, at the address shown on the cover page of this report. The Board has not established any specific qualifications or skills a nominee must meet to serve as a director. Although the Board does not have any process for identifying and evaluating director nominees, the Board does not believe there would be any differences in the manner in which the Board evaluates nominees submitted by shareholders as opposed to nominees submitted by any other person.

CEL-SCI does not have a policy with regard to Board member’s attendance at annual meetings. All Board members attended the last annual shareholder’s meeting held on July 1, 2021.

Holders of CEL-SCI’s common stock can send written communications to CEL-SCI’s entire Board of Directors, or to one or more Board members, by addressing the communication to “the Board of Directors” or to one or more directors, specifying the director or directors by name, and sending the communication to CEL-SCI’s offices in Vienna, Virginia. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.

A security holder communication not sent to the Board of Directors as a whole is not relayed to Board members which did not receive the communication.

ITEM 11. EXECUTIVE COMPENSATION

Components of Compensation — Executive Officers

CEL-SCI’s executive officers are compensated through the following three components:

	·	Base Salary
	·	Long-Term Incentives (“LTIs”) (stock options and/or grants of stock)
	·	Benefits

These components provide a balanced mix of base compensation and compensation that is contingent upon each executive officer’s individual performance. A goal of the compensation program is to provide executive officers with a reasonable level of security through base salary and benefits. CEL-SCI wants to ensure that the compensation programs are appropriately designed to encourage executive officer retention and motivation to create shareholder value. The Compensation Committee believes that CEL-SCI’s stockholders are best served when CEL-SCI can attract and retain talented executives by providing compensation packages that are competitive but fair.

Base Salaries

Base salaries generally have been targeted to be competitive when compared to the salary levels of persons holding similar positions in other pharmaceutical companies and other publicly traded companies of comparable size. Each executive officer’s respective responsibilities, experience, expertise and individual performance are considered.

A further consideration in establishing compensation for the senior employees is their long term history with CEL-SCI. Taken into consideration are factors that have helped CEL-SCI survive in times when it was financially weak, such as: willingness to accept salary cuts, willingness not to be paid at all for extended time periods, and in general an attitude that helped CEL-SCI survive during financially difficult times.

Long-Term Incentives

Stock grants and option grants help to align the interests of CEL-SCI’s employees with those of its shareholders. Options and stock grants are made under CEL-SCI’s Stock Option, Incentive Stock Bonus, Stock Bonus and Stock Compensation Plans. Options are granted with exercise prices equal to the closing price of CEL-SCI’s common stock on the day immediately preceding the date of grant, with pro rata vesting at the end of each of the following three years.

CEL-SCI believes that grants of equity-based compensation:

	·	Enhance the link between the creation of shareholder value and long-term executive incentive compensation;
	·	Provide focus, motivation and retention incentive; and
	·	Provide competitive levels of total compensation.

Benefits

In addition to cash and equity compensation programs, executive officers participate in the health and welfare benefit programs available to other employees. In a few limited circumstances, CEL-SCI provides other benefits to certain executive officers, such as car allowances.

All executive officers are eligible to participate in CEL-SCI’s 401(k) plan on the same basis as its other employees. CEL-SCI matches 100% of each employee’s contribution up to 6% of his or her salary.

The following table sets forth in summary form the compensation received by (i) the Chief Executive and Financial Officer of CEL-SCI and (ii) by each other executive officer of CEL-SCI who received in excess of $100,000 during the two fiscal years ended September 30, 2021.

Name and Principal Position	Fiscal Year	Salary (1)		Bonus (2)		Stock Awards (3)		Option Awards (4)		All Other Compensation (5)		Total

Geert R. Kersten,	2021		580,017		--		17,325		201,280		55,631		854,253
Chief Executive and Financial Officer and Treasurer	2020		756,102		13,800		17,250		2,492,320		55,631		3,335,103

Patricia B. Prichep,	2021		261,021		--		16,201		97,920		9,031		384,173
Senior Vice President of Operations and Secretary	2020		366,722		7,600		14,800		1,212,480		9,031		1,610,633

Eyal Talor, Ph.D.,	2021		314,833		--		9,600		97,920		6,031		428,384
Chief Scientific Officer	2020		308,250		3,200		9,600		1,212,480		6,031		1,539,561

Daniel Zimmerman, Ph.D.,	2021		242,978		--		14,939		54,400		6,031		318,348
Senior Vice President of Research, Cellular Immunology	2020		239,608		2,900		13,760		673,600		6,031		935,899

John Cipriano,	2021		225,333		--		--		54,400		31		279,764
Senior Vice President of Regulatory Affairs	2020		235,212		1,800		--		673,600		31		910,643

(1)	The dollar value of base salary (cash and non-cash) earned. The 2020 amounts in the case of Mr. Kersten and Ms. Prichep are substantially higher than the person’s annual salary because they include voluntarily deferred salary payments from prior years that were paid in 2020.
(2)	The dollar value of bonus (cash and non-cash) earned.
(3)	For all persons listed in the table, the shares issued as CEL-SCI's contribution on behalf of the named officer who participates in CEL-SCI's 401(k) retirement plan. The value of all stock awarded during the periods covered by the table is calculated according to ASC 718-10-30-3 which represented the grant date fair value.
(4)	The fair value of all stock options granted during the periods covered by the table are calculated on the grant date in accordance with ASC 718-10-30-3 which represented the grant date fair value.
(5)	All other compensation received that CEL-SCI could not properly report in any other column of the table including the dollar value of any insurance premiums paid by, or on behalf of, CEL-SCI with respect to term life insurance for the benefit of the named executive officer and car allowances paid by CEL-SCI. Includes board of directors fees for Mr. Kersten.

Employee Pension, Profit Sharing or Other Retirement Plans

CEL-SCI has a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code and covering substantially all CEL-SCI’s employees. CEL-SCI’s contribution to the plan is made in shares of CEL-SCI's common stock. Each participant's contribution is matched by CEL-SCI with shares of common stock which have a value equal to 100% of the participant's contribution, not to exceed the lesser of $10,000 or 6% of the participant's total compensation. CEL-SCI's contribution of common stock is valued each quarter based upon the closing price of its common stock. The fiscal 2021 expenses for this plan were approximately $6,000. Other than the 401(k) Plan, CEL-SCI does not have a defined benefit, pension plan, profit sharing or other retirement plan.

Compensation of Directors During Year Ended September 30, 2021

Name	Fees		Stock Awards (1)		Option Awards (2)		Total
Geert Kersten	$	40,000		-		201,280	$	241,280
Peter R. Young		50,000		-		43,520		93,520
Bruno Baillavoine		45,000		-		43,520		88,520
Robert Watson		45,000		-		43,520		88,520

(1)	The fair value of stock issued for services.

(2)	The fair value of options granted computed in accordance with ASC 718-10-30-3 on the date of grant which represents their grant date fair value.

Directors’ fees paid to Geert Kersten are included in the Executive Compensation table.

Employment Contracts

Geert Kersten

On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Geert Kersten, CEL-SCI’s Chief Executive Officer. The employment agreement with Mr. Kersten, which is essentially the same as Mr. Kersten’s prior employment agreement, as amended on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Mr. Kersten an annual salary of $559,052, plus any increases in proportion to salary increases granted to other senior executive officers of CEL-SCI, as well any increases approved by the Board of Directors during the term of the employment agreement.

During the employment term, Mr. Kersten will be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time employees in accordance with CEL-SCI's policies and practices and subject to Mr. Kersten’s satisfaction of any applicable conditions of eligibility.

If Mr. Kersten resigns within ninety (90) days of the occurrence of any of the following events: (i) a reduction in Mr. Kersten’s salary (ii) a relocation (or demand for relocation) of Mr. Kersten’s place of employment to a location more than ten (10) miles from his current place of employment, (iii) a significant and material reduction in Mr. Kersten’s authority, job duties or level of responsibility or the imposition of significant and material limitations on the Mr. Kersten’s autonomy in his position, or (iv) a Change in Control, then the employment agreement will be terminated and Mr. Kersten will be entitled to receive a lump-sum payment from CEL-SCI equal to 24 months of salary ($1,174,010) and the unvested portion of any stock options would vest immediately. For purposes of the employment agreement a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.

The employment agreement will also terminate upon the death of Mr. Kersten or Mr. Kersten’s physical or mental disability. If the employment agreement is terminated for any of these reasons, Mr. Kersten, or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination, any options or bonus shares of CEL-SCI then held by Mr. Kersten will become fully vested and the expiration date of any options which would expire during the four year period following his termination of employment will be extended to the date which is four years after his termination of employment. The employment agreement will also terminate upon the willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by Mr. Kersten, in which case Mr. Kersten will be paid the salary provided by the employment agreement through the date of termination.

Patricia B. Prichep / Eyal Talor, Ph.D.

On August 31, 2019, CEL-SCI entered into a three-year employment agreement with Patricia B. Prichep, CEL-SCI’s Senior Vice President of Operations. The employment agreement with Ms. Prichep, which is essentially the same as Ms. Prichep’s prior employment agreement entered into on August 30, 2016 provided that, during the term of the agreement, CEL-SCI would pay Ms. Prichep an annual salary of $245,804 plus any increases approved by the Board of Directors during the period of the employment agreement.

On August 31, 2019, CEL-SCI entered into a three-year employment agreement with Eyal Talor, Ph.D., CEL-SCI’s Chief Scientific Officer. The employment agreement with Dr. Talor, which is essentially the same as Dr. Talor’s prior employment agreement entered into on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any increases approved by the Board of Directors during the period of the employment agreement.

If Ms. Prichep or Dr. Talor resigns within ninety (90) days of the occurrence of any of the following events: (i) a relocation (or demand for relocation) of employee’s place of employment to a location more than ten (10) miles from the employee’s current place of employment, (ii) a significant and material reduction in the employee’s authority, job duties or level of responsibility or (iii) the imposition of significant and material limitations on the employee’s autonomy in her or his position, the employment agreement will be terminated and the employee will be paid the salary provided by the employment agreement through the date of termination and the unvested portion of any stock options held by the employee will vest immediately.

In the event there is a change in the control of CEL-SCI, the employment agreements with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or Dr. Talor (as the case may be) to resign from her or his position at CEL-SCI and receive a lump-sum payment from CEL-SCI equal to 18 months of salary ($387,141 and $477,939 respectively). In addition, the unvested portion of any stock options held by the employee will vest immediately. For purposes of the employment agreements, a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.

The employment agreements with Ms. Prichep and Dr. Talor will also terminate upon the death of the employee, the employee’s physical or mental disability, willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by the employee. If the employment agreement is terminated for any of these reasons the employee, or her or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination.

Compensation Committee Interlocks and Insider Participation

CEL-SCI has a compensation committee comprised of Mr. Bruno Baillavoine, Dr. Peter Young and Mr. Robert Watson, all of whom are independent directors.

During the year ended September 30, 2021, no director of CEL-SCI was also an executive officer of another entity, which had an executive officer of CEL-SCI serving as a director of such entity or as a member of the compensation committee of such entity.

Stock Option, Bonus and Compensation Plans

CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and an Incentive Stock Bonus Plan. All Stock Option, Bonus and Compensation Plans have been approved by the stockholders. A summary description of these Plans follows. In some cases these Plans are collectively referred to as the "Plans".

Incentive Stock Option Plans. The Incentive Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons who exercise options granted pursuant to the Plans. Only CEL-SCI’s employees may be granted options pursuant to the Incentive Stock Option Plans.

Options may not be exercised until one year following the date of grant. Options granted to an employee then owning more than 10% of the common stock of CEL-SCI may not be exercisable by its terms after five years from the date of grant. Any other option granted pursuant to the Plans may not be exercisable by its terms after ten years from the date of grant.

The option exercise price is determined by the CEL-SCI’s Compensation Committee but cannot be less than the fair market value of the common stock on the date of the grant of the option (or 110% of the fair market value in the case of a person owning more than 10% of CEL-SCI's outstanding shares).

Non-Qualified Stock Option Plans. The Non-Qualified Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons that exercise options granted pursuant to the Plans. CEL-SCI's employees, directors, officers, consultants and advisors are eligible to be granted options pursuant to the Plans, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI’s common stock. The option exercise price is determined by CEL-SCI’s Compensation Committee.

Stock Bonus Plans. Under the Stock Bonus Plans shares of CEL-SCI’s common stock may be issued to CEL-SCI's employees, directors, officers, consultants and advisors, provided however that bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI’s common stock.

Stock Compensation Plans. Under the Stock Compensation Plans, shares of CEL-SCI’s common stock may be issued to CEL-SCI’s employees, directors, officers, consultants and advisors in payment of salaries, fees and other compensation owed to these persons. However, bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI’s common stock.

Incentive Stock Bonus Plan. Under the 2014 Incentive Stock Bonus Plan, shares of CEL-SCI’s common stock may be issued to executive officers and other employees who contribute significantly to the success of CEL-SCI. The purpose of the Plan is to provide long term incentive for outstanding service to CEL-SCI and its shareholders, to assist in recruiting and retaining people of outstanding ability and initiative in executive and management positions to allow officers and employees to participate in CEL-SCI's future prosperity and growth, and to align the interests of CEL-SCI's officers and employees with those of its shareholders.

Other Information Regarding the Plans. The Plans are administered by CEL-SCI's Compensation Committee (“the Committee”), each member of which is a director of CEL-SCI. The members of the Committee were selected by CEL-SCI's Board of Directors and serve for a one-year tenure and until their successors are elected. A member of the Committee may be removed at any time by action of the Board of Directors. Any vacancies which may occur on the Committee will be filled by the Board of Directors. The Committee is vested with the authority to interpret the provisions of the Plans and supervise the administration of the Plans. In addition, the Committee is empowered to select those persons to whom shares or options are to be granted, to determine the number of shares subject to each grant of a stock bonus or an option and to determine when, and upon what conditions, shares or options granted under the Plans will vest or otherwise be subject to forfeiture and cancellation.

During fiscal year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock, was approved by shareholders. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company’s common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goal: (a) the filing of the first marketing application for any pharmaceutical based upon the Company’s Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company’s common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable.

In the discretion of the Committee, any option granted pursuant to the Plans may include installment exercise terms such that the option becomes fully exercisable in a series of cumulating portions. The Committee may also accelerate the date upon which any option (or any part of any options) is first exercisable. Any shares issued pursuant to the Stock Bonus Plans or Stock Compensation Plans and any options granted pursuant to the Incentive Stock Option Plans or the Non-Qualified Stock Option Plans will be forfeited if the "vesting" schedule established by the Committee administering the Plans at the time of the grant is not met. For this purpose, vesting means the period during which the employee must remain an employee of CEL-SCI or the period of time a non-employee must provide services to CEL-SCI. At the time an employee ceases working for CEL-SCI (or at the time a non-employee ceases to perform services for CEL-SCI), any shares or options not fully vested will be forfeited and cancelled. At the discretion of the Committee payment for the shares of common stock underlying options may be paid through the delivery of shares of CEL-SCI's common stock having an aggregate fair market value equal to the option price, provided such shares have been owned by the option holder for at least one year prior to such exercise. A combination of cash and shares of common stock may also be permitted at the discretion of the Committee.

Options are generally non-transferable except upon death of the option holder. Shares issued pursuant to the Stock Bonus Plans will generally not be transferable until the person receiving the shares satisfies the vesting requirements imposed by the Committee when the shares were issued.

The Board of Directors of CEL-SCI may at any time, and from time to time, amend, terminate, or suspend one or more of the Plans in any manner it deems appropriate, provided that such amendment, termination or suspension may not adversely affect rights or obligations with respect to shares or options previously granted.

Stock Options

The following table show information concerning the options granted during the fiscal year ended September 30, 2021, to the persons named below:

Options Granted

Name	Grant Date	Options Granted		Price Per Share		Expiration Date
Geert Kersten	5/14/2021		592,000	$	20.61	5/13/2031
Eyal Talor	5/14/2021		318,000	$	20.61	5/13/2031
Patricia Prichep	5/14/2021		288,000	$	20.61	5/13/2031
John Cipriano	5/14/2021		130,000	$	20.61	5/13/2031
Dan Zimmerman	5/14/2021		160,000	$	20.61	5/13/2031
Bruno Baillavoine	5/14/2021		128,000	$	20.61	5/13/2031
Peter Young	5/14/2021		128,000	$	20.61	5/13/2031
Robert Watson	5/14/2021		128,000	$	20.61	5/13/2031

The following table shows the outstanding options held by the persons named below on September 30, 2021:

	Shares underlying unexercised
	Option which are:				Exercise		Expiration
Name	Exercisable		Unexercisable		Price		Date
Geert R. Kersten		1,800				97.50	05/17/22
		18,584		1,416		70.00	12/17/22
		1,800				52.50	06/30/23
		3,600				27.25	02/25/24
		180,000				2.18	07/27/27
		530,121				2.45	04/30/28
		542,120		271,060		5.65	04/10/29
		148,000		444,000		10.93	04/19/30
		-		592,000		20.61	05/13/31

Patricia B. Prichep		1,200				97.50	05/17/22
		6,000				70.00	12/17/22
		1,200				52.50	06/30/23
		2,400				27.25	02/25/24
		120,000				2.18	07/27/27
		222,607				2.45	04/30/28
		270,421		135,210		5.65	04/10/29
		72,000		216,000		10.93	04/19/30
		-		288,000		20.61	05/13/31

Eyal Talor, Ph.D		1,200				97.50	05/17/22
		6,000				70.00	12/17/22
		1,200				52.50	06/30/23
		2,400				27.25	02/25/24
		120,000				2.18	07/27/27
		193,934				2.45	04/30/28
		100,000				3.55	09/20/28
		255,142		127,570		5.65	04/10/29
		72,000		216,000		10.93	04/19/30
		-		318,000		20.61	05/13/31

Dan Zimmerman, Ph.D		900				97.50	05/17/22
		900				52.50	06/30/23
		1,800				27.25	02/25/24
		8,000				27.50	08/05/24
		4,000				15.50	06/25/25
		4,000				11.75	07/21/26
		6,000				1.87	06/28/27
		20,000				1.59	09/17/27
		126,194				2.45	04/30/28
		140,973		70,486		5.65	04/10/29
		40,000		120,000		10.93	04/19/30
		-		160,000		20.61	05/13/31

John Cipriano		900				97.50	05/17/22
		900				57.50	06/30/23
		1,800				27.25	02/25/24
		90,000				2.18	07/27/27
		148,347				2.45	04/30/28
		137,920		68,960		5.65	04/10/29
		40,000		120,000		10.93	04/19/30
		-		130,000		20.61	05/13/31

Summary. The following shows certain information as of September 30, 2021 concerning the stock options and stock bonuses granted by CEL-SCI. Each option represents the right to purchase one share of CEL-SCI's common stock.

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		76,829		N/A		213
Non-Qualified Stock Option Plans		11,787,200		10,972,880		N/A		410,592
Stock Bonus Plans		783,760		N/A		363,086		420,641
Stock Compensation Plans		634,000		N/A		153,195		462,395
Incentive Stock Bonus Plan		640,000		N/A		614,500		25,500

Of the shares issued pursuant to CEL-SCI's Stock Bonus Plans, 280,764 shares were issued as part of CEL-SCI's contribution to its 401(k) plan.

The following table shows the weighted average exercise price of the outstanding options granted pursuant to CEL-SCI’s Incentive and Non-Qualified Stock Option Plans as of September 30, 2021, CEL-SCI’s most recent fiscal year end. CEL-SCI's Incentive and Non-Qualified Stock Option Plans have been approved by CEL-SCI's shareholders.

Plan category	Number of Securities to be Issued Upon Exercise of Outstanding Options (a)		Weighted-Average Exercise Price of Outstanding Options		Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans, Excluding Securities Reflected in Column (a)

Incentive Stock Option Plans		76,829	$	30.60		213
Non-Qualified Stock Option Plans		10,972,880	$	9.94		410,592

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table shows, as of December 1, 2021, information with respect to the only persons owning beneficially 5% or more of CEL-SCI’s outstanding common stock and the number and percentage of outstanding shares owned by each director and officer of CEL-SCI and by the officers and directors as a group. Unless otherwise indicated, each owner has sole voting and investment powers over his shares of common stock.

Name and Address	Number of Shares (1)			Percent of Class (2)

Geert R. Kersten 8229 Boone Blvd., Suite 802 Vienna, VA 22182		3,571,542	(3)		7.8	%

Patricia B. Prichep 8229 Boone Blvd., Suite 802 Vienna, VA 22182		921,968			2.1	%

Eyal Talor, Ph.D. 8229 Boone Blvd., Suite 802 Vienna, VA 22182		856,775			1.9	%

Daniel H. Zimmerman, Ph.D. 8229 Boone Blvd., Suite 802 Vienna, VA 22182		469,288			1.1	%

John Cipriano 8229 Boone Blvd., Suite 802 Vienna, VA 22182		482,975			1.1	%

Peter R. Young, Ph.D. 208 Hewitt Drive, Suite 103-143 Waco, TX 76712	294,681	*

Bruno Baillavoine 8229 Boone Blvd., Suite 802 Vienna, VA 22182	230,140	*

Robert Watson 245 N. Highland Ave. NE Suite 230-296 Atlanta, GA 30307	201,098	*

All Officers and Directors as a Group (8 persons)	7,028,467		14.47	%

State Street Corporation State Street Financial Center One Lincoln Street Boston, MA 02111	4,576,724		10.59	%

* Less than 1%

(1)	Includes shares issuable prior to February 28, 2022 upon the exercise of options or warrants granted to the following persons:

Name	Options or Warrants Exercisable Prior to February 28, 2022
Geert R. Kersten, Esq.		2,424,849	(3)
Patricia B. Prichep		714,387
Eyal Talor, Ph.D.		751,876
Daniel Zimmerman, Ph.D.		352,767
John Cipriano		419,867
Peter R. Young, Ph.D.		265,767
Bruno Baillavoine		224,167
Robert Watson		196,667

(2)	Amount includes shares referred to in (1) above but excludes shares which may be issued upon the exercise of options and warrants previously issued by CEL-SCI.

(3)	Amount includes 321,421 shares and 390,928 warrants held in the de Clara Trust, of which Mr. Kersten is a beneficiary. Mr. Kersten is not the trustee of the de Clara Trust and does not control the voting or the trading of the shares held by the Trust.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

During the year ended September 30, 2021, officers and a director of the Company purchased 27,500 restricted shares of the Company’s common stock at an aggregate market value of approximately $220,000 During the year ended September 30, 2020, officers of the Company purchased 20,512 restricted shares of the Company’s common stock at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.

See Note 11 to the financial statements included as part of this report for additional information concerning related party transactions.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

BDO USA, LLP served as CEL-SCI’s independent registered public accountant for the two years ended September 30, 2021. The following table shows the aggregate fees billed to CEL-SCI for these years by BDO USA, LLP:

	Year Ended September 30,
	2021		2020

Audit Fees	$	391,240	$	553,700
Audit Related Fees		-		-
Tax Fees		-		-
All Other Fees		-		-

Audit fees represent amounts billed for professional services rendered for the audit of CEL-SCI’s annual financial statements and the reviews of the financial statements included in CEL-SCI’s 10-Q reports for the fiscal year and all regulatory filings.

Before BDO USA, LLP was engaged by CEL-SCI to render audit or non-audit services, the engagement was approved by CEL-SCI’s audit committee. CEL-SCI’s Board of Directors is of the opinion that the Audit Fees charged by BDO USA, LLP are consistent with BDO USA, LLP maintaining its independence from CEL-SCI.

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

3(a)	Articles of Incorporation	Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.

3(b)	Amended Articles	Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.

3(c)	Amended Articles (Name change only)	Incorporated by reference to Exhibit 3(c) of CEL-SCI's Registration Statement on Form S-1 Registration Statement (No. 33-34878).

3(d)	By laws (as amended)	Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).

4	Shareholders Rights Agreement, as Amended	Incorporated by reference to Exhibit 4 filed with CEL-SCI’s 8-K report dated October 30, 2020.

4(b)	Incentive Stock Option Plan	Incorporated by reference to Exhibit 4 (b) filed on September 25, 2012 with CEL-SCI’s registration statement on Form S¬8 (File number 333-184092.

4(c)	Non-Qualified Stock Option Plan	Incorporated by reference to Exhibit 4 (b) filed on August 19, 2014 with CEL-SCI’s registration statement on Form S¬8 (File number 333-198244).

4(d)	Stock Bonus Plan	Incorporated by reference to Exhibit 4 (d) filed on September 25, 2012 with CEL-SCI’s registration statement on Form S¬8 (File number 333-184092.

4(e)	Stock Compensation Plan	Incorporated by reference to Exhibit 4 (e) filed on September 25, 2012 with CEL-SCI’s registration statement on Form S¬8 (File number 333-184092.

4(f)	2014 Incentive Stock Bonus Plan	Filed with this Amendment No. 2 to CEL-SCI’s annual report on Form 10-K for the year ended September 30, 2014.

10(l)	First Amendment to Development Supply and Distribution Agreement with Orient Europharma.	Incorporated by reference to Exhibit 10(m) filed with CEL-SCI’s 10-K report for the year ended September 30, 2010.

10(m)	Exclusive License and Distribution Agreement with Teva Pharmaceutical Industries Ltd.	Incorporated by reference to Exhibit 10(n) filed with CEL-SCI’s 10-K report for the year ended September 30, 2010.

10(n)	Lease Agreement	Incorporated by reference to Exhibit 10(o) filed with CEL-SCI’s 10-K report for the year ended September 30, 2010.

10(p)	Licensing Agreement with Byron Biopharma	Incorporated by reference to Exhibit 10(i) of CEL-SCI’s report on Form 8-K dated March 27, 2009

10(z)	Development, Supply and Distribution Agreement with Orient Europharma	Incorporated by reference to Exhibit 10(z) filed with CEL-SCI’s report on Form 10-K for the year ended September 30, 2003.

10 (rr)	Assignment and Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and GCP Clinical Studies, Ltd.	Incorporated by reference to Exhibit 10(rr) of CEL-SCI’s report on Form 10-K/A report for the year ended September 30, 2014 dated April 17, 2015.

10 (ss)	Service Agreement with GCP Clinical Studies, Ltd., together with Amendment 1 thereto*	Incorporated by reference to Exhibit 10(ss) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (tt)	Joinder Agreement with PLIVA Hrvatska d.o.o.	Incorporated by reference to Exhibit 10(tt) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (uu)	Master Service Agreement with Ergomed Clinical Research, Ltd., and Clinical Trial Orders thereunder	Incorporated by reference to Exhibit 10(uu) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (vv)	Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research Ltd., dated April 19, 2013, as amended	Incorporated by reference to Exhibit 10(vv) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (ww)	Co-Development and Revenue Sharing Agreement II: Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical Research Ltd., dated October 10, 2013, as amended	Incorporated by reference to Exhibit 10(ww) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (xx)	Co-Development and Revenue Sharing Agreement III: Anal warts and anal intraepithelial neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical Research Ltd., dated October 24, 2013	Incorporated by reference to Exhibit 10(xx) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (yy)	Master Services Agreement with Aptiv Solutions, Inc.	Incorporated by reference to Exhibit 10(yy) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (zz)	Project Agreement Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and 2 thereto*	Incorporated by reference to Exhibit 10(zz) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (aaa)	Second Amendment to Development Supply and Distribution Agreement with Orient Europharma	Incorporated by reference to Exhibit 10(aaa) of CEL-SCI’s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.

10 (iii)	Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated September 15, 2015	Incorporated by reference to Exhibit 10 (iii) filed with CEL-SCI’s 10-K report for the year ended September 30, 2015.

10 (mmm)	Employment Agreement with Geert Kersten (2019-2023)	Incorporated by reference to Exhibit 10(10.7) of CEL-SCI’s report on Form 8-K dated August 31, 2019.

10 (nnn)	Employment Agreement with Patricia Prichep (2019-2022)	Incorporated by reference to Exhibit 10(10.8) of CEL-SCI’s report on Form 8-K dated August 31, 2019.

10 (ooo)	Employment Agreement with Eyal Taylor (2019-2022)	Incorporated by reference to Exhibit 10(10.9) of CEL-SCI’s report on Form 8-K dated August 31, 2019.

10.7	2019 Non-Qualified Stock Option Plan	Incorporated by reference to Exhibit 10.7 of CEL-SCI’s report on Form 8-K dated October 15, 2019.

10.8	2019 Stock Compensation Plan	Incorporated by reference to Exhibit 10.8 of CEL-SCI’s report on Form 8-K dated October 15, 2019.

23.1		Consent of BDO USA, LLP

31		Rule 13a-14(a) Certifications

32		Section 1350 Certifications

* Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)

CEL-SCI CORPORATION

Financial Statements for the Years

Ended September 30, 2021 and 2020, and

Report of Independent Registered Public Accounting Firm

CEL-SCI CORPORATION

TABLE OF CONTENTS

		Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM		F- 2

FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2021 and 2020:

Balance Sheets		F- 4
Statements of Operations		F- 5
Statements of Stockholders’ Equity		F- 6
Statements of Cash Flows		F- 7
Notes to Financial Statements		F- 9

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors

CEL-SCI Corporation

Vienna, Virginia

Opinion on the Financial Statements

We have audited the accompanying balance sheets of CEL-SCI Corporation (the “Company”) as of September 30, 2021 and 2020, the related statements of operations, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

F-2

Table of Contents

Determination of Incremental Borrowing Rates for Leases

As described in Note 10 of the financial statements, the Company modified two leases during the year. The remeasurement of the lease liability requires the determination of an incremental borrowing rate, which involves complex judgment by management.

We identified the determination of the incremental borrowing rates for modified lease contracts as a critical audit matter. Significant judgment is required by management to develop the incremental borrowing rate for lease contracts. Auditing the reasonableness of the incremental borrowing rate involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters including the extent of specialized skill or knowledge needed.

The primary procedures we performed to address this critical audit matter included:

Utilizing professionals with specialized skill and knowledge in valuation to assist with developing independent estimates of fully collateralized incremental borrowing rates for modified lease contracts by (i) developing synthetic credit ratings for the Company; (ii) identifying market interest rates based on the synthetic credit ratings and applicable lease terms; and (iii) comparing the independently developed estimates to the Company’s incremental borrowing rates.

/s/BDO USA, LLP

We have served as the Company's auditor since 2005.

Potomac, Maryland
December 21, 2021

F-3

Table of Contents

CEL-SCI CORPORATION
BALANCE SHEETS
SEPTEMBER 30, 2021 and 2020

	2021			2020
ASSETS
Current Assets:
Cash and cash equivalents	$	36,060,148		$	15,508,909
U.S. Treasury Bills		6,151,385			-
Receivables		54,922			54,922
Prepaid expenses		998,482			1,313,432
Supplies used for R&D and manufacturing		2,006,584			820,052

Total current assets		45,271,521			17,697,315

Finance lease right of use assets		12,691,921			13,811,849
Operating lease right of use assets		2,056,178			1,198,958
Property and equipment, net		13,663,562			5,843,993
Patent costs, net		275,866			313,422
Deposits		1,910,917			1,670,917

Total assets	$	75,869,965		$	40,536,454

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable	$	1,675,813		$	2,023,067
Accrued expenses		859,216			510,515
Due to employees		265,993			448,022
Derivative instruments, current portion		437,380			213,787
Lease liabilities, current portion		698,665			1,070,123

Total current liabilities		3,937,067			4,265,514

Derivative instruments, net of current portion		-			3,551,826
Finance lease liabilities, net of current portion		13,252,364			11,753,100
Operating lease liabilities, net of current portion		2,021,308			1,114,340
Other liabilities		125,000			125,000

Total liabilities		19,335,739			20,809,780

Commitments and Contingencies

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value- 200,000 shares authorized;
-0- shares issued and outstanding		-			-
Common stock, $.01 par value - 600,000,000 shares authorized;
43,207,183 and 38,730,150 shares issued and outstanding
at September 30, 2021 and 2020, respectively		432,072			387,302
Additional paid-in capital		474,298,566			401,174,675
Accumulated deficit		(418,196,412	)		(381,835,303	)

Total stockholders' equity		56,534,226			19,726,674

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	75,869,965		$	40,536,454

See notes to financial statements.

F-4

Table of Contents

CEL-SCI CORPORATION
STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 2021 AND 2020

	2021			2020

Grant income	$	-		$	558,664

Operating expenses:
Research and development		23,108,897			17,840,290
General and administrative		13,085,232			11,703,429
Total operating expenses		36,194,129			29,543,719

Operating loss		(36,194,129	)		(28,985,055	)

Other (expense) income		(8,213	)		38,763
Loss on derivative instruments		(694,858	)		(349,078	)
Warrant inducement expense		-			(805,753	)
Other non-operating gain		1,685,379			887,604
Interest expense, net		(1,149,288	)		(1,041,725	)
Net loss		(36,361,109	)		(30,255,244	)

Modification of warrants		(350,861	)		(21,734	)

Net loss available to common shareholders	$	(36,711,970	)	$	(30,276,978	)

Net loss per common share - basic	$	(0.90	)	$	(0.82	)
Weighted average common shares outstanding - basic		40,662,137			36,759,115

Net loss per common share - diluted	$	(0.93	)	$	(0.82	)
Weighted average common shares outstanding - diluted		40,694,248			36,759,115

See notes to financial statements.

F-5

Table of Contents

CEL-SCI CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED SEPTEMBER 30, 2021 AND 2020

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total

BALANCE, SEPTEMBER 30, 2019		35,231,776		$	352,318		$	358,507,603		$	(353,726,254	)	$	5,133,667

Adoption of ASC 842, Leases											2,146,195			2,146,195
Proceeds from the sale of common stock		1,422,429			14,225			13,978,214			-			13,992,439
Warrant issuances		-			-			805,753			-			805,753
Warrant exercises		1,711,873			17,118			15,127,122			-			15,144,240
Modification of warrants		-			-			5,554						5,554
401(k) contributions paid in common stock		13,870			139			163,201			-			163,340
Stock issued to nonemployees for service		79,950			799			971,868			-			972,667
Equity based compensation - employees		-			-			10,112,968			-			10,112,968
Option exercises		99,740			998			337,330			-			338,328
Purchase of stock by officers and directors		20,512			205			184,785			-			184,990
Share issuance costs		-			-			(787,723	)		-			(787,723	)
Shares issued for settlement of clinical research costs		150,000			1,500			1,768,000			-			1,769,500
Net loss		-			-			-			(30,255,244	)		(30,255,244	)

BALANCE, SEPTEMBER 30, 2020		38,730,150			387,302			401,174,675			(381,835,303	)		19,726,674

Proceeds from the sale of common stock		2,610,000			26,100			47,337,326			-			47,363,426
Warrant exercises		1,597,870			15,978			9,991,328			-			10,007,306
Modification of warrants		-			-			24,387			-			24,387
401(k) contributions paid in common stock		17,990			180			200,919			-			201,099
Stock issued to nonemployees for service		75,885			759			1,194,945			-			1,195,704
Equity based compensation - employees		(2,000	)		(20	)		13,685,066			-			13,685,046
Option exercises		149,788			1,498			744,730			-			746,228
Purchase of stock by officers and directors		27,500			275			219,725			-			220,000
Share issuance costs		-			-			(274,535	)		-			(274,535	)
Net loss		-			-			-			(36,361,109	)		(36,361,109	)

BALANCE, SEPTEMBER 30, 2021		43,207,183		$	432,072		$	474,298,566		$	(418,196,412	)	$	56,534,226

F-6

Table of Contents

CEL-SCI CORPORATION
STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 2021 AND 2020

	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(36,361,109	)	$	(30,255,244	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization		2,231,108			2,159,729
Share-based payments for services		1,226,690			862,796
Equity based compensation		13,685,046			10,112,968
Common stock contributed to 401(k) plan		201,099			163,340
Shares issued for settlement of clinical research costs		-			1,769,500
Gain on short-term investments		(5,621	)		-
Loss on derivative instruments		694,858			349,078
Warrant inducement expense		-			805,753
Modification of warrants		24,387			5,554
(Increase)/decrease in assets:
Receivables		-			7,843
Prepaid expenses		283,964			(623,608	)
Supplies used for R&D and manufacturing		(1,186,532	)		(37,689	)
Deposits		(240,000	)		-
Increase/(decrease) in liabilities:
Accounts payable		445,981			(766,073	)
Accrued expenses		363,701			406,083
Due to employees		(182,029	)		(261,420	)
Other liabilities		31,441			25,229

Net cash used in operating activities		(18,787,016	)		(15,276,161	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net purchases of U.S. Treasury Bills		(6,145,764	)		-
Purchases of property and equipment		(9,016,329	)		(2,654,906	)
Expenditures for patent costs		(22,641	)		(39,975	)

Net cash used in investing activities		(15,184,734	)		(2,694,881	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		47,363,426			13,992,439
Payments of stock issuance costs		(325,034	)		(752,804	)
Proceeds from exercise of warrants		5,984,215			12,072,465
Proceeds from exercises of options		746,228			338,328
Proceeds from the purchase of stock by officers and directors		220,000			184,990
Proceeds from landlord funding of leasehold improvements		1,613,546			-
Payments on obligations under finance leases		(1,079,392	)		(800,241	)

Net cash provided by financing activities		54,522,989			25,035,177

NET INCREASE IN CASH AND CASH EQUIVALENTS		20,551,239			7,064,135

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR		15,508,909			8,444,774

CASH AND CASH EQUIVALENTS, END OF YEAR	$	36,060,148		$	15,508,909

F-7

Table of Contents

CEL-SCI CORPORATION

STATEMENTS OF CASH FLOWS

YEARS ENDED SEPTEMBER 30, 2021 AND 2020

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

	2021		2020
Property and equipment included in accrued expenses and accounts payable	$	435,412	$	1,184,723
Capitalizable patent costs included in accrued expenses and accounts payable	$	6,510	$	15,000
Changes to right of use assets and liabilities	$	551,444	$	399,032
Finance lease obligation included in accounts payable	$	855	$	790
Prepaid consulting services paid with issuance of common stock	$	363,911	$	164,871
Fair value of warrants liabilities on date of exercise	$	4,023,091	$	3,071,775
Financing costs included in accounts payable	$	-	$	50,499
Accrued consulting services to be paid with common stock	$	55,000	$	55,000

Cash paid for interest	$	1,173,702	$	1,155,026

See notes to financial statements.

F-8

Table of Contents

CEL-SCI CORPORATION

NOTES TO FINANCIAL STATEMENTS

1.	ORGANIZATION

	CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.

	The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently announced top line Phase 3 data for its lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.

	CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.

2.	OPERATIONS AND FINANCING

	On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.

	Liquidity

	The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.

F-9

Table of Contents

	Impact of COVID-19 Pandemic

	In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.

	U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.

	Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.

	Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

	Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

	Leases – On October 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases and its related amendments (collectively referred to as Topic 842 and codified as “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company’s statements of operations or cash flows.

F-10

Table of Contents

The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.

Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.

F-11

Table of Contents

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Grant Income – The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.

Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Concentration of Credit Risk – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021.

Income Taxes – The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.

F-12

Table of Contents

	In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.

	Use of Estimates – The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.

	New Accounting Pronouncements

	The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

4.	WARRANTS AND NON-EMPLOYEE OPTIONS

	The following warrants and non-employee options are outstanding at September 30, 2021:

Warrant/Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	8/18/2022
Series UU	6/11/2018		93,603	$	2.80	6/30/2022
Series X	1/13/2016		120,000	$	9.25	7/13/2022
Series Y	2/15/2016		26,000	$	12.00	8/15/2022
Series Z	5/23/2016		184,800	$	13.75	11/23/2021
Series CC	12/8/2016		15,845	$	5.00	12/8/2021
Series HH	2/23/2017		200	$	3.13	2/16/2022
Series AA	8/26/2016		100,000	$	13.75	2/22/2022
Series MM	6/22/2017		333,432	$	1.86	6/22/2022
Series NN	7/24/2017		210,087	$	2.52	7/24/2022
Series RR	10/30/2017		251,761	$	1.65	10/30/2022
Series SS	12/19/2017		200,000	$	2.09	12/18/2022
Series TT	2/5/2018		600	$	2.24	2/5/2023
Consultants	7/28/2017 – 11/18/2020		15,000	$	2.18 - $11.61	11/17/2022 - 7/27/2027

F-13

Table of Contents

The following warrants and non-employee options are outstanding at September 30, 2020:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants/Options		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	2/18/2021
Series UU	6/11/2018		93,603	$	2.80	12/31/2020
Series W	10/28/2015		688,930	$	16.75	10/28/2020
Series X	1/13/2016		120,000	$	9.25	1/13/2021
Series Y	2/15/2016		26,000	$	12.00	2/15/2021
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021
Series BB	8/26/2016		16,000	$	13.75	8/22/2021
Series Z	5/23/2016		264,000	$	13.75	11/23/2021
Series CC	12/8/2016		148,643	$	5.00	12/8/2021
Series HH	2/23/2017		200	$	3.13	2/16/2022
Series AA	8/26/2016		200,000	$	13.75	2/22/2022
Series MM	6/22/2017		797,633	$	1.86	6/22/2022
Series NN	7/24/2017		348,842	$	2.52	7/24/2022
Series RR	10/30/2017		417,649	$	1.65	10/30/2022
Series SS	12/19/2017		326,064	$	2.09	12/18/2022
Series TT	2/5/2018		371,564	$	2.24	2/5/2023
Consultants	7/28/17		10,000	$	2.18	7/27/2027

A. Warrant Liabilities

Warrant liabilities outstanding at September 30 are as follows:

	2021		2020
Series W warrants	$	-	$	73,570
Series Z warrants		64,787		1,207,902
Series ZZ warrants		-		75,044
Series AA warrants		276,035		1,082,212
Series BB warrants		-		65,173
Series CC warrants		94,961		1,259,712
Series HH warrants		1,597		2,000
Total warrant liabilities	$	437,380	$	3,765,613

The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows:

	2021			2020
Series V Warrants	$	-		$	185,652
Series W warrants		73,570			1,119,937
Series Z warrants		252,115			(98,357	)
Series ZZ warrants		(98,692	)		2,594
Series AA warrants		(318,823	)		(165,304	)
Series BB warrants		65,173			(1,207	)
Series CC warrants		(668,605	)		(875,040	)
Series FF warrants		-			(319,706	)
Series HH warrants		404			(34,589	)
Series JJ warrants		-			(64,992	)
Series LL warrants		-			(98,066	)
Net loss on warrant liabilities	$	(694,858	)	$	(349,078	)

F-14

Table of Contents

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.

Changes in Warrant Liabilities

On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75 expired.

On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.

On May 26, 2020, the Company lowered the exercise price of 810,127 Series V warrants from $19.75 to $13.75 per share and extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020. The incremental cost of this modification was approximately $664,000, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, 135,963 Series V warrants, with an exercise price of $13.75 expired. The warrants were valued at approximately $211,000 on the date of expiration.

Exercise of Warrant Liabilities

The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series Z		79,200	$	13.75	$	1,089,000
Series ZZ		20,000	$	13.75		275,000
Series AA		100,000	$	13.75		1,375,000
Series CC		132,798	$	5.00		663,990
		331,998			$	3,402,990

The following warrants recorded as liabilities were exercised during the year ended September 30, 2020:

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series V		674,164	$	13.75	$	9,269,755
Series CC		128,820	$	5.00		644,100
Series FF		68,048	$	3.91		265,812
Series HH		6,300	$	3.13		19,687
Series JJ		9,450	$	3.13		29,531
Series LL		26,398	$	3.59		94,867
		913,180			$	10,323,752

F-15

Table of Contents

B.	Equity Warrants

	Changes in Equity Warrants

	On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $351,000 for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants extension approximated $103,000 and had no impact on the financial statements for the year ended September 30,2021 due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $24,000 for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.

	On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $20.00 per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and 101,839 Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $629,000 and $177,000, respectively. The total expense of approximately $806,000 is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.

	On May 8, 2020, the expiration dates of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

	On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.

F-16

Table of Contents

Exercise of Equity Warrants

The following equity warrants were exercised during the year ended September 30, 2021.

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series MM		464,201	$	1.86	$	863,414
Series NN		138,755	$	2.52		349,663
Series RR		165,888	$	1.65		273,715
Series SS		126,064	$	2.09		263,474
Series TT		370,964	$	2.24		830,959
		1,265,872			$	2,581,225

The following equity warrants were exercised during the year ended September 30, 2020.

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series MM		95,858	$	1.86	$	178,296
Series NN		124,956	$	2.52		314,889
Series OO		50,000	$	2.52		126,000
Series RR		39,467	$	1.65		65,121
Series SS		156,580	$	2.09		327,252
Series TT		188,125	$	2.24		421,400
Series UU		61,207	$	2.80		171,380
Series VV		82,500	$	1.75		144,375
		798,693			$	1,748,713

C.	Options and Shares Issued to Consultants

	The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued 75,885 and 79,950 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $6.86 to $24.95 per share. The weighted average grant price was $15.46 and $12.01, respectively, for stock issued during the years ended September 30, 2021 and 2020.

	During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $1,227,000 and $863,000, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $364,000 and $395,000, respectively, are included in prepaid expenses.

	During the year ended September 30, 2021, the Company issued 5,000 options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of November 17, 2022. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, 15,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.

5.	PROPERTY AND EQUIPMENT

	Property and equipment consisted of the following at September 30:

F-17

Table of Contents

	2021			2020
Research equipment	$	4,211,124		$	3,898,242
Furniture and equipment		99,768			99,768
Leasehold improvements		13,465,123			5,519,161
		17,776,015			9,517,171
Accumulated depreciation and amortization		(4,112,453	)		(3,673,178	)

Net property and equipment	$	13,663,562		$	5,843,993

Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $447,000 and $389,000 respectively.

6.	PATENTS

	Patents consist of the following at September 30:

	2021			2020
Patents	$	910,523		$	896,372
Accumulated amortization		(634,657	)		(582,950	)

Patents, net	$	275,866		$	313,422

During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $52,000 and $53,000, respectively. The total estimated future amortization is as follows:

Years ending September 30,
2022	$	49,000
2023		39,000
2024		31,000
2025		29,000
2026		25,000
Thereafter		103,000
	$	276,000

7.	INCOME TAXES

	At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company’s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.

F-18

Table of Contents

	Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company’s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.

	The Company had federal NOL carryforwards of approximately $77.1 million and $51.5 million at September 30, 2021 and 2020, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (“R&D credit”) of approximately $1.2 million at September 30, 2021 and 2020. The R&D credit expires during the fiscal year ended 2029.

	Significant components of the Company’s deferred tax assets as of September 30, 2021 and 2020 are listed below:

	2021			2020

NOL carryforwards	$	19,789,000		$	13,407,000
Lease liabilities		4,101,000			3,631,000
R&D credit		1,221,000			1,221,000
Stock-based compensation		7,785,000			5,297,000
Capitalized R&D		15,040,000			15,853,000
Vacation and other		126,000			125,000
Total deferred tax assets		48,062,000			39,534,000

Right of use assets		(3,786,000	)		(3,911,000	)
Fixed assets and intangibles		(172,000	)		(169,000	)
Total deferred tax liability		(3,958,000	)		(4,080,000	)

Net deferred tax asset		44,104,000			35,454,000
Valuation allowance		(44,104,000	)		(35,454,000	)
Ending Balance	$	-		$	-

The Company has no federal or state current or deferred tax expense or benefit. The Company’s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:

	2021			2020

Federal Rate		21.00	%		21.00	%
State rate change		(1.37	)		(1.40	)
State tax rate, net of federal benefit		4.72			5.15
Other adjustments		(0.79	)		(3.24	)
Permanent differences		0.23			0.42
Change in valuation allowance		(23.79	)		(21.93	)

Effective tax rate		0.00	%		0.00	%

F-19

Table of Contents

The Company applies the provisions of ASC 740, “Accounting for Uncertainty in Income Taxes,” which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.

8.	STOCK COMPENSATION

	The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:

	Year Ended September 30,
	2021		2020
Employees	$	13,685,046	$	10,112,968
Non-employees	$	1,226,690	$	862,796

During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.

	2021		2020
Expected stock price volatility	90.42 – 97.22%		87.36 – 90.26%
Risk-free interest rate	0.85 – 1.65%		0.62 – 1.87%
Expected life of options	9.68 – 9.69 Years		9.68 – 9.69 Years
Expected dividend yield		-		-

	Non-Qualified Stock Option Plans –

	During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $0.34 and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be 1.3 years. This resulted in compensation expense of approximately $189,000 recorded during the year ended September 30, 2021. The remaining $447,000 will be expensed over the next 11 months.

F-20

Table of Contents

	During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to 3,600,000 options to purchase shares of common stock. On April 20, 2020, the Company granted 1,872,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share, the fair value on the date of issuance. The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $4.21 and an aggregate value of approximately $7.9 million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be 1.7 years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $3.8 million and $2.1 million during the years ended September 30, 2021 and 2020, respectively. The remaining $2.0 million will be expensed over the next 11 months.

	At September 30, 2021, the Company has collectively authorized the issuance of 11,787,200 shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the plans. The Company’s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.

	Incentive Stock Option Plans – At September 30, 2021, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the Plans. Only the Company’s employees are eligible to be granted options under the Incentive Stock Option Plans.

	Activity in the Company’s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:

F-21

Table of Contents

Non-Qualified and Incentive Stock Option Plans

	Outstanding								Exercisable
	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value		Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at September 30, 2019		6,218,216	$	5.54		8.88	$	29,562,594		1,392,241	$	9.15		7.68	$	7,869,555
Vested										2,014,501	$	4.06
Granted		2,563,000	$	10.93
Exercised		99,740	$	3.39						99,740	$	3.39
Forfeited		18,000	$	10.34
Expired		9,773	$	132.75						9,773	$	132.75

Outstanding at September 30, 2020		8,653,703	$	7.01		8.39	$	56,193,415		3,297,229	$	5.85		7.48	$	29,090,662
Vested										2,401,961	$	6.26
Granted (a)		2,605,000	$	20.58
Exercised		149,788	$	4.98						149,788	$	4.98
Forfeited		49,832	$	9.56
Expired		9,374	$	172.73						9,374	$	172.73
Outstanding at September 30, 2021		11,049,709	$	10.08		7.93	$	54,843,283		5,540,028	$	5.77		6.96	$	43,589,598

______________

(a)	Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.

A summary of the status of the Company’s non-vested options for the two years ended September 30, 2021 is presented below:

	Number of Options			Weighted Average Grant Date Fair Value
Unvested at September 30, 2019		4,825,975		$	3.79
Vested		(2,014,501	)
Granted		2,563,000
Forfeited		(18,000	)
Unvested at September 30, 2020		5,356,474		$	4.76
Vested		(2,401,961	)
Granted		2,605,000
Forfeited		(49,832	)
Unvested at September 30, 2021		5,509,681		$	5.17

Incentive Stock Bonus Plan – On September 30, 2021, 614,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company’s Multikine technology, or specified increases in the market price of the Company’s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $8.6 million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0.3 million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $45,000 which is expected to be fully recognized in the next quarter.

F-22

Table of Contents

A summary of the status of the Company’s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:

	Number of Shares			Weighted Average Grant Date Fair Value

Unvested at September 30, 2019		304,500		$	13.75
Forfeited		-
Vested		-
Unvested at September 30, 2020		304,500		$	13.75
Forfeited		(2,000	)
Vested		(151,250	)
Unvested at September 30, 2021		151,250		$	13.75

	Stock Bonus Plans – As of September 30, 2021, the Company has issued a total of 363,086 shares of common stock from the Stock Bonus Plans and was authorized to issue up to 783,760 shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.

	Stock Compensation Plans – On September 30, 2021, 634,000 shares were authorized for use in the Company’s Stock Compensation Plans, of which 154,195 shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.

9.	EMPLOYEE BENEFIT PLAN

	The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant’s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant’s contribution, not to exceed the lesser of $10,000 or 6% of the participant’s total compensation. The Company’s contribution of common stock is valued each quarter based upon the closing bid price of the Company’s common stock. During the year ended September 30, 2021, 17,990 shares were issued to the Company’s 401(k) plan for a cost of approximately $201,000. During the year ended September 30, 2020, 13,870 shares were issued to the Company’s 401(k) plan for a cost of approximately $163,000.

F-23

Table of Contents

10.	COMMITMENTS AND CONTINGENCIES

	Clinical Research Agreements

	In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company’s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.1 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.6 million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $1.6 million and $2.0 million, respectively, as research and development expense related to Ergomed’s services. These amounts were net of Ergomed’s discount of approximately $0.6 million during both the years ended September 30, 2021 and 2020.

	Lease Agreements

	The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.

	Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $16.5 million and a finance lease liability of approximately $13.5 million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $12.7 million and $13.8 million and the balance of the finance lease liability is approximately $13.8 million and $12.7 million, of which approximately $0.6 million and $0.9 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately $1,732,000 and $1,717,000 in the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $2.2 million and $1.9 million, of which approximately $1.2 million was for interest in both years. The weighted average discount rate of the Company’s finance leases is 8.45% and the weighted average time to maturity is 7.1 years.

	In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.

F-24

Table of Contents

	During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.

	The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord’s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $1.9 million and $1.7 million deposit is included in non-current assets.

	Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:

Year ending September 30,
2022	$	1,699,000
2023		2,569,000
2024		2,648,000
2025		2,733,000
2026		2,824,000
Thereafter		6,186,000
Total future minimum lease obligation *		18,659,000
Less imputed interest on finance lease obligations		(4,825,000	)
Net present value of lease finance lease obligations	$	13,834,000

* Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021.

	Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $39,000.

	The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.

	Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $1.0 million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $2.1 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.1 million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $1.2 million and the balance of the operating lease liability is approximately $1.2 million, of which approximately $0.1 million is current. The Company incurred lease expense under operating leases of approximately $0.2 million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $0.3 million and $0.2 million, respectively. The weighted average discount rate of the Company’s operating leases is 9.12% and the weighted average time to maturity is 9.7 years.

F-25

Table of Contents

As of September 30, 2021, future minimum lease payments on operating leases are as follows:

Year ending September 30,
2022	$	309,000
2023		348,000
2024		357,000
2025		366,000
2026		287,000
Thereafter		1,602,000
Total future minimum lease obligation		3,269,000
Less imputed interest on operating lease obligation		(1,130,000	)
Net present value of operating lease obligation	$	2,139,000

	Vendor Obligations

	The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.

11.	RELATED PARTY TRANSACTIONS

	During the year ended September 30, 2021, the de Clara Trust, of which the Company’s CEO, Geert Kerston, is a beneficiary, and two directors purchased 27,500 restricted shares of the Company’s common stock at an aggregate fair market value of approximately $220,000. During the year ended September 30, 2020, officers and directors of the Company purchased 20,512 shares of restricted common stock at market price at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.

	On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $265,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.

	On June 28, 2021, the expiration date of 93,603 Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $24,000 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.

	On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.

F-26

Table of Contents

	On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.

	On May 8, 2020, the expiration date of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company’s officers and were originally issued with convertible debt.

	On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

12.	STOCKHOLDERS’ EQUITY

	Exercise of Warrants

	During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $6.0 million and $12.1 million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, 1,597,870 and 1,711,873 shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.

	Sales of Securities

	In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. At that time, the underwriters fully exercised their option to purchase up to 210,000 additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $4.4 million.

	In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.

	In March 2020, the Company sold 630,500 shares of common stock at a public offering price of $12.22 per share and received aggregate net proceeds of approximately $7.1 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional 94,575 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $1.1 million.

	In December 2019, the Company sold 606,395 shares of common stock at a public offering price of $9.07 per share and received aggregate net proceeds of approximately $5.0 million. In January 2020, the underwriters of that offering fully exercised the option to purchase 90,959 additional shares of common stock at the public offering price of $9.07 per share for aggregate net proceeds to the Company of approximately $0.8 million.

F-27

Table of Contents

	Other Equity Transactions

	The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company’s Clinical Research Organizations responsible for managing the Company’s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.

	During the year ended September 30, 2020, the Company issued Ergomed 150,000 shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $500,000 in amounts prepaid to Ergomed.

	The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:

	2021		2020
Amount realized through the resale of shares	$	1,685,379	$	2,652,605
Fair value of shares upon issuance		-		1,769,500
Other non-operating gain	$	1,685,379	$	883,105

	As of September 30, 2021, all shares held for resale were sold.

13.	FAIR VALUE MEASUREMENTS

	In accordance with the provisions of ASC 820, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.

	ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

	o	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

	o	Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability

	o	Level 3 – Unobservable inputs that reflect management’s assumptions

	For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

F-28

Table of Contents

	The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000. The T-bills mature in December 2021 and yield a weighted average interest rate of 0.10%.

	As of September 30, 2021 and 2020, all of the Company’s derivative liabilities are classified as Level 3.

	The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:

	2021			2020
Beginning balance	$	3,765,613		$	6,488,310
Issuances		-			-
Exercises		(4,023,091	)		(3,071,775	)
N Net realized and unrealized derivative loss		694,858			349,078
Ending balance	$	437,380		$	3,765,613

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock. At September 30, 2021, the Company’s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years. At September 30, 2020, the Company’s Level 3 derivative instruments have a weighted average fair value of $2.81 per share and a weighted average exercise price of $14.32 per share. Fair values were determined using a weighted average risk free interest rate of 0.12% and volatility of 95%. The instruments have a weighted average time to maturity of 1.2 years.

14.	NET LOSS PER COMMON SHARE

	Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.

	The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:

	Year ended September 30,
	2021			2020
Loss per share – basic
Net loss available to common shareholders - basic	$	(36,711,970	)	$	(30,276,978	)
Weighted average shares outstanding - basic		40,662,137			36,759,115
Basic loss per common share	$	(0.90	)	$	(0.82	)

Loss per share – diluted
Net loss available to common shareholders - basic	$	(36,711,970	)	$	(30,276,978	)
Unrealized gain on derivatives ⁽¹⁾		(1,085,540	)		-
Net loss available to common shareholders - diluted	$	(37,797,510	)	$	(30,276,978	)

Weighted average shares outstanding - basic		40,662,137			36,759,115
Incremental shares underlying dilutive warrants ⁽¹⁾		32,111			-
Weighted average shares outstanding - diluted		40,694,248			36,759,115
Diluted loss per common share	$	(0.93	)	$	(0.82	)

F-29

Table of Contents

⁽¹⁾	Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.

	In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:

	2021		2020
Options and Warrants		10,604,850		7,221,696
Unvested Restricted Stock		151,250		308,814
Total		10,756,100		7,530,510

15. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

F-30

In accordance with Section 13 or 15(a) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 21^st day of December 2021.

	CEL-SCI CORPORATION

	By:	/s/ Geert Kersten
		Geert Kersten, Chief Executive Officer

Pursuant to the requirements of the Securities Act of l934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Geert Kersten	Chief Executive, Principal
Geert R. Kersten	Accounting, Principal Financial
	Officer and a Director	December 21, 2021

/s/ Peter Young	Director	December 21, 2021
Dr. Peter R. Young

/s/ Bruno Baillavoine	Director	December 21, 2021
Bruno Baillavoine

/s/ Robert Waton	Director	December 21, 2021
Robert Watson

CEL-SCI CORPORATION

FORM 10-K

EXHIBITS

EX-23.1 2 cvm_ex231.htm CONSENTS OF EXPERTS AND COUNSEL cvm_ex231.htm

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

CEL-SCI Corporation

Vienna, Virginia

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File numbers 333-162039, 333-161504, 333-162792, 333-184094, 333-186103, 333-196243, 333-205444 and 333-226558) and Form S-8 (File numbers 333-117088, 333-140792, 333-162265, 333-179477, 333-184092, 333-198244, 333-206538, 333-214031, 333-222969, 333-228252, 333-236063 and 333-237845) of CEL-SCI Corporation of our report dated December 21, 2021, relating to the financial statements, which appear in this Form 10-K.

		/s/BDO USA, LLP

Potomac, Maryland
December 21, 2021

EX-31 3 cvm_ex31.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 cvm_ex31.htm

EXHIBIT 31

CERTIFICATIONS

I, Geert Kersten, of CEL-SCI Corporation, certify that:

1.	I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

December 21, 2021	By:	/s/ Geert Kersten
		Geert R. Kersten
		Principal Executive Officer

CERTIFICATIONS

I, Geert Kersten, of CEL-SCI Corporation, certify that:

1.	I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

December 21, 2021	By:	/s/ Geert Kersten
		Geert R. Kersten
		Principal Financial Officer

EX-32 4 cvm_ex32.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 cvm_ex32.htm

EXHIBIT 32

In connection with the Annual Report of CEL-SCI Corporation (the “Company”) on Form 10-K for the period ending September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Chief Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects the financial condition and results of the Company.

December 21, 2021

By:

/s/ Geert Kersten

Geert Kersten, Chief Executive and Principal

Financial and Accounting Officer

GRAPHIC 5 cvm_10kimg1.jpg IMAGE begin 644 cvm_10kimg1.jpg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end EX-101.SCH 6 cvm-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - OPERATIONS AND FINANCING link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - STOCK COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - STOCK COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - PATENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - STOCK COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - STOCK COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - STOCK COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - STOCK COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - STOCK COMPENSATION (Details 4) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - STOCK COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative ) link:presentationLink link:calculationLink link:definitionLink 000057 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000061 - Disclosure - NET LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cvm-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cvm-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cvm-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED BALANCE SHEETS ASSETS Current Assets: Cash and cash equivalents U.S. Treasury Bills Receivables Prepaid expenses Supplies used for R&D and manufacturing Total current assets [Assets, Current] Finance lease right of use assets Operating lease right of use assets Property and equipment, net Patent costs, net Deposits Total assets [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Accrued expenses Due to employees Derivative instruments, current portion Lease liabilities, current portion Total current liabilities [Liabilities, Current] Derivative instruments, net of current portion Finance lease liabilities, net of current portion Operating lease liabilities, net of current portion Other liabilities Total liabilities [Liabilities] Commitments and Contingencies STOCKHOLDERS' EQUITY Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Grant income Operating expenses: Research and development General and administrative Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Other (expense) income Loss on derivative instruments Warrant inducement expense [Fair Value Adjustment of Warrants] Other non-operating gain Interest expense, net Net loss [Net Income (Loss) Attributable to Parent] Modification of warrants Net loss available to common shareholders [Net Income (Loss) Available to Common Stockholders, Basic] Net loss per common share - basic Weighted average common shares outstanding - basic Net loss per common share - diluted Weighted average common shares outstanding - diluted STATEMENTS OF STOCKHOLDERS' EQUITY Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Adoption of ASC 842, Leases Proceeds from the sale of common stock, shares Proceeds from the sale of common stock, amount Warrant issuances Warrant exercises, shares Warrant exercises, amount Modification of warrants [Modification of warrants] 401(k) contributions paid in common stock, shares 401(k) contributions paid in common stock, amount Stock issued to nonemployees for service, shares Stock issued to nonemployees for service, amount Equity based compensation - employees Option exercises, shares Option exercises, amount Purchase of stock by officers and directors, shares Purchase of stock by officers and directors, amount Share issuance costs Shares issued for settlement of clinical research costs, shares Shares issued for settlement of clinical research costs, amount Net loss Equity based compensation - employees, shares Balance, shares Balance, amount CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Share-based payments for services Equity based compensation Common stock contributed to 401(k) plan Shares issued for settlement of clinical research costs Gain on short-term investments Loss on derivative instruments [Loss on derivative instruments] Warrant inducement expense Modification of warrants [Modification of warrants 1] (Increase)/decrease in assets: Receivables [Increase (Decrease) in Receivables] Prepaid expenses [Increase (Decrease) in Prepaid Expense] Supplies used for R&D and manufacturing [Supplies used for R&D and manufacturing] Deposits [Deposits] Increase/(decrease) in liabilities: Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Due to employees [Increase (Decrease) in Due to Officers and Stockholders] Other liabilities [Increase (Decrease) in Other Operating Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Net purchases of U.S. Treasury Bills [Net purchases of U.S. Treasury Bills] Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Expenditures for patent costs [Payments to Acquire Intangible Assets] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock Payments of stock issuance costs [Payments of Stock Issuance Costs] Proceeds from exercise of warrants Proceeds from exercises of options Proceeds from the purchase of stock by officers and directors Proceeds from landlord funding of leasehold improvements Payments on obligations under finance leases [Repayments of Debt and Lease Obligation] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE IN CASH AND CASH EQUIVALENTS [Cash and Cash Equivalents, Period Increase (Decrease)] CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR CASH AND CASH EQUIVALENTS, END OF YEAR SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Property and equipment included in accrued expenses and accounts payable Capitalizable patent costs included in accrued expenses and accounts payable Changes to right of use assets and liabilities Finance lease obligation included in accounts payable Prepaid consulting services paid with issuance of common stock Fair value of warrants liabilities on date of exercise Financing costs included in accounts payable Accrued consulting services to be paid with common stock Cash paid for interest ORGANIZATION 1. ORGANIZATION OPERATIONS AND FINANCING 2. OPERATIONS AND FINANCING SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES WARRANTS AND NON-EMPLOYEE OPTIONS 4. WARRANTS AND NON-EMPLOYEE OPTIONS PLANT, PROPERTY AND EQUIPMENT 5. PLANT, PROPERTY AND EQUIPMENT PATENTS 6. PATENTS INCOME TAXES 7. INCOME TAXES STOCK COMPENSATION 8. STOCK COMPENSATION EMPLOYEE BENEFIT PLAN 9. EMPLOYEE BENEFIT PLAN 10. COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS 11. RELATED PARTY TRANSACTIONS STOCKHOLDERS EQUITY 12. STOCKHOLDERS' EQUITY FAIR VALUE MEASUREMENTS 13. FAIR VALUE MEASUREMENTS NET LOSS PER COMMON SHARE 14. NET LOSS PER COMMON SHARE SUBSEQUENT EVENTS 15. SUBSEQUENT EVENTS Cash and Cash Equivalents U.S. Treasury Bills [U.S. Treasury Bills] Supplies used for R&D and manufacturing [Supplies used for R&D and manufacturing 1] Property and Equipment Patents Leases Derivative Instruments Stock-Based Compensation Research and Development Costs Grant Income Net Loss Per Common Share Concentration of Credit Risk Income Taxes Use of Estimates New Accounting Pronouncements Schedule of warrants and non-employee options Schedule of equity warrants were exercised Schedule of warrants recorded as liabilities were exercised Schedule of warrant liabilities Schedule of (losses)/gains on the warrant liabilities Schedule of plant, property and equipment Schedule of patents Schedule of total estimated future amortization Schedule of components of the Company's deferred tax assets Schedule of federal or state current or deferred tax expense or benefit Schedule of expenses for options issued or vested and restricted stock awarded Schedule of fair value of each option granted Schedule of non-qualified and incentive stock option plans Schedule of non-vested options Schedule of restricted common stock issued from the incentive stock bonus plan Schedule of future minimum payments under finance leases Schedule of future minimum payments under operating leases Schedule of other non-operating gains (losses) Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations Schedule of anti-dilutive securities Patent useful life Fully insured amount of non-interest bearing cash balances WARRANTS AND NONEMPLOYEE OPTIONS (Details) Derivative Instrument Risk Axis Class Of Warrant Or Right Axis Related Party [Axis] Series N [Member] Series W [Member] Series X [Member] Series Y [Member] Series ZZ [Member] Series BB [Member] Series Z [Member] Series CC [Member] Series HH [Member] Series AA [Member] Series MM [Member] Series NN [Member] Consultants [Member] Series RR [Member] Series SS [Member] Series TT [Member] Series UU [Member] Issue Date Shares Issuable upon Exercise of Warrant Exercise Price Expiration Date Series FF [Member] Series JJ [Member] Series LL [Member] Series V [Member] Total warrant liabilities Net (loss) gain on warrant liabilities Proceeds Warrants Exercised Exercise Price [Exercise Price] Series OO [Member] Series VV [Member] Equity Warrants Exercised Proceeds from Equity Warrants Exercised Equity Warrants Exercise Price Range Axis Award Type [Axis] Plan Name [Axis] Series V Warrants [Member] Maximum [Member] Minimum [Member] Series XX Warrants [Member] Series YY Warrants [Member] Series UU warrants [Member] Series N and Series X [Member] Series N Warrants [Member] Restricted Stock [Member] Consultants [Member] Consulting Agreements [Member] Incremental cost Common stock issued for service, shares Warrant inducement expense [Warrant inducement expense] Warrants exercised shares Warrants exercised Expiration date description Warrants expired Fair value of warrant Common stock price per share Warrants issued during period Weighted average grant date fair value Total expense Prepaid expenses [Prepaid expenses] Options issued Option issued to related party Option expiration date Stock prices per share Research equipment Furniture and equipment Leasehold improvements Gross Accumulated depreciation and amortization [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Net property and equipment Depreciation expense PATENTS (Details) Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Patents Accumulated amortization Patents, net 2022 2023 2024 2025 2026 Thereafter Total [Total] Amortization of patent costs NOL carryforwards Lease liabilities R&D credit Stock-based compensation Capitalized R&D Vacation and other Total deferred tax assets Right of use assets Fixed assets and intangibles Total deferred tax liability [Deferred Tax Liabilities, Net] Net deferred tax asset Valuation allowance [Deferred Tax Assets, Valuation Allowance] Ending Balance Federal Rate Federal rate change State tax rate, net of federal benefit Other adjustments Permanent differences Change in valuation allowance Effective tax rate Tax Credit Carryforward [Axis] Income Tax [Member] Research and development credit Research and development credit, description Federal net operating loss carryforwards Cumulative change in ownership percentage Net operating loss carryforwards, description Estimated net operating loss carryforwards Employees Non-employees Expected stock price volatility, min Expected stock price volatility, max Risk-free interest rate, min Risk-free interest rate, max Expected life of options, min Expected life of options, max Expected dividend yield Sale of Stock [Axis] Option Indexed to Issuer's Equity [Axis] Exercisable [Member] Outstanding [Member] Number of Options Outstanding, Beginning [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number] Number of Options Vested [Number of Options Vested] Number of Options Exercised Number of Options Expired Number of Options Outstanding, Ending Weighted Average Exercise Price Outstanding, Beginning [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted Average Exercise Price Vested [Weighted Average Exercise Price Vested] Weighted Average Exercise Price Exercised Weighted Average Exercise Price Expired Weighted Average Exercise Price Outstanding, Ending Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending Aggregate Intrinsic Value Outstanding, Beginning Aggregate Intrinsic Value Outstanding, Ending Number of Options Granted Number of Options Forfeited Weighted Average Exercise Price Granted Weighted Average Exercise Price Forfeited Number of unvested options, Beginning Vested options Granted options Forfeited options Number of unvested options, Ending Weighted Average Grant Date Fair Value, Beginning Weighted Average Grant Date Fair Value, Ending Award Type Axis Restricted Stock Awards [Member] Number of unvested shares, Beginning Forfeited Vested shares Number of unvested shares, Ending Weighted Average Grant Date Fair Value, Beginning Weighted Average Grant Date Fair Value, Ending [Weighted Average Grant Date Fair Value, Ending] Stock Bonus Plans [Member] Stock Compensation Plans [Member] Non-Qualified Stock Options Plans [Member] Incentive Stock Option Plans [Member] Incentive Stock Bonus Plan [Member] Common stock, shares issued Common stock, shares authorized Unrecognized compensation expense [Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount] Remaining compensation expense Issuance of common stock options purchase shares Performance based stock options shares granted Stock price Stock options vest description Fair value per share Grant date fair value remaining outstanding Grant date fair value remaining Implicit life of options Expense life over next Vested shares Issuance of restricted stock Unrecognized compensation expense EMPLOYEE BENEFIT PLAN (Detail Narrative) Expense for Company's contribution to employee benefit plan Total compensation Participant compensation Shares issued 2022 [Finance Lease, Liability, to be Paid, Year One] 2023 [Finance Lease, Liability, to be Paid, Year Two] 2024 [Finance Lease, Liability, to be Paid, Year Three] 2025 [Finance Lease, Liability, to be Paid, Year Four] 2026 [Finance Lease, Liability, to be Paid, Year Five] Thereafter [Finance Lease, Liability, to be Paid, after Year Five] Total future minimum lease obligation Less imputed interest on financing obligation Net present value of lease financing obligation [Net present value of lease financing obligation] 2022 [Lessee, Operating Lease, Liability, to be Paid, Year One] 2023 [Lessee, Operating Lease, Liability, to be Paid, Year Two] 2024 [Lessee, Operating Lease, Liability, to be Paid, Year Three] 2025 [Lessee, Operating Lease, Liability, to be Paid, Year Four] 2026 [Lessee, Operating Lease, Liability, to be Paid, Year Five] Thereafter [Lessee, Operating Lease, Liability, to be Paid, after Year Five] Total future minimum lease obligation [Total future minimum lease obligation] Less imputed interest on operating lease obligation [Lessee, Operating Lease, Liability, Undiscounted Excess Amount] Total [Lessee, Operating Lease, Liability, to be Paid] Segments [Axis] Related Party Transaction [Axis] Award Date [Axis] Product Or Service Axis Vendor Obligations [Member] Landlord [Member] TransactionTwoMember [Member] October 1, 2019 [Member] Transaction One [Member] Ergomed [Member] Biologics License Application [Member] Weighted average discount rate Weighted average discount rate operating lease Interest rate Maturity years Operating lease maturity years Research and development expenses Net of discount Lease description Finance lease obligations, net of current portion Additional expenses Lease incentive payable current Additional deposit Cost incurred, initial Estimated cost Non current assets Financing arrangement Change in right of use of assets and liability Cash paid related to operating leases Net book value operating lease right of use assets Current balance Operating lease - liability Operating lease expense Operating lease - liability [Operating Lease, Liability, Current] Finance lease liability Net book value of the finance lease right of use asset Balance of the finance lease liability Cash paid related to finance leases Cash paid related to finance leases interest Clinical service trial Additional clinical trial Weighted average time to maturity Sublease rental income Series N Warrants [Member] Series UU warrants [Member] Series X Warrants [Member] Series N and X Warrants [Member] Officer and Director [Member] Expiration date description Incremental cost [Other Cost and Expense, Operating] Warrants issued Interest expense Restricted Common shares Restricted Common shares, amount Amount realized through the resale of shares Fair value of shares upon issuance Other non-operating gain (loss) Ergomed [Member] Common stock shares issued Proceeds from public offering Proceeds from initial public offering Public offering price per share Proceeds from issuance of warrant Warrants exercised [Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised] Prepaid of resold amount Beginning balance [Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value] Issuances Exercises [Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales] Net realized and unrealized derivative loss Ending balance Fair Value By Fair Value Hierarchy Level Axis Fair Value Inputs Level 3 (Level 3) unrealized gain on short-term T-bills Weighted average risk free interest rate Weighted average fair value, Derivative instruments Weighted average exercise price, Derivative instruments Volatility rate Weighted average time to maturity year Net loss available to common shareholders - basic Weighted average shares outstanding - basic Basic loss per common share Loss per share- diluted Net loss available to common shareholders -basic Unrealized gain on derivatives Net loss available to common shareholders - diluted Weighted average shares outstanding - basic Incremental shares underlying dilutive "in the money" warrants Weighted average shares outstanding - diluted Diluted loss per common share Options and Warrants Unvested Restricted Stock [Member] Antidilutive securities Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an Amount of increase in the fair value of derivatives recognized in the income statement. Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement. The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan. Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are Present value of lessee's discounted obligation for lease payments from finance lease. Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. EX-101.PRE 10 cvm-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.4

Cover - USD ($)
12 Months Ended

Sep. 30, 2021

Dec. 10, 2021

Mar. 31, 2021

Cover [Abstract]

Entity Registrant Name CEL-SCI CORPORATION

Entity Central Index Key 0000725363

Document Type 10-K

Amendment Flag false

Entity Voluntary Filers No

Current Fiscal Year End Date --09-30

Entity Well Known Seasoned Issuer No

Entity Small Business true

Entity Shell Company false

Entity Emerging Growth Company false

Entity Current Reporting Status Yes

Document Period End Date Sep. 30, 2021

Entity Filer Category Non-accelerated Filer

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2021

Entity Common Stock Shares Outstanding 43,244,498

Entity Public Float $ 595,537,907

Document Annual Report true

Document Transition Report false

Entity File Number 1-11889

Entity Incorporation State Country Code CO

Entity Tax Identification Number 84-0916344

Entity Address Address Line 1 8229 Boone Blvd.

Entity Address Address Line 2 Suite 802

Entity Address City Or Town Vienna

Entity Address State Or Province VA

Entity Address Postal Zip Code 22182

City Area Code 703

Local Phone Number 506-9460

Security 12b Title Common Stock

Trading Symbol CVM

Security Exchange Name NYSE

Entity Interactive Data Current Yes

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.4

CONDENSED BALANCE SHEETS - USD ($)

Sep. 30, 2021

Sep. 30, 2020

Current Assets:

Cash and cash equivalents $ 36,060,148 $ 15,508,909

U.S. Treasury Bills 6,151,385 0

Receivables 54,922 54,922

Prepaid expenses 998,482 1,313,432

Supplies used for R&D and manufacturing 2,006,584 820,052

Total current assets 45,271,521 17,697,315

Finance lease right of use assets 12,691,921 13,811,849

Operating lease right of use assets 2,056,178 1,198,958

Property and equipment, net 13,663,562 5,843,993

Patent costs, net 275,866 313,422

Deposits 1,910,917 1,670,917

Total assets 75,869,965 40,536,454

Current Liabilities:

Accounts payable 1,675,813 2,023,067

Accrued expenses 859,216 510,515

Due to employees 265,993 448,022

Derivative instruments, current portion 437,380 213,787

Lease liabilities, current portion 698,665 1,070,123

Total current liabilities 3,937,067 4,265,514

Derivative instruments, net of current portion 0 3,551,826

Finance lease liabilities, net of current portion 13,252,364 11,753,100

Operating lease liabilities, net of current portion 2,021,308 1,114,340

Other liabilities 125,000 125,000

Total liabilities 19,335,739 20,809,780

STOCKHOLDERS' EQUITY

Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively 432,072 387,302

Additional paid-in capital 474,298,566 401,174,675

Accumulated deficit (418,196,412) (381,835,303)

Total stockholders' equity 56,534,226 19,726,674

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 75,869,965 $ 40,536,454

X

- References
No definition available.
+ Details

Name: cvm_LeaseLiabilitiesCurrentPortion

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12))
-URI http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(17))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToOfficersOrStockholdersCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.4

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2021

Sep. 30, 2020

CONDENSED BALANCE SHEETS

Preferred stock, par value $ 0.01 $ 0.01

Preferred stock, shares authorized 200,000 200,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 600,000,000 600,000,000

Common stock, shares issued 43,207,183 38,730,150

Common stock, shares outstanding 43,207,183 38,730,150

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.4

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

Grant income $ 0 $ 558,664

Operating expenses:

Research and development 23,108,897 17,840,290

General and administrative 13,085,232 11,703,429

Total operating expenses 36,194,129 29,543,719

Operating loss (36,194,129) (28,985,055)

Other (expense) income (8,213) 38,763

Loss on derivative instruments (694,858) (349,078)

Warrant inducement expense 0 (805,753)

Other non-operating gain 1,685,379 887,604

Interest expense, net (1,149,288) (1,041,725)

Net loss (36,361,109) (30,255,244)

Modification of warrants (350,861) (21,734)

Net loss available to common shareholders $ (36,711,970) $ (30,276,978)

Net loss per common share - basic $ (0.90) $ (0.82)

Weighted average common shares outstanding - basic 40,662,137 36,759,115

Net loss per common share - diluted $ (0.93) $ (0.82)

Weighted average common shares outstanding - diluted 40,694,248 36,759,115

X

- References
No definition available.
+ Details

Name: cvm_ModificationOfWarrants

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue and income classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.4)
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7,9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.4

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)

Total

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Balance, shares at Sep. 30, 2019 35,231,776

Balance, amount at Sep. 30, 2019 $ 5,133,667 $ 352,318 $ 358,507,603 $ (353,726,254)

Adoption of ASC 842, Leases 2,146,195 2,146,195

Proceeds from the sale of common stock, shares 1,422,429

Proceeds from the sale of common stock, amount 13,992,439 $ 14,225 13,978,214 0

Warrant issuances 805,753 $ 0 805,753 0

Warrant exercises, shares 1,711,873

Warrant exercises, amount 15,144,240 $ 17,118 15,127,122 0

Modification of warrants 5,554 $ 0 5,554

401(k) contributions paid in common stock, shares 13,870

401(k) contributions paid in common stock, amount 163,340 $ 139 163,201 0

Stock issued to nonemployees for service, shares 79,950

Stock issued to nonemployees for service, amount 972,667 $ 799 971,868 0

Equity based compensation - employees 10,112,968 $ 0 10,112,968 0

Option exercises, shares 99,740

Option exercises, amount 338,328 $ 998 337,330 0

Purchase of stock by officers and directors, shares 20,512

Purchase of stock by officers and directors, amount 184,990 $ 205 184,785 0

Share issuance costs (787,723) $ 0 (787,723) 0

Shares issued for settlement of clinical research costs, shares 150,000

Shares issued for settlement of clinical research costs, amount 1,769,500 $ 1,500 1,768,000 0

Net loss (30,255,244) $ 0 0 (30,255,244)

Balance, shares at Sep. 30, 2020 38,730,150

Balance, amount at Sep. 30, 2020 19,726,674 $ 387,302 401,174,675 (381,835,303)

Proceeds from the sale of common stock, shares 2,610,000

Proceeds from the sale of common stock, amount 47,363,426 $ 26,100 47,337,326 0

Warrant exercises, shares 1,597,870

Warrant exercises, amount 10,007,306 $ 15,978 9,991,328 0

Modification of warrants 24,387 $ 0 24,387 0

401(k) contributions paid in common stock, shares 17,990

401(k) contributions paid in common stock, amount 201,099 $ 180 200,919 0

Stock issued to nonemployees for service, shares 75,885

Stock issued to nonemployees for service, amount 1,195,704 $ 759 1,194,945 0

Equity based compensation - employees 13,685,046 $ (20) 13,685,066 0

Option exercises, shares 149,788

Option exercises, amount 746,228 $ 1,498 744,730 0

Purchase of stock by officers and directors, shares 27,500

Purchase of stock by officers and directors, amount 220,000 $ 275 219,725 0

Share issuance costs (274,535) 0 (274,535) 0

Net loss (36,361,109) $ 0 0 (36,361,109)

Equity based compensation - employees, shares (2,000)

Balance, shares at Sep. 30, 2021 43,207,183

Balance, amount at Sep. 30, 2021 $ 56,534,226 $ 432,072 $ 474,298,566 $ (418,196,412)

X

- References
No definition available.
+ Details

Name: cvm_AdoptionOfAsc842Leases

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ModificationOfWarrantsAmount

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ProceedsFromTheSaleOfCommonStockShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.
+ References
No definition available.
+ Details

Name: cvm_ShareIssuanceCosts

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantExercisesAmount

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantExercisesShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantIssuances

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.4

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (36,361,109) $ (30,255,244)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 2,231,108 2,159,729

Share-based payments for services 1,226,690 862,796

Equity based compensation 13,685,046 10,112,968

Common stock contributed to 401(k) plan 201,099 163,340

Shares issued for settlement of clinical research costs 0 1,769,500

Gain on short-term investments (5,621) 0

Loss on derivative instruments 694,858 349,078

Warrant inducement expense 0 805,753

Modification of warrants 24,387 5,554

(Increase)/decrease in assets:

Receivables 0 7,843

Prepaid expenses 283,964 (623,608)

Supplies used for R&D and manufacturing (1,186,532) (37,689)

Deposits (240,000) 0

Increase/(decrease) in liabilities:

Accounts payable 445,981 (766,073)

Accrued expenses 363,701 406,083

Due to employees (182,029) (261,420)

Other liabilities 31,441 25,229

Net cash used in operating activities (18,787,016) (15,276,161)

CASH FLOWS FROM INVESTING ACTIVITIES:

Net purchases of U.S. Treasury Bills (6,145,764) 0

Purchases of property and equipment (9,016,329) (2,654,906)

Expenditures for patent costs (22,641) (39,975)

Net cash used in investing activities (15,184,734) (2,694,881)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock 47,363,426 13,992,439

Payments of stock issuance costs (325,034) (752,804)

Proceeds from exercise of warrants 5,984,215 12,072,465

Proceeds from exercises of options 746,228 338,328

Proceeds from the purchase of stock by officers and directors 220,000 184,990

Proceeds from landlord funding of leasehold improvements 1,613,546 0

Payments on obligations under finance leases (1,079,392) (800,241)

Net cash provided by financing activities 54,522,989 25,035,177

NET INCREASE IN CASH AND CASH EQUIVALENTS 20,551,239 7,064,135

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 15,508,909 8,444,774

CASH AND CASH EQUIVALENTS, END OF YEAR 36,060,148 15,508,909

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Property and equipment included in accrued expenses and accounts payable 435,412 1,184,723

Capitalizable patent costs included in accrued expenses and accounts payable 6,510 15,000

Changes to right of use assets and liabilities 551,444 399,032

Finance lease obligation included in accounts payable 855 790

Prepaid consulting services paid with issuance of common stock 363,911 164,871

Fair value of warrants liabilities on date of exercise 4,023,091 3,071,775

Financing costs included in accounts payable 0 50,499

Accrued consulting services to be paid with common stock 55,000 55,000

Cash paid for interest $ 1,173,702 $ 1,155,026

X

- References
No definition available.
+ Details

Name: cvm_AccruedConsultingServicesToBePaidWithCommonStock

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ChangesToRightOfUseAssetsAndLiabilities

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_CommonStockContributedToEmployeeBenefitPlan

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_FinanceLeaseObligationIncludedInAccountsPayable

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_FinancingCostsIncludedInAccountsPayable

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an
+ References
No definition available.
+ Details

Name: cvm_LossOnDerivativesInstruments

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ModificationOfWarrant

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NetPurchasesOfUSTreasuryBills

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SharesIssuedForSettlementOfClinicalResearchCosts

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ShortTermDeposits

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
No definition available.
+ Details

Name: cvm_ShortTermInvestment

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SuppliesUsedForRDAndManufacturing

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for short-term and long-term debt and lease obligation.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.4

ORGANIZATION
12 Months Ended

Sep. 30, 2021

ORGANIZATION

1. ORGANIZATION
1.
ORGANIZATION

CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.

The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently announced top line Phase 3 data for its lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.

CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.4

OPERATIONS AND FINANCING
12 Months Ended

Sep. 30, 2021

OPERATIONS AND FINANCING

2. OPERATIONS AND FINANCING
2.
OPERATIONS AND FINANCING

On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.

Liquidity

The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.

Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.

Impact of COVID-19 Pandemic

In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended

Sep. 30, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.

U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.

Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.

Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Leases – On October 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases and its related amendments (collectively referred to as Topic 842 and codified as “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company’s statements of operations or cash flows.


The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.

Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Grant Income – The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.

Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Concentration of Credit Risk – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021.

Income Taxes – The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.

Use of Estimates – The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.

New Accounting Pronouncements

The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS
12 Months Ended

Sep. 30, 2021

WARRANTS AND NON-EMPLOYEE OPTIONS

4. WARRANTS AND NON-EMPLOYEE OPTIONS
4.
WARRANTS AND NON-EMPLOYEE OPTIONS

The following warrants and non-employee options are outstanding at September 30, 2021:

Warrant/Options

Issue Date

Shares Issuable upon Exercise
of Warrants/ Options

Exercise Price

Expiration Date

Series N

8/18/2008

85,339

$ 3.00

8/18/2022

Series UU

6/11/2018

93,603

$ 2.80

6/30/2022

Series X

1/13/2016

120,000

$ 9.25

7/13/2022

Series Y

2/15/2016

26,000

$ 12.00

8/15/2022

Series Z

5/23/2016

184,800

$ 13.75

11/23/2021

Series CC

12/8/2016

15,845

$ 5.00

12/8/2021

Series HH

2/23/2017

200

$ 3.13

2/16/2022

Series AA

8/26/2016

100,000

$ 13.75

2/22/2022

Series MM

6/22/2017

333,432

$ 1.86

6/22/2022

Series NN

7/24/2017

210,087

$ 2.52

7/24/2022

Series RR

10/30/2017

251,761

$ 1.65

10/30/2022

Series SS

12/19/2017

200,000

$ 2.09

12/18/2022

Series TT

2/5/2018

600

$ 2.24

2/5/2023

Consultants

7/28/2017 – 11/18/2020

15,000

$
2.18 - $11.61

11/17/2022 - 7/27/2027

The following warrants and non-employee options are outstanding at September 30, 2020:

Warrant

Issue Date

Shares Issuable upon Exercise
of Warrants/Options

Exercise Price

Expiration Date

Series N

8/18/2008

85,339

$ 3.00

2/18/2021

Series UU

6/11/2018

93,603

$ 2.80

12/31/2020

Series W

10/28/2015

688,930

$ 16.75

10/28/2020

Series X

1/13/2016

120,000

$ 9.25

1/13/2021

Series Y

2/15/2016

26,000

$ 12.00

2/15/2021

Series ZZ

5/23/2016

20,000

$ 13.75

5/18/2021

Series BB

8/26/2016

16,000

$ 13.75

8/22/2021

Series Z

5/23/2016

264,000

$ 13.75

11/23/2021

Series CC

12/8/2016

148,643

$ 5.00

12/8/2021

Series HH

2/23/2017

200

$ 3.13

2/16/2022

Series AA

8/26/2016

200,000

$ 13.75

2/22/2022

Series MM

6/22/2017

797,633

$ 1.86

6/22/2022

Series NN

7/24/2017

348,842

$ 2.52

7/24/2022

Series RR

10/30/2017

417,649

$ 1.65

10/30/2022

Series SS

12/19/2017

326,064

$ 2.09

12/18/2022

Series TT

2/5/2018

371,564

$ 2.24

2/5/2023

Consultants

7/28/17

10,000

$ 2.18

7/27/2027

A. Warrant Liabilities

Warrant liabilities outstanding at September 30 are as follows:

2021

2020

Series W warrants

$ -

$ 73,570

Series Z warrants

64,787

1,207,902

Series ZZ warrants

-

75,044

Series AA warrants

276,035

1,082,212

Series BB warrants

-

65,173

Series CC warrants

94,961

1,259,712

Series HH warrants

1,597

2,000

Total warrant liabilities

$ 437,380

$ 3,765,613

The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows:

2021

2020

Series V Warrants

$ -

$ 185,652

Series W warrants

73,570

1,119,937

Series Z warrants

252,115

(98,357 )
Series ZZ warrants

(98,692 )

2,594

Series AA warrants

(318,823 )

(165,304 )
Series BB warrants

65,173

(1,207 )
Series CC warrants

(668,605 )

(875,040 )
Series FF warrants

-

(319,706 )
Series HH warrants

404

(34,589 )
Series JJ warrants

-

(64,992 )
Series LL warrants

-

(98,066 )
Net loss on warrant liabilities

$ (694,858 )

$ (349,078 )

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.

Changes in Warrant Liabilities

On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75 expired.

On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.

On May 26, 2020, the Company lowered the exercise price of 810,127 Series V warrants from $19.75 to $13.75 per share and extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020. The incremental cost of this modification was approximately $664,000, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, 135,963 Series V warrants, with an exercise price of $13.75 expired. The warrants were valued at approximately $211,000 on the date of expiration.

Exercise of Warrant Liabilities

The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series Z

79,200

$ 13.75

$ 1,089,000

Series ZZ

20,000

$ 13.75

275,000

Series AA

100,000

$ 13.75

1,375,000

Series CC

132,798

$ 5.00

663,990

331,998

$ 3,402,990

The following warrants recorded as liabilities were exercised during the year ended September 30, 2020:

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series V

674,164

$ 13.75

$ 9,269,755

Series CC

128,820

$ 5.00

644,100

Series FF

68,048

$ 3.91

265,812

Series HH

6,300

$ 3.13

19,687

Series JJ

9,450

$ 3.13

29,531

Series LL

26,398

$ 3.59

94,867

913,180

$ 10,323,752

B.
Equity Warrants

Changes in Equity Warrants

On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $351,000 for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants extension approximated $103,000 and had no impact on the financial statements for the year ended September 30,2021 due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $24,000 for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.

On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $20.00 per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and 101,839 Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $629,000 and $177,000, respectively. The total expense of approximately $806,000 is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.

On May 8, 2020, the expiration dates of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.

Exercise of Equity Warrants

The following equity warrants were exercised during the year ended September 30, 2021.

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series MM

464,201

$ 1.86

$ 863,414

Series NN

138,755

$ 2.52

349,663

Series RR

165,888

$ 1.65

273,715

Series SS

126,064

$ 2.09

263,474

Series TT

370,964

$ 2.24

830,959

1,265,872

$ 2,581,225

The following equity warrants were exercised during the year ended September 30, 2020.

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series MM

95,858

$ 1.86

$ 178,296

Series NN

124,956

$ 2.52

314,889

Series OO

50,000

$ 2.52

126,000

Series RR

39,467

$ 1.65

65,121

Series SS

156,580

$ 2.09

327,252

Series TT

188,125

$ 2.24

421,400

Series UU

61,207

$ 2.80

171,380

Series VV

82,500

$ 1.75

144,375

798,693

$ 1,748,713

C.
Options and Shares Issued to Consultants

The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued 75,885 and 79,950 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $6.86 to $24.95 per share. The weighted average grant price was $15.46 and $12.01, respectively, for stock issued during the years ended September 30, 2021 and 2020.

During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $1,227,000 and $863,000, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $364,000 and $395,000, respectively, are included in prepaid expenses.

During the year ended September 30, 2021, the Company issued 5,000 options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of November 17, 2022. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, 15,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.

X

- References
No definition available.
+ Details

Name: cvm_WarrantsAndNonEmployeeOptionstextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.4

PLANT, PROPERTY AND EQUIPMENT
12 Months Ended

Sep. 30, 2021

PLANT, PROPERTY AND EQUIPMENT

5. PLANT, PROPERTY AND EQUIPMENT

5.
PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30:

2021

2020

Research equipment

$ 4,211,124

$ 3,898,242

Furniture and equipment

99,768

99,768

Leasehold improvements

13,465,123

5,519,161

17,776,015

9,517,171

Accumulated depreciation and amortization

(4,112,453 )

(3,673,178 )

Net property and equipment

$ 13,663,562

$ 5,843,993

Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $447,000 and $389,000 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.4

PATENTS
12 Months Ended

Sep. 30, 2021

PATENTS

6. PATENTS
6.
PATENTS

Patents consist of the following at September 30:

2021

2020

Patents

$ 910,523

$ 896,372

Accumulated amortization

(634,657 )

(582,950 )

Patents, net

$ 275,866

$ 313,422

During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $52,000 and $53,000, respectively. The total estimated future amortization is as follows:

Years ending September 30,

2022

$ 49,000

2023

39,000

2024

31,000

2025

29,000

2026

25,000

Thereafter

103,000

$ 276,000

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.4

INCOME TAXES
12 Months Ended

Sep. 30, 2021

INCOME TAXES

7. INCOME TAXES
7.
INCOME TAXES

At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company’s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.

Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company’s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.

The Company had federal NOL carryforwards of approximately $77.1 million and $51.5 million at September 30, 2021 and 2020, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (“R&D credit”) of approximately $1.2 million at September 30, 2021 and 2020. The R&D credit expires during the fiscal year ended 2029.

Significant components of the Company’s deferred tax assets as of September 30, 2021 and 2020 are listed below:


2021

2020

NOL carryforwards

$ 19,789,000

$ 13,407,000

Lease liabilities

4,101,000

3,631,000

R&D credit

1,221,000

1,221,000

Stock-based compensation

7,785,000

5,297,000

Capitalized R&D

15,040,000

15,853,000

Vacation and other

126,000

125,000

Total deferred tax assets

48,062,000

39,534,000

Right of use assets

(3,786,000 )

(3,911,000 )
Fixed assets and intangibles

(172,000 )

(169,000 )
Total deferred tax liability

(3,958,000 )

(4,080,000 )

Net deferred tax asset

44,104,000

35,454,000

Valuation allowance

(44,104,000 )

(35,454,000 )
Ending Balance

$ -

$ -

The Company has no federal or state current or deferred tax expense or benefit. The Company’s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:

2021

2020

Federal Rate

21.00 %

21.00 %
State rate change

(1.37 )

(1.40 )
State tax rate, net of federal benefit

4.72

5.15

Other adjustments

(0.79 )

(3.24 )
Permanent differences

0.23

0.42

Change in valuation allowance

(23.79 )

(21.93 )

Effective tax rate

0.00 %

0.00 %

The Company applies the provisions of ASC 740, “Accounting for Uncertainty in Income Taxes,” which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION
12 Months Ended

Sep. 30, 2021

STOCK COMPENSATION

8. STOCK COMPENSATION

8.
STOCK COMPENSATION

The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:


Year Ended September 30,

2021

2020

Employees

$ 13,685,046

$ 10,112,968

Non-employees

$ 1,226,690

$ 862,796

During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.


2021

2020

Expected stock price volatility

90.42 – 97.22%

87.36 – 90.26%

Risk-free interest rate

0.85 – 1.65%

0.62 – 1.87%

Expected life of options

9.68 – 9.69 Years

9.68 – 9.69 Years

Expected dividend yield

-

-

Non-Qualified Stock Option Plans –

During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $0.34 and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be 1.3 years. This resulted in compensation expense of approximately $189,000 recorded during the year ended September 30, 2021. The remaining $447,000 will be expensed over the next 11 months.

During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to 3,600,000 options to purchase shares of common stock. On April 20, 2020, the Company granted 1,872,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share, the fair value on the date of issuance. The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $4.21 and an aggregate value of approximately $7.9 million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be 1.7 years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $3.8 million and $2.1 million during the years ended September 30, 2021 and 2020, respectively. The remaining $2.0 million will be expensed over the next 11 months.

At September 30, 2021, the Company has collectively authorized the issuance of 11,787,200 shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the plans. The Company’s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.

Incentive Stock Option Plans – At September 30, 2021, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the Plans. Only the Company’s employees are eligible to be granted options under the Incentive Stock Option Plans.

Activity in the Company’s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:
Non-Qualified and Incentive Stock Option Plans

Outstanding

Exercisable

Number of Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual Term (Years)

Aggregate Intrinsic Value

Number of Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual Term (Years)

Aggregate Intrinsic Value

Outstanding at September 30, 2019

6,218,216

$ 5.54

8.88

$ 29,562,594

1,392,241

$ 9.15

7.68

$ 7,869,555

Vested

2,014,501

$ 4.06

Granted

2,563,000

$ 10.93

Exercised

99,740

$ 3.39

99,740

$ 3.39

Forfeited

18,000

$ 10.34

Expired

9,773

$ 132.75

9,773

$ 132.75

Outstanding at September 30, 2020

8,653,703

$ 7.01

8.39

$ 56,193,415

3,297,229

$ 5.85

7.48

$ 29,090,662

Vested

2,401,961

$ 6.26

Granted (a)

2,605,000

$ 20.58

Exercised

149,788

$ 4.98

149,788

$ 4.98

Forfeited

49,832

$ 9.56

Expired

9,374

$ 172.73

9,374

$ 172.73

Outstanding at September 30, 2021

11,049,709

$ 10.08

7.93

$ 54,843,283

5,540,028

$ 5.77

6.96

$ 43,589,598

______________
(a)
Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.

A summary of the status of the Company’s non-vested options for the two years ended September 30, 2021 is presented below:


Number of Options

Weighted Average Grant Date Fair Value

Unvested at September 30, 2019

4,825,975

$ 3.79

Vested

(2,014,501 )

Granted

2,563,000

Forfeited

(18,000 )

Unvested at September 30, 2020

5,356,474

$ 4.76

Vested

(2,401,961 )

Granted

2,605,000

Forfeited

(49,832 )

Unvested at September 30, 2021

5,509,681

$ 5.17

Incentive Stock Bonus Plan – On September 30, 2021, 614,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company’s Multikine technology, or specified increases in the market price of the Company’s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $8.6 million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0.3 million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $45,000 which is expected to be fully recognized in the next quarter.

A summary of the status of the Company’s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:


Number of Shares

Weighted Average Grant Date Fair Value

Unvested at September 30, 2019

304,500

$ 13.75

Forfeited

-

Vested

-

Unvested at September 30, 2020

304,500

$ 13.75

Forfeited

(2,000 )

Vested

(151,250 )

Unvested at September 30, 2021

151,250

$ 13.75

Stock Bonus Plans – As of September 30, 2021, the Company has issued a total of 363,086 shares of common stock from the Stock Bonus Plans and was authorized to issue up to 783,760 shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.

Stock Compensation Plans – On September 30, 2021, 634,000 shares were authorized for use in the Company’s Stock Compensation Plans, of which 154,195 shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.4

EMPLOYEE BENEFIT PLAN
12 Months Ended

Sep. 30, 2021

EMPLOYEE BENEFIT PLAN

9. EMPLOYEE BENEFIT PLAN
9.
EMPLOYEE BENEFIT PLAN

The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant’s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant’s contribution, not to exceed the lesser of $10,000 or 6% of the participant’s total compensation. The Company’s contribution of common stock is valued each quarter based upon the closing bid price of the Company’s common stock. During the year ended September 30, 2021, 17,990 shares were issued to the Company’s 401(k) plan for a cost of approximately $201,000. During the year ended September 30, 2020, 13,870 shares were issued to the Company’s 401(k) plan for a cost of approximately $163,000.

X

- Definition
The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-URI http://asc.fasb.org/topic&trid=2197446

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-URI http://asc.fasb.org/topic&trid=2127225

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.4

COMMITMENTS AND CONTINGENCIES
12 Months Ended

Sep. 30, 2021

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES
10.
COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company’s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.1 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.6 million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $1.6 million and $2.0 million, respectively, as research and development expense related to Ergomed’s services. These amounts were net of Ergomed’s discount of approximately $0.6 million during both the years ended September 30, 2021 and 2020.

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.

Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $16.5 million and a finance lease liability of approximately $13.5 million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $12.7 million and $13.8 million and the balance of the finance lease liability is approximately $13.8 million and $12.7 million, of which approximately $0.6 million and $0.9 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately $1,732,000 and $1,717,000 in the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $2.2 million and $1.9 million, of which approximately $1.2 million was for interest in both years. The weighted average discount rate of the Company’s finance leases is 8.45% and the weighted average time to maturity is 7.1 years.

In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.

During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.

The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord’s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $1.9 million and $1.7 million deposit is included in non-current assets.

Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:

Year ending September 30,

2022

$ 1,699,000

2023

2,569,000

2024

2,648,000

2025

2,733,000

2026

2,824,000

Thereafter

6,186,000

Total future minimum lease obligation *

18,659,000

Less imputed interest on finance lease obligations

(4,825,000 )
Net present value of lease finance lease obligations

$ 13,834,000

* Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021.

Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $39,000.

The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.

Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $1.0 million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $2.1 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.1 million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $1.2 million and the balance of the operating lease liability is approximately $1.2 million, of which approximately $0.1 million is current. The Company incurred lease expense under operating leases of approximately $0.2 million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $0.3 million and $0.2 million, respectively. The weighted average discount rate of the Company’s operating leases is 9.12% and the weighted average time to maturity is 9.7 years.

As of September 30, 2021, future minimum lease payments on operating leases are as follows:

Year ending September 30,

2022

$ 309,000

2023

348,000

2024

357,000

2025

366,000

2026

287,000

Thereafter

1,602,000

Total future minimum lease obligation

3,269,000

Less imputed interest on operating lease obligation

(1,130,000 )
Net present value of operating lease obligation

$ 2,139,000

Vendor Obligations

The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.4

RELATED PARTY TRANSACTIONS
12 Months Ended

Sep. 30, 2021

RELATED PARTY TRANSACTIONS

11. RELATED PARTY TRANSACTIONS
11.
RELATED PARTY TRANSACTIONS

During the year ended September 30, 2021, the de Clara Trust, of which the Company’s CEO, Geert Kerston, is a beneficiary, and two directors purchased 27,500 restricted shares of the Company’s common stock at an aggregate fair market value of approximately $220,000. During the year ended September 30, 2020, officers and directors of the Company purchased 20,512 shares of restricted common stock at market price at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.

On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $265,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.

On June 28, 2021, the expiration date of 93,603 Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $24,000 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.

On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.

On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.

On May 8, 2020, the expiration date of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company’s officers and were originally issued with convertible debt.

On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.4

STOCKHOLDERS EQUITY
12 Months Ended

Sep. 30, 2021

STOCKHOLDERS EQUITY

12. STOCKHOLDERS' EQUITY
12.
STOCKHOLDERS’ EQUITY

Exercise of Warrants

During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $6.0 million and $12.1 million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, 1,597,870 and 1,711,873 shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.

Sales of Securities

In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. At that time, the underwriters fully exercised their option to purchase up to 210,000 additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $4.4 million.

In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.

In March 2020, the Company sold 630,500 shares of common stock at a public offering price of $12.22 per share and received aggregate net proceeds of approximately $7.1 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional 94,575 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $1.1 million.

In December 2019, the Company sold 606,395 shares of common stock at a public offering price of $9.07 per share and received aggregate net proceeds of approximately $5.0 million. In January 2020, the underwriters of that offering fully exercised the option to purchase 90,959 additional shares of common stock at the public offering price of $9.07 per share for aggregate net proceeds to the Company of approximately $0.8 million.

Other Equity Transactions

The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company’s Clinical Research Organizations responsible for managing the Company’s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.

During the year ended September 30, 2020, the Company issued Ergomed 150,000 shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $500,000 in amounts prepaid to Ergomed.

The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:


2021

2020

Amount realized through the resale of shares

$ 1,685,379

$ 2,652,605

Fair value of shares upon issuance

-

1,769,500

Other non-operating gain

$ 1,685,379

$ 883,105

As of September 30, 2021, all shares held for resale were sold.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.4

FAIR VALUE MEASUREMENTS
12 Months Ended

Sep. 30, 2021

FAIR VALUE MEASUREMENTS

13. FAIR VALUE MEASUREMENTS
13.
FAIR VALUE MEASUREMENTS

In accordance with the provisions of ASC 820, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.

ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

o
Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

o
Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability

o
Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000. The T-bills mature in December 2021 and yield a weighted average interest rate of 0.10%.

As of September 30, 2021 and 2020, all of the Company’s derivative liabilities are classified as Level 3.

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:


2021

2020

Beginning balance

$ 3,765,613

$ 6,488,310

Issuances

-

-

Exercises

(4,023,091 )

(3,071,775 )
N Net realized and unrealized derivative loss

694,858

349,078

Ending balance

$ 437,380

$ 3,765,613

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock. At September 30, 2021, the Company’s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years. At September 30, 2020, the Company’s Level 3 derivative instruments have a weighted average fair value of $2.81 per share and a weighted average exercise price of $14.32 per share. Fair values were determined using a weighted average risk free interest rate of 0.12% and volatility of 95%. The instruments have a weighted average time to maturity of 1.2 years.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.4

NET LOSS PER COMMON SHARE
12 Months Ended

Sep. 30, 2021

NET LOSS PER COMMON SHARE

14. NET LOSS PER COMMON SHARE

14.
NET LOSS PER COMMON SHARE

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.

The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:


Year ended September 30,

2021

2020

Loss per share – basic

Net loss available to common shareholders - basic

$ (36,711,970 )

$ (30,276,978 )
Weighted average shares outstanding - basic

40,662,137

36,759,115

Basic loss per common share

$ (0.90 )

$ (0.82 )

Loss per share – diluted

Net loss available to common shareholders - basic

$ (36,711,970 )

$ (30,276,978 )
Unrealized gain on derivatives ⁽¹⁾

(1,085,540 )

-

Net loss available to common shareholders - diluted

$ (37,797,510 )

$ (30,276,978 )

Weighted average shares outstanding - basic

40,662,137

36,759,115

Incremental shares underlying dilutive warrants ⁽¹⁾

32,111

-

Weighted average shares outstanding - diluted

40,694,248

36,759,115

Diluted loss per common share

$ (0.93 )

$ (0.82 )
⁽¹⁾
Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:


2021

2020

Options and Warrants

10,604,850

7,221,696

Unvested Restricted Stock

151,250

308,814

Total

10,756,100

7,530,510

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.4

SUBSEQUENT EVENTS
12 Months Ended

Sep. 30, 2021

SUBSEQUENT EVENTS

15. SUBSEQUENT EVENTS
15. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended

Sep. 30, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents
Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.

U.S. Treasury Bills
U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.

Supplies used for R&D and manufacturing

Property and Equipment
Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents
Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Leases
Leases – On October 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases and its related amendments (collectively referred to as Topic 842 and codified as “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company’s statements of operations or cash flows.
The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.

Derivative Instruments
Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption.

Stock-Based Compensation
Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.
The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs
Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Grant Income
Grant Income – The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.

Net Loss Per Common Share
Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Concentration of Credit Risk
Concentration of Credit Risk – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021.

Income Taxes
Income Taxes – The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.

Use of Estimates Use of Estimates – The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.

New Accounting Pronouncements
The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

X

- References
No definition available.
+ Details

Name: cvm_GrantIncomePolicyTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_LeasesPolicyTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SuppliesUsedForRDAndManufacturingPolicytextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_USTreasuryBills

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13572-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13587-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611
+ Details

Name: us-gaap_FairValueConcentrationOfRiskTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)
12 Months Ended

Sep. 30, 2021

WARRANTS AND NON-EMPLOYEE OPTIONS

Schedule of warrants and non-employee options
Warrant/Options

Issue Date

Shares Issuable upon Exercise
of Warrants/ Options

Exercise Price

Expiration Date

Series N

8/18/2008

85,339

$ 3.00

8/18/2022

Series UU

6/11/2018

93,603

$ 2.80

6/30/2022

Series X

1/13/2016

120,000

$ 9.25

7/13/2022

Series Y

2/15/2016

26,000

$ 12.00

8/15/2022

Series Z

5/23/2016

184,800

$ 13.75

11/23/2021

Series CC

12/8/2016

15,845

$ 5.00

12/8/2021

Series HH

2/23/2017

200

$ 3.13

2/16/2022

Series AA

8/26/2016

100,000

$ 13.75

2/22/2022

Series MM

6/22/2017

333,432

$ 1.86

6/22/2022

Series NN

7/24/2017

210,087

$ 2.52

7/24/2022

Series RR

10/30/2017

251,761

$ 1.65

10/30/2022

Series SS

12/19/2017

200,000

$ 2.09

12/18/2022

Series TT

2/5/2018

600

$ 2.24

2/5/2023

Consultants

7/28/2017 – 11/18/2020

15,000

$
2.18 - $11.61

11/17/2022 - 7/27/2027

Warrant

Issue Date

Shares Issuable upon Exercise
of Warrants/Options

Exercise Price

Expiration Date

Series N

8/18/2008

85,339

$ 3.00

2/18/2021

Series UU

6/11/2018

93,603

$ 2.80

12/31/2020

Series W

10/28/2015

688,930

$ 16.75

10/28/2020

Series X

1/13/2016

120,000

$ 9.25

1/13/2021

Series Y

2/15/2016

26,000

$ 12.00

2/15/2021

Series ZZ

5/23/2016

20,000

$ 13.75

5/18/2021

Series BB

8/26/2016

16,000

$ 13.75

8/22/2021

Series Z

5/23/2016

264,000

$ 13.75

11/23/2021

Series CC

12/8/2016

148,643

$ 5.00

12/8/2021

Series HH

2/23/2017

200

$ 3.13

2/16/2022

Series AA

8/26/2016

200,000

$ 13.75

2/22/2022

Series MM

6/22/2017

797,633

$ 1.86

6/22/2022

Series NN

7/24/2017

348,842

$ 2.52

7/24/2022

Series RR

10/30/2017

417,649

$ 1.65

10/30/2022

Series SS

12/19/2017

326,064

$ 2.09

12/18/2022

Series TT

2/5/2018

371,564

$ 2.24

2/5/2023

Consultants

7/28/17

10,000

$ 2.18

7/27/2027

Schedule of equity warrants were exercised
Warrants

Warrants Exercised

Exercise Price

Proceeds

Series MM

464,201

$ 1.86

$ 863,414

Series NN

138,755

$ 2.52

349,663

Series RR

165,888

$ 1.65

273,715

Series SS

126,064

$ 2.09

263,474

Series TT

370,964

$ 2.24

830,959

1,265,872

$ 2,581,225

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series MM

95,858

$ 1.86

$ 178,296

Series NN

124,956

$ 2.52

314,889

Series OO

50,000

$ 2.52

126,000

Series RR

39,467

$ 1.65

65,121

Series SS

156,580

$ 2.09

327,252

Series TT

188,125

$ 2.24

421,400

Series UU

61,207

$ 2.80

171,380

Series VV

82,500

$ 1.75

144,375

798,693

$ 1,748,713

Schedule of warrants recorded as liabilities were exercised
Warrants

Warrants Exercised

Exercise Price

Proceeds

Series Z

79,200

$ 13.75

$ 1,089,000

Series ZZ

20,000

$ 13.75

275,000

Series AA

100,000

$ 13.75

1,375,000

Series CC

132,798

$ 5.00

663,990

331,998

$ 3,402,990

Warrants

Warrants Exercised

Exercise Price

Proceeds

Series V

674,164

$ 13.75

$ 9,269,755

Series CC

128,820

$ 5.00

644,100

Series FF

68,048

$ 3.91

265,812

Series HH

6,300

$ 3.13

19,687

Series JJ

9,450

$ 3.13

29,531

Series LL

26,398

$ 3.59

94,867

913,180

$ 10,323,752

Schedule of warrant liabilities

2021

2020

Series W warrants

$ -

$ 73,570

Series Z warrants

64,787

1,207,902

Series ZZ warrants

-

75,044

Series AA warrants

276,035

1,082,212

Series BB warrants

-

65,173

Series CC warrants

94,961

1,259,712

Series HH warrants

1,597

2,000

Total warrant liabilities

$ 437,380

$ 3,765,613

Schedule of (losses)/gains on the warrant liabilities

2021

2020

Series V Warrants

$ -

$ 185,652

Series W warrants

73,570

1,119,937

Series Z warrants

252,115

(98,357 )
Series ZZ warrants

(98,692 )

2,594

Series AA warrants

(318,823 )

(165,304 )
Series BB warrants

65,173

(1,207 )
Series CC warrants

(668,605 )

(875,040 )
Series FF warrants

-

(319,706 )
Series HH warrants

404

(34,589 )
Series JJ warrants

-

(64,992 )
Series LL warrants

-

(98,066 )
Net loss on warrant liabilities

$ (694,858 )

$ (349,078 )

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.4

PLANT, PROPERTY AND EQUIPMENT (Tables)
12 Months Ended

Sep. 30, 2021

PLANT, PROPERTY AND EQUIPMENT

Schedule of plant, property and equipment

2021

2020

Research equipment

$ 4,211,124

$ 3,898,242

Furniture and equipment

99,768

99,768

Leasehold improvements

13,465,123

5,519,161

17,776,015

9,517,171

Accumulated depreciation and amortization

(4,112,453 )

(3,673,178 )

Net property and equipment

$ 13,663,562

$ 5,843,993

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 980
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.4

PATENTS (Tables)
12 Months Ended

Sep. 30, 2021

PATENTS

Schedule of patents

2021

2020

Patents

$ 910,523

$ 896,372

Accumulated amortization

(634,657 )

(582,950 )

Patents, net

$ 275,866

$ 313,422

Schedule of total estimated future amortization
Years ending September 30,

2022

$ 49,000

2023

39,000

2024

31,000

2025

29,000

2026

25,000

Thereafter

103,000

$ 276,000

X

- References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.4

INCOME TAXES (Tables)
12 Months Ended

Sep. 30, 2021

INCOME TAXES

Schedule of components of the Company's deferred tax assets

2021

2020

NOL carryforwards

$ 19,789,000

$ 13,407,000

Lease liabilities

4,101,000

3,631,000

R&D credit

1,221,000

1,221,000

Stock-based compensation

7,785,000

5,297,000

Capitalized R&D

15,040,000

15,853,000

Vacation and other

126,000

125,000

Total deferred tax assets

48,062,000

39,534,000

Right of use assets

(3,786,000 )

(3,911,000 )
Fixed assets and intangibles

(172,000 )

(169,000 )
Total deferred tax liability

(3,958,000 )

(4,080,000 )

Net deferred tax asset

44,104,000

35,454,000

Valuation allowance

(44,104,000 )

(35,454,000 )
Ending Balance

$ -

$ -

Schedule of federal or state current or deferred tax expense or benefit

2021

2020

Federal Rate

21.00 %

21.00 %
State rate change

(1.37 )

(1.40 )
State tax rate, net of federal benefit

4.72

5.15

Other adjustments

(0.79 )

(3.24 )
Permanent differences

0.23

0.42

Change in valuation allowance

(23.79 )

(21.93 )

Effective tax rate

0.00 %

0.00 %

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Tables)
12 Months Ended

Sep. 30, 2021

STOCK COMPENSATION

Schedule of expenses for options issued or vested and restricted stock awarded

Year Ended September 30,

2021

2020

Employees

$ 13,685,046

$ 10,112,968

Non-employees

$ 1,226,690

$ 862,796

Schedule of fair value of each option granted

2021

2020

Expected stock price volatility

90.42 – 97.22%

87.36 – 90.26%

Risk-free interest rate

0.85 – 1.65%

0.62 – 1.87%

Expected life of options

9.68 – 9.69 Years

9.68 – 9.69 Years

Expected dividend yield

-

-

Schedule of non-qualified and incentive stock option plans

Outstanding

Exercisable

Number of Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual Term (Years)

Aggregate Intrinsic Value

Number of Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual Term (Years)

Aggregate Intrinsic Value

Outstanding at September 30, 2019

6,218,216

$ 5.54

8.88

$ 29,562,594

1,392,241

$ 9.15

7.68

$ 7,869,555

Vested

2,014,501

$ 4.06

Granted

2,563,000

$ 10.93

Exercised

99,740

$ 3.39

99,740

$ 3.39

Forfeited

18,000

$ 10.34

Expired

9,773

$ 132.75

9,773

$ 132.75

Outstanding at September 30, 2020

8,653,703

$ 7.01

8.39

$ 56,193,415

3,297,229

$ 5.85

7.48

$ 29,090,662

Vested

2,401,961

$ 6.26

Granted (a)

2,605,000

$ 20.58

Exercised

149,788

$ 4.98

149,788

$ 4.98

Forfeited

49,832

$ 9.56

Expired

9,374

$ 172.73

9,374

$ 172.73

Outstanding at September 30, 2021

11,049,709

$ 10.08

7.93

$ 54,843,283

5,540,028

$ 5.77

6.96

$ 43,589,598

Schedule of non-vested options

Number of Options

Weighted Average Grant Date Fair Value

Unvested at September 30, 2019

4,825,975

$ 3.79

Vested

(2,014,501 )

Granted

2,563,000

Forfeited

(18,000 )

Unvested at September 30, 2020

5,356,474

$ 4.76

Vested

(2,401,961 )

Granted

2,605,000

Forfeited

(49,832 )

Unvested at September 30, 2021

5,509,681

$ 5.17

Schedule of restricted common stock issued from the incentive stock bonus plan

Number of Shares

Weighted Average Grant Date Fair Value

Unvested at September 30, 2019

304,500

$ 13.75

Forfeited

-

Vested

-

Unvested at September 30, 2020

304,500

$ 13.75

Forfeited

(2,000 )

Vested

(151,250 )

Unvested at September 30, 2021

151,250

$ 13.75

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfNonVestedOptionsTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.4

COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended

Sep. 30, 2021

Commitments and Contingencies

Schedule of future minimum payments under finance leases
Year ending September 30,

2022

$ 1,699,000

2023

2,569,000

2024

2,648,000

2025

2,733,000

2026

2,824,000

Thereafter

6,186,000

Total future minimum lease obligation *

18,659,000

Less imputed interest on finance lease obligations

(4,825,000 )
Net present value of lease finance lease obligations

$ 13,834,000

Schedule of future minimum payments under operating leases
Year ending September 30,

2022

$ 309,000

2023

348,000

2024

357,000

2025

366,000

2026

287,000

Thereafter

1,602,000

Total future minimum lease obligation

3,269,000

Less imputed interest on operating lease obligation

(1,130,000 )
Net present value of operating lease obligation

$ 2,139,000

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.4

STOCKHOLDERS EQUITY (Tables)
12 Months Ended

Sep. 30, 2021

STOCKHOLDERS EQUITY

Schedule of other non-operating gains (losses)

2021

2020

Amount realized through the resale of shares

$ 1,685,379

$ 2,652,605

Fair value of shares upon issuance

-

1,769,500

Other non-operating gain

$ 1,685,379

$ 883,105

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.4

FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended

Sep. 30, 2021

FAIR VALUE MEASUREMENTS

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

2021

2020

Beginning balance

$ 3,765,613

$ 6,488,310

Issuances

-

-

Exercises

(4,023,091 )

(3,071,775 )
N Net realized and unrealized derivative loss

694,858

349,078

Ending balance

$ 437,380

$ 3,765,613

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.4

NET LOSS PER COMMON SHARE (Tables)
12 Months Ended

Sep. 30, 2021

NET LOSS PER COMMON SHARE

Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations

Year ended September 30,

2021

2020

Loss per share – basic

Net loss available to common shareholders - basic

$ (36,711,970 )

$ (30,276,978 )
Weighted average shares outstanding - basic

40,662,137

36,759,115

Basic loss per common share

$ (0.90 )

$ (0.82 )

Loss per share – diluted

Net loss available to common shareholders - basic

$ (36,711,970 )

$ (30,276,978 )
Unrealized gain on derivatives ⁽¹⁾

(1,085,540 )

-

Net loss available to common shareholders - diluted

$ (37,797,510 )

$ (30,276,978 )

Weighted average shares outstanding - basic

40,662,137

36,759,115

Incremental shares underlying dilutive warrants ⁽¹⁾

32,111

-

Weighted average shares outstanding - diluted

40,694,248

36,759,115

Diluted loss per common share

$ (0.93 )

$ (0.82 )

Schedule of anti-dilutive securities

2021

2020

Options and Warrants

10,604,850

7,221,696

Unvested Restricted Stock

151,250

308,814

Total

10,756,100

7,530,510

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock

Namespace Prefix: cvm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
12 Months Ended

Sep. 30, 2021

USD ($)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Patent useful life 17 years

Fully insured amount of non-interest bearing cash balances $ 250,000

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Consultants [Member]

Issue Date 7/28/2017 7/28/17

Shares Issuable upon Exercise of Warrant 15,000 10,000

Exercise Price $ 2.18 $ 2.18

Expiration Date 7/27/2027 7/27/2027

Series W [Member]

Issue Date 10/28/2015

Shares Issuable upon Exercise of Warrant 688,930

Exercise Price $ 16.75

Expiration Date 10/28/2020

Series ZZ [Member]

Issue Date 5/23/2016

Shares Issuable upon Exercise of Warrant 20,000

Exercise Price $ 13.75

Expiration Date 5/18/2021

Series BB [Member]

Issue Date 8/26/2016

Shares Issuable upon Exercise of Warrant 16,000

Exercise Price $ 13.75

Expiration Date 8/22/2021

Series Z [Member]

Issue Date 5/23/2016 5/23/2016

Shares Issuable upon Exercise of Warrant 184,800 264,000

Exercise Price $ 13.75 $ 13.75

Expiration Date 11/23/2021 11/23/2021

Series CC [Member]

Issue Date 12/8/2016 12/8/2016

Shares Issuable upon Exercise of Warrant 15,845 148,643

Exercise Price $ 5.00 $ 5.00

Expiration Date 12/8/2021 12/8/2021

Series HH [Member]

Issue Date 2/23/2017 2/23/2017

Shares Issuable upon Exercise of Warrant 200 200

Exercise Price $ 3.13 $ 3.13

Expiration Date 2/16/2022 2/16/2022

Series AA [Member]

Issue Date 8/26/2016 8/26/2016

Shares Issuable upon Exercise of Warrant 100,000 200,000

Exercise Price $ 13.75 $ 13.75

Expiration Date 2/22/2022 2/22/2022

Series N [Member]

Issue Date 8/18/2008 8/18/2008

Shares Issuable upon Exercise of Warrant 85,339 85,339

Exercise Price $ 3.00 $ 3.00

Expiration Date 8/18/2022 2/18/2021

Series X [Member]

Issue Date 1/13/2016 1/13/2016

Shares Issuable upon Exercise of Warrant 120,000 120,000

Exercise Price $ 9.25 $ 9.25

Expiration Date 7/13/2022 1/13/2021

Series Y [Member]

Issue Date 2/15/2016 2/15/2016

Shares Issuable upon Exercise of Warrant 26,000 26,000

Exercise Price $ 12.00 $ 12.00

Expiration Date 8/15/2022 2/15/2021

Series MM [Member]

Issue Date 6/22/2017 6/22/2017

Shares Issuable upon Exercise of Warrant 333,432 797,633

Exercise Price $ 1.86 $ 1.86

Expiration Date 6/22/2022 6/22/2022

Series NN [Member]

Issue Date 7/24/2017 7/24/2017

Shares Issuable upon Exercise of Warrant 210,087 348,842

Exercise Price $ 2.52 $ 2.52

Expiration Date 7/24/2022 7/24/2022

Series RR [Member]

Issue Date 10/30/2017 10/30/2017

Shares Issuable upon Exercise of Warrant 251,761 417,649

Exercise Price $ 1.65 $ 1.65

Expiration Date 10/30/2022 10/30/2022

Series SS [Member]

Issue Date 12/19/2017 12/19/2017

Shares Issuable upon Exercise of Warrant 200,000 326,064

Exercise Price $ 2.09 $ 2.09

Expiration Date 12/18/2022 12/18/2022

Series TT [Member]

Issue Date 2/5/2018 2/5/2018

Shares Issuable upon Exercise of Warrant 600 371,564

Exercise Price $ 2.24 $ 2.24

Expiration Date 2/5/2023 2/5/2023

Series UU [Member]

Issue Date 6/11/2018 6/11/2018

Shares Issuable upon Exercise of Warrant 93,603 93,603

Exercise Price $ 2.80 $ 2.80

Expiration Date 6/30/2022 12/31/2020

X

- References
No definition available.
+ Details

Name: cvm_ExercisePrice

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_ExpirationDate1

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_Issuedate2

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SharesIssuableUponExerciseOfwarrant

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Total warrant liabilities $ 437,380 $ 3,765,613

Net (loss) gain on warrant liabilities (694,858) (349,078)

Series W [Member]

Total warrant liabilities 0 73,570

Net (loss) gain on warrant liabilities 73,570 1,119,937

Series ZZ [Member]

Total warrant liabilities 0 75,044

Net (loss) gain on warrant liabilities (98,692) 2,594

Series BB [Member]

Total warrant liabilities 0 65,173

Net (loss) gain on warrant liabilities 65,173 (1,207)

Series Z [Member]

Total warrant liabilities 64,787 1,207,902

Net (loss) gain on warrant liabilities (252,115) (98,357)

Series CC [Member]

Total warrant liabilities 94,961 1,259,712

Net (loss) gain on warrant liabilities (668,605) (875,040)

Series HH [Member]

Total warrant liabilities 1,597 2,000

Net (loss) gain on warrant liabilities 404 (34,589)

Series AA [Member]

Total warrant liabilities 276,035 1,082,212

Net (loss) gain on warrant liabilities (318,823) (165,304)

Series FF [Member]

Net (loss) gain on warrant liabilities 0 (319,706)

Series JJ [Member]

Net (loss) gain on warrant liabilities 0 (64,992)

Series LL [Member]

Net (loss) gain on warrant liabilities 0 (98,066)

Series V [Member]

Net (loss) gain on warrant liabilities $ 0 $ 185,652

X

- Definition
Amount of increase in the fair value of derivatives recognized in the income statement.
+ References
No definition available.
+ Details

Name: cvm_NetLossGainOnWarrantLiabilities

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Proceeds $ 3,402,990 $ 10,323,752

Warrants Exercised 331,998 913,180

Series ZZ [Member]

Proceeds $ 275,000

Warrants Exercised 20,000

Exercise Price $ 13.75

Series Z [Member]

Proceeds $ 1,089,000

Warrants Exercised 72,900

Exercise Price $ 13.75

Series CC [Member]

Proceeds $ 663,990 $ 644,100

Warrants Exercised 132,798 128,820

Exercise Price $ 5.00 $ 5.00

Series HH [Member]

Proceeds $ 19,687

Warrants Exercised 6,300

Exercise Price $ 3.13

Series AA [Member]

Proceeds $ 1,375,000

Warrants Exercised 100,000

Exercise Price $ 13.75

Series FF [Member]

Proceeds $ 265,812

Warrants Exercised 68,048

Exercise Price $ 3.91

Series JJ [Member]

Proceeds $ 29,531

Warrants Exercised 9,450

Exercise Price $ 3.13

Series LL [Member]

Proceeds $ 94,867

Warrants Exercised 26,398

Exercise Price $ 3.59

Series V [Member]

Proceeds $ 9,269,755

Warrants Exercised 674,164

Exercise Price $ 13.75

X

- References
No definition available.
+ Details

Name: cvm_ExercisePriceWarrants

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantsExercised

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesFFMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesJJMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesLLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Equity Warrants Exercised 1,265,872 798,693

Proceeds from Equity Warrants Exercised $ 2,581,225 $ 1,748,713

Series MM [Member]

Equity Warrants Exercised 863,414 95,858

Proceeds from Equity Warrants Exercised $ 464,201 $ 178,296

Equity Warrants Exercise Price $ 1.86 $ 1.86

Series NN [Member]

Equity Warrants Exercised 138,755 124,956

Proceeds from Equity Warrants Exercised $ 349,663 $ 314,889

Equity Warrants Exercise Price $ 2.52 $ 2.52

Series RR [Member]

Equity Warrants Exercised 165,888 39,467

Proceeds from Equity Warrants Exercised $ 273,715 $ 65,121

Equity Warrants Exercise Price $ 1.65 $ 1.65

Series SS [Member]

Equity Warrants Exercised 126,064 156,580

Proceeds from Equity Warrants Exercised $ 263,474 $ 327,252

Equity Warrants Exercise Price $ 2.09 $ 2.09

Series TT [Member]

Equity Warrants Exercised 370,964 188,125

Proceeds from Equity Warrants Exercised $ 830,959 $ 421,400

Equity Warrants Exercise Price $ 2.24 $ 2.24

Series UU [Member]

Equity Warrants Exercised 61,207

Proceeds from Equity Warrants Exercised $ 171,380

Equity Warrants Exercise Price $ 2.80

Series OO [Member]

Equity Warrants Exercised 50,000

Proceeds from Equity Warrants Exercised $ 126,000

Equity Warrants Exercise Price $ 2.52

Series VV [Member]

Equity Warrants Exercised 82,500

Proceeds from Equity Warrants Exercised $ 144,375

Equity Warrants Exercise Price $ 1.75

X

- References
No definition available.
+ Details

Name: cvm_EquityWarrantsExercisePrice

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_EquityWarrantsExercised

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ProceedsFromEquityWarrantsExercised

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesOOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesVVMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.4

WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended

Dec. 07, 2020

May 08, 2020

Aug. 22, 2021

Oct. 28, 2020

Jun. 25, 2020

Jun. 20, 2020

May 26, 2020

Jan. 23, 2020

Sep. 30, 2021

Sep. 30, 2020

Incremental cost $ 664,000 $ 664,000

Common stock issued for service, shares 75,885 79,950

Warrant inducement expense $ 806,000

Fair value of warrant $ 0 805,753

Consulting Agreements [Member]

Total expense 1,227,000 863,000

Prepaid expenses $ 364,000 $ 395,000

Consultants [Member]

Options issued 5,000

Option issued to related party 15,000

Option expiration date Nov. 17, 2022

Stock prices per share $ 6.86 $ 24.95

Series Y [Member]

Incremental cost $ 22,000 $ 103,000

Maximum [Member] | Restricted Stock [Member] | Consultants [Member]

Weighted average grant date fair value $ 15.46 12.01

Series W [Member]

Warrants exercised $ 16.75

Warrants expired 688,930

Series BB [Member]

Warrants exercised $ 13.75

Warrants expired 16,000

Series V Warrants [Member]

Warrants exercised shares 810,127

Warrants exercised $ 13.75

Expiration date description extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020

Warrants expired 135,963

Fair value of warrant $ 211,000

Series V Warrants [Member] | Maximum [Member]

Common stock price per share $ 19.75

Series V Warrants [Member] | Minimum [Member]

Common stock price per share $ 13.75

Series XX Warrants [Member]

Fair value of warrant $ 629,000

Common stock price per share 18.00

Warrants issued during period 461,963

Series YY Warrants [Member]

Fair value of warrant $ 177,000

Common stock price per share $ 20.00

Warrants issued during period 101,839

Series UU warrants [Member]

Incremental cost $ 24,000 $ 6,000

Expiration date description from December 31, 2020 to June 30, 2021 extended from June 11, 2020 to December 31, 2020 the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021

Warrants issued during period 93,593 101,839

Series N and Series X [Member]

Incremental cost $ 351,000

Series N Warrants [Member]

Incremental cost $ 22,000

Expiration date description the expiration date of the Series N warrants was extended to February 18, 2021 the expiration date of the Series N warrants was extended to February 18, 2021

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: cvm_CommonStockIssuedForServiceShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ExpirationDateDescription

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_OptionExpirationDate

Namespace Prefix: cvm_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_OptionIssuedToRelatedParty

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_PrepaidExpenses

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_WarrantExercise

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantInducementExpense

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantsExercisedShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
No definition available.
+ Details

Name: cvm_WarrantsExpired

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantsIssuedDuringPeriod

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost recognized for passage of time related to defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesVWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXXWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYYWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.4

PROPERTY AND EQUIPMENT (Details) - USD ($)

Sep. 30, 2021

Sep. 30, 2020

PLANT, PROPERTY AND EQUIPMENT

Research equipment $ 4,211,124 $ 3,898,242

Furniture and equipment 99,768 99,768

Leasehold improvements 13,456,123 5,519,161

Gross 17,776,015 9,517,171

Accumulated depreciation and amortization (4,112,453) (3,673,178)

Net property and equipment $ 13,663,562 $ 5,843,993

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.
+ References
No definition available.
+ Details

Name: us-gaap_FixturesAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_FurnitureAndFixturesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_LeaseholdImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.4

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

PLANT, PROPERTY AND EQUIPMENT

Depreciation expense $ 447,000 $ 389,000

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.4

PATENTS (Details) - USD ($)

Sep. 30, 2021

Sep. 30, 2020

Patents $ 275,866 $ 313,422

Patents [Member]

Patents 910,523 896,372

Accumulated amortization (634,657) (582,950)

Patents, net $ 275,866 $ 313,422

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.4

PATENTS (Details 1)

Sep. 30, 2021

USD ($)

PATENTS (Details)

2022 $ 49,000

2023 39,000

2024 31,000

2025 29,000

2026 25,000

Thereafter 103,000

Total $ 276,000

X

- References
No definition available.
+ Details

Name: cvm_Total

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.4

PATENTS (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

PATENTS (Details)

Amortization of patent costs $ 52,000 $ 53,000

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.4

INCOME TAXES (Details) - USD ($)

Sep. 30, 2021

Sep. 30, 2020

INCOME TAXES

NOL carryforwards $ 19,789,000 $ 13,407,000

Lease liabilities 4,101,000 3,631,000

R&D credit 1,221,000 1,221,000

Stock-based compensation 7,785,000 5,297,000

Capitalized R&D 15,040,000 15,853,000

Vacation and other 126,000 125,000

Total deferred tax assets 48,062,000 39,534,000

Right of use assets (3,786,000) (3,911,000)

Fixed assets and intangibles (172,000) (169,000)

Total deferred tax liability (3,958,000) (4,080,000)

Net deferred tax asset 44,104,000 (35,454,000)

Valuation allowance (44,104,000) (35,454,000)

Ending Balance $ 0 $ 0

X

- References
No definition available.
+ Details

Name: cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_FixedAssetsAndIntangibles

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_LeaseLiabilities

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
No definition available.
+ Details

Name: cvm_NetDeferredTaxAsset

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_RightOfUseAssets

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.4

INCOME TAXES (Details 1)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

INCOME TAXES

Federal Rate 21.00% 21.00%

Federal rate change (1.37%) (1.40%)

State tax rate, net of federal benefit 4.72% 5.15%

Other adjustments (0.79%) (3.24%)

Permanent differences 0.23% 0.42%

Change in valuation allowance (23.79%) (21.93%)

Effective tax rate 0.00% 0.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.
+ References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.4

INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Federal net operating loss carryforwards $ 19,789,000 $ 13,407,000

Estimated net operating loss carryforwards 48,062,000 39,534,000

Income Tax [Member]

Research and development credit $ 1,200,000.0 1,200,000

Research and development credit, description The R&D credit expires during the fiscal year ended 2029.

Federal net operating loss carryforwards $ 77,100,000 51,500,000

Cumulative change in ownership percentage (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.

Net operating loss carryforwards, description Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards

Estimated net operating loss carryforwards $ 188,900,000.0

X

- References
No definition available.
+ Details

Name: cvm_CumulativeChangeInOwnershipPercentage

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ResearchAndDevelopmentCredit

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_ResearchAndDevelopmentCreditDescription

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A description of the origin, nature, and characteristics of the tax credit carryforward.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

STOCK COMPENSATION

Employees $ 13,685,046 $ 10,112,968

Non-employees $ 1,226,690 $ 862,796

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost capitalized for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 57 R47.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details 1)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

STOCK COMPENSATION

Expected stock price volatility, min 90.42% 87.36%

Expected stock price volatility, max 97.22% 90.26%

Risk-free interest rate, min 0.85% 0.62%

Risk-free interest rate, max 1.65% 1.87%

Expected life of options, min 9 years 8 months 4 days 9 years 8 months 4 days

Expected life of options, max 9 years 8 months 8 days 9 years 8 months 8 days

Expected dividend yield 0.00% 0.00%

X

- References
No definition available.
+ Details

Name: cvm_ExpectedLifeOfOptionsMax

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ExpectedLifeOfOptionsMin1

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 58 R48.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details 2) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Outstanding [Member]

Number of Options Outstanding, Beginning 8,653,703 6,218,216

Number of Options Exercised 149,788 99,740

Number of Options Expired 9,374 9,773

Number of Options Outstanding, Ending 11,049,709 8,653,703

Weighted Average Exercise Price Outstanding, Beginning $ 7.01 $ 5.54

Weighted Average Exercise Price Exercised 4.98 3.39

Weighted Average Exercise Price Expired 172.73 132.75

Weighted Average Exercise Price Outstanding, Ending $ 10.08 $ 7.01

Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning 7 years 11 months 4 days 8 years 10 months 17 days

Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending 8 years 10 months 17 days 8 years 4 months 20 days

Aggregate Intrinsic Value Outstanding, Beginning $ 56,193,415 $ 29,562,594

Aggregate Intrinsic Value Outstanding, Ending $ 54,843,283 $ 56,193,415

Number of Options Granted 2,605,000 2,563,000

Number of Options Forfeited 49,832 18,000

Weighted Average Exercise Price Granted $ 20.58 $ 10.93

Weighted Average Exercise Price Forfeited $ 9.56 $ 10.34

Exercisable [Member]

Number of Options Outstanding, Beginning 3,297,229 1,392,241

Number of Options Vested 2,401,961 2,014,501

Number of Options Exercised 149,788 99,740

Number of Options Expired 9,374 9,773

Number of Options Outstanding, Ending 5,540,028 3,297,229

Weighted Average Exercise Price Outstanding, Beginning $ 5.85 $ 9.15

Weighted Average Exercise Price Vested 6.26 4.06

Weighted Average Exercise Price Exercised 4.98 3.39

Weighted Average Exercise Price Expired 172.73 132.75

Weighted Average Exercise Price Outstanding, Ending $ 5.77 $ 5.85

Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning 6 years 11 months 15 days 7 years 8 months 4 days

Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending 7 years 8 months 5 days 7 years 5 months 23 days

Aggregate Intrinsic Value Outstanding, Beginning $ 29,090,662 $ 7,869,555

Aggregate Intrinsic Value Outstanding, Ending $ 43,589,598 $ 29,090,662

X

- References
No definition available.
+ Details

Name: cvm_AggregateIntrinsicValue

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are
+ References
No definition available.
+ Details

Name: cvm_AggregateIntrinsicValueOutstandingEnding

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfOptions

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfOptionsExercised

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfOptionsVested

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageExercisePriceExpired

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageExercisePriceVested

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R49.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details 3) - $ / shares
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

STOCK COMPENSATION

Number of unvested options, Beginning 5,356,474 4,825,975

Vested options (2,401,961) (2,014,501)

Granted options 2,605,000 2,563,000

Forfeited options (49,832) (18,000)

Number of unvested options, Ending 5,509,681 5,356,474

Weighted Average Grant Date Fair Value, Beginning $ 4.76 $ 3.79

Weighted Average Grant Date Fair Value, Ending $ 5.17 $ 4.76

X

- References
No definition available.
+ Details

Name: cvm_ForfeitedOptions

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_GrantedOptions

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfUnvestedOptionsBeginning

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfUnvestedOptionsEnding

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_VestedOptions

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageGrantDateFairValueBeginning

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageGrantDateFairValueEnding

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R50.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details 4) - $ / shares
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Weighted Average Grant Date Fair Value, Beginning $ 4.76 $ 3.79

Restricted Stock Awards [Member]

Number of unvested shares, Beginning 304,500 304,500

Forfeited (2,000) 0

Vested shares (151,250) 0

Number of unvested shares, Ending 151,250 304,500

Weighted Average Grant Date Fair Value, Beginning $ 13.75 $ 13.75

Weighted Average Grant Date Fair Value, Ending $ 13.75 $ 13.75

X

- References
No definition available.
+ Details

Name: cvm_NumberOfUnvestedSharesBeginning

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfUnvestedSharesEnding

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SharesForfeited

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_VestedShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageGrantDateFairValue

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageGrantDateFairValueBeginning

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.4

STOCK COMPENSATION (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Jun. 30, 2021

May 14, 2021

Dec. 31, 2020

Apr. 20, 2020

Mar. 31, 2020

Dec. 31, 2019

Common stock, shares issued 43,207,183 38,730,150 1,400,000 1,000,000 630,500 606,395

Common stock, shares authorized 600,000,000 600,000,000

Stock Compensation Plans [Member]

Common stock, shares issued 154,195

Common stock, shares authorized 634,000

Stock Bonus Plans [Member]

Common stock, shares issued 363,086

Common stock, shares authorized 783,760

Non-Qualified Stock Options Plans [Member]

Common stock, shares authorized 11,787,200

Unrecognized compensation expense $ 3,800,000 $ 2,100,000

Remaining compensation expense $ 189,000 $ 3,800,000.0

Issuance of common stock options purchase shares 1,800,000 3,600,000

Performance based stock options shares granted 72,000 1,800,000 1,872,000

Stock price $ 20.61 $ 10.93

Stock options vest description The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days.

Fair value per share $ 0.34 $ 4.21

Grant date fair value remaining outstanding $ 7,900,000

Grant date fair value remaining $ 447,000 $ 2,000,000.0

Implicit life of options 1 year 3 months 18 days 1 year 8 months 12 days

Expense life over next 11 years 11 years

Incentive Stock Option Plans [Member]

Common stock, shares authorized 138,400

Incentive Stock Bonus Plan [Member]

Common stock, shares authorized 614,500

Grant date fair value remaining outstanding $ 8,600,000

Vested shares 463,250

Issuance of restricted stock $ 300,000

Unrecognized compensation expense $ 45,000

X

- References
No definition available.
+ Details

Name: cvm_ExpenseLifeOverNext

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_FairValuePerShare

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_GrantDateFairValueRemaining

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_IssuanceOfRestrictedStock

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_PerformanceBasedStockOptionsSharesGranted

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_RemainingCompensationExpense

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_RemainingOutstandingFairValueOfShares

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_VestedShares

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCompensationEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 5
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879
+ Details

Name: us-gaap_OptionIndexedToIssuersEquityStrikePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R52.htm IDEA: XBRL DOCUMENT v3.21.4

EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

EMPLOYEE BENEFIT PLAN (Detail Narrative)

Expense for Company's contribution to employee benefit plan $ 163,000 $ 201,000

Total compensation $ 10,000

Participant compensation 6.00%

Shares issued 13,870 17,990

X

- References
No definition available.
+ Details

Name: cvm_ParticipantCompensation

Namespace Prefix: cvm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_TotalCompensation

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of discretionary contributions made by an employer to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 63 R53.htm IDEA: XBRL DOCUMENT v3.21.4

COMMITMENTS AND CONTINGENCIES (Details)

Sep. 30, 2021

USD ($)

Commitments and Contingencies

2022 $ 1,699,000

2023 2,569,000

2024 2,648,000

2025 2,733,000

2026 2,824,000

Thereafter 6,186,000

Total future minimum lease obligation 18,659,000

Less imputed interest on financing obligation 4,825,000

Net present value of lease financing obligation $ (13,834,000)

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
No definition available.
+ Details

Name: cvm_NetPresentValueOfLeaseFinancingObligation

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 64 R54.htm IDEA: XBRL DOCUMENT v3.21.4

COMMITMENTS AND CONTINGENCIES (Details 1)

Sep. 30, 2021

USD ($)

Commitments and Contingencies

2022 $ 309,000

2023 348,000

2024 357,000

2025 366,000

2026 287,000

Thereafter 1,602,000

Total future minimum lease obligation 3,269,000

Less imputed interest on operating lease obligation (1,130,000)

Total $ 2,139,000

X

- References
No definition available.
+ Details

Name: cvm_LesseeOperatingLeaseLiabilityPayments

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 65 R55.htm IDEA: XBRL DOCUMENT v3.21.4

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Weighted average discount rate 8.45%

Weighted average discount rate operating lease 9.12%

Interest rate 0.1019% 0.10%

Maturity years 7 years 1 month 6 days

Operating lease maturity years 9 years 8 months 12 days

Research and development expenses $ 35,100,000

Net of discount $ 11,600,000

Lease description revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%

Finance lease obligations, net of current portion $ 200,000 $ 100,000

Weighted average time to maturity 17 years

Biologics License Application [Member]

Sublease rental income 39,000

Ergomed [Member]

Research and development expenses $ 1,600,000 1,400,000.0

Net of discount 600,000 600,000.0

Clinical service trial 10,000,000

Additional clinical trial $ 2,000,000

Weighted average time to maturity 7 years 1 month 6 days

TransactionTwoMember [Member] | October 1, 2019 [Member]

Change in right of use of assets and liability $ 1,000,000.0

Cash paid related to operating leases 300,000 200,000

Net book value operating lease right of use assets 2,100,000 1,200,000

Current balance 100,000 100,000

Operating lease - liability 2,100,000 1,200,000

Operating lease expense $ 200,000 200,000.0

Transaction One [Member] | October 1, 2019 [Member]

Weighted average discount rate 0.0845%

Change in right of use of assets and liability $ 16,500,000

Current balance 600,000 900,000

Operating lease - liability 1,732,000 1,717,000

Finance lease liability 13,500,000

Net book value of the finance lease right of use asset 12,700,000 13,800,000

Balance of the finance lease liability 13,800,000 12,700,000

Cash paid related to finance leases 2,200,000 1,900,000

Cash paid related to finance leases interest $ 1,200,000 1,200,000.0

Landlord [Member]

Interest rate 8.45%

Lease description The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.

Lease incentive payable current $ 1,600,000.0

Additional deposit 200,000

Cost incurred, initial 10,500,000

Estimated cost 10,700,000

Non current assets 1,900,000 $ 1,700,000

Financing arrangement 2,400,000

Vendor Obligations [Member]

Additional expenses $ 1,100,000

X

- References
No definition available.
+ Details

Name: cvm_AdditionalClinicalTrial

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_BalanceOfTheFinanceLeaseLiability

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_CashPaidRelatedToFinanceLeases

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_CashPaidRelatedToFinanceLeasesInterest

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ClinicalServiceTrial

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_CostIncurredInitial

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_CurrentBalance

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_EstimatedCost

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_FinanceLeaseObligationsNetOfCurrentPortion

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_FinancingLeaseContractualArrangement

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: cvm_MaturityYears

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_NetBookValueOperatingLeaseRightOfUseAssets

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_NetOfDiscount

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_OperatingLeaseMaturityYears

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeVariableInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 15
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121601235&loc=d3e32400-112679

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121554914&loc=SL2265659-115463

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694
+ Details

Name: us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121577943&loc=d3e41614-112719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121549951&loc=d3e40019-112707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121549951&loc=d3e40010-112707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LeaseIncentivePayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of other research and development expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_OtherResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of sublease income excluding finance and operating lease expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_SubleaseIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=cvm_ErgomedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=cvm_TransactionTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=cvm_TransactionOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_LandlordMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cvm_VendorObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R56.htm IDEA: XBRL DOCUMENT v3.21.4

RELATED PARTY TRANSACTIONS (Details Narrative ) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

Dec. 07, 2020

May 08, 2020

Jan. 23, 2020

Jun. 30, 2021

Sep. 30, 2021

Sep. 30, 2020

Jun. 28, 2021

Officer and Director [Member]

Restricted Common shares 27,500 20,512

Restricted Common shares, amount $ 220,000 $ 185,000

Series N Warrants [Member]

Expiration date description the expiration date of the Series N warrants was extended to February 18, 2021 the expiration date of the Series N warrants was extended to February 18, 2021

Incremental cost $ 265,000 $ 265,000 $ 22,000

Series UU warrants [Member]

Expiration date description from December 31, 2020 to June 30, 2021 extended from June 11, 2020 to December 31, 2020 the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021

Warrants issued 93,603 93,593 93,603

Interest expense $ 192 $ 6,000 24,000 $ 24,000

Series X Warrants [Member]

Incremental cost $ 265,000 265,000

Series N and X Warrants [Member]

Incremental cost $ 86,000

X

- References
No definition available.
+ Details

Name: cvm_ExpirationDateDescription

Namespace Prefix: cvm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_NumberOfRestrictedSharesPurchasedByRelatedParty

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WarrantsIssued

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of interest expense incurred on a debt or other obligation to related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherCostAndExpenseOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R57.htm IDEA: XBRL DOCUMENT v3.21.4

STOCKHOLDERS EQUITY (Details) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

STOCKHOLDERS EQUITY

Amount realized through the resale of shares $ 1,685,379 $ 2,652,605

Fair value of shares upon issuance 0 1,769,500

Other non-operating gain (loss) $ 1,685,379 $ 883,105

X

- Definition
Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.
+ References
No definition available.
+ Details

Name: cvm_AmountRealizedThroughTheResaleOfShares

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R58.htm IDEA: XBRL DOCUMENT v3.21.4

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended

Jun. 30, 2021

Dec. 31, 2020

May 31, 2020

Mar. 31, 2020

Jan. 31, 2020

Dec. 31, 2019

Sep. 30, 2021

Sep. 30, 2020

Common stock shares issued 1,400,000 1,000,000 630,500 606,395 43,207,183 38,730,150

Proceeds from public offering $ 210,000 $ 94,575 $ 90,959 $ 90,959

Proceeds from initial public offering $ 29,400,000 $ 13,600,000 $ 1,100,000 $ 7,100,000 $ 800,000 $ 5,000,000.0

Public offering price per share $ 22.62 $ 14.65 $ 12.22 $ 9.07 $ 9.07

Proceeds from issuance of warrant $ 4,400,000 $ 6,000,000.0 $ 12,100,000

Warrants exercised 1,597,870 1,711,873

Ergomed [Member]

Common stock shares issued 150,000

Prepaid of resold amount $ 500,000

X

- References
No definition available.
+ Details

Name: cvm_PrepaidAmountOfResold

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
No definition available.
+ Details

Name: cvm_ProceedFromIssuanceOrSaleOfEquity

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_ProceedsFromPublicOffering

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=cvm_ErgomedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R59.htm IDEA: XBRL DOCUMENT v3.21.4

FAIR VALUE MEASUREMENTS (Details) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

FAIR VALUE MEASUREMENTS

Beginning balance $ 3,765,613 $ 6,488,310

Issuances 0 0

Exercises 4,023,091 3,071,775

Net realized and unrealized derivative loss 694,858 349,078

Ending balance $ 437,380 $ 3,765,613

X

- References
No definition available.
+ Details

Name: cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings

Namespace Prefix: cvm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 70 R60.htm IDEA: XBRL DOCUMENT v3.21.4

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

unrealized gain on short-term T-bills $ 6,000

Weighted average risk free interest rate 0.10%

Fair Value Inputs Level 3 (Level 3)

Weighted average risk free interest rate 0.05% 0.12%

Weighted average fair value, Derivative instruments $ 1.45 $ 2.81

Weighted average exercise price, Derivative instruments $ 13.28 $ 14.32

Volatility rate 109.00% 95.00%

Weighted average time to maturity year 3 months 18 days 1 year 2 months 12 days

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
No definition available.
+ Details

Name: cvm_VolatilityRate

Namespace Prefix: cvm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageExercisePriceDerivativeInstruments

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageFairValueDerivativeInstruments

Namespace Prefix: cvm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageRiskFreeInterestRate

Namespace Prefix: cvm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cvm_WeightedAverageTimeToMaturityYear

Namespace Prefix: cvm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=cvm_FairValueInputsLevelThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R61.htm IDEA: XBRL DOCUMENT v3.21.4

NET LOSS PER COMMON SHARE (Details) - USD ($)
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

NET LOSS PER COMMON SHARE

Net loss available to common shareholders - basic $ (36,711,970) $ (30,276,978)

Weighted average shares outstanding - basic 40,662,137 36,759,115

Basic loss per common share $ (0.90) $ (0.82)

Loss per share- diluted

Net loss available to common shareholders -basic $ (36,711,970) $ (30,276,978)

Unrealized gain on derivatives (1,085,540) 0

Net loss available to common shareholders - diluted $ (37,797,510) $ (30,276,978)

Weighted average shares outstanding - basic 40,694,248 36,759,115

Incremental shares underlying dilutive "in the money" warrants 32,111 0

Weighted average shares outstanding - diluted 40,694,248 36,759,115

Diluted loss per common share $ (0.93) $ (0.82)

X

- References
No definition available.
+ Details

Name: cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants

Namespace Prefix: cvm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 72 R62.htm IDEA: XBRL DOCUMENT v3.21.4

NET LOSS PER COMMON SHARE (Details 1) - shares
12 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Antidilutive securities 10,756,100 7,530,510

Options and Warrants

Antidilutive securities 10,604,850 7,221,696

Unvested Restricted Stock [Member]

Antidilutive securities 151,250 308,814

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 cvm_10k_htm.xml IDEA: XBRL DOCUMENT 0000725363 2020-10-01 2021-09-30 0000725363 cvm:UnvestedRestrictedStockMember 2020-10-01 2021-09-30 0000725363 cvm:UnvestedRestrictedStockMember 2019-10-01 2020-09-30 0000725363 cvm:OptionsMember 2020-10-01 2021-09-30 0000725363 cvm:OptionsMember 2019-10-01 2020-09-30 0000725363 cvm:FairValueInputsLevelThreeMember 2020-10-01 2021-09-30 0000725363 cvm:FairValueInputsLevelThreeMember 2019-10-01 2020-09-30 0000725363 cvm:FairValueInputsLevelThreeMember 2021-09-30 0000725363 cvm:FairValueInputsLevelThreeMember 2020-09-30 0000725363 cvm:ErgomedMember 2020-09-30 0000725363 cvm:ErgomedMember 2021-09-30 0000725363 2019-12-01 2019-12-31 0000725363 2020-01-01 2020-01-31 0000725363 2020-03-01 2020-03-31 0000725363 2020-05-01 2020-05-31 0000725363 2021-06-01 2021-06-30 0000725363 2020-12-31 0000725363 2020-12-01 2020-12-31 0000725363 2019-12-31 0000725363 2020-01-31 0000725363 2021-06-30 0000725363 2020-03-31 0000725363 cvm:OfficerAndDirectorMember 2020-10-01 2021-09-30 0000725363 cvm:OfficerAndDirectorMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesUUWarrantsMember 2021-04-01 2021-06-30 0000725363 cvm:SeriesUUWarrantsMember 2021-06-28 0000725363 cvm:SeriesUUWarrantsMember 2020-12-07 0000725363 cvm:SeriesUUWarrantsMember 2020-05-08 0000725363 cvm:SeriesNAndXWarrantsMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesNWarrantsMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesXWarrantsMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesXWarrantsMember 2021-04-01 2021-06-30 0000725363 cvm:SeriesNWarrantsMember 2021-04-01 2021-06-30 0000725363 cvm:SeriesNWarrantsMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesUUWarrantsMember 2020-12-01 2020-12-07 0000725363 cvm:SeriesNWarrantsMember 2020-12-01 2020-12-07 0000725363 cvm:LandlordMember 2020-09-30 0000725363 us-gaap:LicenseMember 2019-10-01 2020-09-30 0000725363 cvm:LandlordMember 2020-10-01 2021-09-30 0000725363 cvm:ErgomedMember 2019-10-01 2020-09-30 0000725363 cvm:ErgomedMember 2020-10-01 2021-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionOneMember 2019-10-01 2020-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionOneMember 2020-10-01 2021-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionOneMember 2020-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionOneMember 2021-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionTwoMember 2020-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionTwoMember 2021-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionTwoMember 2019-10-01 2020-09-30 0000725363 cvm:OctoberOneTwothousandNineTeenMember cvm:TransactionTwoMember 2020-10-01 2021-09-30 0000725363 cvm:LandlordMember 2021-09-30 0000725363 cvm:VendorObligationsMember 2020-10-01 2021-09-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2021-05-14 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2020-04-20 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2020-10-01 2021-09-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2019-10-01 2020-09-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2020-09-30 0000725363 cvm:IncentiveStockBonusPlanMember 2020-10-01 2021-09-30 0000725363 cvm:IncentiveStockBonusPlanMember 2021-09-30 0000725363 cvm:IncentiveStockOptionPlansMember 2021-09-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2021-09-30 0000725363 cvm:StockCompensationPlansMember 2021-09-30 0000725363 cvm:StockBonusPlansMember 2021-09-30 0000725363 cvm:RestrictedStockAwardsMember 2020-10-01 2021-09-30 0000725363 cvm:RestrictedStockAwardsMember 2019-10-01 2020-09-30 0000725363 cvm:OutstandingMember 2021-09-30 0000725363 cvm:OutstandingMember 2020-10-01 2021-09-30 0000725363 cvm:OutstandingMember 2019-10-01 2020-09-30 0000725363 cvm:OutstandingMember 2020-09-30 0000725363 cvm:OutstandingMember 2019-09-30 0000725363 cvm:ExercisableMember 2021-09-30 0000725363 cvm:ExercisableMember 2020-10-01 2021-09-30 0000725363 cvm:ExercisableMember 2019-10-01 2020-09-30 0000725363 cvm:ExercisableMember 2020-09-30 0000725363 cvm:ExercisableMember 2019-09-30 0000725363 cvm:IncomeTaxMember 2020-10-01 2021-09-30 0000725363 cvm:IncomeTaxMember 2021-09-30 0000725363 cvm:IncomeTaxMember 2020-09-30 0000725363 us-gaap:PatentsMember 2021-09-30 0000725363 us-gaap:PatentsMember 2020-09-30 0000725363 cvm:ConsultingAgreementsMember 2020-09-30 0000725363 cvm:ConsultingAgreementsMember 2021-09-30 0000725363 cvm:ConsultingAgreementsMember 2020-10-01 2021-09-30 0000725363 cvm:ConsultingAgreementsMember 2019-10-01 2020-09-30 0000725363 srt:MaximumMember cvm:RestrictedStocksMember cvm:ConsultantsMember 2020-10-01 2021-09-30 0000725363 srt:MaximumMember cvm:RestrictedStocksMember cvm:ConsultantsMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesYMember 2020-01-01 2020-01-23 0000725363 cvm:SeriesNWarrantsMember 2020-01-01 2020-01-23 0000725363 cvm:SeriesUUWarrantsMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesUUWarrantsMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesNAndXMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesUUWarrantsMember 2020-05-01 2020-05-08 0000725363 cvm:SeriesUUWarrantsMember 2020-06-01 2020-06-20 0000725363 cvm:SeriesYYWarrantsMember 2020-06-01 2020-06-20 0000725363 cvm:SeriesYYWarrantsMember 2020-09-30 0000725363 cvm:SeriesXXWarrantsMember 2020-06-01 2020-06-20 0000725363 cvm:SeriesXXWarrantsMember 2020-09-30 0000725363 cvm:SeriesWMember 2020-10-01 2020-10-28 0000725363 cvm:SeriesBBMember 2021-08-01 2021-08-22 0000725363 srt:MinimumMember cvm:SeriesVWarrantsMember 2020-05-26 0000725363 srt:MaximumMember cvm:SeriesVWarrantsMember 2020-05-26 0000725363 cvm:SeriesVWarrantsMember 2020-06-01 2020-06-25 0000725363 cvm:SeriesVWarrantsMember 2020-05-01 2020-05-26 0000725363 cvm:SeriesVVMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesOOMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesVMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesVMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesLLMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesLLMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesJJMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesJJMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesFFMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesFFMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesBBMember 2021-09-30 0000725363 cvm:SeriesBBMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesZZMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesZZMember 2021-09-30 0000725363 cvm:SeriesWMember 2021-09-30 0000725363 cvm:SeriesWMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesUUMember 2021-09-30 0000725363 cvm:SeriesUUMember 2020-09-30 0000725363 cvm:SeriesUUMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesUUMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesTTMember 2021-09-30 0000725363 cvm:SeriesTTMember 2020-09-30 0000725363 cvm:SeriesTTMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesTTMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesSSMember 2021-09-30 0000725363 cvm:SeriesSSMember 2020-09-30 0000725363 cvm:SeriesSSMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesSSMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesRRMember 2021-09-30 0000725363 cvm:SeriesRRMember 2020-09-30 0000725363 cvm:SeriesRRMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesRRMember 2019-10-01 2020-09-30 0000725363 cvm:ConsultantsMember 2021-09-30 0000725363 cvm:ConsultantsMember 2020-09-30 0000725363 cvm:ConsultantsMember 2020-10-01 2021-09-30 0000725363 cvm:ConsultantsMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesNNMember 2021-09-30 0000725363 cvm:SeriesNNMember 2020-09-30 0000725363 cvm:SeriesNNMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesNNMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesMMMember 2021-09-30 0000725363 cvm:SeriesMMMember 2020-09-30 0000725363 cvm:SeriesMMMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesMMMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesAAMember 2021-09-30 0000725363 cvm:SeriesAAMember 2020-09-30 0000725363 cvm:SeriesAAMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesAAMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesHHMember 2021-09-30 0000725363 cvm:SeriesHHMember 2020-09-30 0000725363 cvm:SeriesHHMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesHHMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesCCMember 2021-09-30 0000725363 cvm:SeriesCCMember 2020-09-30 0000725363 cvm:SeriesCCMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesCCMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesZMember 2021-09-30 0000725363 cvm:SeriesZMember 2020-09-30 0000725363 cvm:SeriesZMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesZMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesBBMember 2020-09-30 0000725363 cvm:SeriesBBMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesZZMember 2020-09-30 0000725363 cvm:SeriesZZMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesYMember 2021-09-30 0000725363 cvm:SeriesYMember 2020-09-30 0000725363 cvm:SeriesYMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesYMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesXMember 2021-09-30 0000725363 cvm:SeriesXMember 2020-09-30 0000725363 cvm:SeriesXMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesXMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesWMember 2020-09-30 0000725363 cvm:SeriesWMember 2019-10-01 2020-09-30 0000725363 cvm:SeriesNMember 2021-09-30 0000725363 cvm:SeriesNMember 2020-09-30 0000725363 cvm:SeriesNMember 2020-10-01 2021-09-30 0000725363 cvm:SeriesNMember 2019-10-01 2020-09-30 0000725363 us-gaap:RetainedEarningsMember 2021-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000725363 us-gaap:CommonStockMember 2021-09-30 0000725363 us-gaap:RetainedEarningsMember 2020-10-01 2021-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-09-30 0000725363 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0000725363 us-gaap:RetainedEarningsMember 2020-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000725363 us-gaap:CommonStockMember 2020-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2020-09-30 0000725363 us-gaap:CommonStockMember 2019-10-01 2020-09-30 0000725363 us-gaap:RetainedEarningsMember 2019-10-01 2020-09-30 0000725363 2019-09-30 0000725363 us-gaap:RetainedEarningsMember 2019-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000725363 us-gaap:CommonStockMember 2019-09-30 0000725363 2019-10-01 2020-09-30 0000725363 2020-09-30 0000725363 2021-09-30 0000725363 2021-12-10 0000725363 2021-03-31 iso4217:USD shares iso4217:USD shares pure 0000725363 false No --09-30 No FY 2021 0.01 0.01 200000 200000 0 0 0 0 0.01 600000000 43207183 38730150 72900 664000 461963 101839 103000 22000 13456123 1200000.0 188900000.0 0 0 P7Y8M5D 29090662 P8Y10M17D 56193415 5356474 4.76 0 0 304500 13.75 3800000.0 4825000 0.001019 0.001 200000.0 1732000 1717000 1200000.0 0.000845 1600000.0 2000000 600000.0 P7Y1M6D 1400000.0 200000 100000 from December 31, 2020 to June 30, 2021 265000 265000 265000 93603 24000 90959 0 10-K true 2021-09-30 false 1-11889 CEL-SCI CORPORATION CO 84-0916344 8229 Boone Blvd. Suite 802 Vienna VA 22182 703 506-9460 Common Stock CVM NYSE Yes Yes Non-accelerated Filer true false false 595537907 43244498 36060148 15508909 6151385 0 54922 54922 998482 1313432 2006584 820052 45271521 17697315 12691921 13811849 2056178 1198958 13663562 5843993 275866 313422 1910917 1670917 75869965 40536454 1675813 2023067 859216 510515 265993 448022 437380 213787 698665 1070123 3937067 4265514 0 3551826 13252364 11753100 2021308 1114340 125000 125000 19335739 20809780 0.01 600000000 43207183 38730150 432072 387302 474298566 401174675 -418196412 -381835303 56534226 19726674 75869965 40536454 0 558664 23108897 17840290 13085232 11703429 36194129 29543719 -36194129 -28985055 -8213 38763 -694858 -349078 0 805753 1685379 887604 -1149288 -1041725 -36361109 -30255244 -350861 -21734 -36711970 -30276978 -0.90 -0.82 40662137 36759115 -0.93 -0.82 40694248 36759115 35231776 352318 358507603 -353726254 5133667 2146195 2146195 1422429 14225 13978214 0 13992439 0 805753 0 805753 1711873 17118 15127122 0 15144240 0 5554 5554 13870 139 163201 0 163340 79950 799 971868 0 972667 0 10112968 0 10112968 99740 998 337330 0 338328 20512 205 184785 0 184990 0 -787723 0 -787723 150000 1500 1768000 0 1769500 0 0 -30255244 -30255244 38730150 387302 401174675 -381835303 19726674 2610000 26100 47337326 0 47363426 1597870 15978 9991328 0 10007306 0 24387 0 24387 17990 180 200919 0 201099 75885 759 1194945 0 1195704 -2000 -20 13685066 0 13685046 149788 1498 744730 0 746228 27500 275 219725 0 220000 0 -274535 0 -274535 0 0 -36361109 -36361109 43207183 432072 474298566 -418196412 56534226 -36361109 -30255244 2231108 2159729 1226690 862796 13685046 10112968 201099 163340 0 1769500 -5621 0 694858 349078 0 805753 24387 5554 0 7843 283964 -623608 -1186532 -37689 -240000 0 445981 -766073 363701 406083 -182029 -261420 31441 25229 -18787016 -15276161 6145764 0 9016329 2654906 22641 39975 -15184734 -2694881 47363426 13992439 325034 752804 5984215 12072465 746228 338328 220000 184990 1613546 0 1079392 800241 54522989 25035177 20551239 7064135 15508909 8444774 36060148 15508909 435412 1184723 6510 15000 551444 399032 855 790 363911 164871 4023091 3071775 0 50499 55000 55000 1173702 1155026 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">1. </td><td style="vertical-align:top;">ORGANIZATION </td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has recently announced top line Phase 3 data for its lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">CEL-SCI is investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">2. </td><td style="vertical-align:top;">OPERATIONS AND FINANCING</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Liquidity</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. Primarily as a result of CEL-SCI's losses incurred to date, CEL-SCI's expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI's ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that because there is more than enough cash on hand to meet the Company's budgeted cash requirements, the substantial doubt about the Company's ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Impact of COVID-19 Pandemic</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">3. </td><td style="vertical-align:top;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Leases – On October 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases and its related amendments (collectively referred to as Topic 842 and codified as “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company’s statements of operations or cash flows.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period. In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td>The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period. Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. Grant Income – The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. Concentration of Credit Risk – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. Income Taxes – The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Use of Estimates – The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">New Accounting Pronouncements</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</td></tr></tbody></table> Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents. U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value. Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired. Patents – Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. P17Y Leases – On October 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases and its related amendments (collectively referred to as Topic 842 and codified as “ASC 842”). ASC 842 requires that lessees recognize right-of-use assets and lease liabilities measured at the present value of the future lease payments at the lease commencement date. The Company adopted the new leases standard utilizing the modified retrospective transition method, under which amounts in prior periods presented were not restated. The impact of adopting ASC 842 was to record a cumulative effect adjustment of approximately $2.1 million to the opening accumulated deficit balance. The adoption of ASC 842 did not have a significant impact on the Company’s statements of operations or cash flows.The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted, but only as of the beginning of the annual fiscal year of adoption. The Company will adopt ASU 2020-06 effective October 1, 2021. No financial impact is expected as of that date or on the annual and interim periods in the period of adoption. Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period. In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation — Stock Compensation (Topic 718), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, and thus, the accounting for share-based payments to non-employees will be substantially aligned. The Company adopted ASU 2018-07 as of October 1, 2019 with no impact on its financial statements and related disclosures.The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period. Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. Grant Income – The Company's grant arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred. Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. Concentration of Credit Risk – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2021. 250000 Income Taxes – The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2021 and 2020.In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements. Use of Estimates – The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant. The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">4. </td><td style="vertical-align:top;">WARRANTS AND NON-EMPLOYEE OPTIONS</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The following warrants and non-employee options are outstanding at September 30, 2021: </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant/Options</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2022 </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/13/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/15/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,845</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,087</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,761</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/2017 – 11/18/2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">2.18 - $11.61</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/17/2022 - 7/27/2027</td><td style="width:1%;"> </td></tr></tbody></table>The following warrants and non-employee options are outstanding at September 30, 2020: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/Options</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/18/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/31/2020</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W</td><td style="width:1%;white-space: nowrap;"> </td><td>10/28/2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,930</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/28/2020</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5/18/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/22/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,643</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/17</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/27/2027</td><td style="width:1%;"> </td></tr></tbody></table> A. Warrant Liabilities Warrant liabilities outstanding at September 30 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total warrant liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The (losses)/gains on the warrant liabilities for the years ended September 30 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V Warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,652</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,119,937</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,115</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,357</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,692</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,594</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(318,823</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(165,304</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,207</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(668,605</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(875,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(319,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(34,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series JJ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,992</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series LL warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(98,066</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(694,858</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(349,078</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td>The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded. In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations. Changes in Warrant Liabilities On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75 expired. On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired. On May 26, 2020, the Company lowered the exercise price of 810,127 Series V warrants from $19.75 to $13.75 per share and extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020. The incremental cost of this modification was approximately $664,000, which was included in the net loss on derivatives for the year ended September 30, 2020. On June 25, 2020, 135,963 Series V warrants, with an exercise price of $13.75 expired. The warrants were valued at approximately $211,000 on the date of expiration. Exercise of Warrant Liabilities The following warrants recorded as liabilities were exercised during the year ended September 30, 2021:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,089,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">275,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,375,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,798</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">663,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,402,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The following warrants recorded as liabilities were exercised during the year ended September 30, 2020: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,164</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,269,755</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,820</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series FF</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,812</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,687</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series JJ</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,531</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series LL</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.59</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">94,867</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">913,180</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,323,752</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">B. </td><td style="vertical-align:top;">Equity Warrants</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Changes in Equity Warrants</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On December 7, 2020, the expiration dates of the Series N, Series X, Series Y and Series UU warrants were extended six months. On June 28, 2021, the expiration dates of these same warrants were extended one year. The incremental costs of both warrant extensions were recorded consistent with the accounting for the initial warrant issuances. The incremental costs of the Series N and Series X warrant extensions were recorded as a deemed dividend and totaled approximately $351,000 for the year ended September 30, 2021. The Series N and Series X warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. The incremental cost of the Series Y warrants extension approximated $103,000 and had no impact on the financial statements for the year ended September 30,2021 due to offsetting entries recorded within additional paid in capital. The incremental cost of the Series UU warrant extension was recorded as interest expense, because these warrants were initially issued as an inducement to convert notes payable into common stock, and totaled approximately $24,000 for the year ended September 30, 2021. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On May 26, 2020, the Company provided that for each Series V liability warrant exercised on or before June 10, 2020, the former holder of the Series V warrant received one Series XX warrant. Each Series XX warrant allowed the holder to purchase one share of the Company's common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V liability warrant exercised after June 10, 2020 but on or before June 25, 2020, the former holder of the Series V warrant received one Series YY warrant. Every two Series YY warrants allowed the holder to purchase one share of the Company's common stock at a price of $20.00 per share at any time on or before September 25, 2020. In June 2020, 461,953 Series XX warrants and 101,839 Series YY warrants were issued to the former holders of the Series V warrants. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. The Company recognized a warrant inducement expense equal to the fair value of the Series XX and Series YY warrants issued as of the date the inducement offers were accepted. The fair values of the Series XX and Series YY warrants were calculated to be approximately $629,000 and $177,000, respectively. The total expense of approximately $806,000 is reported as warrant inducement expense in the statement of operations for the year ended September 30, 2020. All Series XX and YY warrants expired in September 2020.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On May 8, 2020, the expiration dates of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense during the year ended September 30, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td>Exercise of Equity Warrants The following equity warrants were exercised during the year ended September 30, 2021.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,201</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">863,414</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,755</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,663</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,888</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">273,715</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,474</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">370,964</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">830,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,265,872</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,581,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The following equity warrants were exercised during the year ended September 30, 2020. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,858</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,296</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,956</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">314,889</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series OO</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,467</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,121</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,580</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">327,252</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,125</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">421,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,207</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,380</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series VV</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">82,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,375</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">798,693</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,748,713</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">C. </td><td style="vertical-align:top;">Options and Shares Issued to Consultants</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2021 and 2020 the Company issued 75,885 and 79,950 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $6.86 to $24.95 per share. The weighted average grant price was $15.46 and $12.01, respectively, for stock issued during the years ended September 30, 2021 and 2020.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020, the Company recorded total expense of approximately $1,227,000 and $863,000, respectively, relating to these consulting agreements. At September 30, 2021 and 2020, costs of approximately $364,000 and $395,000, respectively, are included in prepaid expenses.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the year ended September 30, 2021, the Company issued 5,000 options to a consultant to purchase common stock with an exercise price of $11.61 and an expiration of November 17, 2022. No options were issued to consultants during the year ended September 30, 2020. As of September 30, 2021, 15,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plan and are fully vested.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant/Options</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2022 </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/13/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/15/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,845</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,087</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,761</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/2017 – 11/18/2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">2.18 - $11.61</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/17/2022 - 7/27/2027</td><td style="width:1%;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/Options</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/18/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/31/2020</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W</td><td style="width:1%;white-space: nowrap;"> </td><td>10/28/2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,930</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/28/2020</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5/18/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/22/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,643</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/17</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/27/2027</td><td style="width:1%;"> </td></tr></tbody></table> 8/18/2008 85339 3.00 8/18/2022 6/11/2018 93603 2.80 6/30/2022 1/13/2016 120000 9.25 7/13/2022 2/15/2016 26000 12.00 8/15/2022 5/23/2016 184800 13.75 11/23/2021 12/8/2016 15845 5.00 12/8/2021 2/23/2017 200 3.13 2/16/2022 8/26/2016 100000 13.75 2/22/2022 6/22/2017 333432 1.86 6/22/2022 7/24/2017 210087 2.52 7/24/2022 10/30/2017 251761 1.65 10/30/2022 12/19/2017 200000 2.09 12/18/2022 2/5/2018 600 2.24 2/5/2023 7/28/2017 15000 2.18 7/27/2027 8/18/2008 85339 3.00 2/18/2021 6/11/2018 93603 2.80 12/31/2020 10/28/2015 688930 16.75 10/28/2020 1/13/2016 120000 9.25 1/13/2021 2/15/2016 26000 12.00 2/15/2021 5/23/2016 20000 13.75 5/18/2021 8/26/2016 16000 13.75 8/22/2021 5/23/2016 264000 13.75 11/23/2021 12/8/2016 148643 5.00 12/8/2021 2/23/2017 200 3.13 2/16/2022 8/26/2016 200000 13.75 2/22/2022 6/22/2017 797633 1.86 6/22/2022 7/24/2017 348842 2.52 7/24/2022 10/30/2017 417649 1.65 10/30/2022 12/19/2017 326064 2.09 12/18/2022 2/5/2018 371564 2.24 2/5/2023 7/28/17 10000 2.18 7/27/2027 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total warrant liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0 73570 64787 1207902 0 75044 276035 1082212 0 65173 94961 1259712 1597 2000 437380 3765613 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V Warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,652</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,119,937</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,115</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,357</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(98,692</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,594</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(318,823</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(165,304</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,207</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(668,605</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(875,040</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(319,706</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(34,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series JJ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,992</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series LL warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(98,066</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(694,858</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(349,078</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 0 185652 73570 1119937 -252115 -98357 -98692 2594 -318823 -165304 65173 -1207 -668605 -875040 0 -319706 404 -34589 0 -64992 0 -98066 -694858 -349078 16000 13.75 688930 16.75 810127 19.75 13.75 extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020 664000 135963 13.75 211000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,089,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">275,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,375,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,798</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">663,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,402,990</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,164</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,269,755</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">128,820</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series FF</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,812</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,687</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series JJ</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,450</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,531</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series LL</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.59</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">94,867</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">913,180</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,323,752</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 13.75 1089000 20000 13.75 275000 100000 13.75 1375000 132798 5.00 663990 331998 3402990 674164 13.75 9269755 128820 5.00 644100 68048 3.91 265812 6300 3.13 19687 9450 3.13 29531 26398 3.59 94867 913180 10323752 351000 24000 18.00 20.00 101839 629000 177000 806000 93593 extended from June 11, 2020 to December 31, 2020 6000 the expiration date of the Series N warrants was extended to February 18, 2021 22000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,201</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">863,414</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,755</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,663</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,888</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">273,715</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,474</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">370,964</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">830,959</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,265,872</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,581,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Proceeds</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,858</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,296</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,956</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">314,889</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series OO</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,467</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,121</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">156,580</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">327,252</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,125</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">421,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,207</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,380</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series VV</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">82,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,375</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">798,693</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,748,713</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 464201 1.86 863414 138755 2.52 349663 165888 1.65 273715 126064 2.09 263474 370964 2.24 830959 1265872 2581225 95858 1.86 178296 124956 2.52 314889 50000 2.52 126000 39467 1.65 65121 156580 2.09 327252 188125 2.24 421400 61207 2.80 171380 82500 1.75 144375 798693 1748713 75885 79950 6.86 24.95 15.46 12.01 1227000 863000 364000 395000 5000 2022-11-17 15000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">5. </td><td style="vertical-align:top;">PROPERTY AND EQUIPMENT</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td>Property and equipment consisted of the following at September 30:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,211,124</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,898,242</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Furniture and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,465,123</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,519,161</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,776,015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,517,171</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated depreciation and amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,112,453</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,673,178</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net property and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,663,562</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,843,993</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Depreciation expense for the years ended September 30, 2021 and 2020 totaled approximately $447,000 and $389,000 respectively.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,211,124</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,898,242</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Furniture and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,768</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,465,123</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,519,161</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,776,015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,517,171</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated depreciation and amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,112,453</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,673,178</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net property and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,663,562</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,843,993</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 4211124 3898242 99768 99768 5519161 17776015 9517171 4112453 3673178 13663562 5843993 447000 389000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">6. </td><td style="vertical-align:top;">PATENTS</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Patents consist of the following at September 30:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">910,523</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">896,372</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(634,657</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(582,950</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">275,866</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">313,422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020, there was no impairment of patent costs. Amortization expense for the years ended September 30, 2021 and 2020 totaled approximately $52,000 and $53,000, respectively. The total estimated future amortization is as follows:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Years ending September 30, </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">103,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">910,523</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">896,372</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(634,657</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(582,950</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">275,866</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">313,422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 910523 896372 -634657 -582950 275866 313422 52000 53000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Years ending September 30, </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">103,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">276,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 49000 39000 31000 29000 25000 103000 276000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;">7. </td><td style="vertical-align:top;">INCOME TAXES</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="width:1%;"> </td><td style="vertical-align:top;">At September 30, 2021 and 2020, the Company had net deferred tax assets of $44.1 million and $35.5 million, respectively. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered the history of the Company’s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company’s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes for the year ended September 30, 2021 occurred and no such shifts were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company had federal NOL carryforwards of approximately $77.1 million and $51.5 million at September 30, 2021 and 2020, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards, which were generated post Tax Cuts and Jobs Act, have an indefinite life. In addition, the Company has a general business credit as a result of the credit for increasing research activities (“R&D credit”) of approximately $1.2 million at September 30, 2021 and 2020. The R&D credit expires during the fiscal year ended 2029.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Significant components of the Company’s deferred tax assets as of September 30, 2021 and 2020 are listed below:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">NOL carryforwards</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,789,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,407,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,101,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,631,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">R&D credit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,785,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,297,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capitalized R&D</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,040,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,853,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vacation and other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,062,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,534,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Right of use assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,786,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,911,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fixed assets and intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(172,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(169,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total deferred tax liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,080,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,104,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,454,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,104,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(35,454,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending Balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">The Company has no federal or state current or deferred tax expense or benefit. The Company’s effective tax rate differs from the applicable federal statutory tax rate. The reconciliation of these rates is as follows at for the years ended September 30:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Federal Rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">State rate change </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">State tax rate, net of federal benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.72</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.15</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other adjustments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.79</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Permanent differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.79</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.93</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effective tax rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">The Company applies the provisions of ASC 740, “Accounting for Uncertainty in Income Taxes,” which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense. The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2021. The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2018.</td></tr></tbody></table> (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. 77100000 51500000 Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards 1200000 The R&D credit expires during the fiscal year ended 2029. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">NOL carryforwards</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,789,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,407,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,101,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,631,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">R&D credit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,785,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,297,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capitalized R&D</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,040,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,853,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vacation and other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,062,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,534,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Right of use assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,786,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,911,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fixed assets and intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(172,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(169,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total deferred tax liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,080,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,104,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,454,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,104,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(35,454,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending Balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 19789000 13407000 4101000 3631000 1221000 1221000 7785000 5297000 15040000 15853000 126000 125000 48062000 39534000 -3786000 -3911000 -172000 -169000 3958000 4080000 44104000 -35454000 44104000 35454000 0 0 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Federal Rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">State rate change </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.37</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.40</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">State tax rate, net of federal benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.72</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.15</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other adjustments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.79</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Permanent differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.79</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.93</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effective tax rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0.2100 0.2100 -0.0137 -0.0140 0.0472 0.0515 -0.0079 -0.0324 0.0023 0.0042 -0.2379 -0.2193 0.0000 0.0000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">8. </td><td style="vertical-align:top;">STOCK COMPENSATION</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year Ended September 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,685,046</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,112,968</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,226,690</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,796</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected stock price volatility</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">90.42 – 97.22%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">87.36 – 90.26%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Risk-free interest rate</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">0.85 – 1.65%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">0.62 – 1.87%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected life of options</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">9.68 – 9.69 Years</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">9.68 – 9.69 Years</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Non-Qualified Stock Option Plans –</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the year ended September 30, 2021, the Company adopted the 2021 Non-Qualified Stock Option Plan, which provides for the issuance of up to 1,800,000 options to purchase shares of common stock. On May 14, 2021, the Company granted 1,800,000 performance-based stock options from the 2021 Non-Qualified Stock Option Plan and 72,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share, the fair value on the date of issuance. The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $42.00. None of the options will be exercisable before May 13, 2022. All options which have not vested as of May 13, 2031, will be canceled and will no longer be exercisable. The options were recorded in permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. That valuation resulted in a per share fair value of $0.34 and an aggregate value of approximately $636,000 on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was determined to be 1.3 years. This resulted in compensation expense of approximately $189,000 recorded during the year ended September 30, 2021. The remaining $447,000 will be expensed over the next 11 months.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:1%;"> </td><td style="vertical-align:top;">During the year ended September 30, 2020, the Company adopted the 2020 Non-Qualified Stock Option Plan, which provides for the issuance of up to 3,600,000 options to purchase shares of common stock. On April 20, 2020, the Company granted 1,872,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers and directors. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share, the fair value on the date of issuance. The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. Additionally, 100% of the options will vest when either (a) the first marketing application for any pharmaceutical based upon the Company's Multikine technology, in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia is filed, i.e., the performance condition, or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. All options which have not vested as of April 19, 2030, will be canceled and will no longer be exercisable. The options were recorded as permanent equity in accordance with ASC 718, Compensation – Stock Compensation. On the grant date, the options were valued using a Monte Carlo Simulation approach. That valuation resulted in a per share fair value of $4.21 and an aggregate value of approximately $7.9 million on the grant date. The aggregate value will be expensed over the requisite service period of the options, which was originally determined to be 1.7 years. In May 2021, it became probable that the performance condition would be met approximately 8 months later than originally estimated. Because the valuation and related requisite service period were based on achievement of the performance condition, the Company adjusted the requisite service period when it became probable that the marketing application would be filed within a different period. Compensation expense relating to this Plan was approximately $3.8 million and $2.1 million during the years ended September 30, 2021 and 2020, respectively. The remaining $2.0 million will be expensed over the next 11 months.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="width:1%;"> </td><td style="vertical-align:top;">At September 30, 2021, the Company has collectively authorized the issuance of 11,787,200 shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the plans. The Company’s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="width:1%;"> </td><td style="vertical-align:top;">Incentive Stock Option Plans – At September 30, 2021, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company’s Compensation Committee which administers the Plans. Only the Company’s employees are eligible to be granted options under the Incentive Stock Option Plans.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="width:1%;"> </td><td style="vertical-align:top;">Activity in the Company’s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2021 is summarized as follows:</td></tr></tbody></table>Non-Qualified and Incentive Stock Option Plans <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Term (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Term (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,218,216</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.54</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.88</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,562,594</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,392,241</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.15</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.68</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,869,555</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,014,501</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.06</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.34</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8,653,703</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.01</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">56,193,415</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,297,229</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.85</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.48</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,090,662</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,401,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.26</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted (a)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">20.58</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">49,832</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.56</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>______________<table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"> (a)</td><td style="vertical-align:top;">Includes 1,872,000 performance based options issued to officers and directors, 728,000 options issued to employees and 5,000 options issued to Consultants.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">A summary of the status of the Company’s non-vested options for the two years ended September 30, 2021 is presented below:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Grant Date Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,825,975</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.79</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,014,501</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,356,474</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,401,961</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(49,832</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Incentive Stock Bonus Plan – On September 30, 2021, 614,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company’s Multikine technology, or specified increases in the market price of the Company’s stock. The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued that remain outstanding as of September 30, 2021 was approximately $8.6 million. The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not rendered. During each of the years ended September 30, 2021 and 2020, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0.3 million. At September 30, 2021, the Company has unrecognized compensation expense of approximately $45,000 which is expected to be fully recognized in the next quarter.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">A summary of the status of the Company’s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2021 is presented below:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Grant Date Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Stock Bonus Plans – As of September 30, 2021, the Company has issued a total of 363,086 shares of common stock from the Stock Bonus Plans and was authorized to issue up to 783,760 shares of common stock under its Stock Bonus Plans. All employees, directors, officers, consultants, and advisors are eligible to be granted shares.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Stock Compensation Plans – On September 30, 2021, 634,000 shares were authorized for use in the Company’s Stock Compensation Plans, of which 154,195 shares were issued and outstanding. No shares were issued from the Stock Compensation Plans to consultants for payment of services during the years ended September 30, 2021, and 2020.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year Ended September 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,685,046</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,112,968</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,226,690</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">862,796</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 13685046 10112968 1226690 862796 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected stock price volatility</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">90.42 – 97.22%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">87.36 – 90.26%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Risk-free interest rate</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">0.85 – 1.65%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">0.62 – 1.87%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected life of options</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">9.68 – 9.69 Years</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">9.68 – 9.69 Years</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0.9042 0.9722 0.8736 0.9026 0.0085 0.0165 0.0062 0.0187 P9Y8M4D P9Y8M8D P9Y8M4D P9Y8M8D 1800000 1800000 72000 20.61 0.34 P1Y3M18D 189000 447000 P11Y 3600000 1872000 10.93 The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days. 4.21 7900000 P1Y8M12D 3800000 2100000 2000000.0 P11Y 11787200 138400 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Term (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Term (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,218,216</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.54</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.88</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,562,594</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,392,241</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.15</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.68</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,869,555</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,014,501</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.06</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">99,740</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.34</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,773</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">132.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8,653,703</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.01</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.39</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">56,193,415</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,297,229</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.85</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.48</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">29,090,662</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,401,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.26</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted (a)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">20.58</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">149,788</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.98</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">49,832</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.56</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,374</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">172.73</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 6218216 5.54 P8Y10M17D 29562594 1392241 9.15 P7Y8M4D 7869555 2014501 4.06 2563000 10.93 99740 3.39 99740 3.39 18000 10.34 9773 132.75 9773 132.75 8653703 7.01 P8Y4M20D 56193415 3297229 5.85 P7Y5M23D 29090662 2401961 6.26 2605000 20.58 149788 4.98 149788 4.98 49832 9.56 9374 172.73 9374 172.73 11049709 10.08 P7Y11M4D 54843283 5540028 5.77 P6Y11M15D 43589598 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Grant Date Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,825,975</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.79</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,014,501</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,563,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,356,474</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,401,961</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,605,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(49,832</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 4825975 3.79 -2014501 2563000 -18000 5356474 4.76 -2401961 2605000 -49832 5509681 5.17 614500 463250 8600000 300000 45000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Grant Date Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested at September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested at September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 304500 13.75 304500 13.75 -2000 -151250 151250 13.75 363086 783760 634000 154195 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">9. </td><td style="vertical-align:top;">EMPLOYEE BENEFIT PLAN</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant’s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant’s contribution, not to exceed the lesser of $10,000 or 6% of the participant’s total compensation. The Company’s contribution of common stock is valued each quarter based upon the closing bid price of the Company’s common stock. During the year ended September 30, 2021, 17,990 shares were issued to the Company’s 401(k) plan for a cost of approximately $201,000. During the year ended September 30, 2020, 13,870 shares were issued to the Company’s 401(k) plan for a cost of approximately $163,000.</td></tr></tbody></table> 10000 0.06 17990 201000 13870 163000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">10. </td><td style="vertical-align:top;">COMMITMENTS AND CONTINGENCIES </td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Clinical Research Agreements</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company’s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.1 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.6 million. During the years ended September 30, 2021 and 2020, the Company recorded approximately $1.6 million and $2.0 million, respectively, as research and development expense related to Ergomed’s services. These amounts were net of Ergomed’s discount of approximately $0.6 million during both the years ended September 30, 2021 and 2020.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Lease Agreements</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded a finance lease right of use asset of approximately $16.5 million and a finance lease liability of approximately $13.5 million. As of September 30, 2021 and 2020, respectively, the net book value of the finance lease right of use asset is approximately $12.7 million and $13.8 million and the balance of the finance lease liability is approximately $13.8 million and $12.7 million, of which approximately $0.6 million and $0.9 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being amortized using a straight-line method over the underlying lease terms and totaled approximately $1,732,000 and $1,717,000 in the years ended September 30, 2021 and 2020, respectively. Total cash paid related to finance leases during the years ended September 30, 2021 and 2020, respectively, was approximately $2.2 million and $1.9 million, of which approximately $1.2 million was for interest in both years. The weighted average discount rate of the Company’s finance leases is 8.45% and the weighted average time to maturity is 7.1 years.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.7 million, of which approximately $10.5 million has been incurred as of September 30, 2021. The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. Approximately $1.6 million was received from the landlord as of September 30, 2021. The leasehold improvements are recorded in property and equipment and will be amortized over the remaining lease term when the assets are placed in service.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease. Under the landlord’s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. As September 30, 2021 and 2020, respectively, the approximate $1.9 million and $1.7 million deposit is included in non-current assets.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Approximate future minimum lease payments under finance leases as of September 30, 2021 are as follows:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,699,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,186,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation *</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,659,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,825,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of lease finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,834,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> * Amount is net of landlord incentive of approximately $0.8 million expected to be realized in quarter ended December 31, 2021. <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space was needed to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the year ended September 30, 2020 was approximately $39,000.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on March 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Upon adoption of ASC 842 on October 1, 2019, the Company recorded an operating lease right of use asset and an operating lease liability of approximately $1.0 million. As of September 30, 2021, the net book value of the operating lease right of use asset is approximately $2.1 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.1 million is current. As of September 30, 2020, the net book value of the operating lease right of use asset is approximately $1.2 million and the balance of the operating lease liability is approximately $1.2 million, of which approximately $0.1 million is current. The Company incurred lease expense under operating leases of approximately $0.2 million for each of the years ended September 30, 2021 and 2020. Total cash paid related to operating leases during the years ended September 30, 2021 and 2020 was approximately $0.3 million and $0.2 million, respectively. The weighted average discount rate of the Company’s operating leases is 9.12% and the weighted average time to maturity is 9.7 years.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">As of September 30, 2021, future minimum lease payments on operating leases are as follows:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">309,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,269,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,130,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,139,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Vendor Obligations</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company has contingent obligations with vendors for work that will be completed in relation to the Phase 3 clinical trial. The timing of these obligations cannot be determined at this time. The Company estimates it will incur additional expenses of approximately $1.1 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report with the FDA. This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs.</td></tr><tr style="height:15px"><td> </td><td> </td></tr></tbody></table> 10000000 35100000 11600000 1600000 600000 16500000 13500000 12700000 13800000 13800000 12700000 600000 900000 2200000 1900000 1200000 0.0845 P7Y1M6D 10700000 10500000 The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. 0.0845 revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80% 2400000 200000 1900000 1700000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,699,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,186,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation *</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,659,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,825,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of lease finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,834,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1699000 2569000 2648000 2733000 2824000 6186000 18659000 13834000 39000 1100000 1000000.0 2100000 2100000 100000 1200000 1200000 100000 200000 300000 200000 0.0912 P9Y8M12D <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">309,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,269,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,130,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,139,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 309000 348000 357000 366000 287000 1602000 3269000 1130000 2139000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">11. </td><td style="vertical-align:top;">RELATED PARTY TRANSACTIONS</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the year ended September 30, 2021, the de Clara Trust, of which the Company’s CEO, Geert Kerston, is a beneficiary, and two directors purchased 27,500 restricted shares of the Company’s common stock at an aggregate fair market value of approximately $220,000. During the year ended September 30, 2020, officers and directors of the Company purchased 20,512 shares of restricted common stock at market price at an aggregate fair market value of approximately $185,000. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On June 28, 2021, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by twelve months (Note 4). The incremental cost of these modifications was approximately $265,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On June 28, 2021, the expiration date of 93,603 Series UU warrants was extended by twelve months (Note 4). The incremental cost of this extension was $24,000 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and the de Clara Trust and were originally issued with convertible debt.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note 4). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the year ended September 30, 2021.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the year ended September 30, 2021. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On May 8, 2020, the expiration date of 93,593 Series UU warrants were extended from June 11, 2020 to December 31, 2020. The incremental cost of this extension was approximately $6,000 and was recorded as interest expense for the year ended September 30, 2020. The Series UU warrants are held by the Company’s officers and were originally issued with convertible debt.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On January 23, 2020, the expiration date of the Series N warrants was extended to February 18, 2021. The incremental cost of this extension was approximately $22,000, which was recorded as a deemed dividend in the financial statements for the year ended September 30, 2020. The Series N warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.</td></tr></tbody></table> 27500 220000 20512 185000 265000 93603 24000 86000 the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021 192 93593 6000 the expiration date of the Series N warrants was extended to February 18, 2021 22000 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">12. </td><td style="vertical-align:top;">STOCKHOLDERS’ EQUITY </td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Exercise of Warrants</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the years ended September 30, 2021 and 2020, the Company received proceeds of approximately $6.0 million and $12.1 million, respectively, from the exercise of warrants, as detailed in Note 4. Upon exercise, 1,597,870 and 1,711,873 shares of common stock were issued during the years ended September 30, 2021 and 2020, respectively.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Sales of Securities</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In June 2021, the Company sold 1,400,000 shares of common stock at a public offering price of $22.62 per share and received aggregate net proceeds of approximately $29.4 million. At that time, the underwriters fully exercised their option to purchase up to 210,000 additional shares of common stock to cover over-allotments, resulting in additional net proceeds to the Company of approximately $4.4 million.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In March 2020, the Company sold 630,500 shares of common stock at a public offering price of $12.22 per share and received aggregate net proceeds of approximately $7.1 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 45-day option to purchase up to an additional 94,575 shares of common stock solely to cover over-allotments. The underwriter fully exercised this option in May 2020 resulting in additional net proceeds to the Company of approximately $1.1 million.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In December 2019, the Company sold 606,395 shares of common stock at a public offering price of $9.07 per share and received aggregate net proceeds of approximately $5.0 million. In January 2020, the underwriters of that offering fully exercised the option to purchase 90,959 additional shares of common stock at the public offering price of $9.07 per share for aggregate net proceeds to the Company of approximately $0.8 million.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">Other Equity Transactions</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company’s Clinical Research Organizations responsible for managing the Company’s Phase 3 clinical trial, to facilitate payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">During the year ended September 30, 2020, the Company issued Ergomed 150,000 shares. No shares were issued during the year ended September 30, 2021. All outstanding shares have been resold as of September 30, 2021 and the Company has approximately $500,000 in amounts prepaid to Ergomed.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The following table summarizes the Other Non-operating gains (losses) for the years ended September 30 relating to these agreements:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amount realized through the resale of shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,652,605</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of shares upon issuance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,769,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other non-operating gain</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">883,105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td> </td><td colspan="2" style="vertical-align:top;">As of September 30, 2021, all shares held for resale were sold.</td></tr><tr style="height:15px"><td style="width:3%;"> </td><td style="width:3%;"> </td><td> </td></tr></tbody></table> 6000000.0 12100000 1597870 1711873 1400000 22.62 29400000 210000 4400000 1000000 14.65 13600000 630500 12.22 7100000 94575 1100000 606395 9.07 5000000.0 90959 9.07 800000 150000 500000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amount realized through the resale of shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,652,605</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of shares upon issuance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,769,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other non-operating gain</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,685,379</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">883,105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1685379 2652605 0 1769500 1685379 883105 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td>13. </td><td colspan="2" style="vertical-align:top;">FAIR VALUE MEASUREMENTS</td></tr><tr style="height:15px"><td style="width:3%;"> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td colspan="2" style="vertical-align:top;">In accordance with the provisions of ASC 820, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to the future amounts.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td colspan="2" style="vertical-align:top;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">o </td><td style="vertical-align:top;">Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">o </td><td style="vertical-align:top;">Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs other than quoted prices that are observable for the asset or liability</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">o </td><td style="vertical-align:top;">Level 3 – Unobservable inputs that reflect management’s assumptions</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td colspan="2" style="vertical-align:top;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000. The T-bills mature in December 2021 and yield a weighted average interest rate of 0.10%.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">As of September 30, 2021 and 2020, all of the Company’s derivative liabilities are classified as Level 3.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,488,310</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,071,775</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">N Net realized and unrealized derivative loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">349,078</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"> </td><td style="vertical-align:top;">The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock. At September 30, 2021, the Company’s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years. At September 30, 2020, the Company’s Level 3 derivative instruments have a weighted average fair value of $2.81 per share and a weighted average exercise price of $14.32 per share. Fair values were determined using a weighted average risk free interest rate of 0.12% and volatility of 95%. The instruments have a weighted average time to maturity of 1.2 years.</td></tr></tbody></table> 6000 0.0010 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,488,310</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,071,775</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">N Net realized and unrealized derivative loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">349,078</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 3765613 6488310 0 0 -4023091 -3071775 694858 349078 437380 3765613 1.45 13.28 0.0005 1.09 P0Y3M18D 2.81 14.32 0.0012 0.95 P1Y2M12D <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">14. </td><td style="vertical-align:top;">NET LOSS PER COMMON SHARE</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock have not been included in the computation of diluted net loss per share for all periods presented, as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ended September 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Loss per share – basic</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.90</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss per share – diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unrealized gain on derivatives (1)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,085,540</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,797,510</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incremental shares underlying dilutive warrants (1)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,111</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,694,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.93</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">(1) </td><td style="vertical-align:top;">Includes Series Z, AA, CC and HH warrants for the year ended September 30, 2021.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options and Warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,604,850</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,221,696</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested Restricted Stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">308,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,756,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,530,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ended September 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Loss per share – basic</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.90</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss per share – diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(36,711,970</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unrealized gain on derivatives (1)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,085,540</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,797,510</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,276,978</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,662,137</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incremental shares underlying dilutive warrants (1)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,111</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,694,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">36,759,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.93</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.82</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -36711970 -30276978 40662137 36759115 -0.90 -0.82 -36711970 -30276978 -1085540 0 -37797510 -30276978 36759115 32111 40694248 36759115 -0.93 -0.82 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options and Warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,604,850</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,221,696</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested Restricted Stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">308,814</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,756,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,530,510</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 10604850 7221696 151250 308814 10756100 7530510 15. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure. EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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a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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 201 484 1 false 59 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://cvm.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://cvm.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://cvm.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfOperationsUnaudited CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://cvm.com/role/StatementsOfStockholdersEquity STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION Sheet http://cvm.com/role/ORGANIZATION ORGANIZATION Notes 7 false false R8.htm 000008 - Disclosure - OPERATIONS AND FINANCING Sheet http://cvm.com/role/OperationsAndFinancing OPERATIONS AND FINANCING Notes 8 false false R9.htm 000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cvm.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptions WARRANTS AND NON-EMPLOYEE OPTIONS Notes 10 false false R11.htm 000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT Sheet http://cvm.com/role/PlantPropertyAndEquipment PLANT, PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 000012 - Disclosure - PATENTS Sheet http://cvm.com/role/PATENTS PATENTS Notes 12 false false R13.htm 000013 - Disclosure - INCOME TAXES Sheet http://cvm.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 000014 - Disclosure - STOCK COMPENSATION Sheet http://cvm.com/role/StockCompensation STOCK COMPENSATION Notes 14 false false R15.htm 000015 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://cvm.com/role/EmployeeBenefitPlan EMPLOYEE BENEFIT PLAN Notes 15 false false R16.htm 000016 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://cvm.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 000017 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://cvm.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 000018 - Disclosure - STOCKHOLDERS EQUITY Sheet http://cvm.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 18 false false R19.htm 000019 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://cvm.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 19 false false R20.htm 000020 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://cvm.com/role/NetLossPerCommonShare NET LOSS PER COMMON SHARE Notes 20 false false R21.htm 000021 - Disclosure - SUBSEQUENT EVENTS Sheet http://cvm.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables) Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables WARRANTS AND NON-EMPLOYEE OPTIONS (Tables) Tables http://cvm.com/role/WarrantsAndNonEmployeeOptions 23 false false R24.htm 000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables) Sheet http://cvm.com/role/PlantPropertyAndEquipmentTables PLANT, PROPERTY AND EQUIPMENT (Tables) Tables http://cvm.com/role/PlantPropertyAndEquipment 24 false false R25.htm 000025 - Disclosure - PATENTS (Tables) Sheet http://cvm.com/role/PatentsTables PATENTS (Tables) Tables http://cvm.com/role/PATENTS 25 false false R26.htm 000026 - Disclosure - INCOME TAXES (Tables) Sheet http://cvm.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://cvm.com/role/IncomeTaxes 26 false false R27.htm 000027 - Disclosure - STOCK COMPENSATION (Tables) Sheet http://cvm.com/role/StockCompensationTables STOCK COMPENSATION (Tables) Tables http://cvm.com/role/StockCompensation 27 false false R28.htm 000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://cvm.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://cvm.com/role/CommitmentsAndContingencies 28 false false R29.htm 000029 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://cvm.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://cvm.com/role/StockholdersEquity 29 false false R30.htm 000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://cvm.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://cvm.com/role/FairValueMeasurements 30 false false R31.htm 000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://cvm.com/role/NetLossPerCommonShareTables NET LOSS PER COMMON SHARE (Tables) Tables http://cvm.com/role/NetLossPerCommonShare 31 false false R32.htm 000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies 32 false false R33.htm 000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details) Sheet http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails WARRANTS AND NONEMPLOYEE OPTIONS (Details) Details 33 false false R34.htm 000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1 WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) Details http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables 34 false false R35.htm 000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2 WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2) Details http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables 35 false false R36.htm 000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3) Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3 WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3) Details http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables 36 false false R37.htm 000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) Sheet http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) Details http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables 37 false false R38.htm 000038 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://cvm.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details 38 false false R39.htm 000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://cvm.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details 39 false false R40.htm 000040 - Disclosure - PATENTS (Details) Sheet http://cvm.com/role/PatentsDetails PATENTS (Details) Details http://cvm.com/role/PatentsTables 40 false false R41.htm 000041 - Disclosure - PATENTS (Details 1) Sheet http://cvm.com/role/PatentsDetails1 PATENTS (Details 1) Details http://cvm.com/role/PatentsTables 41 false false R42.htm 000042 - Disclosure - PATENTS (Details Narrative) Sheet http://cvm.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://cvm.com/role/PatentsTables 42 false false R43.htm 000043 - Disclosure - INCOME TAXES (Details) Sheet http://cvm.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://cvm.com/role/IncomeTaxesTables 43 false false R44.htm 000044 - Disclosure - INCOME TAXES (Details 1) Sheet http://cvm.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://cvm.com/role/IncomeTaxesTables 44 false false R45.htm 000045 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://cvm.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://cvm.com/role/IncomeTaxesTables 45 false false R46.htm 000046 - Disclosure - STOCK COMPENSATION (Details) Sheet http://cvm.com/role/StockCompensationDetails STOCK COMPENSATION (Details) Details http://cvm.com/role/StockCompensationTables 46 false false R47.htm 000047 - Disclosure - STOCK COMPENSATION (Details 1) Sheet http://cvm.com/role/StockCompensationDetails1 STOCK COMPENSATION (Details 1) Details http://cvm.com/role/StockCompensationTables 47 false false R48.htm 000048 - Disclosure - STOCK COMPENSATION (Details 2) Sheet http://cvm.com/role/StockCompensationDetails2 STOCK COMPENSATION (Details 2) Details http://cvm.com/role/StockCompensationTables 48 false false R49.htm 000049 - Disclosure - STOCK COMPENSATION (Details 3) Sheet http://cvm.com/role/StockCompensationDetails3 STOCK COMPENSATION (Details 3) Details http://cvm.com/role/StockCompensationTables 49 false false R50.htm 000050 - Disclosure - STOCK COMPENSATION (Details 4) Sheet http://cvm.com/role/StockCompensationDetails4 STOCK COMPENSATION (Details 4) Details http://cvm.com/role/StockCompensationTables 50 false false R51.htm 000051 - Disclosure - STOCK COMPENSATION (Details Narrative) Sheet http://cvm.com/role/StockCompensationDetailsNarrative STOCK COMPENSATION (Details Narrative) Details http://cvm.com/role/StockCompensationTables 51 false false R52.htm 000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative) Sheet http://cvm.com/role/EmployeeBenefitPlanDetailNarrative EMPLOYEE BENEFIT PLAN (Detail Narrative) Details http://cvm.com/role/EmployeeBenefitPlan 52 false false R53.htm 000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://cvm.com/role/CommitmentsAndContingenciesTables 53 false false R54.htm 000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails1 COMMITMENTS AND CONTINGENCIES (Details 1) Details http://cvm.com/role/CommitmentsAndContingenciesTables 54 false false R55.htm 000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://cvm.com/role/CommitmentsAndContingenciesTables 55 false false R56.htm 000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative ) Sheet http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative ) Details http://cvm.com/role/RelatedPartyTransactions 56 false false R57.htm 000057 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://cvm.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://cvm.com/role/StockholdersEquityTables 57 false false R58.htm 000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cvm.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://cvm.com/role/StockholdersEquityTables 58 false false R59.htm 000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://cvm.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://cvm.com/role/FairValueMeasurementsTables 59 false false R60.htm 000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) Sheet http://cvm.com/role/FairValueMeasurementsDetailsNarrative FAIR VALUE MEASUREMENTS (Details Narrative) Details http://cvm.com/role/FairValueMeasurementsTables 60 false false R61.htm 000061 - Disclosure - NET LOSS PER COMMON SHARE (Details) Sheet http://cvm.com/role/NetLossPerCommonShareDetails NET LOSS PER COMMON SHARE (Details) Details http://cvm.com/role/NetLossPerCommonShareTables 61 false false R62.htm 000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1) Sheet http://cvm.com/role/NetLossPerCommonShareDetails1 NET LOSS PER COMMON SHARE (Details 1) Details http://cvm.com/role/NetLossPerCommonShareTables 62 false false All Reports Book All Reports cvm_10k.htm cvm-20210930.xsd cvm-20210930_cal.xml cvm-20210930_def.xml cvm-20210930_lab.xml cvm-20210930_pre.xml cvm_ex231.htm cvm_ex31.htm cvm_ex32.htm cvm_10kimg1.jpg http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvm_10k.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 201, "dts": { "calculationLink": { "local": [ "cvm-20210930_cal.xml" ] }, "definitionLink": { "local": [ "cvm-20210930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cvm_10k.htm" ] }, "labelLink": { "local": [ "cvm-20210930_lab.xml" ] }, "presentationLink": { "local": [ "cvm-20210930_pre.xml" ] }, "schema": { "local": [ "cvm-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 532, "entityCount": 1, "hidden": { "http://cvm.com/20210930": 25, "http://fasb.org/us-gaap/2020-01-31": 33, "http://xbrl.sec.gov/dei/2020-01-31": 7, "total": 65 }, "keyCustom": 144, "keyStandard": 340, "memberCustom": 52, "memberStandard": 7, "nsprefix": "cvm", "nsuri": "http://cvm.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://cvm.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:WarrantsAndNonEmployeeOptionstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptions", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:WarrantsAndNonEmployeeOptionstextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT", "role": "http://cvm.com/role/PlantPropertyAndEquipment", "shortName": "PLANT, PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - PATENTS", "role": "http://cvm.com/role/PATENTS", "shortName": "PATENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - INCOME TAXES", "role": "http://cvm.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - STOCK COMPENSATION", "role": "http://cvm.com/role/StockCompensation", "shortName": "STOCK COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - EMPLOYEE BENEFIT PLAN", "role": "http://cvm.com/role/EmployeeBenefitPlan", "shortName": "EMPLOYEE BENEFIT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://cvm.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://cvm.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - STOCKHOLDERS EQUITY", "role": "http://cvm.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://cvm.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED BALANCE SHEETS", "role": "http://cvm.com/role/CondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - NET LOSS PER COMMON SHARE", "role": "http://cvm.com/role/NetLossPerCommonShare", "shortName": "NET LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - SUBSEQUENT EVENTS", "role": "http://cvm.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "cvm:WarrantsAndNonEmployeeOptionstextblock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "cvm:WarrantsAndNonEmployeeOptionstextblock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - PLANT, PROPERTY AND EQUIPMENT (Tables)", "role": "http://cvm.com/role/PlantPropertyAndEquipmentTables", "shortName": "PLANT, PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - PATENTS (Tables)", "role": "http://cvm.com/role/PatentsTables", "shortName": "PATENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - INCOME TAXES (Tables)", "role": "http://cvm.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - STOCK COMPENSATION (Tables)", "role": "http://cvm.com/role/StockCompensationTables", "shortName": "STOCK COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://cvm.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "role": "http://cvm.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://cvm.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "role": "http://cvm.com/role/NetLossPerCommonShareTables", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueConcentrationOfRiskTextBlock", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock", "cvm:WarrantsAndNonEmployeeOptionstextblock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30_cvm_ConsultantsMember", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:Issuedate2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)", "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails", "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock", "cvm:WarrantsAndNonEmployeeOptionstextblock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30_cvm_ConsultantsMember", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:Issuedate2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:EquityWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:EquityWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanInterestCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)", "role": "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "shortName": "WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanInterestCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FixturesAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://cvm.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FixturesAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - PATENTS (Details)", "role": "http://cvm.com/role/PatentsDetails", "shortName": "PATENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30_us-gaap_PatentsMember", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - PATENTS (Details 1)", "role": "http://cvm.com/role/PatentsDetails1", "shortName": "PATENTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - PATENTS (Details Narrative)", "role": "http://cvm.com/role/PatentsDetailsNarrative", "shortName": "PATENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - INCOME TAXES (Details)", "role": "http://cvm.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "cvm:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - INCOME TAXES (Details 1)", "role": "http://cvm.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://cvm.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2020-09-30_cvm_IncomeTaxMember", "decimals": "-5", "lang": null, "name": "cvm:ResearchAndDevelopmentCredit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - STOCK COMPENSATION (Details)", "role": "http://cvm.com/role/StockCompensationDetails", "shortName": "STOCK COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - STOCK COMPENSATION (Details 1)", "role": "http://cvm.com/role/StockCompensationDetails1", "shortName": "STOCK COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfFairValueOfEachOptionGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2020-09-30_cvm_OutstandingMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - STOCK COMPENSATION (Details 2)", "role": "http://cvm.com/role/StockCompensationDetails2", "shortName": "STOCK COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2019-09-30_cvm_OutstandingMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfNonVestedOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2019-10-01to2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:NumberOfUnvestedOptionsBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - STOCK COMPENSATION (Details 3)", "role": "http://cvm.com/role/StockCompensationDetails3", "shortName": "STOCK COMPENSATION (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfNonVestedOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2019-10-01to2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:NumberOfUnvestedOptionsBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://cvm.com/role/StatementsOfStockholdersEquity", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfNonVestedOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "cvm:WeightedAverageGrantDateFairValueBeginning", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - STOCK COMPENSATION (Details 4)", "role": "http://cvm.com/role/StockCompensationDetails4", "shortName": "STOCK COMPENSATION (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30_cvm_RestrictedStockAwardsMember", "decimals": "0", "lang": null, "name": "cvm:NumberOfUnvestedSharesBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - STOCK COMPENSATION (Details Narrative)", "role": "http://cvm.com/role/StockCompensationDetailsNarrative", "shortName": "STOCK COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30_cvm_StockCompensationPlansMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)", "role": "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative", "shortName": "EMPLOYEE BENEFIT PLAN (Detail Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1", "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:NumberOfRestrictedSharesPurchasedByRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )", "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30_cvm_OfficerAndDirectorMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:NumberOfRestrictedSharesPurchasedByRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:AmountRealizedThroughTheResaleOfShares", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - STOCKHOLDERS EQUITY (Details)", "role": "http://cvm.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfOtherNonOperatingGainsLossesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "cvm:AmountRealizedThroughTheResaleOfShares", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "cvm:ProceedsFromPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "role": "http://cvm.com/role/FairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "AsOf2019-09-30", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)", "role": "http://cvm.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - NET LOSS PER COMMON SHARE (Details)", "role": "http://cvm.com/role/NetLossPerCommonShareDetails", "shortName": "NET LOSS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)", "role": "http://cvm.com/role/NetLossPerCommonShareDetails1", "shortName": "NET LOSS PER COMMON SHARE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION", "role": "http://cvm.com/role/ORGANIZATION", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - OPERATIONS AND FINANCING", "role": "http://cvm.com/role/OperationsAndFinancing", "shortName": "OPERATIONS AND FINANCING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://cvm.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10k.htm", "contextRef": "From2020-10-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "cvm_AccruedConsultingServicesToBePaidWithCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued consulting services to be paid with common stock" } } }, "localname": "AccruedConsultingServicesToBePaidWithCommonStock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_AdditionalClinicalTrial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Additional clinical trial" } } }, "localname": "AdditionalClinicalTrial", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_AdoptionOfAsc842Leases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Adoption of ASC 842, Leases" } } }, "localname": "AdoptionOfAsc842Leases", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_AggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value Outstanding, Beginning" } } }, "localname": "AggregateIntrinsicValue", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "monetaryItemType" }, "cvm_AggregateIntrinsicValueOutstandingEnding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are", "label": "Aggregate Intrinsic Value Outstanding, Ending" } } }, "localname": "AggregateIntrinsicValueOutstandingEnding", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "monetaryItemType" }, "cvm_AmountRealizedThroughTheResaleOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.", "label": "Amount realized through the resale of shares" } } }, "localname": "AmountRealizedThroughTheResaleOfShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cvm_BalanceOfTheFinanceLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Balance of the finance lease liability" } } }, "localname": "BalanceOfTheFinanceLeaseLiability", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capitalizable patent costs included in accrued expenses and accounts payable" } } }, "localname": "CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_CashPaidRelatedToFinanceLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash paid related to finance leases" } } }, "localname": "CashPaidRelatedToFinanceLeases", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CashPaidRelatedToFinanceLeasesInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash paid related to finance leases interest" } } }, "localname": "CashPaidRelatedToFinanceLeasesInterest", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ChangesToRightOfUseAssetsAndLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Changes to right of use assets and liabilities" } } }, "localname": "ChangesToRightOfUseAssetsAndLiabilities", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ClinicalServiceTrial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Clinical service trial" } } }, "localname": "ClinicalServiceTrial", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CommonStockContributedToEmployeeBenefitPlan": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock contributed to 401(k) plan" } } }, "localname": "CommonStockContributedToEmployeeBenefitPlan", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_CommonStockIssuedForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for service, shares" } } }, "localname": "CommonStockIssuedForServiceShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "verboseLabel": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements [Member]" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_CostIncurredInitial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cost incurred, initial" } } }, "localname": "CostIncurredInitial", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CumulativeChangeInOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative change in ownership percentage" } } }, "localname": "CumulativeChangeInOwnershipPercentage", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_CurrentBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current balance" } } }, "localname": "CurrentBalance", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capitalized R&D" } } }, "localname": "DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_EquityWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Warrants Exercise Price" } } }, "localname": "EquityWarrantsExercisePrice", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" ], "xbrltype": "perShareItemType" }, "cvm_EquityWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Warrants Exercised" } } }, "localname": "EquityWarrantsExercised", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" ], "xbrltype": "sharesItemType" }, "cvm_ErgomedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ergomed [Member]", "verboseLabel": "Ergomed [Member]" } } }, "localname": "ErgomedMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_EstimatedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Estimated cost" } } }, "localname": "EstimatedCost", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ExercisableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable [Member]" } } }, "localname": "ExercisableMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "domainItemType" }, "cvm_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "localname": "ExercisePrice", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "perShareItemType" }, "cvm_ExercisePriceWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Exercise Price]", "verboseLabel": "Exercise Price" } } }, "localname": "ExercisePriceWarrants", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "perShareItemType" }, "cvm_ExpectedLifeOfOptionsMax": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected life of options, max" } } }, "localname": "ExpectedLifeOfOptionsMax", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "durationItemType" }, "cvm_ExpectedLifeOfOptionsMin1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected life of options, min" } } }, "localname": "ExpectedLifeOfOptionsMin1", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "durationItemType" }, "cvm_ExpenseLifeOverNext": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense life over next" } } }, "localname": "ExpenseLifeOverNext", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_ExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "localname": "ExpirationDate1", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "cvm_ExpirationDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration date description", "verboseLabel": "Expiration date description" } } }, "localname": "ExpirationDateDescription", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_FairValueInputsLevelThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Inputs Level 3 (Level 3)" } } }, "localname": "FairValueInputsLevelThreeMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net realized and unrealized derivative loss" } } }, "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfWarrantsLiabilitiesOnDateOfExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of warrants liabilities on date of exercise" } } }, "localname": "FairValueOfWarrantsLiabilitiesOnDateOfExercise", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FairValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value per share" } } }, "localname": "FairValuePerShare", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_FinanceLeaseObligationIncludedInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Finance lease obligation included in accounts payable" } } }, "localname": "FinanceLeaseObligationIncludedInAccountsPayable", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseObligationsNetOfCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance lease obligations, net of current portion" } } }, "localname": "FinanceLeaseObligationsNetOfCurrentPortion", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingCostsIncludedInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing costs included in accounts payable" } } }, "localname": "FinancingCostsIncludedInAccountsPayable", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingLeaseContractualArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing arrangement" } } }, "localname": "FinancingLeaseContractualArrangement", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FixedAssetsAndIntangibles": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fixed assets and intangibles" } } }, "localname": "FixedAssetsAndIntangibles", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_ForfeitedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Forfeited options" } } }, "localname": "ForfeitedOptions", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "sharesItemType" }, "cvm_GrantDateFairValueRemaining": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Grant date fair value remaining" } } }, "localname": "GrantDateFairValueRemaining", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_GrantIncomePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant Income" } } }, "localname": "GrantIncomePolicyTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_GrantedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted options" } } }, "localname": "GrantedOptions", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "sharesItemType" }, "cvm_IncentiveStockBonusPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Bonus Plan [Member]" } } }, "localname": "IncentiveStockBonusPlanMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_IncentiveStockOptionPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Option Plans [Member]" } } }, "localname": "IncentiveStockOptionPlansMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_IncomeTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax [Member]" } } }, "localname": "IncomeTaxMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in right of use of assets and liability" } } }, "localname": "IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental shares underlying dilutive \"in the money\" warrants" } } }, "localname": "IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "cvm_IssuanceOfRestrictedStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of restricted stock" } } }, "localname": "IssuanceOfRestrictedStock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_Issuedate2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issue Date" } } }, "localname": "Issuedate2", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "cvm_LandlordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Landlord [Member]" } } }, "localname": "LandlordMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_LeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_LeaseLiabilitiesCurrentPortion": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liabilities, current portion" } } }, "localname": "LeaseLiabilitiesCurrentPortion", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_LeasesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesPolicyTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_LesseeOperatingLeaseLiabilityPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total future minimum lease obligation]", "verboseLabel": "Total future minimum lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityPayments", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_LossOnDerivativesInstruments": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an", "label": "[Loss on derivative instruments]", "verboseLabel": "Loss on derivative instruments" } } }, "localname": "LossOnDerivativesInstruments", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_MaturityYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Maturity years" } } }, "localname": "MaturityYears", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_ModificationOfWarrant": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Modification of warrants 1]", "verboseLabel": "Modification of warrants" } } }, "localname": "ModificationOfWarrant", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfWarrants": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "localname": "ModificationOfWarrants", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfWarrantsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Modification of warrants]", "verboseLabel": "Modification of warrants" } } }, "localname": "ModificationOfWarrantsAmount", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net book value of the finance lease right of use asset" } } }, "localname": "NetBookValueOfTheFinanceLeaseRightOfUseAsset", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetBookValueOperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net book value operating lease right of use assets" } } }, "localname": "NetBookValueOperatingLeaseRightOfUseAssets", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetDeferredTaxAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net deferred tax asset" } } }, "localname": "NetDeferredTaxAsset", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NetLossGainOnWarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Net (loss) gain on warrant liabilities" } } }, "localname": "NetLossGainOnWarrantLiabilities", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_NetOfDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net of discount" } } }, "localname": "NetOfDiscount", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetPresentValueOfLeaseFinancingObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "[Net present value of lease financing obligation]", "negatedLabel": "Net present value of lease financing obligation" } } }, "localname": "NetPresentValueOfLeaseFinancingObligation", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NetPurchasesOfUSTreasuryBills": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net purchases of U.S. Treasury Bills]", "negatedLabel": "Net purchases of U.S. Treasury Bills" } } }, "localname": "NetPurchasesOfUSTreasuryBills", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_NonQualifiedStockOptionsPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Qualified Stock Options Plans [Member]" } } }, "localname": "NonQualifiedStockOptionsPlansMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_NumberOfOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Expired" } } }, "localname": "NumberOfOptions", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercised" } } }, "localname": "NumberOfOptionsExercised", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfOptionsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Number of Options Vested]", "periodStartLabel": "Number of Options Vested" } } }, "localname": "NumberOfOptionsVested", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfRestrictedSharesPurchasedByRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Common shares" } } }, "localname": "NumberOfRestrictedSharesPurchasedByRelatedParty", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfUnvestedOptionsBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of unvested options, Beginning" } } }, "localname": "NumberOfUnvestedOptionsBeginning", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfUnvestedOptionsEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of unvested options, Ending" } } }, "localname": "NumberOfUnvestedOptionsEnding", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfUnvestedSharesBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of unvested shares, Beginning" } } }, "localname": "NumberOfUnvestedSharesBeginning", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "sharesItemType" }, "cvm_NumberOfUnvestedSharesEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of unvested shares, Ending" } } }, "localname": "NumberOfUnvestedSharesEnding", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "sharesItemType" }, "cvm_OctoberOneTwothousandNineTeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 1, 2019 [Member]" } } }, "localname": "OctoberOneTwothousandNineTeenMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_OfficerAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officer and Director [Member]" } } }, "localname": "OfficerAndDirectorMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_OperatingLeaseMaturityYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease maturity years" } } }, "localname": "OperatingLeaseMaturityYears", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_OptionExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option expiration date" } } }, "localname": "OptionExpirationDate", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "cvm_OptionIssuedToRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option issued to related party" } } }, "localname": "OptionIssuedToRelatedParty", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options and Warrants" } } }, "localname": "OptionsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "cvm_OutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding [Member]" } } }, "localname": "OutstandingMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "domainItemType" }, "cvm_ParticipantCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Participant compensation" } } }, "localname": "ParticipantCompensation", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" ], "xbrltype": "percentItemType" }, "cvm_PerformanceBasedStockOptionsSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Performance based stock options shares granted" } } }, "localname": "PerformanceBasedStockOptionsSharesGranted", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_PrepaidAmountOfResold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid of resold amount" } } }, "localname": "PrepaidAmountOfResold", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid consulting services paid with issuance of common stock" } } }, "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_PrepaidExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Prepaid expenses]", "verboseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenses", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedFromIssuanceOrSaleOfEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of warrant" } } }, "localname": "ProceedFromIssuanceOrSaleOfEquity", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromEquityWarrantsExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from Equity Warrants Exercised" } } }, "localname": "ProceedsFromEquityWarrantsExercised", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromLandlordFundingOfLeaseholdImprovements": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from landlord funding of leasehold improvements" } } }, "localname": "ProceedsFromLandlordFundingOfLeaseholdImprovements", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from public offering" } } }, "localname": "ProceedsFromPublicOffering", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromRestrictedSharesPurchasedByRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Restricted Common shares, amount" } } }, "localname": "ProceedsFromRestrictedSharesPurchasedByRelatedParty", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromTheSaleOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock, shares" } } }, "localname": "ProceedsFromTheSaleOfCommonStockShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cvm_PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Property and equipment included in accrued expenses and accounts payable" } } }, "localname": "PropertyAndEquipmentIncludedInAccruedExpensesAndAccountsPayable", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_RemainingCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Remaining compensation expense" } } }, "localname": "RemainingCompensationExpense", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_RemainingOutstandingFairValueOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Grant date fair value remaining outstanding" } } }, "localname": "RemainingOutstandingFairValueOfShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ResearchAndDevelopmentCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Research and development credit" } } }, "localname": "ResearchAndDevelopmentCredit", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ResearchAndDevelopmentCreditDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and development credit, description" } } }, "localname": "ResearchAndDevelopmentCreditDescription", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_RestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Awards [Member]" } } }, "localname": "RestrictedStockAwardsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "domainItemType" }, "cvm_RestrictedStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStocksMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_RightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right of use assets" } } }, "localname": "RightOfUseAssets", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive securities" } } }, "localname": "ScheduleOfAntiDilutiveSecuritiestabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of components of the Company's deferred tax assets" } } }, "localname": "ScheduleOfComponentsOfTheCompanySDeferredTaxAssetstabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of equity warrants were exercised" } } }, "localname": "ScheduleOfEquityWarrantsWereExercisedTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of expenses for options issued or vested and restricted stock awarded" } } }, "localname": "ScheduleOfExpensesForOptionsIssuedOrVestedAndRestrictedStockAwardedtabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfFairValueOfEachOptionGrantedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value of each option granted" } } }, "localname": "ScheduleOfFairValueOfEachOptionGrantedTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of federal or state current or deferred tax expense or benefit" } } }, "localname": "ScheduleOfFederalOrStateCurrentOrDeferredTaxExpenseOrBenefittabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of (losses)/gains on the warrant liabilities" } } }, "localname": "ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-qualified and incentive stock option plans" } } }, "localname": "ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfNonVestedOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-vested options" } } }, "localname": "ScheduleOfNonVestedOptionsTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfOtherNonOperatingGainsLossesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of other non-operating gains (losses)" } } }, "localname": "ScheduleOfOtherNonOperatingGainsLossesTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations" } } }, "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of restricted common stock issued from the incentive stock bonus plan" } } }, "localname": "ScheduleOfRestrictedCommonStockIssuedFromTheIncentiveStockBonusPlantabletextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants and non-employee options" } } }, "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants recorded as liabilities were exercised" } } }, "localname": "ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" ], "xbrltype": "textBlockItemType" }, "cvm_SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of shares upon issuance" } } }, "localname": "SecuritiesPurchaseAgreementsFairValueOfSharesUponIssuance", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cvm_SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other non-operating gain (loss)" } } }, "localname": "SecuritiesPurchaseAgreementsOtherNonoperatingGainsLosses", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cvm_SeriesAAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series AA [Member]" } } }, "localname": "SeriesAAMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesBBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series BB [Member]" } } }, "localname": "SeriesBBMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesCCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series CC [Member]" } } }, "localname": "SeriesCCMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesFFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series FF [Member]" } } }, "localname": "SeriesFFMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "domainItemType" }, "cvm_SeriesHHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series HH [Member]" } } }, "localname": "SeriesHHMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesJJMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series JJ [Member]" } } }, "localname": "SeriesJJMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "domainItemType" }, "cvm_SeriesLLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series LL [Member]" } } }, "localname": "SeriesLLMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "domainItemType" }, "cvm_SeriesMMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series MM [Member]" } } }, "localname": "SeriesMMMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesNAndXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N and Series X [Member]" } } }, "localname": "SeriesNAndXMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesNAndXWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N and X Warrants [Member]" } } }, "localname": "SeriesNAndXWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N [Member]" } } }, "localname": "SeriesNMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesNNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series NN [Member]" } } }, "localname": "SeriesNNMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesNWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N Warrants [Member]", "verboseLabel": "Series N Warrants [Member]" } } }, "localname": "SeriesNWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesOOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series OO [Member]" } } }, "localname": "SeriesOOMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesRRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series RR [Member]" } } }, "localname": "SeriesRRMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesSSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series SS [Member]" } } }, "localname": "SeriesSSMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesTTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series TT [Member]" } } }, "localname": "SeriesTTMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesUUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series UU [Member]" } } }, "localname": "SeriesUUMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesUUWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series UU warrants [Member]", "verboseLabel": "Series UU warrants [Member]" } } }, "localname": "SeriesUUWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series V [Member]" } } }, "localname": "SeriesVMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "domainItemType" }, "cvm_SeriesVVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series VV [Member]" } } }, "localname": "SeriesVVMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesVWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series V Warrants [Member]" } } }, "localname": "SeriesVWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesWMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series W [Member]" } } }, "localname": "SeriesWMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series X [Member]" } } }, "localname": "SeriesXMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesXWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series X Warrants [Member]" } } }, "localname": "SeriesXWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesXXWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series XX Warrants [Member]" } } }, "localname": "SeriesXXWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Y [Member]" } } }, "localname": "SeriesYMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesYYWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series YY Warrants [Member]" } } }, "localname": "SeriesYYWarrantsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z [Member]" } } }, "localname": "SeriesZMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_SeriesZZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series ZZ [Member]" } } }, "localname": "SeriesZZMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "cvm_ShareIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.", "label": "Share issuance costs" } } }, "localname": "ShareIssuanceCosts", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_SharesForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Forfeited" } } }, "localname": "SharesForfeited", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "sharesItemType" }, "cvm_SharesIssuableUponExerciseOfwarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issuable upon Exercise of Warrant" } } }, "localname": "SharesIssuableUponExerciseOfwarrant", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "sharesItemType" }, "cvm_SharesIssuedForSettlementOfClinicalResearchCosts": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for settlement of clinical research costs" } } }, "localname": "SharesIssuedForSettlementOfClinicalResearchCosts", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_SharesIssuedForSettlementOfClinicalResearchCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for settlement of clinical research costs, amount" } } }, "localname": "SharesIssuedForSettlementOfClinicalResearchCostsAmount", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_SharesIssuedForSettlementOfClinicalResearchCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for settlement of clinical research costs, shares" } } }, "localname": "SharesIssuedForSettlementOfClinicalResearchCostsShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cvm_ShortTermDeposits": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Deposits]", "verboseLabel": "Deposits" } } }, "localname": "ShortTermDeposits", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ShortTermInvestment": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Gain on short-term investments" } } }, "localname": "ShortTermInvestment", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_StockBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Bonus Plans [Member]" } } }, "localname": "StockBonusPlansMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_StockCompensationPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Compensation Plans [Member]" } } }, "localname": "StockCompensationPlansMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of stock by officers and directors, shares" } } }, "localname": "StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssues", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cvm_StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of stock by officers and directors, amount" } } }, "localname": "StockIssuedToOfficersAndDirectorsDuringPeriodSharesNewIssuesAmount", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_SuppliesUsedForRDAndManufacturing": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Supplies used for R&D and manufacturing]", "verboseLabel": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturing", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_SuppliesUsedForRDAndManufacturingPolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Supplies used for R&D and manufacturing 1]", "verboseLabel": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturingPolicytextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_Total": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "Total", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_TotalCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total compensation" } } }, "localname": "TotalCompensation", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_TransactionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transaction One [Member]" } } }, "localname": "TransactionOneMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_TransactionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TransactionTwoMember [Member]" } } }, "localname": "TransactionTwoMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_USTreasuryBills": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[U.S. Treasury Bills]", "verboseLabel": "U.S. Treasury Bills" } } }, "localname": "USTreasuryBills", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_UnvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock [Member]" } } }, "localname": "UnvestedRestrictedStockMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "cvm_VendorObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor Obligations [Member]" } } }, "localname": "VendorObligationsMember", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_VestedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested options" } } }, "localname": "VestedOptions", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "sharesItemType" }, "cvm_VestedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested shares", "verboseLabel": "Vested shares" } } }, "localname": "VestedShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4", "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_VolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.", "label": "Volatility rate" } } }, "localname": "VolatilityRate", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "cvm_WarrantExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "WarrantExercise", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_WarrantExercisesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrant exercises, amount" } } }, "localname": "WarrantExercisesAmount", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercises, shares" } } }, "localname": "WarrantExercisesShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cvm_WarrantInducementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Warrant inducement expense]", "verboseLabel": "Warrant inducement expense" } } }, "localname": "WarrantInducementExpense", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantIssuances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant issuances" } } }, "localname": "WarrantIssuances", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantsAndNonEmployeeOptionstextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "4. WARRANTS AND NON-EMPLOYEE OPTIONS" } } }, "localname": "WarrantsAndNonEmployeeOptionstextblock", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptions" ], "xbrltype": "textBlockItemType" }, "cvm_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "sharesItemType" }, "cvm_WarrantsExercisedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised shares" } } }, "localname": "WarrantsExercisedShares", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_WarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Warrants expired" } } }, "localname": "WarrantsExpired", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_WarrantsIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued during period" } } }, "localname": "WarrantsIssuedDuringPeriod", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_WeightedAverageExercisePriceDerivativeInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Derivative instruments" } } }, "localname": "WeightedAverageExercisePriceDerivativeInstruments", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageExercisePriceExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Expired" } } }, "localname": "WeightedAverageExercisePriceExpired", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageExercisePriceVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Exercise Price Vested]", "periodStartLabel": "Weighted Average Exercise Price Vested" } } }, "localname": "WeightedAverageExercisePriceVested", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageFairValueDerivativeInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average fair value, Derivative instruments" } } }, "localname": "WeightedAverageFairValueDerivativeInstruments", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Grant Date Fair Value, Ending]", "verboseLabel": "Weighted Average Grant Date Fair Value, Ending" } } }, "localname": "WeightedAverageGrantDateFairValue", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageGrantDateFairValueBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Beginning", "verboseLabel": "Weighted Average Grant Date Fair Value, Beginning" } } }, "localname": "WeightedAverageGrantDateFairValueBeginning", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3", "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageGrantDateFairValueEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Ending" } } }, "localname": "WeightedAverageGrantDateFairValueEnding", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails3" ], "xbrltype": "perShareItemType" }, "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning" } } }, "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "durationItemType" }, "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending" } } }, "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingEnding", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "durationItemType" }, "cvm_WeightedAverageRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average risk free interest rate" } } }, "localname": "WeightedAverageRiskFreeInterestRate", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "cvm_WeightedAverageTimeToMaturityYear": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average time to maturity year" } } }, "localname": "WeightedAverageTimeToMaturityYear", "nsuri": "http://cvm.com/20210930", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r375", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r200", "r201", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r358", "r360" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r200", "r201", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r358", "r360" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r141", "r181", "r182", "r326", "r357", "r359" ], "lang": { "en-us": { "role": { "label": "Product Or Service Axis" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r141", "r181", "r182", "r326", "r357", "r359" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r187", "r200", "r201", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r358", "r360" ], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r187", "r200", "r201", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r358", "r360" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r24", "r143", "r144" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r222" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r80", "r81", "r82", "r219", "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r66", "r151", "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of patent costs" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Award Type [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r76", "r128", "r133", "r139", "r146", "r251", "r253", "r281", "r341", "r350" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r44", "r76", "r146", "r251", "r253", "r281" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r15", "r16", "r17", "r18", "r19", "r76", "r146", "r251", "r253", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r206", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r206", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r30", "r68" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]", "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r69", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Fully insured amount of non-interest bearing cash balances" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r179", "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right Axis" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockCompensationDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockCompensationDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Common stock price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r169", "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "10. COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "terseLabel": "Common stock shares issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "http://cvm.com/role/StockCompensationDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r183", "r184", "r202", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "9. EMPLOYEE BENEFIT PLAN" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock options vest description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Total expense" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r42", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Unrecognized compensation expense" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total deferred tax assets", "verboseLabel": "Estimated net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails", "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Ending Balance" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r239", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "NOL carryforwards", "verboseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails", "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r237", "r239", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "R&D credit" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": { "auth_ref": [ "r239", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).", "label": "Vacation and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r239", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "[Deferred Tax Assets, Valuation Allowance]", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r227", "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "[Deferred Tax Liabilities, Net]", "negatedLabel": "Total deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r185", "r186", "r195", "r197", "r198", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Incremental cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Expense for Company's contribution to employee benefit plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Additional deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r66", "r160" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r66", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r45", "r47", "r262", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Total warrant liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r261" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Loss on derivative instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r260", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk Axis" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative instruments, current portion" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative instruments, net of current portion" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Interest rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r74", "r78", "r256", "r257", "r258", "r259", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": { "auth_ref": [ "r168", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Lease description" } } }, "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "8. STOCK COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r20", "r77", "r306", "r348", "r366" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to employees" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r52", "r85", "r86", "r87", "r88", "r89", "r93", "r96", "r99", "r100", "r101", "r105", "r106", "r346", "r355" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share - basic", "verboseLabel": "Basic loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share - diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r52", "r85", "r86", "r87", "r88", "r89", "r96", "r99", "r100", "r101", "r105", "r106", "r346", "r355" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per share- diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r74", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r102", "r103", "r104", "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "14. NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r228", "r245" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r228", "r245" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r228", "r245" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "State tax rate, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r228", "r245" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r228", "r245" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Federal rate change" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT PLAN (Detail Narrative)" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Employees" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "[Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount]", "verboseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r80", "r81", "r82", "r84", "r90", "r92", "r108", "r147", "r176", "r178", "r219", "r220", "r221", "r242", "r243", "r282", "r283", "r284", "r285", "r286", "r287", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r66", "r173" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "[Fair Value Adjustment of Warrants]", "negatedLabel": "Warrant inducement expense", "terseLabel": "Fair value of warrant", "verboseLabel": "Warrant inducement expense" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r198", "r272", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskTextBlock": { "auth_ref": [ "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.", "label": "Concentration of Credit Risk" } } }, "localname": "FairValueConcentrationOfRiskTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "13. FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r273", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r274" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]", "negatedLabel": "Exercises" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r198", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r295", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Schedule of future minimum payments under finance leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r295" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance lease liabilities, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Total future minimum lease obligation" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, Year One]", "verboseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, Year Five]", "verboseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, Year Four]", "verboseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, Year Three]", "verboseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finance Lease, Liability, to be Paid, Year Two]", "verboseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Less imputed interest on financing obligation" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r294" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance lease right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Patent useful life", "verboseLabel": "Weighted average time to maturity" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r152", "r153", "r155", "r158", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r152", "r154" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r155", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PATENTS (Details)" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r155" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patent costs, net", "verboseLabel": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Research equipment" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r236", "r244", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "7. INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r50", "r74", "r225", "r226", "r230", "r231", "r235", "r241", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.", "label": "[Increase (Decrease) in Due to Officers and Stockholders]", "verboseLabel": "Due to employees" } } }, "localname": "IncreaseDecreaseInDueToOfficersAndStockholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase)/decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase/(decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "[Increase (Decrease) in Other Operating Liabilities]", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "verboseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Receivables]", "verboseLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "6. PATENTS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PATENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r74", "r154", "r323", "r324", "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patents" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PATENTS" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r347" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r61", "r63", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r43" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Supplies used for R&D and manufacturing" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r66" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Share-based payments for services", "verboseLabel": "Non-employees" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/StockCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating lease expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseIncentivePayableCurrent": { "auth_ref": [ "r38", "r290", "r291", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Lease incentive payable current" } } }, "localname": "LeaseIncentivePayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r10", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "[Lessee, Operating Lease, Liability, to be Paid]", "verboseLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less imputed interest on operating lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r76", "r134", "r146", "r252", "r253", "r254", "r281" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r76", "r146", "r281", "r342", "r352" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r76", "r146", "r252", "r253", "r254", "r281" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "Biologics License Application [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS AND NON-EMPLOYEE OPTIONS" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r109", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "2. OPERATIONS AND FINANCING" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/OperationsAndFinancing" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 30.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 31.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r64", "r67" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 32.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r48", "r49", "r51", "r67", "r76", "r83", "r85", "r86", "r87", "r88", "r91", "r92", "r97", "r128", "r132", "r135", "r138", "r140", "r146", "r281", "r345", "r354" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r85", "r86", "r87", "r88", "r93", "r94", "r98", "r101", "r128", "r132", "r135", "r138", "r140" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "totalLabel": "Net loss available to common shareholders", "verboseLabel": "Net loss available to common shareholders -basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r95", "r98", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net loss available to common shareholders - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [ "r94", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.", "label": "Net loss available to common shareholders - basic" } } }, "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Options issued" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r128", "r132", "r135", "r138", "r140" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease - liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "[Operating Lease, Liability, Current]", "verboseLabel": "Operating lease - liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r295" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r294" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate operating lease" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r175", "r267", "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2", "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r174", "r269" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Stock price" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2", "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "1. ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/ORGANIZATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "[Other Cost and Expense, Operating]", "verboseLabel": "Incremental cost" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r356" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Grant income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingGainsLosses": { "auth_ref": [ "r56" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.", "label": "Other non-operating gain" } } }, "localname": "OtherNonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Research and development expenses" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r60" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "[Payments of Stock Issuance Costs]", "negatedLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r58" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Expenditures for patent costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r206", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r148", "r149" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from the sale of common stock, amount", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from the purchase of stock by officers and directors" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r59", "r218" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercises of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PLANT, PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r165", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "5. PLANT, PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PlantPropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r163", "r353" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r31", "r74", "r163", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATIONS AND FINANCING" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r196", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r196", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r196", "r305", "r307", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r303", "r304", "r306", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "11. RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "[Repayments of Debt and Lease Obligation]", "negatedLabel": "Payments on obligations under finance leases" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r224", "r372" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r74", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r178", "r222", "r351", "r364", "r365" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r80", "r81", "r82", "r84", "r90", "r92", "r147", "r219", "r220", "r221", "r242", "r243", "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r299", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Additional expenses" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Public offering price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of warrant liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r152", "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of patents" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of future minimum payments under operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of total estimated future amortization" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r32", "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of plant, property and equipment" } } }, "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/PlantPropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r357" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Equity based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility, max" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility, min" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, max" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, min" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised]", "verboseLabel": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Number of Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted Average Exercise Price Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r210", "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of Options Outstanding, Ending", "periodStartLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r204", "r208" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails4" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock prices per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Implicit life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r180", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Stock-Based Compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r21", "r343", "r344", "r349" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "U.S. Treasury Bills" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r150", "r164", "r166", "r167", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r41", "r80", "r81", "r82", "r84", "r90", "r92", "r108", "r147", "r176", "r178", "r219", "r220", "r221", "r242", "r243", "r282", "r283", "r284", "r285", "r286", "r287", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/FairValueMeasurementsDetailsNarrative", "http://cvm.com/role/IncomeTaxesDetailsNarrative", "http://cvm.com/role/NetLossPerCommonShareDetails1", "http://cvm.com/role/PatentsDetails", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquity", "http://cvm.com/role/StockCompensationDetails2", "http://cvm.com/role/StockCompensationDetails4", "http://cvm.com/role/StockCompensationDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r80", "r81", "r82", "r108", "r326" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/FairValueMeasurementsDetailsNarrative", "http://cvm.com/role/IncomeTaxesDetailsNarrative", "http://cvm.com/role/NetLossPerCommonShareDetails1", "http://cvm.com/role/PatentsDetails", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquity", "http://cvm.com/role/StockCompensationDetails2", "http://cvm.com/role/StockCompensationDetails4", "http://cvm.com/role/StockCompensationDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails1", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails2", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetails3", "http://cvm.com/role/WarrantsAndNonEmployeeOptionsDetailsNarrative", "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r22", "r23", "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Issuance of common stock options purchase shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock issued to nonemployees for service, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Equity based compensation - employees, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r176", "r178", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, amount" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock issued to nonemployees for service, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r178", "r205", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Equity based compensation - employees" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r41", "r176", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Option exercises, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r76", "r145", "r146", "r281" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r75", "r178", "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "12. STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r297", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease rental income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "15. SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/StockCompensationDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardDescription": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.", "label": "Net operating loss carryforwards, description" } } }, "localname": "TaxCreditCarryforwardDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized gain on derivatives" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "unrealized gain on short-term T-bills" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r110", "r111", "r112", "r113", "r114", "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r95", "r101" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares outstanding - diluted", "verboseLabel": "Weighted average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r101" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding - basic", "verboseLabel": "Weighted average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121554914&loc=SL2265659-115463" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13572-108611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13587-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121601235&loc=d3e32400-112679" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40010-112707" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e40019-112707" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121577943&loc=d3e41614-112719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r374": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r375": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r376": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r377": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r378": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r379": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 81 0001654954-21-013417-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-013417-xbrl.zip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�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
NHW"07Y>WB MJ@S&&DL;BAH>:Y"3,R>G_LMQU_@U)R]>"A'PZO"DU6^9@!DP03&/ M;"R:Q/H7#Q3X?;I>PHZN1D/.B$<3N/P6LWM>;P/QH!WWIG,)J1(%Y7H K/E^4 &64XT\U/C.9=1V/FD9RM)-5-YX(:^&3#[(^N#BP,+B=IP@5?PCK?'Q\5 M8&!707BK);LP]1SS*@^VYZ1N_\"TG40N$\BE WY]&\Y#D35L'LYQ3=W?B!7Y,3,.Z*#GFZ#KUK#TG"M6)\;4'4VA$8 M6;=D'F.S8G)G"CC@'SV2J!.I2ZQ:![Q]>&\(WW'^NYT!]0&/]8K9J!N@3P:> M0>[^1=JMMFE%,[^K6YC)O1\.>-OETU@T-YWY4R\0M7M\>(Y(P<9Z-N1&FDVS[Y;)4.U"W#-?&? %"G^!_X"Q M8.ET+#'S22EFZC8IL4?@W(P+[_8TVSKEMP; OQ&NHL/$VLZ>%"QBC M,"AIM(M"J0%.[QGRPBB\;WDR$1>4@-3,#>9"(R[:_DYQ$!WX$C@'0IB(]*$F MIL2E3&/X**T'OQ0T$DBN2H:I%C)>NBP43QJF%-=(&57)+]XCGFPM7V^2I1/ MW8QWO>(F02-YHJTPQ'J>Z)GXJ"0##*]72&T_&/-Q)MP>.ASZ/*7# MFUT=-AUCQ)J<7' *1>#0/-XSWNTHZK=X0"N-:#(0$$UUWTZ=7J3R9)D6]ID MUX@I(!<)6WATT=42?(-)-)3$V(<0\Q&$]A880>. +)B^/8WSA>PPC\EKYI^B4 M-[H-+67W8NMB9+VUSQP;& Z_ MORR"G;%W"BWMQ!,HT%9%E6N0OI&UA*F&I4255'O2Y^1A/>#O))5L3F[+ M SRZXMXLNCB;D-]NZ>RNDJN1I:9!'X^Z;GB_,&45VB7B%"_ M1",=E_U!U, >7BOC@2,QX#U&6)WD(X.[Z5R+S TN/H]R[6?I8W%GHD@(\M+> M^%>2E 87'Z'I$MN8@H=/RYQGMLJ76<\,0*F!;4+S/440DF,P/^5RPTJD>7"% MQ7AV0=F9):YY?K>9ZU(#_D2?Q*95'D.ET"KF.!IL\T0BWVJ.+U#W M!1A1O4A7*BDKT]@X=N")+:G&*(8"#T3^C)?]+G-CWLIA5[@DS'S')6')M6"G M5U^O>Y>W1;@U[D6+T U=,1QBA'H"X/A ,R=63]6G9Q0SRBHFW'G\D/2I) M$E16W7%LB5/EV)E->AG%6?,@QO$.9WD6[.HT\9;&EN_VBJ%DSF!_-V"AANRA M>$%S8-;,YK!=Z5H-J](8#EFE.QHV*V:S53='';/=-#L'[7\H7=&+N_/(\?Q #H7?[$WC MEJZ/X"W)EFTL0L:O/Y2"5NU6;=3H-IJ50:O1KC1,-JCT:_!7^+C=Z;1&K;[5 MW89(R(G6^9[W_X)!NQNS(&V'HIIH<"?[H F 0<%SM+_S@60T2%FV:%;0W ?1 M"8%HSK_G$\3@Q2*P6+*5Z5,#&X!BG"V/#1$PQ.?DWJ-.G#=+0Y*%V'R 0CSB M.,LA8-;62^)@M2G')0_:E?!V$T$(370$08P"">AB&.NY/5 M&]CA1T(^VX(-DZWPL%<01I[YI!!$!]_H/4NUV/*OL6\3[WZ8A02;^W-7G?6N MBW43ZVNSW=^GN^.6Q%C0L#P_N9<^N?HC! W)9%M#?YX].#ORRLM4/D%*+9?M M0 P5$W4(8]'H%13'Z#LT/Y6H17#>J_ M2GHOJSLL>,(3DH>%TBC>MYO4WAJIH8:B[2-+2TKIB6K?\A:VKUX 2D8SG]-B M_H0+J!B?1BSIF>@\)YHH,)DZWA,3#:')Q1:BY&B,#@@?.N'?(B[[B@!MCJD=%O1M3B M?L339K 97AV,B;8!;XJ4/ Y<%1AS/^%EBUQ.IM3FA3%8_\J/XKY'^6RL@14W M?01Q%Y$4/")4NAW.ABR:XIBY#=G_DUXX'H_8.-]1;'"7*KO3PW../Q)U"W7J>'8"T1G MWN)E0.0JB7#E65&T!I_)HO8LH^__N< MFXP]PNEE %2^ '1^<>E@R_T!VF'PX_$XAN$Y=^1Z#!R/GS#Q[UX]!)/'[7@I M@CW7I,0@U(J/D>1$:[X(65X'KC0!'J7D00[1EI$'$_V9/,22D=)BFE%V(Y?G M1"6YD"H=]"2)$S$8IR*Z@-,>@T[#ZC1LG'-J=$>=4;LVK-".V:HTVK11Z0RM M4851JS6@K#VB5G,+.:>>.^:.O2AS=[_%4P&XLL'87U9V+24 1.<_6BWNT281 MB!UKQC2SK^:VY#YSV.UVF_T!K3#6-"N-8:=5Z9JT7AGTV_U&W:P/^L-M)-.O M94IJY W0"*4R.#)K(M,[,6D^X1>EH,A@-!Q9W1%(4\,<82YW5*'=YK#2MH;U MUG#4:77,T18IDLXE)/F"T ME[!^)1S5W2=_WY9_B5'>1/=S4 $Z>2J7!.#TJ M+S.-:V3EE5,]R/--TF+^$G-&(HW*D9K*",+A(P(-:'A M8 Q[0>\J]M*CWZ4"!#?T[;[H8YWQ$*OUUVA2I>?S^ZQ$\J>HM+J;CUJ$:\Q" M7MX+(L5OG9Y,,/O%K]58.G&)IQ?VG\BA_2$U,#&I44&YS!R?F+ZH]M"&I^$E M(IP29%TZG$D]\SCV$N!<['A5,OSB!Z Y'W*4NM,5[P89V<$@NM&5B.3<+9N& M8DI"O2;+1U6)0Q;CAZVEU;*38W^I\7]2Z;$%T][WPM";;,)'N42I%C/HH^[' M:WE6D!F)C$%!$H9GEF4-6$?";XNC";UTC72-=(UTCO7"0 M-=(UTG>V]>>]PT_)%)G* *?Y'/UE,&!L-)K+N6_GS/]GAF,?;ZKD5^8'(7,- M%5 UYRMO.DK @QLU-JF.$"X*WJN1G8_,RPN<:T;-;"NPHS)"WA05*Q4%-E-& MR)LBH-DVZE93@0V5$?*FB&C53,/JU!3841DA;\PB-HU6W51@0V6$O"DB=IH- MPVK6][TC-4.&U2JV\-,[[.?'6P_58(_M!A4U-399 .EK-UN&6;,4V%$9(6_, M)ZT;G9KV9G).Q#;804W$?!/1,AI="P)$3<=\TU&'%@4@8MVHUYO@WN0KN!CQ M?W092^ZWJQ%=>$1K$A<>T9K$A4>T)G'A$:U)7'A$:Q(K%\KL[)SDFH:^/; I M.:EBM_)@S*:ZNDK+WCJ)NY9I<'SN?4=EA*RKJW(.>6.'("W#JFDIS#<1NVVC MJT] \DY$HZ8/0').PWJG89CM?!U_["QFN!4C\'_'&<77/@OXG;DXI^IJ*D?: MR^G(;(!7>N 54"HPAZZLRHGLM5I&V]*55?FF8MMHZ<*JG-/0;.CJN/P3T;!, MRVCHGHV$1K4FL7"BSLS.2WA-UR!T%H :Y'E?/JKJJ2DO>.H<@F'O=?YZ@I)!U M557.(6\NZ:I/L7)/0UU4E7\BMO3I1^YIV+ Z1KW3V/>.U P8Q,"JVX&-5_B. M[$$THTH-'M"U4_D0L7JMHV?AY)^*AJ6]SIS34$<.^:>A+ITJ!AUU\)!_&II& ML]XUFJV]TU&73I7NB$DCN@R(UB0N/*(UB0N/:$WBPB-:D[CPB-8D5BZ4V=E) MR!EU;>:0?]N3"?/A2UU I>5O_7R!U;",;KNCP([*"%D74.4<\@9;R+OUK@(; M*B/DC=WIT# :^C KYT34AR#YIV'=[!CUQMZ=&C7CAF?'4MVP@%%_,#;(*:!_ MYE"?G$\F,Q?6=Z]G4VD!7">JJ&-=Q]X%L*20-W?76%>[,SFGH5DWVBU-Q'P3 ML=6NZS*Y_%-11Q:YIV&WWC0ZW;TG:G1Q5>D.H32BRX!H3>+"(UJ3N/"(UB0N M/*(UB0N/:$UBY4*9G1V2_,,;N^34GOHV=3U=4J6E;IVTN=4TZGHF5/V0^WZ[MWA_5^'[X MSI:@2 S5:G\]($B#*1T.X9F_']0PP!$;R0R,#M+T&T_[8S]9S\LAU5SD=')U M<]:[J9QLTK?9_1;A8[@)4>$.H_T*?CQ\RI!H7C;TFZ?)?S[N>MU\BZ^_X'B MZ5)XY'K^A#KBLT>QA?1'_)71)RG<.FP4?G)LEU7&;0_$"R5-^NUW$W9F3H.=@%]4"=&<.HOD\#(#&%SY[(X8 &8T+=(2@KMX)_ M^4 8]5TVK!)\%L-A0B?>S T#8KLDA,\&^#R\YZM?);\R/PB9R]_P-:B2:]\> MC-F44!] S/I!"*QA4\=Y(F.@$//A!52\90I/>N[__:5CF>U/ ;S G5$G6E:? M#>@,H, /GP#LP)D-&7GP'%@&L!N\;$=][-;5P.X7X%,0#RD- M 7%L$*=A)&E<&QO\7X,QB!2(8!#,X'L:D-/>1>7V]/S'@ Q O_IV?Q;:GDO@ MOWTVILX(Z80/NG0"#WABOCQY''L@![A'>TI#QF4Z>5.C9AY^^T!\%MH^0WDB M4X>Z0A/$Q,?E!J$'YI,^4C 00S*<^:":(ZFVO2&N"3 )7_6?DHW XD%W. -, M*>(>!@.P+_Q!CQS?GI*VV:F8M4H=_@OK!#T""YG"IM'Z#OEK[GU0)V0(CQ/, M1HHUY8#9&FHP&Y(QP=L\+;TILD\@4+P&35'1IXCJN8N$ @83E*;N@)%'.QP7 MG-A--8A]#*3U0C2Y V\R96Y N7[PV8#9#QS%8!>EZ,-/9@ZJ<1!XWP-Z@X4% M30)ABOM/!@'U ME]981KPBSBC #U,V"%%!@.\\ >TX8JG7C3R? ^TSEXWL<%[CL>]L "KQ@<6Z M#RW5@')]ZSWB"^)U1%"KY%SX&@&8.-!M^,8AJ,)!Z($G,6+P.<),.3Z+_+@= MUSSEH&^/87X*0M]S[^'/*;AH$@K_Y9"!_'+V.9JY$!&@NW[PN3>9.MX38^0: MF N^,\#Y\Y ,MV"JD!\ 4U><;6X2>W(-]B3XZ2." "1%$+>[L2SLO8D<(FZQ M73P>.VIP11.QZQ@L,D6O%% SG+?("];4(/\%1Q=6ABCBZ"2WPVE^)1N? M8]#I@D]\PQZ8"^)TZH$3S)D8%3$^/N]AHS*7ZXG=:B:)%%0%%I9^,+=4E#-4 M^+!,--83.N3Z6_H>L*ZTTS&9>*XP'E72HZ# 8[_"#1>]$OZR$"*#M+0)&4]> MGGZEM EC"O)+I3IAB#A<(T:%$9:>!VIP?08_9]\'3-H4AP4!(!R>_<&L&;5: M#9FT]&GMN8#$)=]K80^P:[YR4$:('UB^#R3E\=>0S*;25@X<+T!B M0M RX#K3#A?0*Z%R\VT'8$,PA#%A7[@PJ9/",4#CA..Q#IV"(O]N ](9<,8/ M+=QK58IC'())?KOF7!D19>@A]P/F).XCGI9*UB!3(>Z2F:="YH-$YH6I6/0A M]R#C>]>0IVG#"X0]BTW)F?"N_H1PB?1<]*%OV31DDSY@KEXS")Y!+^C(-6%C M)>R^M.S+2:3%Y,_6]7 M,2(0WUTA+QZE1M$U1';[^X&U!:\V3L!^ 4NV7XQJ$KZ3A+?<-!YCZB @A^8' M3(::OI>F;%_IFT_,.G> ]HE3-BLF?&;PV/OQ0 MY(Q[$7(V*V6OYX>53LI7X<_X_E<>7RF(EC) WA01==58ONEGU4S#TC<:*J06 MK882%'GKZ*7MFM5KAOFQFRKY$\#?JVI7\Z<&FMH6YY^(VA;GFWZ-NM&TM!#F MFXA=)8BH9E!\XL][V;EOS75O4!U-;;]S3T1MO_--/VV_"T#$ M3D<%(JH9?=]X?"O:>UO( MYLPWTFVM%LSEUIBHA)?W6V&%;<#\!WO @NJ:/< ;J#6OOSX':>N>Z0X[30EX2]I P /M>8E+,FD+F.=^QF M>$8!Q57+LF= ],'PSIG0(_.5,-@-)MMUXR;&7MR(,U"C&1*[VOZHP7;GD>'8/?R5U$\O\S6[2><%+[KC< M@%Q1L#DSOX(][+*)AS,,O?>9Z*K@:FP.<\92<\_IV&:CE !>B4XXT=#[_%M3 M_6V&5()V0+!U)FHUXAW)=,*P$3GUZQBP:,#/@F#@(_ D;WKP$FSPI@>SQ1M* M'NRA;% TTGVHO 50=NJDWA=W$_$>QBE]6AA,L#!: 'M_FLVN46M: ,R9!;)' M<> S&HB&:.R!]/RH(TH^E_PBLB_PG>AU"<3\Q*6.PW3+%-_W(_A*"^!XH\Y# MTE5[$O4=)LTBSZ @"[L[U*>E'@03W459W$$PNW4Q$@Y/<34RNS$GS(\VR$^? MH::T0T>(H&QH3G4IRTZU0*HN]$D2I>*EFO>R!#;J7QO- !3N+FFAS/(CDY=- M@7T&-DJT"UH(C3H&"_QOP:S_']G&G*4LT2$*1G00M8GA3D MP.NXB T\=V@+ MSQ:^9( ZNV\[=OA4W:"3L"JE]L4AY_/C9G!([3T@!&D 5''!C0B?R&&W]@'\ M\J<@4I'>8##S?>8.XEYT^<7(PQYPY#GLK0V#(W)H?P";"^9W)N@ ;\VFE1B; M8\N?.]Y N+.'P#E#-D%R8["8?/-A851.8B-!\_!UI5D>#7_\SHGG,]FM"7L^ M-&%W(,),#KG!AD^QO3#K708NDJ\2464#?V/4@NO#IE ?[/CKNZ6S<.SYP&H& M^8_7!T,4(H/#]AQ FX/PL$,?.%-R))$-^?9DZ@5VQ,_/PG?LB1U2R=HB6'AF M%9[K3=!J\DU'[^;3 P[M!]SC*6#IGCDB.G1_/(9P<_"4@><*&-F_PK1*<(S.=^8 :%KSD(,#"!S&J>/>Q M0%?*4R$31EV4"/,#_\6$^?>B9WJN;YNZ0E%R[ !M8+5HUT#9@ M,YSWA\C0XUW&WB,HU1 8BL*6FJ*O^\$+430'=&IC![;$@-A4,/,?[ ?^M0?; M%<'$)VPTDDZI([(W2YWQD>,(7FR87@@\6Q?/TL%_9[9D6_#&$/EB+ _^.I%% MN"3Z>/P48)8)O$ ZX+-K1CZ= ;;NJ>T&81(W(C<1C!P&XQ0*#OJ./Y!KD>5\^J.J4E4UK .XR]EM/* M0.IR9NO9*RNN0#T(E_+5+%>0>O_K6:[DURMDN>8WOISFVDB6*SUN,RO+936: M1J?6R$IRK9=UDAIW-WDGU1V13;/[DK9X+HU[.["1,R&06C6/>X:_$&]^E;_C MWVZ NS>2Q(T7E,W<]5K=:#3KFKDWGF9)J15 ?D*&[>5<5DRB1(FXC650$H*G M7OI:2F7UC$KFZ]^24A&)G/>?J XV )2E.B$#>NXVAU[ERMXYGJIM=S@6D+, MBQ'#8J+3V[DN-B,R'X]C< Q$=>J031DOJRZG,D[5VHC,5.;X8N5 MJO<93II_MI0Z20Q<%7,Y#7+"C_506.9TE2IS^3"U(P62"IGW(@H%O3Z/81;@5XF4B01?PJ"? 4]P!3Z>F?$O>X&? M12$2N!GR'B[,NPD/XX#_]"!OLK8R]ZPJ=R]P5B1H*[XI$DR1[W^)8Z/TXO^8 MB#N"8$9E)O:U2QR0@M$M5'A+%"AJ?V#C36\+;340K.);P^@@G0.NDBO7>5HZ MN4AJ)X7+&;\D>NGBRU[:W":MM%HL=26Q@4@2062,_B&9 3[ AW&EO4[2Z$L- M2U5RM4"K4%CI* 7!:S<@:L>GDZ#83&[3F&.(=%IA:6$\60FZ!NMLT>N/ZB9& M2#M12!'GV!<6>1Q7Z@HN>)FSUH"-.?X701>5?U M2%S&8BNN$X%X<,A$5);8 MAJ7SQ>RHI3\+P02X$O=X=4IR=0AO? .#\HV%20/>,@?-=]6%\:U>T5G1-#[V M,5-8:7$Q7GS4),)O$+JH0*_*";)':4T[=T3G\?CL=K3NN< M-_':CS?D4?#;YM9U*5*=&I$?821!NQ%W;1B8"0]F#B:-I9<]?+ #3,ZBPRI: M)D .X>TKN"#2BX]S8&/OD3V(:Y-"K(JD8..&+&X')Q,L?>AC;@Y)(+0LCSG3 MB\*@-5X3;PF!'\R_0NI9&\-7UY57@HET?91.K_C4YG=%A;"'(.H8\7&M$Y%W M7[[>*WU-UQIV8C4;45B+NEYPG41P;_;L?^,WP2'_+464RX*62=[(Q98C"^8[ MG=XH/^\4 ^4D0+-K9FIB8UR[G*(PWLN]R['DNC8 .WKE^7!T_FOC6_@< _QE MQC6IP.Q1I7@0W54.%ND7(02&%H"<"D!F[FU-]D^+3%H$K)K9>"&Y]W9)R.A3 M3=@V2;%@UB:^CY*EJ\.PUM.31_"# 09RR1J$5R K$*(([%K> (H>G# Q/&0 MZ;!ZTXZWB.>3+B4P1+8PL -^OS#(LC^S.>^*\HZ0VCRL MFS)O*DH"TD#DJ:UXLPO/\1-.?%&")U$-YT(X(6Z@E)4D?$.B4&4.DPD.P[GK MT>=O1Q_-PIGH)0ZP:%0NX=[W'L.Q(8K2\.U8RB(._;%(-@@7/.1G ',I!T\[ MB*\ 36.L]'(K;BX]=T+7 :Y%23FCQ3.+C M$.72JGWBN9+H4_Z9^>F#(2YS34Z?XM)JFG5<)A8C?AW7]R2@^&6M <.$^N+B M,LJ6N=D &1.21S$I*,K+0^8B:^+W(ET8\DE%4MJ30(B#P>. ^<.S9#U2]_AL MP@\3:,CK#W@?/);5Q#WJV775(K?W0$'G\%9X@1I\)Z\*CO)!J>W+ H01_/E2 MP;; 8O(%#2)*/%&%19$'?1)9E%8X2DJK4"$MQ&K M^#2]41F.+A6#S:T'1-E[9/(H1%!4RG,< WOB&#HR WX<@B)QYH)3KB'C@(P# M3SJ:D"G"/CS!J5=D1T$D">AGU2265O/EQS%RANWA=S2,Z]\G 2-C MK5'X/(OMGD!F4MX6S5!X1*SV67JAP+8C9H<1KR*?,,?)9;W(RBI.'KC+FYM? M.7.7;#7E,R"&@'-Y<36_\/F57$UTTBXM=G0O]'S29C;E%9%&IR;OOY[&AA%\ M@,$8,ZS95W(;XN0_=+:JR_&!I>TQ4[5C/!+SZ-TBI@1($Y !4KF4(K'-QQ=*96+ MB,GV %'M)O>!_V#5JBT3]R5>821)*>>VIBB E'4%3*-H4= M3.B S?A$O\6[T!>Q\A6")_L;5X%L,'8]Q[M_,J+3@-]N#7(*3MZ0&N2W7PWR M,\,UPO=??%RJ0,>FO."S+[:R= W[JU02 M]\H'Y(>&5<7;U2^1R',G&T&J^SAU%[!A:7.A<42!__SG=#\;!\CPJB- MFDMD\A2VGT6O%XI4-F+P#UV/>^Q\'$X:^BX/4F1\AE6RL<-(D4*8 MNC!"X0.?9,"5$S$HU,N;;I,*BQB93GG#%!>J6-Z>O48Y\5*%>F;O'K^%(<( MPG7$KE-!]P/4BX#< Q(,QFPX P+ ![!C.QBGSKIC7"=AX%S02"1U>8PS=TAM MBXK^"0M%ET;(FU)$HL0@$KKHN!!AAN@DE;VE@G!S'2 \QP>A%;7=N;*,5*&% MQ$JJ*16716$A;F7^/5%>)LX@)DD7H'AJ3VE( ]$A^^CYW[A/"N BR)ROTH_- MPY1/BB,]] 82P*FW?! RN!PU("+GAH(LDS45$/ 8-7Q-WI.N'R_5KK+DMXI( MQ7GBCDJJT":I>T_5L3,'V%6T&+]ZO D&6N2L"+V_]]E]/!!XKG0A[D)*J1#N M8Z3.5D0J6,!+2OJ\QU3-AGQ2NI8C02S1>1.7!HF.;0P_>768Z:K$T+I4F$\D4$6.B M&D6:BH]QYJV1=/?P2"28!=B,P$486Y,\G\VGJ+BE>,)<-A"?V"&P%9O(*!S$ MG;]G;MB"D'T.3+2LSPTQBB &O#E>%M;1(:B\ *MYZ6B$B1I^WX)0WV!-[VD4 MRH3CJ#^2*YDE)3_UV8/MS0(GCO?SIA V7G!?J)KZ5UK\4I6I(O ;>X_ P$G* M?N"!=??=2"1.W9M\QLX-:*2YR@DWG3SJXOV!D/YR[8>185J]^\ MDS#CUMB?OWPB4N*EP\MT7J-3^: MC8_HA:JQTSU"WM3E?LVNI>])78"S_A&/ M<+>E]G=V:70ROK2H--,Z?VLZOVYVM,[7.E\E>N18Y^_,U8\GM,NI;46EG-;\ M6]/\5D=K?JWYE:)'CC7_SKS]?WACEYS:>/+L>D4EFU;[6U/[9KVFU;Y6^RK1 M(\=J?V<._QEUR;]Q:CDV6!25;%KM;T_MM[3:UVI?*7KD6.WOS-M?FKI=5-)I MU;\]U6_I1(]6_4K1(\>J?W":O_9B2QZ%,^V1O$T5H*I1_&\K]=7#!5(CVK-N@\WHUL7 M!Y@M]_?NL(=7C1;60O9DQ:UQK3>8L1VT8XM?TN[V@ZG,^.RBU'+ZDJ%:Q,3UJ4 M/[0Y4=31Y1D<#Y&ZW02\9EZK$*A:'J;R[3="T@7?D@%$W/ M7(\_69QYDH.:"#'AY*:JUI"3(IP;X:40"NQ'&4SN+_-2)J0K0^XW"TZW76V6 M6G"V:*!JS8]F^Z-E[:"JHU@T*8!QZ,L%8NVW3)"WI@!K)H=!;932/O7_FCA?W7XEQ_(&TNKU&N&:96Z M+U9=*A9MNV6$O#G[U]#QWY;L7X.G/SLZ_LL/Y(W9OX8%]D_'?_FFHM4VC5I+ M4S'?5&Q66]K$;%X$R'K$9@ZL&Q^RN9/)RL6BB;IR5;3M MEA&R)G'A(6L2EPG1FPD0HP>V?.G\256M>^?599XUV@$M'8>H2<.B;;>,D/6X MEWR$FGK<2[X@;TJN6CH-IRH-B[;=,D+6PV#4-W]Z&$S^(.OH+_^0M?DK/&0] M#$9]\Z>'P>0/\L8.\(V&-G]JTK!HVRTC9#T,)@?F3P^#R1WDS5W:K8?!*$O% MHFVWC)#U,!CU[9\>!I,[R!L3*\LR6K6V CLJ(V1M_PH/60^#4=_^Z6$PN8.\ MN;Q*S6CH86@YIZ)9;QJ6J:/X?%-1#X/9:J.\'@:3+\@;*QS3?=;Y)Z)EZC+= M_%-1SX+9KHG3LV#R!5G/@LDWY(U9MXZ>5U< *NI9,%MMT-.S8/(%69_N%!ZR M)G'A(6L2EPG1FPD0HP>V,PNF]T0=BG+.?H5L <0%9"^LN M:&5)K ?!*!)GZD$P^8*L!\'D'[(V?X6'K ?!J&_^]""8_$'6T5_^(6OS5WC( M>A",^N9/#X+)'V0]"";_D+7Y*SQD/0@F!^9/#X+)'60]"*8(D+4!+#QD/0A& M??NG!\'D#O+&[%^W;G3K#05V5$;(VOX5'K(>!*.^_=.#8'('>7.MN3K^4Y:* M1=MN&2%O2E#KU::V?UNR?]V/UC;MGX[_U!4KJ]DTS(:EP([*"'ES6>RVT6QK M+R;?5-2#T+89XFUU$)H.\=05*ST(K0!$U(/0BD!%/0AMNR9NFX/0=!2GKESI M06CYIE_=U(/0\D]%/0AMNPWJVQR$I@,X?;JC(6L2:\B:Q&5&]&8"Q.B![0Q" M.Z,N^;<]F3 ?OM&ST#;JPW9U%*(F!8NVW3)"UI/0\A%HZE$P^8*LC5_>(6OC M5WC(>A!,#HR?'@23.\B;FX/6T>9/31H6;;MEA*P'P>3 _.E!,+F#O"FYT@48 MRM*P:-LM(^0-FC\=_6W+_'4^UK9I_G3TIZY<-;3Y4Y6&1=MN&2%O+$G3U.9O MB\E/C/Z:.OK+#V1M_O(/69N_PD/>F/DSJVV=_-R2^6M_M,R/5DM'?_F!K*\ MS#]D;?X*#WECYJ_::2NPG4):/PC^.EN<@:V#/W7%2E\!H2X1B[;=,D+>G/EK M=A783B'-7Y=W/>@K('($>7/#(UN&V=570"A)Q:)MMXR0]140ZMN_AKX"(F^0 M-V;_&C6CVR[U6,("4+%=,QJ=E@(;*B-D/0$[#Q9NJQ.P=82GKE@U=((S_T0T M=9JZ"%34$["W:N*V.0%;!W'JRI6>@)UO^L&+M77+/17U!.PM6K^C9U/46(IRS;Z/&?RD-60O#+ M@&AE2:QG7RL28FYS]K4.,166*VW\U*1@T;9;1L@;JX_1QF^;'8!;G7VM3P_5 ME2L]^UI9&A9MNV6$K&=?Y\#\;7GVM8[]U)6KKJZ]4):(1=MN&2%OK@'0["BP MG4*:/^Q^U_-?<@5Y*/5D)76I6+3MEA&R;H!7W_YMN0%>AW_JBI59 M;QM=2\=_^:9BJV-T6YJ(^2:B;H#/;0.\CO#4%2O= %\ (NH&^$)043? Y[8! M7@=QZLJ5;H#/-_W,NK9N^:>B;H!7KP'^8]CWAD_X)^T[;/,+_,\L".W1TZ5\\NSWN7=$6DTGX7[$Q#6C0#R7PS9P/-I:'ON$=AOYCNVRPX^ MW\XF0+VGGS[B[S]7R=V8D9'G.-ZC[=Z38.P]!F0 K$YME]CNR/,G_!6$!L0; MD5LV#=FDSWP"JHI8-F,W\PI@$CG@M MQM1GN![YBA]AS=YDXKD"6'5SZ'^-QIR?(D!]SP<\D3Z#CAZQ)Q^)X'GV,,%MD-,9$ECE*=Z!69"BA^G])Y5^CZCWRIT!"\Y M(M1YI$_!CY\3B7[M;:L+]_LUVLOD3>'$8:-P>^3.)MI?:OR?%-FR;=0&E/PE MG7!YNW:HFZE[=VVEQ\,Y*_TJ9E8WXQ%W@T9Q4$?^_< ZV*)%N_-"ZI!;5&@! MN0'-YS^ =OP-%3;'=K!?=&OZOI.^BY0%BTJN9F$0@FE$FWDE+*6F<@&HO!6W M(X9Q'@0S-M2,DFM&N6$3\*Q3@O]1*@@U-/[*GEP1XM3%B#_% 4O1?\%"=(UT MC72-=(WT'1N1?<[+.G?1"-L/C-SRA)2PO\+B$A70IA*OON,(HV,T]!%&SJG8 M;AD=J]3W;!: B)R_S53,\ M%T;\U)M,F1M0'99OG/M:]89N%,@]%;4MSSL%S6;=,+NE[M8O !4;+C1! :BHK7G>*=@R&T93RV'.J6@U52!BD;I.:]6F M[3X#^&HDNCY%$;O-6Q2P5S.849?W;28=FDNI?8-8G9K1;C6BQQ^9SZ)WT(!, MJ1\N-GFZH6_W9SRE "^WPX T:N;AMP]D"F_<8=_G;K$\WZ0KFQ)YJRXB_Y%[ MBH@S$!)ZSPC[SOR!'3 R]>T![]O#GWFIKJ.H/S?JQLV@V/_]I6.9[4\!23Q M[.9]K?3BV49A8^G%$R\(B<_P[61D!R#]19OK+;J<<8'CTC>8 M^79HPPM H/N,B-XQ\ML4Q*07:0?X848G(CFD'W236:X9X0]I$"K'TB#$)+^. M#()N02T:T3.E/VDW/'Z@ML-MT!?/)U]FX97=A[W_SNSP*>/@Q@ . M&C@SSBVIMV^WW_6&C1PV0._$=F%-SFSB[EDWZ>[(,K0O::1KI)<#Z?DX<="- M>KK%:R>0LW&7O9X?-E\75JOJZLR<"Y5NV'ICPY;6Z[K1I\"ZO5OM-A1$2AD@ M%[%K)[_GBL^,K@U]S[W_?'[7^TI,JTI6GF7;._WMYOSN3W+UQV7OYO:7\VMR M]86<]F[NCL\OR4GOLO?E_/3\^$)^3XXOSV YE\<_][[V+N_X7V]Z%\=WO3-R M>W=U^NLO5Q=GO1OXR=T=_%R.R(4_Q/+R?+CXPN#@9\\6#7F4=\8&XB3/C [R MTG.!'^UP3'P63-F GQ[RDT;7>2)3Y@=XG. ]\OQCG[EL9 ]LZL!WS;\2SR<3 M;VZ(;WPNF#ZH3(_UY>=_^'Y7I#KQKP %HT5,U+1*?G,=%@ (^+G_B.EU M&T#CV=;0$. 0N$_&\$S@ 5H?O!!7AB^TW0<6A!,\^IQZCPC&>\"?VD&\\-'\ M3./M9%OU4..EH<:M-9.]>1IJ+/Z?Z!/IQ=G&*)/'PR$(WI[/P?9]+/6NG:3. MH(02.S3U67*.Z'\+ T2-_RT<_&O=.?&0 D-U7R M*_C*(7.W[0UW+*M+3CR\;.3$>1A6#7([ \*03LW:,N3?;>:ZU""_'Q/+,CN6 M"MRBDHB^_8#%:+9-H]EX/H>S3I+PL/Y! =SDGRKM:FDD,M$XKSY56?4M9E#?JF2?]N3 M"?/A,>U@:?E\DVENM+J&U=&)JWQ3T=2)JT)!+I/U+2GD,I$X;P[6/[RQ2T[M MJ6]3U],^E1;)-7VJCF5T==(JYU3MJ*GDKUG(?*R/_1,6=K^; M -JJ=<@O[-$.0W+FVP\L4O9FK5XQ&_4M0_^##CR#W/V+M%MM4ZO[C54-=!M& MJ[/WBXWVB\MM#NR+$/TW%3:K8^-]LUJ) B>5$*T;?11U9$[\F>N1$VH[#GWP M;)?IB+6D(OIV%Z9>,\Q&N> MJ]?:*K"D2GK@[7Y2S31JW7)72V@_2?M):HAMT;:K#**UGZ2HGW3L..0J/67Q M+)JRN&67@L]P_!EG.)+#3C2H,GO058GEYLU^1=NH61VCT6HKL*AKH2,W^0M0M2>,AE(G'>')[;D(9XJY'/6$A./7\J9YIO.UN3!OO%=JF+ M8[C)*1\DNF785RXC%[8+-'#E"K8,\,0+0L\UX)>D9IFFJ0*?JJP05J\#-9KM MEM&V]$46^::C6:LV-]_ O+M:T+^1"QRZ'XZI2\R_;EF;K%QXFD7G!XHE]^&1 MBY-%%93SWT)LK5P^6*=Y8HOB&+GPZ-#]DWNF4 M">W$\#2UUG M'5UK#P\]4A_OMD^NN)=W4R177ED J>"OCN@L]*(/N)"+ M3P2!.\U]3^7?N$SBO/Y,G5R:&>^;OFGY*A&;/R*QD5>&([]N1&R#](+_5A7Q7/+O,UE&PVH8G<9F_*9X=/26[VK%%_V5+;]LT4!&+)I&IUV:]\[RIN.E.-L,F?9[)\Y\L^6]:9E MM/=_M)@W/;D\!&#_+)%_9FR87:.3,V940$<^WZR\?];(/U-:K:;6D)MJ/-L_ M6Q2 (2%V-G/&D IHR>4V@OVS1/Z9T>RVC)8BS*C@ !5]CK5PCF6M<8ZUS5K9 M"6BGD-@+)V4^&S'?%Z=;MHO7[1+:]QX8Z<]"PK[/_QA8>S F$_I$^HR?L<%S M+QZC84UN?(XV]=F#[796Q=W..]ORYV3MY3I$;RMLKP4S0 MGJ<;RK6.6E]'U=74477+-!J6&:D?U";U;LWH6IU$JXR9,T3-A2IHR/#6:9^2 M.Q_>:: F$BKKJY_<^VIC[7Z?N6R$)Q'^4W7Q6]<+^=M"? GC^FSYY7PQ0X^) MGP\ T;[G\-\]>"$6!^"1)'\)'?*_BI?(G?!%@_;#C_CK=J[_MD?$GP) A7O_ M^?RN]Y68]2IPEOSDI_C/*74C^/P=0S:0E8Q'X$(S'P7IX/-I[^;N^/R2W/0N MCN_.KRYO?SF_OB7'EV?BD]X9N;LYOKP]/N5? AAX[><$VLX*>S8"9$YQ-YK/ MIX=G/O(3!/#U M1*8S?S"F ;S$:AO-6@U<@@!/Z;#D1;+K_!/_]Y>.9;8_!<#UDXF'A/3 !E$4 M"4+O[WUVC]6BP'W?6$@>J#/C(D2G4]_[;D_@.W ?K"LFH'%#2MNIY;:SO/K MKQE-T]K0^D?4]E_;A-EIXB:JY"X1;?@_$LSZ_P%<1Q5#H!V&MBR0&)&;&5@F ML]$@G-/Y#V[9 - 0VO#X,3P&/S*[]?H&I^^MRES[8NI;4+.7'D[^,^,RJ[C, M.,#JXPE#92\M [ SN)/4#P5E;71CIQ[\=03LC086D0U/VNX(K3#^#8D W.,B ML_G,H<@=^(8GU-!N0 >>+@'!=R(%6(U^H*LJH"O;\XO3\^OCR_(\>GI MU6^7=^>7/Y,OO9Y0PK>]F]_/3WME4;PG9U?DM]MC@UQ<7). ^0^"#64 $RL5 M&] W12T&C@RH$AM<" ROIK.^8P$'0S0Q0'/A?,J]Q >/:[Z@F=5N= O2=VA M=&['WF/ WY!26@PVVK<=1P1TK!UC:K!_]$P]];9GXER_?*QC\YJD)%7;E?C&H2OI^$M9**_=Y/1$HSYD(C M7?7#T_5/\]^XRN,9!(OD"[C-*N#HG67A/VR^5JYK&E;)!Z&J19%FLVZT:WNG MR)9+(=XES3OZJ&BP%[*"+DP]%/3_M_1[UI/%(K/2@JY,/13U+/ M28/AF/E:6Q2*VTH*N3#TVU\5[$[/'D5@PT_W?#;U68"GBY172\7G?7C(-_6] M$0L" M/J>WW2489JWR3WE>'\0K&MD!$LH >'E*J!O?78_@TC.\Y_@:\=V[X/J!@\J M52^).&& &S9W3DL>*1X2W]/[N=I9/.D5)(X(ZX/$N17QEX@+#%&DRY]&(O&7 M\7J6A[FW);S '\<:&3L,&:LN_>#$H_X0V2">NHO5IJ\JG*^ZF;-%_7^]7QY>GY\06YO3N&'0+3D=O37WIGOUWLL[YHK2KR-POT:OF/YYRSC00X M)/Z?[1Y\KA_2EV>9[\ =KK^^T[=3/KW=YSPN!.V(VM%S=[ P:G45Q&R3,3/A M-VO[15F")F';>6L1-\W@H/2^C^T^. #(6RG/\T=>A=L'+3 D-[Q:3F"9W$;. M)(&_?/'\";FMF-PUO/:"L-(;C<#EL!_ KX ?#?D/#P^RWW#PP9A_]Z4'GJ15 MZ32;C7;E3+05U"OM9MU<+,-_WZCQ'7" AI9':,IVMJ\@Y?7#_H?]44D%#'"- M _HJ,A'EQL8;M?[KREXK;0U-)6CY5MH#K;3GE#8YQ"G F(IR[QFH'>>IY A: M48\/%O2XV,P*KOLS/SF\]*JHR.N-3KOS8>4V6!WU[U1[#%?/!^P\[-UWIN#D MB3CT$10*YM.%EE$86SE)$@P7U,RS03]7'_CL"BI(ZIIZQ;*Z5K>YI&VTXZBA M:<=Q;B^-3XWF=HFW?+"+ MN)N&7#O4+3UB5M#2!!B(""6-CG3;5K;J]M/>=[#L?0-&VM:G#CG\ M F\F[DRT^(,K;G8:M:ZE%;N&IA7[*XJ]["G<2\^M_',&GXYLG!2BE?M[E?OQ M[!XG&9I=KMD;F];LW8[5:.@DBX:F5?MKJGU88&5#OH:REUII6Z4JI(0]-*'97ZJ.1*G6<(%G/K MVF,7J_J2'&KR<>3S]2E6:A;S8JNU/.^,5+59J_P:-T6_,!#?;.2D5*[(S:_= M C>_EK 2\AEV-VN'CL(%??LN?_QB^T&84GB@ZL[8 W.\*?_K[6PZ=9[$)K!G MXPP=5;L_XZYJ7$HC5.>5;\._B]_V9KXW'5-_0E^^UU474[X64P#_3CZ\6GO# M#4_J%@VP/^*9EXR0+LC1T'3D\+*," M.;AC#U1\<U1"XVA 47ED6&5K.#8%; MEEUGL5<.WDVS6X03+'S5_Q\>DU. M'=OEO[@-9\/XZW)C>E7?'U@RZ^*%C#*@C\=KIW0:,E@XGOJV0TP>)YA-;2PT M-&TL7C4605!R8W$K;@I9- W/:WP#=-L]X[=B\5\F14 FZBN?A=[?RHW25:T" M\%Z651CQVBJ:KJW":T^22E%M(#2TW$#+NX$(PY(;B']X-K]E:L% 7%^<_WY, M?O$?:!A\HV18]> _Y<;4JGH?6$KK?36UE8:F];[0^[-9R?7^5QJ$H$N>B0]Z M_KTW =T2QP@W+&!X6BF#!+&GI ,@_MV=C[=&7OE\N":/%_B58.7&]:J6 YA2 M(@:7S)OZM# IGB-^B_GOW_\Y?IW,O JMHOW8&!E"=@F MUUC'4D43UD\W8H'#L%B4NYX&MH/Y-9S>/<"&"G0M7I*T+LM$;"D M0I9(1S8:FD*1C0HN)=J-_Y6]H>W:]_X#04K*)ER*><;F"\;AN4+5 )["*,G2 M]:IKF0K@0FTJU%1P&IHV%<)44$I+;BMNV<##MK>7AY,N]4-GSR75K=!K&@GD M/VTEU-1M&IJV$L)*V+9=R372\UJ\]X2-Q?0):*<5^!L4 M>%M?4RMK#4TKZ]64=:?3[W)E+D!U4IZ+27=V:B2WG5_%EF_@X?_ M]8'Z-G7#(Q>V1QWQV:,0_?1'_)71)ZEE.&P4?G)LEU7&4\\-,.(& MQCXYNR*_W1X;Y.+B6NQ@0_[$FW8H6 B'5 +KU9_9\C;0N/EW;MEL;H:#(X:H M+[/OOIDU6MK-##276:<5LW%(/Y!3?'0$#_/F ,VQI>-82W*LI1['RJ7=L@%W MLDMK$]]^)OY!H\(-P4FI%P; >$2:=I3!\8Z3/F$F]BAWP< MP
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�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
~~]T@*"9LP-4P M*?=#E!3?&B.S+P38>8_T M%G UYLZ,Z^\TM:]3\#OV=\H3\)G67WS&_FLY[/^E0O]),P(6S_*^#1^+!BPS M&~~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end

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Sep. 30, 2021	Dec. 10, 2021	Mar. 31, 2021
Cover [Abstract]
Entity Registrant Name	CEL-SCI CORPORATION
Entity Central Index Key	0000725363
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--09-30
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		43,244,498
Entity Public Float			$ 595,537,907
Document Annual Report	true
Document Transition Report	false
Entity File Number	1-11889
Entity Incorporation State Country Code	CO
Entity Tax Identification Number	84-0916344
Entity Address Address Line 1	8229 Boone Blvd.
Entity Address Address Line 2	Suite 802
Entity Address City Or Town	Vienna
Entity Address State Or Province	VA
Entity Address Postal Zip Code	22182
City Area Code	703
Local Phone Number	506-9460
Security 12b Title	Common Stock
Trading Symbol	CVM
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Current Assets:
Cash and cash equivalents	$ 36,060,148	$ 15,508,909
U.S. Treasury Bills	6,151,385	0
Receivables	54,922	54,922
Prepaid expenses	998,482	1,313,432
Supplies used for R&D and manufacturing	2,006,584	820,052
Total current assets	45,271,521	17,697,315
Finance lease right of use assets	12,691,921	13,811,849
Operating lease right of use assets	2,056,178	1,198,958
Property and equipment, net	13,663,562	5,843,993
Patent costs, net	275,866	313,422
Deposits	1,910,917	1,670,917
Total assets	75,869,965	40,536,454
Current Liabilities:
Accounts payable	1,675,813	2,023,067
Accrued expenses	859,216	510,515
Due to employees	265,993	448,022
Derivative instruments, current portion	437,380	213,787
Lease liabilities, current portion	698,665	1,070,123
Total current liabilities	3,937,067	4,265,514
Derivative instruments, net of current portion	0	3,551,826
Finance lease liabilities, net of current portion	13,252,364	11,753,100
Operating lease liabilities, net of current portion	2,021,308	1,114,340
Other liabilities	125,000	125,000
Total liabilities	19,335,739	20,809,780
STOCKHOLDERS' EQUITY
Common stock, $.01 par value - 600,000,000 shares authorized;43,207,183 and 38,730,150 shares issued and outstanding at September 30, 2021 and 2020, respectively	432,072	387,302
Additional paid-in capital	474,298,566	401,174,675
Accumulated deficit	(418,196,412)	(381,835,303)
Total stockholders' equity	56,534,226	19,726,674
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 75,869,965	$ 40,536,454

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
CONDENSED BALANCE SHEETS
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	43,207,183	38,730,150
Common stock, shares outstanding	43,207,183	38,730,150

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
Grant income	$ 0	$ 558,664
Operating expenses:
Research and development	23,108,897	17,840,290
General and administrative	13,085,232	11,703,429
Total operating expenses	36,194,129	29,543,719
Operating loss	(36,194,129)	(28,985,055)
Other (expense) income	(8,213)	38,763
Loss on derivative instruments	(694,858)	(349,078)
Warrant inducement expense	0	(805,753)
Other non-operating gain	1,685,379	887,604
Interest expense, net	(1,149,288)	(1,041,725)
Net loss	(36,361,109)	(30,255,244)
Modification of warrants	(350,861)	(21,734)
Net loss available to common shareholders	$ (36,711,970)	$ (30,276,978)
Net loss per common share - basic	$ (0.90)	$ (0.82)
Weighted average common shares outstanding - basic	40,662,137	36,759,115
Net loss per common share - diluted	$ (0.93)	$ (0.82)
Weighted average common shares outstanding - diluted	40,694,248	36,759,115

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Sep. 30, 2019		35,231,776
Balance, amount at Sep. 30, 2019	$ 5,133,667	$ 352,318	$ 358,507,603	$ (353,726,254)
Adoption of ASC 842, Leases	2,146,195			2,146,195
Proceeds from the sale of common stock, shares		1,422,429
Proceeds from the sale of common stock, amount	13,992,439	$ 14,225	13,978,214	0
Warrant issuances	805,753	$ 0	805,753	0
Warrant exercises, shares		1,711,873
Warrant exercises, amount	15,144,240	$ 17,118	15,127,122	0
Modification of warrants	5,554	$ 0	5,554
401(k) contributions paid in common stock, shares		13,870
401(k) contributions paid in common stock, amount	163,340	$ 139	163,201	0
Stock issued to nonemployees for service, shares		79,950
Stock issued to nonemployees for service, amount	972,667	$ 799	971,868	0
Equity based compensation - employees	10,112,968	$ 0	10,112,968	0
Option exercises, shares		99,740
Option exercises, amount	338,328	$ 998	337,330	0
Purchase of stock by officers and directors, shares		20,512
Purchase of stock by officers and directors, amount	184,990	$ 205	184,785	0
Share issuance costs	(787,723)	$ 0	(787,723)	0
Shares issued for settlement of clinical research costs, shares		150,000
Shares issued for settlement of clinical research costs, amount	1,769,500	$ 1,500	1,768,000	0
Net loss	(30,255,244)	$ 0	0	(30,255,244)
Balance, shares at Sep. 30, 2020		38,730,150
Balance, amount at Sep. 30, 2020	19,726,674	$ 387,302	401,174,675	(381,835,303)
Proceeds from the sale of common stock, shares		2,610,000
Proceeds from the sale of common stock, amount	47,363,426	$ 26,100	47,337,326	0
Warrant exercises, shares		1,597,870
Warrant exercises, amount	10,007,306	$ 15,978	9,991,328	0
Modification of warrants	24,387	$ 0	24,387	0
401(k) contributions paid in common stock, shares		17,990
401(k) contributions paid in common stock, amount	201,099	$ 180	200,919	0
Stock issued to nonemployees for service, shares		75,885
Stock issued to nonemployees for service, amount	1,195,704	$ 759	1,194,945	0
Equity based compensation - employees	13,685,046	$ (20)	13,685,066	0
Option exercises, shares		149,788
Option exercises, amount	746,228	$ 1,498	744,730	0
Purchase of stock by officers and directors, shares		27,500
Purchase of stock by officers and directors, amount	220,000	$ 275	219,725	0
Share issuance costs	(274,535)	0	(274,535)	0
Net loss	(36,361,109)	$ 0	0	(36,361,109)
Equity based compensation - employees, shares		(2,000)
Balance, shares at Sep. 30, 2021		43,207,183
Balance, amount at Sep. 30, 2021	$ 56,534,226	$ 432,072	$ 474,298,566	$ (418,196,412)

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (36,361,109)	$ (30,255,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,231,108	2,159,729
Share-based payments for services	1,226,690	862,796
Equity based compensation	13,685,046	10,112,968
Common stock contributed to 401(k) plan	201,099	163,340
Shares issued for settlement of clinical research costs	0	1,769,500
Gain on short-term investments	(5,621)	0
Loss on derivative instruments	694,858	349,078
Warrant inducement expense	0	805,753
Modification of warrants	24,387	5,554
(Increase)/decrease in assets:
Receivables	0	7,843
Prepaid expenses	283,964	(623,608)
Supplies used for R&D and manufacturing	(1,186,532)	(37,689)
Deposits	(240,000)	0
Increase/(decrease) in liabilities:
Accounts payable	445,981	(766,073)
Accrued expenses	363,701	406,083
Due to employees	(182,029)	(261,420)
Other liabilities	31,441	25,229
Net cash used in operating activities	(18,787,016)	(15,276,161)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net purchases of U.S. Treasury Bills	(6,145,764)	0
Purchases of property and equipment	(9,016,329)	(2,654,906)
Expenditures for patent costs	(22,641)	(39,975)
Net cash used in investing activities	(15,184,734)	(2,694,881)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	47,363,426	13,992,439
Payments of stock issuance costs	(325,034)	(752,804)
Proceeds from exercise of warrants	5,984,215	12,072,465
Proceeds from exercises of options	746,228	338,328
Proceeds from the purchase of stock by officers and directors	220,000	184,990
Proceeds from landlord funding of leasehold improvements	1,613,546	0
Payments on obligations under finance leases	(1,079,392)	(800,241)
Net cash provided by financing activities	54,522,989	25,035,177
NET INCREASE IN CASH AND CASH EQUIVALENTS	20,551,239	7,064,135
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	15,508,909	8,444,774
CASH AND CASH EQUIVALENTS, END OF YEAR	36,060,148	15,508,909
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in accrued expenses and accounts payable	435,412	1,184,723
Capitalizable patent costs included in accrued expenses and accounts payable	6,510	15,000
Changes to right of use assets and liabilities	551,444	399,032
Finance lease obligation included in accounts payable	855	790
Prepaid consulting services paid with issuance of common stock	363,911	164,871
Fair value of warrants liabilities on date of exercise	4,023,091	3,071,775
Financing costs included in accounts payable	0	50,499
Accrued consulting services to be paid with common stock	55,000	55,000
Cash paid for interest	$ 1,173,702	$ 1,155,026

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Sep. 30, 2021 USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Patent useful life	17 years
Fully insured amount of non-interest bearing cash balances	$ 250,000

WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares	12 Months Ended
WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Consultants [Member]
Issue Date	7/28/2017	7/28/17
Shares Issuable upon Exercise of Warrant	15,000	10,000
Exercise Price	$ 2.18	$ 2.18
Expiration Date	7/27/2027	7/27/2027
Series W [Member]
Issue Date		10/28/2015
Shares Issuable upon Exercise of Warrant		688,930
Exercise Price		$ 16.75
Expiration Date		10/28/2020
Series ZZ [Member]
Issue Date		5/23/2016
Shares Issuable upon Exercise of Warrant		20,000
Exercise Price		$ 13.75
Expiration Date		5/18/2021
Series BB [Member]
Issue Date		8/26/2016
Shares Issuable upon Exercise of Warrant		16,000
Exercise Price		$ 13.75
Expiration Date		8/22/2021
Series Z [Member]
Issue Date	5/23/2016	5/23/2016
Shares Issuable upon Exercise of Warrant	184,800	264,000
Exercise Price	$ 13.75	$ 13.75
Expiration Date	11/23/2021	11/23/2021
Series CC [Member]
Issue Date	12/8/2016	12/8/2016
Shares Issuable upon Exercise of Warrant	15,845	148,643
Exercise Price	$ 5.00	$ 5.00
Expiration Date	12/8/2021	12/8/2021
Series HH [Member]
Issue Date	2/23/2017	2/23/2017
Shares Issuable upon Exercise of Warrant	200	200
Exercise Price	$ 3.13	$ 3.13
Expiration Date	2/16/2022	2/16/2022
Series AA [Member]
Issue Date	8/26/2016	8/26/2016
Shares Issuable upon Exercise of Warrant	100,000	200,000
Exercise Price	$ 13.75	$ 13.75
Expiration Date	2/22/2022	2/22/2022
Series N [Member]
Issue Date	8/18/2008	8/18/2008
Shares Issuable upon Exercise of Warrant	85,339	85,339
Exercise Price	$ 3.00	$ 3.00
Expiration Date	8/18/2022	2/18/2021
Series X [Member]
Issue Date	1/13/2016	1/13/2016
Shares Issuable upon Exercise of Warrant	120,000	120,000
Exercise Price	$ 9.25	$ 9.25
Expiration Date	7/13/2022	1/13/2021
Series Y [Member]
Issue Date	2/15/2016	2/15/2016
Shares Issuable upon Exercise of Warrant	26,000	26,000
Exercise Price	$ 12.00	$ 12.00
Expiration Date	8/15/2022	2/15/2021
Series MM [Member]
Issue Date	6/22/2017	6/22/2017
Shares Issuable upon Exercise of Warrant	333,432	797,633
Exercise Price	$ 1.86	$ 1.86
Expiration Date	6/22/2022	6/22/2022
Series NN [Member]
Issue Date	7/24/2017	7/24/2017
Shares Issuable upon Exercise of Warrant	210,087	348,842
Exercise Price	$ 2.52	$ 2.52
Expiration Date	7/24/2022	7/24/2022
Series RR [Member]
Issue Date	10/30/2017	10/30/2017
Shares Issuable upon Exercise of Warrant	251,761	417,649
Exercise Price	$ 1.65	$ 1.65
Expiration Date	10/30/2022	10/30/2022
Series SS [Member]
Issue Date	12/19/2017	12/19/2017
Shares Issuable upon Exercise of Warrant	200,000	326,064
Exercise Price	$ 2.09	$ 2.09
Expiration Date	12/18/2022	12/18/2022
Series TT [Member]
Issue Date	2/5/2018	2/5/2018
Shares Issuable upon Exercise of Warrant	600	371,564
Exercise Price	$ 2.24	$ 2.24
Expiration Date	2/5/2023	2/5/2023
Series UU [Member]
Issue Date	6/11/2018	6/11/2018
Shares Issuable upon Exercise of Warrant	93,603	93,603
Exercise Price	$ 2.80	$ 2.80
Expiration Date	6/30/2022	12/31/2020

WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)	12 Months Ended
WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Total warrant liabilities	$ 437,380	$ 3,765,613
Net (loss) gain on warrant liabilities	(694,858)	(349,078)
Series W [Member]
Total warrant liabilities	0	73,570
Net (loss) gain on warrant liabilities	73,570	1,119,937
Series ZZ [Member]
Total warrant liabilities	0	75,044
Net (loss) gain on warrant liabilities	(98,692)	2,594
Series BB [Member]
Total warrant liabilities	0	65,173
Net (loss) gain on warrant liabilities	65,173	(1,207)
Series Z [Member]
Total warrant liabilities	64,787	1,207,902
Net (loss) gain on warrant liabilities	(252,115)	(98,357)
Series CC [Member]
Total warrant liabilities	94,961	1,259,712
Net (loss) gain on warrant liabilities	(668,605)	(875,040)
Series HH [Member]
Total warrant liabilities	1,597	2,000
Net (loss) gain on warrant liabilities	404	(34,589)
Series AA [Member]
Total warrant liabilities	276,035	1,082,212
Net (loss) gain on warrant liabilities	(318,823)	(165,304)
Series FF [Member]
Net (loss) gain on warrant liabilities	0	(319,706)
Series JJ [Member]
Net (loss) gain on warrant liabilities	0	(64,992)
Series LL [Member]
Net (loss) gain on warrant liabilities	0	(98,066)
Series V [Member]
Net (loss) gain on warrant liabilities	$ 0	$ 185,652

WARRANTS AND NON-EMPLOYEE OPTIONS (Details Narrative) - USD ($)			1 Months Ended						12 Months Ended
	Dec. 07, 2020	May 08, 2020	Aug. 22, 2021	Oct. 28, 2020	Jun. 25, 2020	Jun. 20, 2020	May 26, 2020	Jan. 23, 2020	Sep. 30, 2021	Sep. 30, 2020
Incremental cost									$ 664,000	$ 664,000
Common stock issued for service, shares									75,885	79,950
Warrant inducement expense										$ 806,000
Fair value of warrant									$ 0	805,753
Consulting Agreements [Member]
Total expense									1,227,000	863,000
Prepaid expenses									$ 364,000	$ 395,000
Consultants [Member]
Options issued									5,000
Option issued to related party									15,000
Option expiration date									Nov. 17, 2022
Stock prices per share									$ 6.86	$ 24.95
Series Y [Member]
Incremental cost								$ 22,000	$ 103,000
Maximum [Member] \| Restricted Stock [Member] \| Consultants [Member]
Weighted average grant date fair value									$ 15.46	12.01
Series W [Member]
Warrants exercised				$ 16.75
Warrants expired				688,930
Series BB [Member]
Warrants exercised			$ 13.75
Warrants expired			16,000
Series V Warrants [Member]
Warrants exercised shares							810,127
Warrants exercised					$ 13.75
Expiration date description							extended the expiration dates of the Series V warrants from May 28, 2020 to June 25, 2020
Warrants expired					135,963
Fair value of warrant					$ 211,000
Series V Warrants [Member] \| Maximum [Member]
Common stock price per share							$ 19.75
Series V Warrants [Member] \| Minimum [Member]
Common stock price per share							$ 13.75
Series XX Warrants [Member]
Fair value of warrant						$ 629,000
Common stock price per share										18.00
Warrants issued during period						461,963
Series YY Warrants [Member]
Fair value of warrant						$ 177,000
Common stock price per share										$ 20.00
Warrants issued during period						101,839
Series UU warrants [Member]
Incremental cost									$ 24,000	$ 6,000
Expiration date description	from December 31, 2020 to June 30, 2021	extended from June 11, 2020 to December 31, 2020							the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021
Warrants issued during period		93,593				101,839
Series N and Series X [Member]
Incremental cost									$ 351,000
Series N Warrants [Member]
Incremental cost								$ 22,000
Expiration date description	the expiration date of the Series N warrants was extended to February 18, 2021							the expiration date of the Series N warrants was extended to February 18, 2021

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
PLANT, PROPERTY AND EQUIPMENT
Research equipment	$ 4,211,124	$ 3,898,242
Furniture and equipment	99,768	99,768
Leasehold improvements	13,456,123	5,519,161
Gross	17,776,015	9,517,171
Accumulated depreciation and amortization	(4,112,453)	(3,673,178)
Net property and equipment	$ 13,663,562	$ 5,843,993

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
PLANT, PROPERTY AND EQUIPMENT
Depreciation expense	$ 447,000	$ 389,000

PATENTS (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Patents	$ 275,866	$ 313,422
Patents [Member]
Patents	910,523	896,372
Accumulated amortization	(634,657)	(582,950)
Patents, net	$ 275,866	$ 313,422

PATENTS (Details 1)	Sep. 30, 2021 USD ($)
PATENTS (Details)
2022	$ 49,000
2023	39,000
2024	31,000
2025	29,000
2026	25,000
Thereafter	103,000
Total	$ 276,000

PATENTS (Details Narrative) - USD ($)	12 Months Ended
PATENTS (Details Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
PATENTS (Details)
Amortization of patent costs	$ 52,000	$ 53,000

INCOME TAXES (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
INCOME TAXES
NOL carryforwards	$ 19,789,000	$ 13,407,000
Lease liabilities	4,101,000	3,631,000
R&D credit	1,221,000	1,221,000
Stock-based compensation	7,785,000	5,297,000
Capitalized R&D	15,040,000	15,853,000
Vacation and other	126,000	125,000
Total deferred tax assets	48,062,000	39,534,000
Right of use assets	(3,786,000)	(3,911,000)
Fixed assets and intangibles	(172,000)	(169,000)
Total deferred tax liability	(3,958,000)	(4,080,000)
Net deferred tax asset	44,104,000	(35,454,000)
Valuation allowance	(44,104,000)	(35,454,000)
Ending Balance	$ 0	$ 0

INCOME TAXES (Details 1)	12 Months Ended
INCOME TAXES (Details 1)	Sep. 30, 2021	Sep. 30, 2020
INCOME TAXES
Federal Rate	21.00%	21.00%
Federal rate change	(1.37%)	(1.40%)
State tax rate, net of federal benefit	4.72%	5.15%
Other adjustments	(0.79%)	(3.24%)
Permanent differences	0.23%	0.42%
Change in valuation allowance	(23.79%)	(21.93%)
Effective tax rate	0.00%	0.00%

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Federal net operating loss carryforwards	$ 19,789,000	$ 13,407,000
Estimated net operating loss carryforwards	48,062,000	39,534,000
Income Tax [Member]
Research and development credit	$ 1,200,000.0	1,200,000
Research and development credit, description	The R&D credit expires during the fiscal year ended 2029.
Federal net operating loss carryforwards	$ 77,100,000	51,500,000
Cumulative change in ownership percentage	(NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
Net operating loss carryforwards, description	Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2022 and become fully expired by 2038 and approximately $57.9 million of NOL carryforwards
Estimated net operating loss carryforwards		$ 188,900,000.0

STOCK COMPENSATION (Details) - USD ($)	12 Months Ended
STOCK COMPENSATION (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
STOCK COMPENSATION
Employees	$ 13,685,046	$ 10,112,968
Non-employees	$ 1,226,690	$ 862,796

STOCK COMPENSATION (Details 1)	12 Months Ended
STOCK COMPENSATION (Details 1)	Sep. 30, 2021	Sep. 30, 2020
STOCK COMPENSATION
Expected stock price volatility, min	90.42%	87.36%
Expected stock price volatility, max	97.22%	90.26%
Risk-free interest rate, min	0.85%	0.62%
Risk-free interest rate, max	1.65%	1.87%
Expected life of options, min	9 years 8 months 4 days	9 years 8 months 4 days
Expected life of options, max	9 years 8 months 8 days	9 years 8 months 8 days
Expected dividend yield	0.00%	0.00%

STOCK COMPENSATION (Details 2) - USD ($)	12 Months Ended
STOCK COMPENSATION (Details 2) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Outstanding [Member]
Number of Options Outstanding, Beginning	8,653,703	6,218,216
Number of Options Exercised	149,788	99,740
Number of Options Expired	9,374	9,773
Number of Options Outstanding, Ending	11,049,709	8,653,703
Weighted Average Exercise Price Outstanding, Beginning	$ 7.01	$ 5.54
Weighted Average Exercise Price Exercised	4.98	3.39
Weighted Average Exercise Price Expired	172.73	132.75
Weighted Average Exercise Price Outstanding, Ending	$ 10.08	$ 7.01
Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning	7 years 11 months 4 days	8 years 10 months 17 days
Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending	8 years 10 months 17 days	8 years 4 months 20 days
Aggregate Intrinsic Value Outstanding, Beginning	$ 56,193,415	$ 29,562,594
Aggregate Intrinsic Value Outstanding, Ending	$ 54,843,283	$ 56,193,415
Number of Options Granted	2,605,000	2,563,000
Number of Options Forfeited	49,832	18,000
Weighted Average Exercise Price Granted	$ 20.58	$ 10.93
Weighted Average Exercise Price Forfeited	$ 9.56	$ 10.34
Exercisable [Member]
Number of Options Outstanding, Beginning	3,297,229	1,392,241
Number of Options Vested	2,401,961	2,014,501
Number of Options Exercised	149,788	99,740
Number of Options Expired	9,374	9,773
Number of Options Outstanding, Ending	5,540,028	3,297,229
Weighted Average Exercise Price Outstanding, Beginning	$ 5.85	$ 9.15
Weighted Average Exercise Price Vested	6.26	4.06
Weighted Average Exercise Price Exercised	4.98	3.39
Weighted Average Exercise Price Expired	172.73	132.75
Weighted Average Exercise Price Outstanding, Ending	$ 5.77	$ 5.85
Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning	6 years 11 months 15 days	7 years 8 months 4 days
Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending	7 years 8 months 5 days	7 years 5 months 23 days
Aggregate Intrinsic Value Outstanding, Beginning	$ 29,090,662	$ 7,869,555
Aggregate Intrinsic Value Outstanding, Ending	$ 43,589,598	$ 29,090,662

STOCK COMPENSATION (Details 3) - $ / shares	12 Months Ended
STOCK COMPENSATION (Details 3) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
STOCK COMPENSATION
Number of unvested options, Beginning	5,356,474	4,825,975
Vested options	(2,401,961)	(2,014,501)
Granted options	2,605,000	2,563,000
Forfeited options	(49,832)	(18,000)
Number of unvested options, Ending	5,509,681	5,356,474
Weighted Average Grant Date Fair Value, Beginning	$ 4.76	$ 3.79
Weighted Average Grant Date Fair Value, Ending	$ 5.17	$ 4.76

STOCK COMPENSATION (Details 4) - $ / shares	12 Months Ended
STOCK COMPENSATION (Details 4) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Weighted Average Grant Date Fair Value, Beginning	$ 4.76	$ 3.79
Restricted Stock Awards [Member]
Number of unvested shares, Beginning	304,500	304,500
Forfeited	(2,000)	0
Vested shares	(151,250)	0
Number of unvested shares, Ending	151,250	304,500
Weighted Average Grant Date Fair Value, Beginning	$ 13.75	$ 13.75
Weighted Average Grant Date Fair Value, Ending	$ 13.75	$ 13.75

STOCK COMPENSATION (Details Narrative) - USD ($)	12 Months Ended
STOCK COMPENSATION (Details Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	May 14, 2021	Dec. 31, 2020	Apr. 20, 2020	Mar. 31, 2020	Dec. 31, 2019
Common stock, shares issued	43,207,183	38,730,150	1,400,000		1,000,000		630,500	606,395
Common stock, shares authorized	600,000,000	600,000,000
Stock Compensation Plans [Member]
Common stock, shares issued	154,195
Common stock, shares authorized	634,000
Stock Bonus Plans [Member]
Common stock, shares issued	363,086
Common stock, shares authorized	783,760
Non-Qualified Stock Options Plans [Member]
Common stock, shares authorized	11,787,200
Unrecognized compensation expense	$ 3,800,000	$ 2,100,000
Remaining compensation expense	$ 189,000	$ 3,800,000.0
Issuance of common stock options purchase shares	1,800,000	3,600,000
Performance based stock options shares granted		72,000		1,800,000		1,872,000
Stock price	$ 20.61	$ 10.93
Stock options vest description		The stock options vest upon the achievement of the following market conditions: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; and iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days.
Fair value per share	$ 0.34	$ 4.21
Grant date fair value remaining outstanding		$ 7,900,000
Grant date fair value remaining	$ 447,000	$ 2,000,000.0
Implicit life of options	1 year 3 months 18 days	1 year 8 months 12 days
Expense life over next	11 years	11 years
Incentive Stock Option Plans [Member]
Common stock, shares authorized	138,400
Incentive Stock Bonus Plan [Member]
Common stock, shares authorized	614,500
Grant date fair value remaining outstanding	$ 8,600,000
Vested shares	463,250
Issuance of restricted stock	$ 300,000
Unrecognized compensation expense	$ 45,000

EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)	12 Months Ended
EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
EMPLOYEE BENEFIT PLAN (Detail Narrative)
Expense for Company's contribution to employee benefit plan	$ 163,000	$ 201,000
Total compensation	$ 10,000
Participant compensation	6.00%
Shares issued	13,870	17,990

COMMITMENTS AND CONTINGENCIES (Details)	Sep. 30, 2021 USD ($)
Commitments and Contingencies
2022	$ 1,699,000
2023	2,569,000
2024	2,648,000
2025	2,733,000
2026	2,824,000
Thereafter	6,186,000
Total future minimum lease obligation	18,659,000
Less imputed interest on financing obligation	4,825,000
Net present value of lease financing obligation	$ (13,834,000)

COMMITMENTS AND CONTINGENCIES (Details 1)	Sep. 30, 2021 USD ($)
Commitments and Contingencies
2022	$ 309,000
2023	348,000
2024	357,000
2025	366,000
2026	287,000
Thereafter	1,602,000
Total future minimum lease obligation	3,269,000
Less imputed interest on operating lease obligation	(1,130,000)
Total	$ 2,139,000

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Weighted average discount rate	8.45%
Weighted average discount rate operating lease	9.12%
Interest rate	0.1019%	0.10%
Maturity years	7 years 1 month 6 days
Operating lease maturity years	9 years 8 months 12 days
Research and development expenses	$ 35,100,000
Net of discount	$ 11,600,000
Lease description	revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%
Finance lease obligations, net of current portion	$ 200,000	$ 100,000
Weighted average time to maturity	17 years
Biologics License Application [Member]
Sublease rental income		39,000
Ergomed [Member]
Research and development expenses	$ 1,600,000	1,400,000.0
Net of discount	600,000	600,000.0
Clinical service trial	10,000,000
Additional clinical trial	$ 2,000,000
Weighted average time to maturity	7 years 1 month 6 days
TransactionTwoMember [Member] \| October 1, 2019 [Member]
Change in right of use of assets and liability	$ 1,000,000.0
Cash paid related to operating leases	300,000	200,000
Net book value operating lease right of use assets	2,100,000	1,200,000
Current balance	100,000	100,000
Operating lease - liability	2,100,000	1,200,000
Operating lease expense	$ 200,000	200,000.0
Transaction One [Member] \| October 1, 2019 [Member]
Weighted average discount rate	0.0845%
Change in right of use of assets and liability	$ 16,500,000
Current balance	600,000	900,000
Operating lease - liability	1,732,000	1,717,000
Finance lease liability	13,500,000
Net book value of the finance lease right of use asset	12,700,000	13,800,000
Balance of the finance lease liability	13,800,000	12,700,000
Cash paid related to finance leases	2,200,000	1,900,000
Cash paid related to finance leases interest	$ 1,200,000	1,200,000.0
Landlord [Member]
Interest rate	8.45%
Lease description	The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.
Lease incentive payable current	$ 1,600,000.0
Additional deposit	200,000
Cost incurred, initial	10,500,000
Estimated cost	10,700,000
Non current assets	1,900,000	$ 1,700,000
Financing arrangement	2,400,000
Vendor Obligations [Member]
Additional expenses	$ 1,100,000

STOCKHOLDERS EQUITY (Details) - USD ($)	12 Months Ended
STOCKHOLDERS EQUITY (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
STOCKHOLDERS EQUITY
Amount realized through the resale of shares	$ 1,685,379	$ 2,652,605
Fair value of shares upon issuance	0	1,769,500
Other non-operating gain (loss)	$ 1,685,379	$ 883,105

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	1 Months Ended						12 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	May 31, 2020	Mar. 31, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2021	Sep. 30, 2020
Common stock shares issued	1,400,000	1,000,000		630,500		606,395	43,207,183	38,730,150
Proceeds from public offering	$ 210,000			$ 94,575	$ 90,959	$ 90,959
Proceeds from initial public offering	$ 29,400,000	$ 13,600,000	$ 1,100,000	$ 7,100,000	$ 800,000	$ 5,000,000.0
Public offering price per share	$ 22.62	$ 14.65		$ 12.22	$ 9.07	$ 9.07
Proceeds from issuance of warrant	$ 4,400,000						$ 6,000,000.0	$ 12,100,000
Warrants exercised							1,597,870	1,711,873
Ergomed [Member]
Common stock shares issued								150,000
Prepaid of resold amount							$ 500,000